{"insert":{"user_id":"1000314537","type":"published_papers","id":"54449726"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/41776599","label":"url"},{"@id":"https://www.scopus.com/pages/publications/105039815578","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=464210","label":"url"}],"paper_title":{"en":"An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study","ja":"An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study"},"authors":{"en":[{"name":"Miyazaki Katsuki"},{"name":"Montcusí Blanca"},{"name":"Morine Yuji"},{"name":"Okuno Keisuke"},{"name":"Pascual Marta"},{"name":"Tokunaga Takuya"},{"name":"Noma Takayuki"},{"name":"Kinugasa Yusuke"},{"name":"Shimada Mitsuo"},{"name":"Cai Guoxiang"},{"name":"Pera Miguel"},{"name":"Goel Ajay"}],"ja":[{"name":"宮崎 克己"},{"name":"Montcusí Blanca"},{"name":"森根 裕二"},{"name":"Okuno Keisuke"},{"name":"Pascual Marta"},{"name":"徳永 卓哉"},{"name":"野間 隆礼"},{"name":"Kinugasa Yusuke"},{"name":"島田 光生"},{"name":"Cai Guoxiang"},{"name":"Pera Miguel"},{"name":"Goel Ajay"}]},"description":{"en":"BACKGROUND: Exosomal miRNAs have drawn increasing attention in the field of liquid biopsy owing to their high degree of cancer specificity and stability. This study aimed to establish an exosome-based liquid biopsy signature to predict molecular residual disease (MRD) in stage II and III colorectal cancer (CRC). METHODS: We analyzed 175 postoperative serum samples from stage II and III CRC patients from 2 independent institutions, performed quantitative reverse-transcription polymerase chain reaction, and developed and validated a risk-stratification model using logistic regression. RESULTS: We first evaluated the expression of the 8 miRNAs identified in our previous tissue-based study in exosomes, and found that 5 of 8 were significantly downregulated in the recurrent group. A panel of 5 miRNAs robustly predicted recurrence after surgery in a training cohort (area under the curve [AUC]: 0.83). Subgroup analysis of the adjuvant chemotherapy (ACT) naïve group demonstrated that recurrence rates were 3.1% (1/32) in the low-risk group and 64.7% (11/17) in the high-risk group. We successfully validated the performance of this exosomal miRNA panel in an independent testing cohort (AUC: 0.77). Furthermore, when we developed our risk model, named Clinical Liquid Biopsy via Exosomes for Assessment of Molecular Residual Disease in Colorectal Cancer Score (CLEAR score), by adding tumor factor and stage to the panel, predictive accuracy was dramatically improved (AUC: 0.84). CONCLUSIONS: We have developed an exosome-based liquid biopsy signature that enables robust detection of MRD in patients with stage II-III CRC. These findings could help facilitate more informed clinical decision-making for ACT. TRIAL REGISTRATION: NCT06654622.","ja":"BACKGROUND: Exosomal miRNAs have drawn increasing attention in the field of liquid biopsy owing to their high degree of cancer specificity and stability. This study aimed to establish an exosome-based liquid biopsy signature to predict molecular residual disease (MRD) in stage II and III colorectal cancer (CRC). METHODS: We analyzed 175 postoperative serum samples from stage II and III CRC patients from 2 independent institutions, performed quantitative reverse-transcription polymerase chain reaction, and developed and validated a risk-stratification model using logistic regression. RESULTS: We first evaluated the expression of the 8 miRNAs identified in our previous tissue-based study in exosomes, and found that 5 of 8 were significantly downregulated in the recurrent group. A panel of 5 miRNAs robustly predicted recurrence after surgery in a training cohort (area under the curve [AUC]: 0.83). Subgroup analysis of the adjuvant chemotherapy (ACT) naïve group demonstrated that recurrence rates were 3.1% (1/32) in the low-risk group and 64.7% (11/17) in the high-risk group. We successfully validated the performance of this exosomal miRNA panel in an independent testing cohort (AUC: 0.77). Furthermore, when we developed our risk model, named Clinical Liquid Biopsy via Exosomes for Assessment of Molecular Residual Disease in Colorectal Cancer Score (CLEAR score), by adding tumor factor and stage to the panel, predictive accuracy was dramatically improved (AUC: 0.84). CONCLUSIONS: We have developed an exosome-based liquid biopsy signature that enables robust detection of MRD in patients with stage II-III CRC. These findings could help facilitate more informed clinical decision-making for ACT. TRIAL REGISTRATION: NCT06654622."},"publication_date":"2026-03-03","publication_name":{"en":"Molecular Cancer","ja":"Molecular Cancer"},"volume":"25","number":"1","starting_page":"136","ending_page":"136","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12943-026-02624-7"],"issn":["1476-4598"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"54449727"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/41604539","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=465996","label":"url"}],"paper_title":{"en":"A machine learning-based transcriptomic signature for predicting tumor recurrence after curative resection in T1 colorectal cancer: a retrospective multicenter cohort study (The Tw1CE trial).","ja":"A machine learning-based transcriptomic signature for predicting tumor recurrence after curative resection in T1 colorectal cancer: a retrospective multicenter cohort study (The Tw1CE trial)."},"authors":{"en":[{"name":"Noma Takayuki"},{"name":"Saez de Gordoa Karmele"},{"name":"Daca-Alvarez María"},{"name":"Miyazaki Katsuki"},{"name":"Wada Yuuma"},{"name":"Mannucci Alessandro"},{"name":"Onoyama Takumi"},{"name":"Shimada Mitsuo"},{"name":"Cuatrecasas Míriam"},{"name":"Bujanda Luis"},{"name":"Pellise Maria"},{"name":"Goel Ajay"}],"ja":[{"name":"野間 隆礼"},{"name":"Saez de Gordoa Karmele"},{"name":"Daca-Alvarez María"},{"name":"宮崎 克己"},{"name":"和田 佑馬"},{"name":"Mannucci Alessandro"},{"name":"Onoyama Takumi"},{"name":"島田 光生"},{"name":"Cuatrecasas Míriam"},{"name":"Bujanda Luis"},{"name":"Pellise Maria"},{"name":"Goel Ajay"}]},"description":{"en":"T1 colorectal cancer (T1 CRC) is increasingly treated with curative-intent endoscopic resection, but tumor recurrence remains a critical factor influencing patient prognosis. However there is no validated biomarker exists to reliably predict post-resection recurrence, limiting risk-adapted follow-up and adjuvant therapy decisions. In this multicenter retrospective cohort study across academic centers in Spain, 138 patients with T1 CRC (2023-2025; ClinicalTrials.gov NCT06314971) were enrolled. From FFPE endoscopic specimens, expression of five mRNAs and two miRNAs was quantified by RT-qPCR, and an XGBoost-based transcriptomic panel was developed. Patients were assigned to training and independent testing cohorts by treatment type. The primary outcome was 3-year recurrence-free survival (RFS); secondary outcomes included 5-year RFS and overall survival (OS). The transcriptomic panel demonstrated high predictive performance in both the training (AUROC = 91.7%) and testing (AUROC = 88.2%) cohorts. Patients classified as high-risk by the panel exhibited significantly worse RFS and OS compared with those classified as low-risk (log-rank P < 0.001). Furthermore, integrating lymphatic invasion with the transcriptomic panel into a combined risk stratification model further improved predictive accuracy (AUROC = 94.6%), and decision curve analysis confirmed its superior clinical utility compared to conventional criteria. This study established a validated machine learning-based transcriptomic classifier derived from endoscopic resection specimens that accurately predicts tumor recurrence in patients with T1 CRC. Our findings highlight the potential of this biomarker panel to enable risk-adapted surveillance strategies and guide decisions regarding additional therapy after curative resection.","ja":"T1 colorectal cancer (T1 CRC) is increasingly treated with curative-intent endoscopic resection, but tumor recurrence remains a critical factor influencing patient prognosis. However there is no validated biomarker exists to reliably predict post-resection recurrence, limiting risk-adapted follow-up and adjuvant therapy decisions. In this multicenter retrospective cohort study across academic centers in Spain, 138 patients with T1 CRC (2023-2025; ClinicalTrials.gov NCT06314971) were enrolled. From FFPE endoscopic specimens, expression of five mRNAs and two miRNAs was quantified by RT-qPCR, and an XGBoost-based transcriptomic panel was developed. Patients were assigned to training and independent testing cohorts by treatment type. The primary outcome was 3-year recurrence-free survival (RFS); secondary outcomes included 5-year RFS and overall survival (OS). The transcriptomic panel demonstrated high predictive performance in both the training (AUROC = 91.7%) and testing (AUROC = 88.2%) cohorts. Patients classified as high-risk by the panel exhibited significantly worse RFS and OS compared with those classified as low-risk (log-rank P < 0.001). Furthermore, integrating lymphatic invasion with the transcriptomic panel into a combined risk stratification model further improved predictive accuracy (AUROC = 94.6%), and decision curve analysis confirmed its superior clinical utility compared to conventional criteria. This study established a validated machine learning-based transcriptomic classifier derived from endoscopic resection specimens that accurately predicts tumor recurrence in patients with T1 CRC. Our findings highlight the potential of this biomarker panel to enable risk-adapted surveillance strategies and guide decisions regarding additional therapy after curative resection."},"publication_date":"2026-01-28","publication_name":{"en":"International Journal of Surgery","ja":"International Journal of Surgery"},"volume":"112","number":"4","starting_page":"9039","ending_page":"9051","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1097/JS9.0000000000004690"],"issn":["1743-9159"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"54442141"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=465893","label":"url"}],"paper_title":{"en":"胆管非拡張型膵・胆管合流異常の至適術式は?","ja":"胆管非拡張型膵・胆管合流異常の至適術式は?"},"authors":{"en":[{"name":"Morine Yuji"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Teraoku Hiroki"},{"name":"Miyazaki Katsuki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"森根 裕二"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"寺奥 大貴"},{"name":"宮崎 克己"},{"name":"池本 哲也"},{"name":"島田 光生"}]},"publication_date":"2025-10","publication_name":{"en":"Journal of Biliary Tract & Pancreas","ja":"胆と膵"},"volume":"46","number":"10","starting_page":"955","ending_page":"960","languages":["jpn"],"referee":true,"identifiers":{"issn":["0388-9408"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.scopus.com/pages/publications/85218710490","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=418483","label":"url"}],"paper_title":{"en":"Light-emitting diode irradiation targets aerobic glycolysis in cancer-associated fibroblasts to inhibit metabolic coupling with colon cancer cells","ja":"Light-emitting diode irradiation targets aerobic glycolysis in cancer-associated fibroblasts to inhibit metabolic coupling with colon cancer cells"},"authors":{"en":[{"name":"Nishi Masaaki"},{"name":"Nakasu Chiharu"},{"name":"Yoshimoto Toshiaki"},{"name":"Tokunaga Takuya"},{"name":"Kashihara T. Hideya"},{"name":"Takasu Chie"},{"name":"Ishikawa Daichi"},{"name":"Wada Yuma"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"西 正暁"},{"name":"Nakasu Chiharu"},{"name":"Yoshimoto Toshiaki"},{"name":"徳永 卓哉"},{"name":"Kashihara T. Hideya"},{"name":"Takasu Chie"},{"name":"Ishikawa Daichi"},{"name":"Wada Yuma"},{"name":"島田 光生"}]},"publication_date":"2025-07-01","publication_name":{"en":"Annals of Gastroenterological Surgery","ja":"Annals of Gastroenterological Surgery"},"volume":"9","number":"4","starting_page":"761","ending_page":"768","referee":true,"identifiers":{"doi":["10.1002/ags3.70004"],"issn":["2475-0328"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"52197493"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/40195696","label":"url"},{"@id":"https://www.scopus.com/pages/publications/105003314016","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=434236","label":"url"}],"paper_title":{"en":"Surgical Technique of Robotic Distal Gastrectomy for Gastric Cancer Using the Hinotori Surgical System","ja":"Surgical Technique of Robotic Distal Gastrectomy for Gastric Cancer Using the Hinotori Surgical System"},"authors":{"en":[{"name":"Nishi Masaaki"},{"name":"Takasu Chie"},{"name":"Wada Yuuma"},{"name":"Tokunaga Takuya"},{"name":"Kashihara Hideya"},{"name":"Ishikawa Daichi"},{"name":"Yoshimoto Toshiaki"},{"name":"Nakasu Chiharu"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"西 正暁"},{"name":"髙須 千絵"},{"name":"和田 佑馬"},{"name":"徳永 卓哉"},{"name":"柏原 秀也"},{"name":"石川 大地"},{"name":"良元 俊昭"},{"name":"仲須 千春"},{"name":"島田 光生"}]},"description":{"en":"The da Vinci Surgical System (Intuitive Surgical) currently dominates robotic gastrectomy for gastric cancer. The hinotori Surgical Robot System (Medicaroid Corporation) is a newly developed, Japan-made surgical assist robot. This study aimed to introduce the initial experience of robotic gastrectomy using the hinotori and discuss key techniques and challenges. This single-center retrospective study involved 10 eligible patients who underwent curative robotic distal gastrectomy using the hinotori for primary Stage I to III gastric cancer. Short-term surgical outcomes were evaluated. Lymph node dissection was mainly performed using the conventional double bipolar technique, left-handed double bipolar technique, or laparoscopic coagulation shears from the assist port. No patients developed intraoperative complications, and all procedures were successfully completed without conversion to open or laparoscopic surgery. All patients achieved R0 resection. The median operation time was 275 minutes (range, 252 to 336 min), and the estimated blood loss was 5 mL (range, 3 to 20 mL). The drain amylase content on postoperative day 1 was 220.5 IU/L (range, 66 to 1207 IU/L). The median number of retrieved lymph nodes was 29.5 (range, 11 to 58). No patients developed postoperative Clavien-Dindo grade ≥IIIa complications, and there was no mortality. Robotic gastrectomy using the hinotori shows potential benefits for gastric cancer. Further studies are needed to validate these advantages.","ja":"The da Vinci Surgical System (Intuitive Surgical) currently dominates robotic gastrectomy for gastric cancer. The hinotori Surgical Robot System (Medicaroid Corporation) is a newly developed, Japan-made surgical assist robot. This study aimed to introduce the initial experience of robotic gastrectomy using the hinotori and discuss key techniques and challenges. This single-center retrospective study involved 10 eligible patients who underwent curative robotic distal gastrectomy using the hinotori for primary Stage I to III gastric cancer. Short-term surgical outcomes were evaluated. Lymph node dissection was mainly performed using the conventional double bipolar technique, left-handed double bipolar technique, or laparoscopic coagulation shears from the assist port. No patients developed intraoperative complications, and all procedures were successfully completed without conversion to open or laparoscopic surgery. All patients achieved R0 resection. The median operation time was 275 minutes (range, 252 to 336 min), and the estimated blood loss was 5 mL (range, 3 to 20 mL). The drain amylase content on postoperative day 1 was 220.5 IU/L (range, 66 to 1207 IU/L). The median number of retrieved lymph nodes was 29.5 (range, 11 to 58). No patients developed postoperative Clavien-Dindo grade ≥IIIa complications, and there was no mortality. Robotic gastrectomy using the hinotori shows potential benefits for gastric cancer. Further studies are needed to validate these advantages."},"publication_date":"2025-06-01","publication_name":{"en":"Surgical Laparoscopy, Endoscopy & Percutaneous Techniques","ja":"Surgical Laparoscopy, Endoscopy & Percutaneous Techniques"},"volume":"35","number":"3","starting_page":"e1369","ending_page":"e1369","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1097/SLE.0000000000001369"],"issn":["1530-4515"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/40371143","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=465608","label":"url"}],"paper_title":{"en":"The relationship between the tumor microenvironment of hepatocellular carcinoma - including cancer-associated fibroblasts and tumor-associated macrophages - and apparent diffusion coefficient.","ja":"The relationship between the tumor microenvironment of hepatocellular carcinoma - including cancer-associated fibroblasts and tumor-associated macrophages - and apparent diffusion coefficient."},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Morine Yuji"},{"name":"Yamada Shin-ichiro"},{"name":"Teraoku Hiroki"},{"name":"Miyazaki Katsuki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"森根 裕二"},{"name":"山田 眞一郎"},{"name":"寺奥 大貴"},{"name":"宮崎 克己"},{"name":"池本 哲也"},{"name":"島田 光生"}]},"description":{"en":"The tumor microenvironment is critical for the acquisition of tumor malignancy in various cancer types. The objectives of this study were to investigate whether the levels of cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) reflect the prognosis of patients with hepatocellular carcinoma (HCC) after hepatectomy (Hx) and to determine whether the apparent diffusion coefficient (ADC) from diffusion-weighted imaging (DWI) reflects CAF and TAM expression. The study cohort comprised 109 patients who underwent initial curative resection for HCC. Alpha smooth muscle actin (αSMA) was selected as a CAF marker and CD204 as a TAM marker. Protein expression was immunohistochemically evaluated in the intratumoral regions of resected specimens. Clinicopathological factors, including the long-term prognosis after Hx, were investigated between αSMA-negative and -positive tumors and between CD204-negative and -positive tumors. The correlation between CAF/TAM marker expression and the calculated minimum ADC using DWI was also evaluated. αSMA-positive expression was correlated with tumor number, invasive growth pattern, and advanced stage. CD204-positive expression was correlated with the presence of venous invasion. Both αSMA-positive expression and CD204-positive expression were significant prognostic factors in the univariate analysis of overall survival and disease-free survival. αSMA/CD204 double positivity was associated with an extremely poor prognosis after Hx and was a significant independent prognostic factor for overall survival (P=0.02, hazard ratio: 3.27). Patients with double positivity also showed a significantly higher ADClow rate (83%). In conclusion, expression of both CAF and TAM markers reflected a poor prognosis after Hx. Furthermore, the preoperative ADC could be a clinical surrogate marker in the tumor microenvironment in patients with HCC.","ja":"The tumor microenvironment is critical for the acquisition of tumor malignancy in various cancer types. The objectives of this study were to investigate whether the levels of cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) reflect the prognosis of patients with hepatocellular carcinoma (HCC) after hepatectomy (Hx) and to determine whether the apparent diffusion coefficient (ADC) from diffusion-weighted imaging (DWI) reflects CAF and TAM expression. The study cohort comprised 109 patients who underwent initial curative resection for HCC. Alpha smooth muscle actin (αSMA) was selected as a CAF marker and CD204 as a TAM marker. Protein expression was immunohistochemically evaluated in the intratumoral regions of resected specimens. Clinicopathological factors, including the long-term prognosis after Hx, were investigated between αSMA-negative and -positive tumors and between CD204-negative and -positive tumors. The correlation between CAF/TAM marker expression and the calculated minimum ADC using DWI was also evaluated. αSMA-positive expression was correlated with tumor number, invasive growth pattern, and advanced stage. CD204-positive expression was correlated with the presence of venous invasion. Both αSMA-positive expression and CD204-positive expression were significant prognostic factors in the univariate analysis of overall survival and disease-free survival. αSMA/CD204 double positivity was associated with an extremely poor prognosis after Hx and was a significant independent prognostic factor for overall survival (P=0.02, hazard ratio: 3.27). Patients with double positivity also showed a significantly higher ADClow rate (83%). In conclusion, expression of both CAF and TAM markers reflected a poor prognosis after Hx. Furthermore, the preoperative ADC could be a clinical surrogate marker in the tumor microenvironment in patients with HCC."},"publication_date":"2025-04-15","publication_name":{"en":"American Journal of Cancer Research","ja":"American Journal of Cancer Research"},"volume":"15","number":"4","starting_page":"1747","ending_page":"1758","languages":["eng"],"referee":true,"identifiers":{"doi":["10.62347/ZGGJ9531"],"issn":["2156-6976"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"54442142"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=465895","label":"url"}],"paper_title":{"en":"【肝切除の手術支援システムの最前線-シミュレーションとナビゲーション-】術前3次元画像によるシミュレーション ロボット支援下肝切除extended realityシミュレーション","ja":"【肝切除の手術支援システムの最前線-シミュレーションとナビゲーション-】術前3次元画像によるシミュレーション ロボット支援下肝切除extended realityシミュレーション"},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Morine Yuji"},{"name":"Teraoku Hiroki"},{"name":"Yamada Shin-ichiro"},{"name":"Miyazaki Katsuki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"森根 裕二"},{"name":"寺奥 大貴"},{"name":"山田 眞一郎"},{"name":"宮崎 克己"},{"name":"池本 哲也"},{"name":"島田 光生"}]},"publication_date":"2025","publication_name":{"en":"KAN TAN SUI","ja":"肝·胆·膵"},"volume":"90","number":"6","starting_page":"673","ending_page":"677","languages":["jpn"],"referee":true,"identifiers":{"issn":["0389-4991"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"54442143"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=465892","label":"url"}],"paper_title":{"en":"【胆道癌の早期発見をめざして】先天性胆道拡張症,膵・胆管合流異常における胆道癌の特徴","ja":"【胆道癌の早期発見をめざして】先天性胆道拡張症,膵・胆管合流異常における胆道癌の特徴"},"authors":{"en":[{"name":"Morine Yuji"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Teraoku Hiroki"},{"name":"Miyazaki Katsuki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"森根 裕二"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"寺奥 大貴"},{"name":"宮崎 克己"},{"name":"池本 哲也"},{"name":"島田 光生"}]},"publication_date":"2025","publication_name":{"en":"Journal of Biliary Tract & Pancreas","ja":"胆と膵"},"volume":"46","number":"6","starting_page":"533","ending_page":"539","languages":["jpn"],"referee":true,"identifiers":{"issn":["0388-9408"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38407681","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=408163","label":"url"}],"paper_title":{"en":"Gastric fundic gland polyposis and cancer development after eradication of Helicobacter pylori in patient with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS).","ja":"Gastric fundic gland polyposis and cancer development after eradication of Helicobacter pylori in patient with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)."},"authors":{"en":[{"name":"Okamoto Koichi"},{"name":"Kawaguchi Tomoyuki"},{"name":"Kagemoto Kaizo"},{"name":"Kida Yoshifumi"},{"name":"Mitsui Yasuhiro"},{"name":"Nakamura Fumika"},{"name":"Yoshikawa Kouzou"},{"name":"Sogabe Masahiro"},{"name":"Sato Yasushi"},{"name":"Shunto Joji"},{"name":"Bando Yoshimi"},{"name":"Shimada Mitsuo"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"岡本 耕一"},{"name":"川口 智之"},{"name":"影本 開三"},{"name":"喜田 慶史"},{"name":"三井 康裕"},{"name":"中村 文香"},{"name":"吉川 幸造"},{"name":"曽我部 正弘"},{"name":"佐藤 康史"},{"name":"Shunto Joji"},{"name":"坂東 良美"},{"name":"島田 光生"},{"name":"高山 哲治"}]},"description":{"en":"A 44-year-old woman with gastric cancer (GC) and fundic gland polyposis (FGPs) was referred to our hospital for further diagnosis and treatment. She successfully underwent eradication therapy for Helicobacter pylori (HP) 6 years ago, but did not exhibit FGPs at that time. When she underwent an esophagogastroduodenoscopy 2, 4, and 5 years after the eradication of HP, her imaging results revealed the existence of FGPs which gradually increased in her gastric fundus and body. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) was suspected and a mutational analysis was performed, revealing an APC promoter 1B variant c.-191T > C. A robotic total gastrectomy with lymphadenectomy was performed. Histopathological analysis of the surgical specimens revealed GC with no lymph node metastasis. GAPPS is characterized by GC and FGPs. However, our case shows different gastric phenotypes that are dependent on the status of HP infection.","ja":"A 44-year-old woman with gastric cancer (GC) and fundic gland polyposis (FGPs) was referred to our hospital for further diagnosis and treatment. She successfully underwent eradication therapy for Helicobacter pylori (HP) 6 years ago, but did not exhibit FGPs at that time. When she underwent an esophagogastroduodenoscopy 2, 4, and 5 years after the eradication of HP, her imaging results revealed the existence of FGPs which gradually increased in her gastric fundus and body. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) was suspected and a mutational analysis was performed, revealing an APC promoter 1B variant c.-191T > C. A robotic total gastrectomy with lymphadenectomy was performed. Histopathological analysis of the surgical specimens revealed GC with no lymph node metastasis. GAPPS is characterized by GC and FGPs. However, our case shows different gastric phenotypes that are dependent on the status of HP infection."},"publication_date":"2024-05","publication_name":{"en":"Gastric Cancer","ja":"Gastric Cancer"},"volume":"27","number":"3","starting_page":"635","ending_page":"640","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10120-024-01473-x"],"issn":["1436-3305"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37840060","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405966","label":"url"}],"paper_title":{"en":"Preoperative Weight Loss Program for Hepatocellular Carcinoma Patients with High Body Mass Index in Hepatectomy.","ja":"Preoperative Weight Loss Program for Hepatocellular Carcinoma Patients with High Body Mass Index in Hepatectomy."},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Yamada Shin-ichiro"},{"name":"Teraoku Hiroki"},{"name":"Yasui-Yamada Sonoko"},{"name":"Nishi Maki"},{"name":"Sakaue Hiroshi"},{"name":"Kamada Motomu"},{"name":"Matsuura Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"山田 眞一郎"},{"name":"寺奥 大貴"},{"name":"山田 苑子"},{"name":"Nishi Maki"},{"name":"阪上 浩"},{"name":"Kamada Motomu"},{"name":"松浦 哲也"},{"name":"島田 光生"}]},"description":{"en":"This study aimed to investigate the usefulness of a weight-loss program (WLP) in patients with a high body mass index (BMI) prior to liver resection (Hx) for hepatocellular carcinoma (HCC). Among 445 patients with HCC who underwent initial Hx between 2000 and 2020, 19 with a high BMI (25.0) were enrolled in our WLP since 2014. For calorie restriction, the amount of energy consumed was calculated as the standard body weight (SBW) kg × 20-25 kcal/day. Protein mass was calculated as SBW kg × 1.0-1.2 g/day to maintain skeletal muscle mass. Patients also performed both aerobic and resistance exercises. The before-and-after changes were compared, and the effect of WLP on the short- and long-term results was investigated. The average length of WLP was 21 days, and weight loss was successfully achieved in all patients. Body fat mass was reduced during the program, while skeletal muscle mass was maintained. WLP led to improvements in liver function and fibrotic markers, without tumor progression. There were no postoperative complications (Clavien-Dindo [CD] III). A retrospective comparison between with and without WLP using propensity score-matching analysis revealed that WLP group showed better NLR value, however, there were no significant differences in both short and long-term outcomes after Hx based on participation in the WLP. WLP with multidisciplinary intervention improved immune-nutrition status and liver function of obese patients. WLP had not affected both short and long-term outcomes after Hx.","ja":"This study aimed to investigate the usefulness of a weight-loss program (WLP) in patients with a high body mass index (BMI) prior to liver resection (Hx) for hepatocellular carcinoma (HCC). Among 445 patients with HCC who underwent initial Hx between 2000 and 2020, 19 with a high BMI (25.0) were enrolled in our WLP since 2014. For calorie restriction, the amount of energy consumed was calculated as the standard body weight (SBW) kg × 20-25 kcal/day. Protein mass was calculated as SBW kg × 1.0-1.2 g/day to maintain skeletal muscle mass. Patients also performed both aerobic and resistance exercises. The before-and-after changes were compared, and the effect of WLP on the short- and long-term results was investigated. The average length of WLP was 21 days, and weight loss was successfully achieved in all patients. Body fat mass was reduced during the program, while skeletal muscle mass was maintained. WLP led to improvements in liver function and fibrotic markers, without tumor progression. There were no postoperative complications (Clavien-Dindo [CD] III). A retrospective comparison between with and without WLP using propensity score-matching analysis revealed that WLP group showed better NLR value, however, there were no significant differences in both short and long-term outcomes after Hx based on participation in the WLP. WLP with multidisciplinary intervention improved immune-nutrition status and liver function of obese patients. WLP had not affected both short and long-term outcomes after Hx."},"publication_date":"2023-10-15","publication_name":{"en":"World Journal of Surgery","ja":"World Journal of Surgery"},"volume":"47","number":"12","starting_page":"3348","ending_page":"3355","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s00268-023-07220-0"],"issn":["1432-2323"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2011773","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36259178","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=395817","label":"url"}],"paper_title":{"en":"Characteristic submucosal alteration in biliary carcinogenesis of pancreaticobiliary maljunction with a focus on inflammasome activation.","ja":"Characteristic submucosal alteration in biliary carcinogenesis of pancreaticobiliary maljunction with a focus on inflammasome activation."},"authors":{"en":[{"name":"Yamashita Shoko"},{"name":"Takasu Chie"},{"name":"Morine Yuji"},{"name":"Ishibashi Hiroki"},{"name":"Ikemoto Tetsuya"},{"name":"Mori Hiroki"},{"name":"Yamada Shin-ichiro"},{"name":"Oya Takeshi"},{"name":"Tsuneyama Koichi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"山下 祥子"},{"name":"髙須 千絵"},{"name":"森根 裕二"},{"name":"石橋 広樹"},{"name":"池本 哲也"},{"name":"森 大樹"},{"name":"山田 眞一郎"},{"name":"尾矢 剛志"},{"name":"常山 幸一"},{"name":"島田 光生"}]},"description":{"en":"Activated fibroblasts and M2 macrophages in the GB lamina propria may be associated with biliary carcinogenesis of PBM, possibly through inflammasome activation.","ja":"Compared with the control and cholecystitis groups, αSMA expression was higher in the cancerous part (stroma) of the GB in patients with GB cancer + PBM and in the lamina propria of patients with PBM. The CD204/CD68 ratio in the lamina propria was higher in the PBM group than in the control and cholecystitis groups. NLRP3 and caspase 1 expression in both the lamina propria and epithelium was higher in the PBM than control group. In the PBM group, NLRP3- and caspase 1-positive cells in the lamina propria were located near the epithelium."},"publication_date":"2023-03-01","publication_name":{"en":"Journal of Hepato-Biliary-Pancreatic Sciences","ja":"Journal of Hepato-Biliary-Pancreatic Sciences"},"volume":"30","number":"4","starting_page":"462","ending_page":"472","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/jhbp.1253"],"issn":["1868-6982"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2010975","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37164730","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=398472","label":"url"}],"paper_title":{"en":"Histological and immunohistochemical analysis of epithelial cells in epidermoid cysts in intrapancreatic accessory spleen.","ja":"Histological and immunohistochemical analysis of epithelial cells in epidermoid cysts in intrapancreatic accessory spleen."},"authors":{"en":[{"name":"Sumida Satoshi"},{"name":"Shimizu Mayuko"},{"name":"Miyakami Yuko"},{"name":"Kakimoto Takumi"},{"name":"Kobayashi Tomoko"},{"name":"Saijo Yasuyo"},{"name":"Matsumoto Minoru"},{"name":"Ogawa Hirohisa"},{"name":"Oya Takeshi"},{"name":"Bando Yoshimi"},{"name":"Uehara Hisanori"},{"name":"Taira Shu"},{"name":"Shimada Mitsuo"},{"name":"Tsuneyama Koichi"}],"ja":[{"name":"住田 智志"},{"name":"清水 真祐子"},{"name":"宮上 侑子"},{"name":"柿本 拓海"},{"name":"小林 智子"},{"name":"西條 康代"},{"name":"松本 穣"},{"name":"小川 博久"},{"name":"尾矢 剛志"},{"name":"坂東 良美"},{"name":"上原 久典"},{"name":"Taira Shu"},{"name":"島田 光生"},{"name":"常山 幸一"}]},"description":{"en":"Novel histological features of epithelial cells of ECIPAS were indicated. Although more cases need to be evaluated, we propose that the cause of ECIPAS may be different from that of pancreatic ductal origin. J. Med. Invest. 70 : 251-259, February, 2023.","ja":"Novel histological features of epithelial cells of ECIPAS were indicated. Although more cases need to be evaluated, we propose that the cause of ECIPAS may be different from that of pancreatic ductal origin. J. Med. Invest. 70 : 251-259, February, 2023."},"publication_date":"2023","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"70","number":"1.2","starting_page":"251","ending_page":"259","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.70.251"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35669900","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=395815","label":"url"}],"paper_title":{"en":"Gastric carcinoma with lymphoid stroma derived from hamartomatous inverted polyp with osteoclast-like giant cells: a case report.","ja":"Gastric carcinoma with lymphoid stroma derived from hamartomatous inverted polyp with osteoclast-like giant cells: a case report."},"authors":{"en":[{"name":"Yamashita Shoko"},{"name":"Nishi Masaaki"},{"name":"Yoshikawa Kozo"},{"name":"Nakao Toshihiro"},{"name":"Tokunaga Takuya"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Wada Yuma"},{"name":"Yoshimoto Toshiaki"},{"name":"Iwakawa Yosuke"},{"name":"Oya Takeshi"},{"name":"Tsuneyama Koichi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"山下 祥子"},{"name":"西 正暁"},{"name":"Yoshikawa Kozo"},{"name":"Nakao Toshihiro"},{"name":"徳永 卓哉"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"Wada Yuma"},{"name":"良元 俊昭"},{"name":"Iwakawa Yosuke"},{"name":"尾矢 剛志"},{"name":"常山 幸一"},{"name":"島田 光生"}]},"description":{"en":"Gastric carcinomas with lymphoid stroma (GCLS) are characterized by prominent stromal infiltration of lymphocyte and account for 1-4% of gastric cancers. Although, osteoclast-like giant cells (OGC) have been reported in some GCLS, OGCs in gastric tumors is exceedingly rare. A 60-year-old woman presented to our hospital after the finding of a positive fecal blood test during a routine medical check. Esophagogastroduodenoscopy revealed a Type 0-III + IIc tumor in the middle part of the gastric body. Biopsy revealed a poorly differentiated tumor and she was referred to our department. Early phase computed tomography showed thickening of the wall in the middle of the gastric body and enlargement of nearby lymph nodes. Laparoscopic total gastrectomy was performed. Pathological examination revealed a hamartomatous inverted polyp (HIP) in the submucosal layer with tub2-por1 tumor in the HIP. Prominent lymphocytic infiltration and OGCs were found around the tumor. Immunohistochemical analysis showed that the tumor cells were negative for EBER, MLH-1, and MSH2, 6. These findings suggest that this tumor was a non-microsatellite instability (MSI)-high GCLS without Epstein-Barr virus (EBV) infection. The patient's postoperative course was uneventful and she was discharged 11 days after surgery. She remains well 3 years after surgery.","ja":"Gastric carcinomas with lymphoid stroma (GCLS) are characterized by prominent stromal infiltration of lymphocyte and account for 1-4% of gastric cancers. Although, osteoclast-like giant cells (OGC) have been reported in some GCLS, OGCs in gastric tumors is exceedingly rare. A 60-year-old woman presented to our hospital after the finding of a positive fecal blood test during a routine medical check. Esophagogastroduodenoscopy revealed a Type 0-III + IIc tumor in the middle part of the gastric body. Biopsy revealed a poorly differentiated tumor and she was referred to our department. Early phase computed tomography showed thickening of the wall in the middle of the gastric body and enlargement of nearby lymph nodes. Laparoscopic total gastrectomy was performed. Pathological examination revealed a hamartomatous inverted polyp (HIP) in the submucosal layer with tub2-por1 tumor in the HIP. Prominent lymphocytic infiltration and OGCs were found around the tumor. Immunohistochemical analysis showed that the tumor cells were negative for EBER, MLH-1, and MSH2, 6. These findings suggest that this tumor was a non-microsatellite instability (MSI)-high GCLS without Epstein-Barr virus (EBV) infection. The patient's postoperative course was uneventful and she was discharged 11 days after surgery. She remains well 3 years after surgery."},"publication_date":"2022-04-06","publication_name":{"en":"International Cancer Conference Journal","ja":"International Cancer Conference Journal"},"volume":"11","number":"3","starting_page":"196","ending_page":"200","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s13691-022-00547-w"],"issn":["2192-3183"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2010111","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35261944","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387245","label":"url"}],"paper_title":{"en":"Essential updates 2020/2021: Current topics of simulation and navigation in hepatectomy.","ja":"Essential updates 2020/2021: Current topics of simulation and navigation in hepatectomy."},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Shimada Mitsuo"},{"name":"Morine Yuji"},{"name":"Yamada Shin-ichiro"},{"name":"Sugimoto Maki"}],"ja":[{"name":"齋藤 裕"},{"name":"島田 光生"},{"name":"森根 裕二"},{"name":"山田 眞一郎"},{"name":"Sugimoto Maki"}]},"description":{"en":"With the development of three-dimensional (3D) simulation software, preoperative simulation technology is almost completely established. The remaining issue is how to recognize anatomy three-dimensionally. Extended reality is a newly developed technology with several merits for surgical application: no requirement for a sterilized display monitor, better spatial awareness, and the ability to share 3D images among all surgeons. Various technology or devices for intraoperative navigation have also been developed to support the safety and certainty of liver surgery. Consensus recommendations regarding indocyanine green fluorescence were determined in 2021. Extended reality has also been applied to intraoperative navigation, and artificial intelligence (AI) is one of the topics of real-time navigation. AI might overcome the problem of liver deformity with automatic registration. Including the issues described above, this article focuses on recent advances in simulation and navigation in liver surgery from 2020 to 2021.","ja":"With the development of three-dimensional (3D) simulation software, preoperative simulation technology is almost completely established. The remaining issue is how to recognize anatomy three-dimensionally. Extended reality is a newly developed technology with several merits for surgical application: no requirement for a sterilized display monitor, better spatial awareness, and the ability to share 3D images among all surgeons. Various technology or devices for intraoperative navigation have also been developed to support the safety and certainty of liver surgery. Consensus recommendations regarding indocyanine green fluorescence were determined in 2021. Extended reality has also been applied to intraoperative navigation, and artificial intelligence (AI) is one of the topics of real-time navigation. AI might overcome the problem of liver deformity with automatic registration. Including the issues described above, this article focuses on recent advances in simulation and navigation in liver surgery from 2020 to 2021."},"publication_date":"2021-12-23","publication_name":{"en":"Annals of Gastroenterological Surgery","ja":"Annals of Gastroenterological Surgery"},"volume":"6","number":"2","starting_page":"190","ending_page":"196","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/ags3.12542"],"issn":["2475-0328"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31599805","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=367228","label":"url"}],"paper_title":{"en":"Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.","ja":"Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors."},"authors":{"en":[{"name":"Uemura Jun"},{"name":"Okano Keiichi"},{"name":"Oshima Minoru"},{"name":"Suto Hironobu"},{"name":"Ando Yasuhisa"},{"name":"Kumamoto Kensuke"},{"name":"Kadota Kyuichi"},{"name":"Ichihara Shuji"},{"name":"Kokudo Yasutaka"},{"name":"Maeba Takashi"},{"name":"Nanno Yoshihide"},{"name":"Toyama Hirochika"},{"name":"Takada Yasutsugu"},{"name":"Shimada Mitsuo"},{"name":"Hanazaki Kazuhiro"},{"name":"Masaki Tsutomu"},{"name":"Suzuki Yasuyuki"}],"ja":[{"name":"Uemura Jun"},{"name":"Okano Keiichi"},{"name":"Oshima Minoru"},{"name":"Suto Hironobu"},{"name":"Ando Yasuhisa"},{"name":"Kumamoto Kensuke"},{"name":"Kadota Kyuichi"},{"name":"Ichihara Shuji"},{"name":"Kokudo Yasutaka"},{"name":"Maeba Takashi"},{"name":"Nanno Yoshihide"},{"name":"Toyama Hirochika"},{"name":"Takada Yasutsugu"},{"name":"島田 光生"},{"name":"Hanazaki Kazuhiro"},{"name":"Masaki Tsutomu"},{"name":"Suzuki Yasuyuki"}]},"description":{"en":"The goal of this retrospective study was to clarify the clinical implications of immunohistochemically detected protein expression for genes that are frequently mutated in pancreatic neuroendocrine tumors (PNETs). The clinical management of PNETs is hindered by their heterogenous biological behavior. Whole-exome sequencing recently showed that 5 genes (DAXX/ATRX, MEN1, TSC2, and PTEN) are frequently mutated in PNETs. However, the clinical implications of the associated alterations in protein expression remain unclear. We collected Grade 1 and 2 (World Health Organization 2017 Classification) primary PNETs samples from 100 patients who underwent surgical resection. ATRX, DAXX, MEN1, TSC2, and PTEN expression were determined immunohistochemically to clarify their relationships with prognosis and clinicopathological findings. Kaplan-Meier analysis indicated that loss of TSC2 (n = 58) or PTEN (n = 37) was associated with significantly shorter overall survival, and that loss of TSC2 or ATRX (n = 41) was associated with significantly shorter recurrence-free survival. Additionally, loss of ATRX or TSC2 was significantly associated with nodal metastasis. In a multivariate analysis, combined loss of TSC2 and ATRX (n = 31) was an independent prognostic factor for shorter recurrence-free survival (hazard ratio 10.1, 95% confidence interval 2.1-66.9, P = 0.003) in G2 PNETs. Loss of ATRX, TSC2, and PTEN expression might be useful as a method of clarifying the behavior and clinical outcomes of Grade 1 and 2 PNETs in routine clinical practice. Combined loss of TSC2 and ATRX had an especially strong, independent association with shorter recurrence-free survival in patients with G2 PNETs. Loss of pairs in ATRX, TSC2, or PTEN would be useful for selecting the candidate for postoperative adjuvant therapy.","ja":"The goal of this retrospective study was to clarify the clinical implications of immunohistochemically detected protein expression for genes that are frequently mutated in pancreatic neuroendocrine tumors (PNETs). The clinical management of PNETs is hindered by their heterogenous biological behavior. Whole-exome sequencing recently showed that 5 genes (DAXX/ATRX, MEN1, TSC2, and PTEN) are frequently mutated in PNETs. However, the clinical implications of the associated alterations in protein expression remain unclear. We collected Grade 1 and 2 (World Health Organization 2017 Classification) primary PNETs samples from 100 patients who underwent surgical resection. ATRX, DAXX, MEN1, TSC2, and PTEN expression were determined immunohistochemically to clarify their relationships with prognosis and clinicopathological findings. Kaplan-Meier analysis indicated that loss of TSC2 (n = 58) or PTEN (n = 37) was associated with significantly shorter overall survival, and that loss of TSC2 or ATRX (n = 41) was associated with significantly shorter recurrence-free survival. Additionally, loss of ATRX or TSC2 was significantly associated with nodal metastasis. In a multivariate analysis, combined loss of TSC2 and ATRX (n = 31) was an independent prognostic factor for shorter recurrence-free survival (hazard ratio 10.1, 95% confidence interval 2.1-66.9, P = 0.003) in G2 PNETs. Loss of ATRX, TSC2, and PTEN expression might be useful as a method of clarifying the behavior and clinical outcomes of Grade 1 and 2 PNETs in routine clinical practice. Combined loss of TSC2 and ATRX had an especially strong, independent association with shorter recurrence-free survival in patients with G2 PNETs. Loss of pairs in ATRX, TSC2, or PTEN would be useful for selecting the candidate for postoperative adjuvant therapy."},"publication_date":"2021-12-09","publication_name":{"en":"Annals of Surgery","ja":"Annals of Surgery"},"volume":"274","number":"6","starting_page":"e949","ending_page":"e956","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1097/SLA.0000000000003624"],"issn":["1528-1140"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34596803","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386678","label":"url"}],"paper_title":{"en":"Stromal tumor-infiltrating lymphocytes level as a prognostic factor for resected intrahepatic cholangiocarcinoma and its prediction by apparent diffusion coefficient.","ja":"Stromal tumor-infiltrating lymphocytes level as a prognostic factor for resected intrahepatic cholangiocarcinoma and its prediction by apparent diffusion coefficient."},"authors":{"en":[{"name":"Miyazaki Katsuki"},{"name":"Morine Yuji"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Tokuda Kazunori"},{"name":"Okikawa Shohei"},{"name":"Yamashita Shoko"},{"name":"Oya Takeshi"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Hu Haun"},{"name":"Morioka Hisayoshi"},{"name":"Tsuneyama Koichi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"宮崎 克己"},{"name":"森根 裕二"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"徳田 和憲"},{"name":"沖川 昌平"},{"name":"山下 祥子"},{"name":"尾矢 剛志"},{"name":"池本 哲也"},{"name":"居村 暁"},{"name":"Hu Haun"},{"name":"森岡 久尚"},{"name":"常山 幸一"},{"name":"島田 光生"}]},"description":{"en":"Tumor-infiltrating lymphocytes (TILs) are a prognostic factor or an indicator of chemotherapy response for various malignancies. The aim of this study was to investigate the prognostic impact of TILs in resected intrahepatic cholangiocarcinoma (IHCC). We also investigated the usefulness of the apparent diffusion coefficient (ADC) in diffusion-weighted magnetic resonance imaging (DW-MRI) to predict TILs. We enrolled 23 patients with IHCC who underwent initial hepatic resection in Tokushima University Hospital from 2006 to 2017. We evaluated stromal TILs in the tumor marginal area and central area in surgical specimens. Patients were divided into low vs high stromal TILs groups. We analyzed the patients' clinicopathological factors, including prognosis, according to the degree of stromal TILs. We also analyzed the correlation between stromal TILs and the minimum ADC value. Stromal TILs in the marginal area reflected overall survival more accurately than that in the central area. Additionally, marginal low TILs was significantly associated with lymph node metastasis and portal vein invasion. Both overall- and disease-free survival rates in the marginal low TILs group were significantly worse than those in the marginal high TILs group (P < 0.05). In the multivariate analysis, marginal low TILs were an independent prognostic factor for both overall- and disease-free survival (P < 0.05), and marginal low TILs were significantly associated with lower minimum ADC values (P < 0.02). Stromal TILs, especially in the marginal area, might demonstrate prognostic impact in patients with IHCC. Moreover, the ADC values from MRI may predict TILs in IHCC tumor tissue.","ja":"Tumor-infiltrating lymphocytes (TILs) are a prognostic factor or an indicator of chemotherapy response for various malignancies. The aim of this study was to investigate the prognostic impact of TILs in resected intrahepatic cholangiocarcinoma (IHCC). We also investigated the usefulness of the apparent diffusion coefficient (ADC) in diffusion-weighted magnetic resonance imaging (DW-MRI) to predict TILs. We enrolled 23 patients with IHCC who underwent initial hepatic resection in Tokushima University Hospital from 2006 to 2017. We evaluated stromal TILs in the tumor marginal area and central area in surgical specimens. Patients were divided into low vs high stromal TILs groups. We analyzed the patients' clinicopathological factors, including prognosis, according to the degree of stromal TILs. We also analyzed the correlation between stromal TILs and the minimum ADC value. Stromal TILs in the marginal area reflected overall survival more accurately than that in the central area. Additionally, marginal low TILs was significantly associated with lymph node metastasis and portal vein invasion. Both overall- and disease-free survival rates in the marginal low TILs group were significantly worse than those in the marginal high TILs group (P < 0.05). In the multivariate analysis, marginal low TILs were an independent prognostic factor for both overall- and disease-free survival (P < 0.05), and marginal low TILs were significantly associated with lower minimum ADC values (P < 0.02). Stromal TILs, especially in the marginal area, might demonstrate prognostic impact in patients with IHCC. Moreover, the ADC values from MRI may predict TILs in IHCC tumor tissue."},"publication_date":"2021-10-01","publication_name":{"en":"International Journal of Clinical Oncology","ja":"International Journal of Clinical Oncology"},"volume":"26","number":"12","starting_page":"2265","ending_page":"2274","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10147-021-02026-3"],"issn":["1437-7772"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34318615","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387244","label":"url"}],"paper_title":{"en":"Effective three-dimensional culture of hepatocyte-like cells generated from human adipose-derived mesenchymal stem cells.","ja":"Effective three-dimensional culture of hepatocyte-like cells generated from human adipose-derived mesenchymal stem cells."},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Ikemoto Tetsuya"},{"name":"Tokuda Kazunori"},{"name":"Miyazaki Katsuki"},{"name":"Yamada Shin-ichiro"},{"name":"Imura Satoru"},{"name":"Miyake Masato"},{"name":"Morine Yuji"},{"name":"Oyadomari Seiichi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"池本 哲也"},{"name":"徳田 和憲"},{"name":"宮崎 克己"},{"name":"山田 眞一郎"},{"name":"居村 暁"},{"name":"三宅 雅人"},{"name":"森根 裕二"},{"name":"親泊 政一"},{"name":"島田 光生"}]},"description":{"en":"The aim of this study was to clarify the effectiveness of a new three-dimensional (3D) culture system for hepatocyte-like cells (HLCs) generated from human adipose-derived mesenchymal stem cells (ADSCs). Human ADSCs (2 × 10 ) with or without 0.1 mg/mL human recombinant peptide μ-piece per well were seeded in a 96-well U-bottom plate and then our three-step differentiation protocol was applied for 21 days. At each step, cell morphology and gene expression were investigated. Mature hepatocyte functions were evaluated after HLC differentiation. These parameters were compared between 2D- and 3D-cultured HLCs, and, DNA microarray analysis was also performed. Finally, HLCs were transplanted in to CCl induced acute liver failure model mice. Two-dimensional-cultured HLCs at day 21 did not have a spindle shape and had formed spheroids after day 6, which gradually increased in size for 3D-cultured HLCs. Definitive endoderm, hepatoblast, and hepatocyte genes showed significantly higher expression in the 3D culture group. Three-dimensional-cultured HLCs also had higher albumin expression, CYP3A4 activity, urea synthesis, and ammonium metabolism, and much higher expression of ion transporter, blood coagulation, and cell communication genes. HLC transplantation improved serum liver function, especially in T-Bil levels, and engrafted into immunodeficient mice with HLA class I positive staining. Our new 3D culture protocol is effective to improve hepatocyte functions. Our HLCs might be promising for clinical cell transplantation to treat metabolic disease.","ja":"The aim of this study was to clarify the effectiveness of a new three-dimensional (3D) culture system for hepatocyte-like cells (HLCs) generated from human adipose-derived mesenchymal stem cells (ADSCs). Human ADSCs (2 × 10 ) with or without 0.1 mg/mL human recombinant peptide μ-piece per well were seeded in a 96-well U-bottom plate and then our three-step differentiation protocol was applied for 21 days. At each step, cell morphology and gene expression were investigated. Mature hepatocyte functions were evaluated after HLC differentiation. These parameters were compared between 2D- and 3D-cultured HLCs, and, DNA microarray analysis was also performed. Finally, HLCs were transplanted in to CCl induced acute liver failure model mice. Two-dimensional-cultured HLCs at day 21 did not have a spindle shape and had formed spheroids after day 6, which gradually increased in size for 3D-cultured HLCs. Definitive endoderm, hepatoblast, and hepatocyte genes showed significantly higher expression in the 3D culture group. Three-dimensional-cultured HLCs also had higher albumin expression, CYP3A4 activity, urea synthesis, and ammonium metabolism, and much higher expression of ion transporter, blood coagulation, and cell communication genes. HLC transplantation improved serum liver function, especially in T-Bil levels, and engrafted into immunodeficient mice with HLA class I positive staining. Our new 3D culture protocol is effective to improve hepatocyte functions. Our HLCs might be promising for clinical cell transplantation to treat metabolic disease."},"publication_date":"2021-07-28","publication_name":{"en":"Journal of Hepato-Biliary-Pancreatic Sciences","ja":"Journal of Hepato-Biliary-Pancreatic Sciences"},"volume":"28","number":"9","starting_page":"705","ending_page":"715","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/jhbp.1024"],"issn":["1868-6982"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2010178","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34239808","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387246","label":"url"}],"paper_title":{"en":"Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.","ja":"Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update."},"authors":{"en":[{"name":"Kudo Masatoshi"},{"name":"Kawamura Yusuke"},{"name":"Hasegawa Kiyoshi"},{"name":"Tateishi Ryosuke"},{"name":"Kariyama Kazuya"},{"name":"Shiina Shuichiro"},{"name":"Toyoda Hidenori"},{"name":"Imai Yasuharu"},{"name":"Hiraoka Atsushi"},{"name":"Ikeda Masafumi"},{"name":"Izumi Namiki"},{"name":"Moriguchi Michihisa"},{"name":"Ogasawara Sadahisa"},{"name":"Minami Yasunori"},{"name":"Ueshima Kazuomi"},{"name":"Murakami Takamichi"},{"name":"Miyayama Shiro"},{"name":"Nakashima Osamu"},{"name":"Yano Hirohisa"},{"name":"Sakamoto Michiie"},{"name":"Hatano Etsuro"},{"name":"Shimada Mitsuo"},{"name":"Kokudo Norihiro"},{"name":"Mochida Satoshi"},{"name":"Takehara Tetsuo"}],"ja":[{"name":"Kudo Masatoshi"},{"name":"Kawamura Yusuke"},{"name":"Hasegawa Kiyoshi"},{"name":"Tateishi Ryosuke"},{"name":"Kariyama Kazuya"},{"name":"Shiina Shuichiro"},{"name":"Toyoda Hidenori"},{"name":"Imai Yasuharu"},{"name":"Hiraoka Atsushi"},{"name":"Ikeda Masafumi"},{"name":"Izumi Namiki"},{"name":"Moriguchi Michihisa"},{"name":"Ogasawara Sadahisa"},{"name":"Minami Yasunori"},{"name":"Ueshima Kazuomi"},{"name":"Murakami Takamichi"},{"name":"Miyayama Shiro"},{"name":"Nakashima Osamu"},{"name":"Yano Hirohisa"},{"name":"Sakamoto Michiie"},{"name":"Hatano Etsuro"},{"name":"島田 光生"},{"name":"Kokudo Norihiro"},{"name":"Mochida Satoshi"},{"name":"Takehara Tetsuo"}]},"description":{"en":"The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.","ja":"The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC."},"publication_date":"2021-05-19","publication_name":{"en":"Liver Cancer","ja":"Liver Cancer"},"volume":"10","number":"3","starting_page":"181","ending_page":"223","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1159/000514174"],"issn":["2235-1795"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2009864","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33962620","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=384223","label":"url"}],"paper_title":{"en":"A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2.","ja":"A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2."},"authors":{"en":[{"name":"Yamashita Shoko"},{"name":"Morine Yuji"},{"name":"Imura Satoru"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Takasu Chie"},{"name":"Yamada Shinichiro"},{"name":"Tokuda Kazunori"},{"name":"Okikawa Shohei"},{"name":"Miyazaki Katsuki"},{"name":"Oya Takeshi"},{"name":"Tsuneyama Koichi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"山下 祥子"},{"name":"森根 裕二"},{"name":"居村 暁"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"髙須 千絵"},{"name":"Yamada Shinichiro"},{"name":"徳田 和憲"},{"name":"沖川 昌平"},{"name":"宮崎 克己"},{"name":"尾矢 剛志"},{"name":"常山 幸一"},{"name":"島田 光生"}]},"description":{"en":"This method could be used to classify IHCC into peripheral and perihilar type by embryological expression patterns of SSTR2 and Bcl2.","ja":"This method could be used to classify IHCC into peripheral and perihilar type by embryological expression patterns of SSTR2 and Bcl2."},"publication_date":"2021-05-07","publication_name":{"en":"World Journal of Surgical Oncology","ja":"World Journal of Surgical Oncology"},"volume":"19","number":"1","starting_page":"142","ending_page":"142","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12957-021-02216-3"],"issn":["1477-7819"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2009437","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34759156","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=387243","label":"url"}],"paper_title":{"en":"Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer.","ja":"Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer."},"authors":{"en":[{"name":"Arakawa Yusuke"},{"name":"Miyazaki Katsuki"},{"name":"Yoshikawa Masato"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"荒川 悠佑"},{"name":"宮崎 克己"},{"name":"吉川 雅登"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"池本 哲也"},{"name":"居村 暁"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"Background : Several prognostic factors were reported in pancreatic cancer. The fibrinogen-platelet ratio (FPR) was reported as a prognostic factor of resectable gastric cancer. In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods : Between 2004 and 2019, 163 patients with curative resection for pancreatic cancer were enrolled. Cases of non-curative resection were excluded. The FPR was calculated using the preoperative plasma fibrinogen and the platelet counts and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. The patients were divided into high and low FPR groups according to this cut-off value. Results : The cut-off value of FPR was 25.2. Among age, sex, body mass index (BMI), and surgical factors including surgery type, volume of blood loss and surgery time, there was no significant difference between the two groups. Patients in the low FPR group had significantly better overall survival (OS) and relapse-free survival (RFS) compared with the high FPR group (P < 0.05). On multivariate analysis, a high FPR, CA19-9 > 300 U /l, and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. Conclusions : The FPR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 342-346, August, 2021.","ja":"Background : Several prognostic factors were reported in pancreatic cancer. The fibrinogen-platelet ratio (FPR) was reported as a prognostic factor of resectable gastric cancer. In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods : Between 2004 and 2019, 163 patients with curative resection for pancreatic cancer were enrolled. Cases of non-curative resection were excluded. The FPR was calculated using the preoperative plasma fibrinogen and the platelet counts and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. The patients were divided into high and low FPR groups according to this cut-off value. Results : The cut-off value of FPR was 25.2. Among age, sex, body mass index (BMI), and surgical factors including surgery type, volume of blood loss and surgery time, there was no significant difference between the two groups. Patients in the low FPR group had significantly better overall survival (OS) and relapse-free survival (RFS) compared with the high FPR group (P < 0.05). On multivariate analysis, a high FPR, CA19-9 > 300 U /l, and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. Conclusions : The FPR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 342-346, August, 2021."},"publication_date":"2021","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"68","number":"3.4","starting_page":"342","ending_page":"346","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.68.342"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31177123","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353150","label":"url"}],"paper_title":{"en":"The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer.","ja":"The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer."},"authors":{"en":[{"name":"Ishikawa Daichi"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Nishi Masaaki"},{"name":"Tokunaga Takuya"},{"name":"Higashijima Jun"},{"name":"Yoshikawa Kouzou"},{"name":"Yasutomo Koji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"石川 大地"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"西 正暁"},{"name":"徳永 卓哉"},{"name":"東島 潤"},{"name":"吉川 幸造"},{"name":"安友 康二"},{"name":"島田 光生"}]},"description":{"en":"miR-449a level might be a prognostic indicator for colorectal cancer and miR-449a might regulate HDAC1 expression.","ja":"miR-449a level might be a prognostic indicator for colorectal cancer and miR-449a might regulate HDAC1 expression."},"publication_date":"2019-06","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"39","number":"6","starting_page":"2855","ending_page":"2860","languages":["eng"],"referee":true,"identifiers":{"doi":["10.21873/anticanres.13414"],"issn":["1791-7530"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2011411","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30842364","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85067126364","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352296","label":"url"}],"paper_title":{"en":"Development of monoclonal mouse antibodies that specifically recognize pancreatic polypeptide.","ja":"Development of monoclonal mouse antibodies that specifically recognize pancreatic polypeptide."},"authors":{"en":[{"name":"Hara Akemi"},{"name":"Nakagawa Yuko"},{"name":"Nakao Keiko"},{"name":"Tamaki Motoyuki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"},{"name":"Matsuhisa Munehide"},{"name":"Mizukami Hiroki"},{"name":"Maruyama Nobuhiro"},{"name":"Watada Hirotaka"},{"name":"Fujitani Yoshio"}],"ja":[{"name":"Hara Akemi"},{"name":"Nakagawa Yuko"},{"name":"Nakao Keiko"},{"name":"田蒔 基行"},{"name":"池本 哲也"},{"name":"島田 光生"},{"name":"松久 宗英"},{"name":"Mizukami Hiroki"},{"name":"Maruyama Nobuhiro"},{"name":"Watada Hirotaka"},{"name":"Fujitani Yoshio"}]},"description":{"en":"Pancreatic polypeptide (PP) is a 36-amino acid peptide encoded by the Ppy gene, which is produced by a small population of cells located in the periphery of the islets of Langerhans. Owing to the high amino acid sequence similarity among neuropeptide Y family members, antibodies against PP that are currently available are not convincingly specific to PP. Here we report the development of mouse monoclonal antibodies that specifically bind to PP. We generated Ppy knockout (Ppy-KO) mice in which the Ppy-coding region was replaced by Cre recombinase. The Ppy-KO mice were immunized with mouse PP peptide, and stable hybridoma cell lines producing anti-PP antibodies were isolated. Firstly, positive clones were selected in an enzyme-linked immunosorbent assay for reactivity with PP coupled to bovine serum albumin. During the screening, hybridoma clones producing antibodies that cross-react to the peptide YY (PYY) were excluded. In the second screening, hybridoma clones in which their culture media produce no signal in Ppy-KO islets but detect specific cells in the peripheral region of wild-type islets, were selected. Further studies demonstrated that the selected monoclonal antibody (23-2D3) specifically recognizes PP-producing cells, not only in mouse, but also in human and rat islets. The monoclonal antibodies with high binding specificity for PP developed in this study will be fundamental for future studies towards elucidating the expression profiles and the physiological roles of PP.","ja":"Pancreatic polypeptide (PP) is a 36-amino acid peptide encoded by the Ppy gene, which is produced by a small population of cells located in the periphery of the islets of Langerhans. Owing to the high amino acid sequence similarity among neuropeptide Y family members, antibodies against PP that are currently available are not convincingly specific to PP. Here we report the development of mouse monoclonal antibodies that specifically bind to PP. We generated Ppy knockout (Ppy-KO) mice in which the Ppy-coding region was replaced by Cre recombinase. The Ppy-KO mice were immunized with mouse PP peptide, and stable hybridoma cell lines producing anti-PP antibodies were isolated. Firstly, positive clones were selected in an enzyme-linked immunosorbent assay for reactivity with PP coupled to bovine serum albumin. During the screening, hybridoma clones producing antibodies that cross-react to the peptide YY (PYY) were excluded. In the second screening, hybridoma clones in which their culture media produce no signal in Ppy-KO islets but detect specific cells in the peripheral region of wild-type islets, were selected. Further studies demonstrated that the selected monoclonal antibody (23-2D3) specifically recognizes PP-producing cells, not only in mouse, but also in human and rat islets. The monoclonal antibodies with high binding specificity for PP developed in this study will be fundamental for future studies towards elucidating the expression profiles and the physiological roles of PP."},"publication_date":"2019-03-06","publication_name":{"en":"Endocrine Journal","ja":"Endocrine Journal"},"volume":"66","number":"5","starting_page":"459","ending_page":"468","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1507/endocrj.EJ18-0441"],"issn":["1348-4540"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2006436","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30396944","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85056084372","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351467","label":"url"}],"paper_title":{"en":"Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy.","ja":"Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy."},"authors":{"en":[{"name":"Enkhbat Tumenjin"},{"name":"Nishi Masaaki"},{"name":"Yoshikawa Kouzou"},{"name":"Higashijima Jun"},{"name":"Tokunaga Takuya"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Ishikawa Daichi"},{"name":"Tominaga Masahide"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Tumenjin Enkhbat"},{"name":"西 正暁"},{"name":"吉川 幸造"},{"name":"東島 潤"},{"name":"徳永 卓哉"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"石川 大地"},{"name":"富永 正英"},{"name":"島田 光生"}]},"description":{"en":"Epigallocatechin-3-gallate (EGCG) is a major polyphenolic component of green tea. EGCG plays a potential role in radio-sensitizing cancer cells. The combined effect of EGCG and radiation was investigated in a colorectal cancer cell line, focusing on nuclear factor (erythroid-derived 2)-like 2 (Nrf2) autophagy signalling. HCT-116 cells were treated with 12.5 μM EGCG for different periods of time, 2 Gy radiation, or both. Cell viability was determined with the WST-8 assay. The number of colonies was determined with the colony formation assay. mRNA expression of LC3 and caspase-9 was analyzed with quantitative real-time polymerase chain reaction. Combination treatment with EGCG and radiation significantly decreased the growth of HCT-116 cells. The number of colonies was reduced to 34.2% compared to the control group. Immunofluorescence microscopy images showed that nuclear translocation of Nrf2 was significantly increased when cells were treated with the combination of EGCG and radiation compared to the control and single-treatment groups. Combined treatment with EGCG and radiation significantly induced LC3 and caspase-9 mRNA expression. EGCG increased the sensitivity of colorectal cancer cells to radiation by inhibiting cell proliferation and inducing Nrf2 nuclear translocation and autophagy.","ja":"Epigallocatechin-3-gallate (EGCG) is a major polyphenolic component of green tea. EGCG plays a potential role in radio-sensitizing cancer cells. The combined effect of EGCG and radiation was investigated in a colorectal cancer cell line, focusing on nuclear factor (erythroid-derived 2)-like 2 (Nrf2) autophagy signalling. HCT-116 cells were treated with 12.5 μM EGCG for different periods of time, 2 Gy radiation, or both. Cell viability was determined with the WST-8 assay. The number of colonies was determined with the colony formation assay. mRNA expression of LC3 and caspase-9 was analyzed with quantitative real-time polymerase chain reaction. Combination treatment with EGCG and radiation significantly decreased the growth of HCT-116 cells. The number of colonies was reduced to 34.2% compared to the control group. Immunofluorescence microscopy images showed that nuclear translocation of Nrf2 was significantly increased when cells were treated with the combination of EGCG and radiation compared to the control and single-treatment groups. Combined treatment with EGCG and radiation significantly induced LC3 and caspase-9 mRNA expression. EGCG increased the sensitivity of colorectal cancer cells to radiation by inhibiting cell proliferation and inducing Nrf2 nuclear translocation and autophagy."},"publication_date":"2018-11","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"38","number":"11","starting_page":"6247","ending_page":"6252","languages":["eng"],"referee":true,"identifiers":{"doi":["10.21873/anticanres.12980"],"issn":["1791-7530"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2007486","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30180849","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85053152003","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351465","label":"url"}],"paper_title":{"en":"Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction","ja":"Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction"},"authors":{"en":[{"name":"Feng Rui"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Iwahashi Shuichi"},{"name":"Saitou Yu"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"馮 睿"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"居村 暁"},{"name":"岩橋 衆一"},{"name":"齋藤 裕"},{"name":"島田 光生"}]},"description":{"en":"The M2 phenotype of tumor-associated macrophages (TAM) inhibits the anti-tumor inflammation, increases angiogenesis and promotes tumor progression. The transcription factor Nuclear Factor (erythroid-derived 2)-Like 2 (Nrf2) not only modulates the angiogenesis but also plays the anti-inflammatory role through inhibiting pro-inflammatory cytokines expression; however, the role of Nrf2 in the cancer cell and macrophages interaction is not clear. Hepatocellular carcinoma cells (Hep G2 and Huh 7) and pancreatic cancer cells (SUIT2 and Panc-1) were co-cultured with monocytes cells (THP-1) or peripheral blood monocytes derived macrophages, then the phenotype changes of macrophages and epithelial-mesenchymal transition of cancer cells were detected. Also, the role of Nrf2 in cancer cells and macrophages interaction were investigated. In this study, we found that cancer cells could induce an M2-like macrophage characterized by up-regulation of CD163 and Arg1, and down-regulation of IL-1b and IL-6 through Nrf2 activation. Also, Nrf2 activation of macrophages promoted VEGF expression. The Nrf2 activation of macrophages correlated with the reactive oxygen species induced by cancer cells derived lactate. Cancer cells educated macrophages could activate Nrf2 of the cancer cells, in turn, to increase cancer cells epithelial-mesenchymal transition (EMT) through paracrine VEGF. These findings suggested that Nrf2 played the important role in the cancer cells and macrophages interaction. Macrophage Nrf2 activation by cancer cell-derived lactate skews macrophages polarization towards an M2-like phenotype and educated macrophages activate Nrf2 of the cancer cells to promote EMT of cancer cells. This study provides a new understanding of the role of Nrf2 in the cancer cell and TAM interaction and suggests a potential therapeutic target.","ja":"The M2 phenotype of tumor-associated macrophages (TAM) inhibits the anti-tumor inflammation, increases angiogenesis and promotes tumor progression. The transcription factor Nuclear Factor (erythroid-derived 2)-Like 2 (Nrf2) not only modulates the angiogenesis but also plays the anti-inflammatory role through inhibiting pro-inflammatory cytokines expression; however, the role of Nrf2 in the cancer cell and macrophages interaction is not clear. Hepatocellular carcinoma cells (Hep G2 and Huh 7) and pancreatic cancer cells (SUIT2 and Panc-1) were co-cultured with monocytes cells (THP-1) or peripheral blood monocytes derived macrophages, then the phenotype changes of macrophages and epithelial-mesenchymal transition of cancer cells were detected. Also, the role of Nrf2 in cancer cells and macrophages interaction were investigated. In this study, we found that cancer cells could induce an M2-like macrophage characterized by up-regulation of CD163 and Arg1, and down-regulation of IL-1b and IL-6 through Nrf2 activation. Also, Nrf2 activation of macrophages promoted VEGF expression. The Nrf2 activation of macrophages correlated with the reactive oxygen species induced by cancer cells derived lactate. Cancer cells educated macrophages could activate Nrf2 of the cancer cells, in turn, to increase cancer cells epithelial-mesenchymal transition (EMT) through paracrine VEGF. These findings suggested that Nrf2 played the important role in the cancer cells and macrophages interaction. Macrophage Nrf2 activation by cancer cell-derived lactate skews macrophages polarization towards an M2-like phenotype and educated macrophages activate Nrf2 of the cancer cells to promote EMT of cancer cells. This study provides a new understanding of the role of Nrf2 in the cancer cell and TAM interaction and suggests a potential therapeutic target."},"publication_date":"2018-09-04","publication_name":{"en":"Cell Communication & Signaling","ja":"Cell Communication & Signaling"},"volume":"16","number":"1","starting_page":"54","ending_page":"54","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1186/s12964-018-0262-x"],"issn":["1478-811X"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://cir.nii.ac.jp/crid/1390845702315677568/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353852","label":"url"}],"paper_title":{"en":"肝癌手術エキスパートへの道 (特集 癌手術エキスパートになるための道)","ja":"肝癌手術エキスパートへの道 (特集 癌手術エキスパートになるための道)"},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Imura Satoru"},{"name":"Ikemoto Tetsuya"},{"name":"Morine Yuji"},{"name":"杉本 真樹"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"居村 暁"},{"name":"池本 哲也"},{"name":"森根 裕二"},{"name":"杉本 真樹"},{"name":"島田 光生"}]},"publication_date":"2018-09","publication_name":{"en":"Journal of Clinical Surgery","ja":"臨床外科"},"volume":"73","number":"9","starting_page":"1108","ending_page":"1114","languages":["jpn"],"referee":true,"identifiers":{"issn":["0386-9857"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://ci.nii.ac.jp/naid/40021644777/","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1521980703420258944/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353853","label":"url"}],"paper_title":{"en":"胆道再建を含む肝切除術 (ビギナーズ特集 手術で臓器が「どうなる?」から術後ケアが見える! わかる! イラスト理解 消化器外科の術式・術後ケア)","ja":"胆道再建を含む肝切除術 (ビギナーズ特集 手術で臓器が「どうなる?」から術後ケアが見える! わかる! イラスト理解 消化器外科の術式・術後ケア)"},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Iwahashi Shuichi"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"岩橋 衆一"},{"name":"池本 哲也"},{"name":"居村 暁"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"publication_date":"2018-08","publication_name":{"en":"Gastroenterological Surgery Nursing","ja":"消化器外科Nursing"},"volume":"23","number":"8","starting_page":"709","ending_page":"714","languages":["jpn"],"referee":true,"identifiers":{"issn":["1341-7819"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30061267","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353849","label":"url"}],"paper_title":{"en":"The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period.","ja":"The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period."},"authors":{"en":[{"name":"Kashihara Hideya"},{"name":"Shimada Mitsuo"},{"name":"Yoshikawa Kouzou"},{"name":"Higashijima Jun"},{"name":"Miyatani Tomohiko"},{"name":"Tokunaga Takuya"},{"name":"Nishi Masaaki"},{"name":"Takasu Chie"}],"ja":[{"name":"柏原 秀也"},{"name":"島田 光生"},{"name":"吉川 幸造"},{"name":"東島 潤"},{"name":"宮谷 知彦"},{"name":"徳永 卓哉"},{"name":"西 正暁"},{"name":"髙須 千絵"}]},"description":{"en":"The aim of this study was to investigate the effect of Roux-en-Y (RY) reconstruction on type 2 diabetes with gastric cancer in the early postoperative period. A total of 44 patients with gastric cancer with type 2 diabetes who underwent total gastrectomy (TG) or distal gastrectomy (DG) with Roux-en-Y reconstruction or DG with Bilroth I were enrolled. All three groups had their fasting glucose and daily insulin dose recorded preoperatively, on day 2 postoperatively (POD2) and at discharge. The TG group showed low fasting glucose and daily insulin dose on POD2 compared to their preoperative state. On discharge, the fasting glucose and daily insulin dose were significantly lower in both TG and DG Roux-en-Y groups than preoperatively. Roux-en-Y reconstruction showed early improvement of type 2 diabetes regardless of any body weight loss. The effect of Roux-en-Y reconstruction in TG on type 2 diabetes was more remarkable than that of DG.","ja":"The aim of this study was to investigate the effect of Roux-en-Y (RY) reconstruction on type 2 diabetes with gastric cancer in the early postoperative period. A total of 44 patients with gastric cancer with type 2 diabetes who underwent total gastrectomy (TG) or distal gastrectomy (DG) with Roux-en-Y reconstruction or DG with Bilroth I were enrolled. All three groups had their fasting glucose and daily insulin dose recorded preoperatively, on day 2 postoperatively (POD2) and at discharge. The TG group showed low fasting glucose and daily insulin dose on POD2 compared to their preoperative state. On discharge, the fasting glucose and daily insulin dose were significantly lower in both TG and DG Roux-en-Y groups than preoperatively. Roux-en-Y reconstruction showed early improvement of type 2 diabetes regardless of any body weight loss. The effect of Roux-en-Y reconstruction in TG on type 2 diabetes was more remarkable than that of DG."},"publication_date":"2018-08","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"38","number":"8","starting_page":"4901","ending_page":"4905","languages":["eng"],"referee":true,"identifiers":{"doi":["10.21873/anticanres.12805"],"issn":["1791-7530"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29424768","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353840","label":"url"}],"paper_title":{"en":"Current Status of Surgical Incisions Used in Donors During Living Related Liver Transplantation-A Nationwide Survey in Japan.","ja":"Current Status of Surgical Incisions Used in Donors During Living Related Liver Transplantation-A Nationwide Survey in Japan."},"authors":{"en":[{"name":"Shirabe Ken"},{"name":"Eguchi Susumu"},{"name":"Okajima Hideaki"},{"name":"Hasegawa Kiyoshi"},{"name":"Marubashi Shigeru"},{"name":"Umeshita Koji"},{"name":"Kawasaki Seiji"},{"name":"Yanaga Katsuhiko"},{"name":"Shimada Mitsuo"},{"name":"Kaido Toshimi"},{"name":"Kawagishi Naoki"},{"name":"Taketomi Akinobu"},{"name":"Mizuta Koichi"},{"name":"Kokudo Norihiro"},{"name":"Uemoto Shinji"},{"name":"Maehara Yoshihiko"}],"ja":[{"name":"Shirabe Ken"},{"name":"Eguchi Susumu"},{"name":"Okajima Hideaki"},{"name":"Hasegawa Kiyoshi"},{"name":"Marubashi Shigeru"},{"name":"Umeshita Koji"},{"name":"Kawasaki Seiji"},{"name":"Yanaga Katsuhiko"},{"name":"島田 光生"},{"name":"Kaido Toshimi"},{"name":"Kawagishi Naoki"},{"name":"Taketomi Akinobu"},{"name":"Mizuta Koichi"},{"name":"Kokudo Norihiro"},{"name":"Uemoto Shinji"},{"name":"Maehara Yoshihiko"}]},"description":{"en":"Smaller surgical incisions have recently been introduced in living donor liver procurement. This study used national data from Japan to clarify the present status of surgical incisions in living donor liver procurement. A nationwide, questionnaire-based survey related to 3121 donors and recipients was used. Donors were divided into 2 groups: left lateral segment graft (LLSG) procurement (n = 690) and other types (n = 2431). Incisions were classified into 6 types: type I, upper midline and bilateral subcostal; type II, upper midline and right subcostal; type III, upper midline and right subcostal to the right lateral margin of the abdominal rectus muscle; type IV, upper midline without laparoscopy; type V, upper midline with laparoscopy; and type VI, lower abdominal using the full laparoscopic technique. Types I, II, and III were regarded as standard, and types IV, V, and VI as small incisions. In LLSGs, blood transfusion and postoperative complication rates were significantly less frequent in the small incision group than in the standard group. In other graft types, there were no significant differences in blood transfusion, postoperative complication, and recipients' graft loss rates. The rates of wound extension during surgery were 2.8% and 2.1% in the small incision group in LLSGs and in other graft types, respectively. A small incision was adapted more frequently and postoperative complications were less common in high-volume centers. Various incisions have been adopted in living donor liver procurement. Donor safety and graft integrity appear to have been retained for donors receiving small incisions.","ja":"Smaller surgical incisions have recently been introduced in living donor liver procurement. This study used national data from Japan to clarify the present status of surgical incisions in living donor liver procurement. A nationwide, questionnaire-based survey related to 3121 donors and recipients was used. Donors were divided into 2 groups: left lateral segment graft (LLSG) procurement (n = 690) and other types (n = 2431). Incisions were classified into 6 types: type I, upper midline and bilateral subcostal; type II, upper midline and right subcostal; type III, upper midline and right subcostal to the right lateral margin of the abdominal rectus muscle; type IV, upper midline without laparoscopy; type V, upper midline with laparoscopy; and type VI, lower abdominal using the full laparoscopic technique. Types I, II, and III were regarded as standard, and types IV, V, and VI as small incisions. In LLSGs, blood transfusion and postoperative complication rates were significantly less frequent in the small incision group than in the standard group. In other graft types, there were no significant differences in blood transfusion, postoperative complication, and recipients' graft loss rates. The rates of wound extension during surgery were 2.8% and 2.1% in the small incision group in LLSGs and in other graft types, respectively. A small incision was adapted more frequently and postoperative complications were less common in high-volume centers. Various incisions have been adopted in living donor liver procurement. Donor safety and graft integrity appear to have been retained for donors receiving small incisions."},"publication_date":"2018-08","publication_name":{"en":"Transplantation","ja":"Transplantation"},"volume":"102","number":"8","starting_page":"1293","ending_page":"1299","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1097/TP.0000000000002126"],"issn":["1534-6080"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2006046","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29902349","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85050858344","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351464","label":"url"}],"paper_title":{"en":"Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro.","ja":"Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro."},"authors":{"en":[{"name":"Feng Rui"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Iwahashi Shuichi"},{"name":"Saitou Yu"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"馮 睿"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"居村 暁"},{"name":"岩橋 衆一"},{"name":"齋藤 裕"},{"name":"島田 光生"}]},"description":{"en":"Cancer-associated fibroblasts (CAF), derived from stroma of cancer tissues, interact with cancer cells and play an important role in cancer initiation, growth, and metastasis. Nab-paclitaxel (nab-PTX) is a 130 nm albumin-binding paclitaxel and recommended for many types of cancer chemotherapy. The nab-PTX stromal-disrupting effect during pancreatic cancer treatment has been reported. The aim of the present study was to determine the role of nab-PTX in cancer cells and CAF interaction. Cancer cells (MIA PaCa-2 and Panc-1) were cocultured with CAF or treated with CAF conditioned medium, after which their migration and invasion ability, epithelial-mesenchymal transition (EMT)-related marker expression and C-X-C motif chemokine 10 (CXCL10) expression and secretion were detected. Nab-PTX treatment was carried out during the coculture system or during preparation of CAF conditioned medium. Then cancer cell migration and invasion ability, EMT-related marker expression, CXCL10 expression and secretion, and interleukin-6 (IL-6) expression and secretion by CAF were checked After coculture with CAF, migration and invasion ability of cancer cells increased. CAF also downregulated E-cadherin and upregulated N-cadherin and vimentin expression in cancer cells. During coculture or stimulation with cancer cell-cultured medium, CAF significantly increased IL-6 expression and secretion. However, nab-PTX in the coculture system canceled CAF-induced migration and invasion promotion and EMT-related gene changes. Moreover, nab-PTX increased CXCL10 expression of cancer cells which blocked CAF IL-6 expression and secretion. Nab-PTX treatment could increase CXCL10 expression of cancer cells which blocks CAF cancer cell migration and invasion-promoting effect by inhibiting IL-6 expression.","ja":"Cancer-associated fibroblasts (CAF), derived from stroma of cancer tissues, interact with cancer cells and play an important role in cancer initiation, growth, and metastasis. Nab-paclitaxel (nab-PTX) is a 130 nm albumin-binding paclitaxel and recommended for many types of cancer chemotherapy. The nab-PTX stromal-disrupting effect during pancreatic cancer treatment has been reported. The aim of the present study was to determine the role of nab-PTX in cancer cells and CAF interaction. Cancer cells (MIA PaCa-2 and Panc-1) were cocultured with CAF or treated with CAF conditioned medium, after which their migration and invasion ability, epithelial-mesenchymal transition (EMT)-related marker expression and C-X-C motif chemokine 10 (CXCL10) expression and secretion were detected. Nab-PTX treatment was carried out during the coculture system or during preparation of CAF conditioned medium. Then cancer cell migration and invasion ability, EMT-related marker expression, CXCL10 expression and secretion, and interleukin-6 (IL-6) expression and secretion by CAF were checked After coculture with CAF, migration and invasion ability of cancer cells increased. CAF also downregulated E-cadherin and upregulated N-cadherin and vimentin expression in cancer cells. During coculture or stimulation with cancer cell-cultured medium, CAF significantly increased IL-6 expression and secretion. However, nab-PTX in the coculture system canceled CAF-induced migration and invasion promotion and EMT-related gene changes. Moreover, nab-PTX increased CXCL10 expression of cancer cells which blocked CAF IL-6 expression and secretion. Nab-PTX treatment could increase CXCL10 expression of cancer cells which blocks CAF cancer cell migration and invasion-promoting effect by inhibiting IL-6 expression."},"publication_date":"2018-08","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"109","number":"8","starting_page":"2509","ending_page":"2519","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/cas.13694"],"issn":["1349-7006"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30148230","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85052017722","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353838","label":"url"}],"paper_title":{"en":"A learning curve for laparoscopic liver resection: an effective training system and standardization of technique.","ja":"A learning curve for laparoscopic liver resection: an effective training system and standardization of technique."},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Imura Satoru"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Iwahashi Shuichi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"居村 暁"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"岩橋 衆一"},{"name":"島田 光生"}]},"description":{"en":"The incidence of laparoscopic liver resection (LHx) has been increased in the past decade. There have been some reports about some advantages of LHx, in both short and long-term outcomes after operation. The use of a minor LHx was regarded as a standard surgical practice, and some peri-operative complications hindered worldwide increase of LHx in the Second International Consensus Conference on LHx at Morioka. However, no suggestions were described in terms with how to provide the best teaching and training necessary to shorten the learning curve for inexperienced surgeons using a new surgical technique while continuing to maintain a low rate of morbidity from the very beginning. This study includes a literature review of published research which looked at a learning curve for LHx. As well, it proposes a new step-wise training method for inexperienced surgeons and standardization of a technique for LHx focusing especially on laparoscopic left hepatectomy (LLHx).","ja":"The incidence of laparoscopic liver resection (LHx) has been increased in the past decade. There have been some reports about some advantages of LHx, in both short and long-term outcomes after operation. The use of a minor LHx was regarded as a standard surgical practice, and some peri-operative complications hindered worldwide increase of LHx in the Second International Consensus Conference on LHx at Morioka. However, no suggestions were described in terms with how to provide the best teaching and training necessary to shorten the learning curve for inexperienced surgeons using a new surgical technique while continuing to maintain a low rate of morbidity from the very beginning. This study includes a literature review of published research which looked at a learning curve for LHx. As well, it proposes a new step-wise training method for inexperienced surgeons and standardization of a technique for LHx focusing especially on laparoscopic left hepatectomy (LLHx)."},"publication_date":"2018-07-23","publication_name":{"en":"Translational Gastroenterology and Hepatology","ja":"Translational Gastroenterology and Hepatology"},"volume":"3","starting_page":"45","ending_page":"45","languages":["eng"],"referee":true,"identifiers":{"doi":["10.21037/tgh.2018.07.03"],"issn":["2415-1289"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29278438","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85043330492","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351460","label":"url"}],"paper_title":{"en":"Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas.","ja":"Role of heat shock factor 1 expression in the microenvironment of intrahepatic cholangiocarcinomas."},"authors":{"en":[{"name":"Kawashita Youichiro"},{"name":"Morine Yuji"},{"name":"Saitou Yu"},{"name":"Takasu Chie"},{"name":"Ikemoto Tetsuya"},{"name":"Iwahashi Shuichi"},{"name":"Teraoku Hiroki"},{"name":"Yoshikawa Masato"},{"name":"Imura Satoru"},{"name":"Yagi Toshiyuki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"川下 陽一郎"},{"name":"森根 裕二"},{"name":"齋藤 裕"},{"name":"髙須 千絵"},{"name":"池本 哲也"},{"name":"岩橋 衆一"},{"name":"寺奥 大貴"},{"name":"吉川 雅登"},{"name":"居村 暁"},{"name":"八木 淑之"},{"name":"島田 光生"}]},"description":{"en":"Heat shock factor 1 (HSF1), a master regulator of heat shock response, has been shown to play a multifaceted role in cancer progression. However, the clinical significance and biological effect of HSF1 expression in intrahepatic cholangiocarcinoma (IHCC) remain unknown. Forty-nine patients with IHCC who underwent hepatic resection were enrolled in this study. HSF1 expression in tumor tissue was determined by immunohistochemistry, and patients were divided into two groups, those with high (n = 20) and low (n = 29) HSF1 expression. Clinicopathological factors including prognosis were compared in these two groups. HSF1 expression was significantly higher in tumors than in normal tissue. The overall survival rate was significantly lower in patients with high than low HSF1. Multivariate analysis showed that high HSF1 expression was a factor independently prognostic of patient survival. High HSF1 expression in tumor tissues may be a prognostic biomarker in patients with IHCC.","ja":"Heat shock factor 1 (HSF1), a master regulator of heat shock response, has been shown to play a multifaceted role in cancer progression. However, the clinical significance and biological effect of HSF1 expression in intrahepatic cholangiocarcinoma (IHCC) remain unknown. Forty-nine patients with IHCC who underwent hepatic resection were enrolled in this study. HSF1 expression in tumor tissue was determined by immunohistochemistry, and patients were divided into two groups, those with high (n = 20) and low (n = 29) HSF1 expression. Clinicopathological factors including prognosis were compared in these two groups. HSF1 expression was significantly higher in tumors than in normal tissue. The overall survival rate was significantly lower in patients with high than low HSF1. Multivariate analysis showed that high HSF1 expression was a factor independently prognostic of patient survival. High HSF1 expression in tumor tissues may be a prognostic biomarker in patients with IHCC."},"publication_date":"2018-07","publication_name":{"en":"Journal of Gastroenterology and Hepatology","ja":"Journal of Gastroenterology and Hepatology"},"volume":"33","number":"7","starting_page":"1407","ending_page":"1412","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/jgh.14078"],"issn":["1440-1746"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29848685","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85048247787","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351466","label":"url"}],"paper_title":{"en":"Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.","ja":"Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer."},"authors":{"en":[{"name":"Enkhbat Tumenjin"},{"name":"Nishi Masaaki"},{"name":"Takasu Chie"},{"name":"Yoshikawa Kouzou"},{"name":"Higashijima Jun"},{"name":"Tokunaga Takuya"},{"name":"Kashihara Hideya"},{"name":"Ishikawa Daichi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Tumenjin Enkhbat"},{"name":"西 正暁"},{"name":"髙須 千絵"},{"name":"吉川 幸造"},{"name":"東島 潤"},{"name":"徳永 卓哉"},{"name":"柏原 秀也"},{"name":"石川 大地"},{"name":"島田 光生"}]},"description":{"en":"Programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1(PD-L1) axis is associated with immune tolerance via inhibition of T cell activation. The aim of this study was to clarify the significance of PD-1 and PD-L1 expressions and analyze the relationships between PD-1, PD-L1, transforming growth factor-β (TGF-β) and Forkhead box P3 (Foxp3) expressions in colorectal cancer (CRC). A total of 116 patients who underwent curative colectomy for stage II/III CRC were included in the study. PD-1, PD-L1, TGF-β, and Foxp3 expressions were examined by immunohistochemistry and related to prognostic factors by Kaplan-Meier. PD-1 expression was correlated with PD-L1, TGF-β, and Foxp3 expressions. Overall survival rates were significantly poorer in the PD-1 and PD-L1-positive groups. Multivariate analysis showed that PD-L1-positive is an independent risk factor. Disease-free survival (DFS) was tended in the PD-L1-positive group. The group with double-positive expression had significantly poorer prognosis. PD-1 and PD-L1 expressions were associated with a poor prognosis and correlated with TGF-β and Foxp3 expressions in patients with CRC.","ja":"Programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1(PD-L1) axis is associated with immune tolerance via inhibition of T cell activation. The aim of this study was to clarify the significance of PD-1 and PD-L1 expressions and analyze the relationships between PD-1, PD-L1, transforming growth factor-β (TGF-β) and Forkhead box P3 (Foxp3) expressions in colorectal cancer (CRC). A total of 116 patients who underwent curative colectomy for stage II/III CRC were included in the study. PD-1, PD-L1, TGF-β, and Foxp3 expressions were examined by immunohistochemistry and related to prognostic factors by Kaplan-Meier. PD-1 expression was correlated with PD-L1, TGF-β, and Foxp3 expressions. Overall survival rates were significantly poorer in the PD-1 and PD-L1-positive groups. Multivariate analysis showed that PD-L1-positive is an independent risk factor. Disease-free survival (DFS) was tended in the PD-L1-positive group. The group with double-positive expression had significantly poorer prognosis. PD-1 and PD-L1 expressions were associated with a poor prognosis and correlated with TGF-β and Foxp3 expressions in patients with CRC."},"publication_date":"2018-06","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"38","number":"6","starting_page":"3367","ending_page":"3373","languages":["eng"],"referee":true,"identifiers":{"doi":["10.21873/anticanres.12603"],"issn":["1791-7530"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29848687","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85048212303","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351459","label":"url"}],"paper_title":{"en":"The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer.","ja":"The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer."},"authors":{"en":[{"name":"Nishi Masaaki"},{"name":"Yoshikawa Kouzou"},{"name":"Higashijima Jun"},{"name":"Tokunaga Takuya"},{"name":"Kashihara Hideya"},{"name":"Takasu Chie"},{"name":"Ishikawa Daichi"},{"name":"Wada Yuma"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"西 正暁"},{"name":"吉川 幸造"},{"name":"東島 潤"},{"name":"徳永 卓哉"},{"name":"柏原 秀也"},{"name":"髙須 千絵"},{"name":"石川 大地"},{"name":"和田 佑馬"},{"name":"島田 光生"}]},"description":{"en":"Indoleamine 2,3-dioxygenase (IDO) down-regulates T cell activation, attenuates regulatory T cell (Treg) activation and is related to immune tolerance. The aim of the study was to clarify the significance of IDO expression and analyze the relationships between the expression of IDO, TGF-β, and Foxp3 in gastric cancer (GC). A total of 60 patients who underwent curative gastrectomy for stage III gastric cancer were included in the study. The expression of IDO, TGF-β, and Foxp3 was examined by immunohistochemistry and the relationship of each expression level to several prognostic factors was examined using univariate and multivariate analyses. IDO expression was not positively correlated with any of the factors examined. IDO expression was positively correlated with TGF-β expression (p<0.05), and TGF-β expression was positively correlated with FoxP3 expression (p<0.05). Overall survival (OS) rates were significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year OS, 78.5% vs. 90%, respectively; p<0.05). Multivariate analysis confirmed IDO expression as independent prognostic factors in OS. Disease-free survival (DFS) was significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year DFS, 59.3% vs. 69.3%, respectively; p<0.05). IDO is associated with poor prognosis and immuno-tolerance through attenuation of Treg activation in Stage III GC.","ja":"Indoleamine 2,3-dioxygenase (IDO) down-regulates T cell activation, attenuates regulatory T cell (Treg) activation and is related to immune tolerance. The aim of the study was to clarify the significance of IDO expression and analyze the relationships between the expression of IDO, TGF-β, and Foxp3 in gastric cancer (GC). A total of 60 patients who underwent curative gastrectomy for stage III gastric cancer were included in the study. The expression of IDO, TGF-β, and Foxp3 was examined by immunohistochemistry and the relationship of each expression level to several prognostic factors was examined using univariate and multivariate analyses. IDO expression was not positively correlated with any of the factors examined. IDO expression was positively correlated with TGF-β expression (p<0.05), and TGF-β expression was positively correlated with FoxP3 expression (p<0.05). Overall survival (OS) rates were significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year OS, 78.5% vs. 90%, respectively; p<0.05). Multivariate analysis confirmed IDO expression as independent prognostic factors in OS. Disease-free survival (DFS) was significantly poorer in the IDO-positive group compared to the IDO-negative group (3-year DFS, 59.3% vs. 69.3%, respectively; p<0.05). IDO is associated with poor prognosis and immuno-tolerance through attenuation of Treg activation in Stage III GC."},"publication_date":"2018-06","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"38","number":"6","starting_page":"3387","ending_page":"3392","languages":["eng"],"referee":true,"identifiers":{"doi":["10.21873/anticanres.12605"],"issn":["1791-7530"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://ci.nii.ac.jp/naid/40021573998/","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1520572357910337920/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353857","label":"url"}],"paper_title":{"en":"CURRENT STATUS OF SUPPORT FOR FEMALE DOCTORS IN THE SPECIALIST MEDICAL SOCIETIES OF THE JAPANESE ASSOCIATION OF MEDICAL SCIENCE IN 2015 : RESULTS OF A QUESTIONNAIRE SURVEY","ja":"女性外科医総活躍社会を目指して 日本医学会分科会における女性医師支援2015年 : 第3回アンケート調査"},"authors":{"en":[{"name":"野村 幸世"},{"name":"冨澤 康子"},{"name":"大津 洋"},{"name":"小川 朋子"},{"name":"柴崎 郁子"},{"name":"Shimada Mitsuo"},{"name":"竹下 恵美子"},{"name":"花崎 和弘"},{"name":"葉梨 智子"},{"name":"山下 啓子"},{"name":"明石 定子"},{"name":"山内 英子"},{"name":"岩瀬 弘敬"},{"name":"田口 智章"},{"name":"前田 耕太郎"},{"name":"中村 清吾"}],"ja":[{"name":"野村 幸世"},{"name":"冨澤 康子"},{"name":"大津 洋"},{"name":"小川 朋子"},{"name":"柴崎 郁子"},{"name":"島田 光生"},{"name":"竹下 恵美子"},{"name":"花崎 和弘"},{"name":"葉梨 智子"},{"name":"山下 啓子"},{"name":"明石 定子"},{"name":"山内 英子"},{"name":"岩瀬 弘敬"},{"name":"田口 智章"},{"name":"前田 耕太郎"},{"name":"中村 清吾"}]},"publication_date":"2018-04","publication_name":{"en":"Journal of Japan Surgical Society","ja":"日本外科学会雑誌"},"volume":"119","number":"1","starting_page":"97","ending_page":"99","languages":["jpn"],"referee":true,"identifiers":{"issn":["0301-4894"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29064880","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353844","label":"url"}],"paper_title":{"en":"Usefulness of the Transoral Anvil Delivery System for Esophagojejunostomy After Laparoscopic Total Gastrectomy: A Single-institution Comparative Study of Transoral Anvil Delivery System and the Overlap Method.","ja":"Usefulness of the Transoral Anvil Delivery System for Esophagojejunostomy After Laparoscopic Total Gastrectomy: A Single-institution Comparative Study of Transoral Anvil Delivery System and the Overlap Method."},"authors":{"en":[{"name":"Yoshikawa Kouzou"},{"name":"Shimada Mitsuo"},{"name":"Higashijima Jun"},{"name":"Tokunaga Takuya"},{"name":"Nishi Masaaki"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Ishikawa Daichi"}],"ja":[{"name":"吉川 幸造"},{"name":"島田 光生"},{"name":"東島 潤"},{"name":"徳永 卓哉"},{"name":"西 正暁"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"石川 大地"}]},"description":{"en":"Many reconstruction techniques have been reported after laparoscopic total gastrectomy (LTG), but it is not clear which anastomosis technique is most useful, and no standard methods have been established. This study examined whether LTG using the transoral anvil delivery system (TOADS) is a feasible and safe procedure for gastric cancer. A series of 47 patients underwent the overlap method and 36 underwent the hemi-double-stapling technique with TOADS. Intraoperative and postoperative outcomes were compared between the 2 groups. In the TOADS group, operation time for reconstruction was shorter (16 3 vs. 45 10in, P=0.003), and blood loss was reduced (45 15 vs. 126 13L, P=0.0002). There were no significant differences in intraoperative complications, conversion to open surgery, and intraoperative anastomosis-related complications between the 2 groups. Furthermore, there were no significant differences in the incidence of complications, reoperation, mortality, and postoperative hospital stay. LTG using TOADS for gastric cancer may be a technically feasible surgical procedure with acceptable morbidity.","ja":"Many reconstruction techniques have been reported after laparoscopic total gastrectomy (LTG), but it is not clear which anastomosis technique is most useful, and no standard methods have been established. This study examined whether LTG using the transoral anvil delivery system (TOADS) is a feasible and safe procedure for gastric cancer. A series of 47 patients underwent the overlap method and 36 underwent the hemi-double-stapling technique with TOADS. Intraoperative and postoperative outcomes were compared between the 2 groups. In the TOADS group, operation time for reconstruction was shorter (16 3 vs. 45 10in, P=0.003), and blood loss was reduced (45 15 vs. 126 13L, P=0.0002). There were no significant differences in intraoperative complications, conversion to open surgery, and intraoperative anastomosis-related complications between the 2 groups. Furthermore, there were no significant differences in the incidence of complications, reoperation, mortality, and postoperative hospital stay. LTG using TOADS for gastric cancer may be a technically feasible surgical procedure with acceptable morbidity."},"publication_date":"2018-04","publication_name":{"en":"Surgical Laparoscopy, Endoscopy & Percutaneous Techniques","ja":"Surgical Laparoscopy, Endoscopy & Percutaneous Techniques"},"volume":"28","number":"2","starting_page":"e40","ending_page":"e43","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1097/SLE.0000000000000495"],"issn":["1534-4908"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29517636","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85044238547","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351458","label":"url"}],"paper_title":{"en":"A new 2-step acceleration protocol using a histone deacetylase inhibitor to generate insulin-producing cells from adipose-derived mesenchymal stem cells","ja":"A new 2-step acceleration protocol using a histone deacetylase inhibitor to generate insulin-producing cells from adipose-derived mesenchymal stem cells"},"authors":{"en":[{"name":"Ikemoto Tetsuya"},{"name":"Feng Rui"},{"name":"Shimada Mitsuo"},{"name":"Saitou Yu"},{"name":"Iwahashi Shuichi"},{"name":"Morine Yuji"},{"name":"Imura Satoru"}],"ja":[{"name":"池本 哲也"},{"name":"馮 睿"},{"name":"島田 光生"},{"name":"齋藤 裕"},{"name":"岩橋 衆一"},{"name":"森根 裕二"},{"name":"居村 暁"}]},"description":{"en":"We aimed to develop a simple protocol for deriving insulin-producing cells (IPCs) from adipose-derived mesenchymal stem cells (ADSCs). We established a 2-step creation method and an acceleration strategy with a histone deacetylase inhibitor that promoted a pro-endocrine pancreatic lineage. We seeded ADSCs in 96-well dishes and cultured in Dulbecco's modified Eagle's medium/F12 medium containing 1% fetal bovine serum, 1% B27 supplement, 1% N2 supplement, 50-ng/mL human activin A, and 10-nM exendin-4 for step 1 of differentiation (7 days). Then 10-mM nicotinamide and 50-ng/mL human hepatocyte growth factor, with or without 1 mM histone deacetylase inhibitor, were added for step 2 of differentiation (14 days). After the 2-step differentiation was complete, cell morphology, immunohistochemistry, messenger RNA expression, and function were investigated. Our new differentiation protocol with the histone deacetylase inhibitor significantly accelerated IPC differentiation compared with the conventional protocol without the histone deacetylase inhibitor (median, 21.6 vs 38.8 days; P < 0.05). It also improved the islet morphology score (P < 0.05) and the glucose stimulation index (3.1). By applying our new and easy 2-step protocol using a histone deacetylase inhibitor, ADSCs may be an effective cell source for differentiation of IPCs.","ja":"We aimed to develop a simple protocol for deriving insulin-producing cells (IPCs) from adipose-derived mesenchymal stem cells (ADSCs). We established a 2-step creation method and an acceleration strategy with a histone deacetylase inhibitor that promoted a pro-endocrine pancreatic lineage. We seeded ADSCs in 96-well dishes and cultured in Dulbecco's modified Eagle's medium/F12 medium containing 1% fetal bovine serum, 1% B27 supplement, 1% N2 supplement, 50-ng/mL human activin A, and 10-nM exendin-4 for step 1 of differentiation (7 days). Then 10-mM nicotinamide and 50-ng/mL human hepatocyte growth factor, with or without 1 mM histone deacetylase inhibitor, were added for step 2 of differentiation (14 days). After the 2-step differentiation was complete, cell morphology, immunohistochemistry, messenger RNA expression, and function were investigated. Our new differentiation protocol with the histone deacetylase inhibitor significantly accelerated IPC differentiation compared with the conventional protocol without the histone deacetylase inhibitor (median, 21.6 vs 38.8 days; P < 0.05). It also improved the islet morphology score (P < 0.05) and the glucose stimulation index (3.1). By applying our new and easy 2-step protocol using a histone deacetylase inhibitor, ADSCs may be an effective cell source for differentiation of IPCs."},"publication_date":"2018-04","publication_name":{"en":"Pancreas","ja":"Pancreas"},"volume":"47","number":"4","starting_page":"477","ending_page":"481","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1097/MPA.0000000000001017"],"issn":["1536-4828"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29491110","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353847","label":"url"}],"paper_title":{"en":"Ki-67 and Survivin as Predictive Factors for Rectal Cancer Treated with Preoperative Chemoradiotherapy.","ja":"Ki-67 and Survivin as Predictive Factors for Rectal Cancer Treated with Preoperative Chemoradiotherapy."},"authors":{"en":[{"name":"Yoshikawa Kouzou"},{"name":"Shimada Mitsuo"},{"name":"Higashijima Jun"},{"name":"Nakao Toshihiro"},{"name":"Nishi Masaaki"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Eto Syohei"},{"name":"Bando Yoshimi"}],"ja":[{"name":"吉川 幸造"},{"name":"島田 光生"},{"name":"東島 潤"},{"name":"中尾 寿宏"},{"name":"西 正暁"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"江藤 祥平"},{"name":"坂東 良美"}]},"description":{"en":"To evaluate the usefulness of Ki-67 index and survivin as predictive prognostic factors for rectal cancer treated with preoperative chemoradiotherapy. The Ki-67 index and survivin expression were examined in patients with stage II/III rectal cancer (n=46) by immunohistochemistry. Patients were divided into a high-group and a low-group for the Ki-67 index, and positive and negative groups for survivin expression. Overall and disease-free survival were compared between the groups, and the correlation between Ki-67 index and survivin expression was assessed. The 5-year disease-free survival rate of the group with high Ki-67 index was significantly lower than that of the group with low Ki-67 index (53% and 88%, p=0.03), as was the 5-year overall survival rate (68% and 100%, p=0.03). Findings for survivin were not significant. Ki-67 index and survivin may be useful biomarkers for rectal cancer with preoperative CRT.","ja":"To evaluate the usefulness of Ki-67 index and survivin as predictive prognostic factors for rectal cancer treated with preoperative chemoradiotherapy. The Ki-67 index and survivin expression were examined in patients with stage II/III rectal cancer (n=46) by immunohistochemistry. Patients were divided into a high-group and a low-group for the Ki-67 index, and positive and negative groups for survivin expression. Overall and disease-free survival were compared between the groups, and the correlation between Ki-67 index and survivin expression was assessed. The 5-year disease-free survival rate of the group with high Ki-67 index was significantly lower than that of the group with low Ki-67 index (53% and 88%, p=0.03), as was the 5-year overall survival rate (68% and 100%, p=0.03). Findings for survivin were not significant. Ki-67 index and survivin may be useful biomarkers for rectal cancer with preoperative CRT."},"publication_date":"2018-03","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"38","number":"3","starting_page":"1735","ending_page":"1739","languages":["eng"],"referee":true,"identifiers":{"doi":["10.21873/anticanres.12409"],"issn":["1791-7530"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28889651","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353842","label":"url"}],"paper_title":{"en":"Living donor liver transplantation for biliary atresia: An analysis of 2085 cases in the registry of the Japanese Liver Transplantation Society.","ja":"Living donor liver transplantation for biliary atresia: An analysis of 2085 cases in the registry of the Japanese Liver Transplantation Society."},"authors":{"en":[{"name":"Kasahara Mureo"},{"name":"Umeshita Koji"},{"name":"Sakamoto Seisuke"},{"name":"Fukuda Akinari"},{"name":"Furukawa Hiroyuki"},{"name":"Sakisaka Shotaro"},{"name":"Kobayashi Eiji"},{"name":"Tanaka Eiji"},{"name":"Inomata Yukihiro"},{"name":"Kawasaki Seiji"},{"name":"Shimada Mitsuo"},{"name":"Kokudo Norihiro"},{"name":"Egawa Hiroto"},{"name":"Ohdan Hideki"},{"name":"Uemoto Shinji"}],"ja":[{"name":"Kasahara Mureo"},{"name":"Umeshita Koji"},{"name":"Sakamoto Seisuke"},{"name":"Fukuda Akinari"},{"name":"Furukawa Hiroyuki"},{"name":"Sakisaka Shotaro"},{"name":"Kobayashi Eiji"},{"name":"Tanaka Eiji"},{"name":"Inomata Yukihiro"},{"name":"Kawasaki Seiji"},{"name":"島田 光生"},{"name":"Kokudo Norihiro"},{"name":"Egawa Hiroto"},{"name":"Ohdan Hideki"},{"name":"Uemoto Shinji"}]},"description":{"en":"Biliary atresia (BA) is the most common indication for liver transplantation (LT) in pediatric population. This study analyzed the comprehensive factors that might influence the outcomes of patients with BA who undergo living donor LT by evaluating the largest cohort with the longest follow-up in the world. Between November 1989 and December 2015, 2,085 BA patients underwent LDLT in Japan. There were 763 male and 1,322 female recipients with a mean age of 5.9 years and body weight of 18.6 kg. The 1-, 5-, 10-, 15-, and 20-year graft survival rates for the BA patients undergoing LDLT were 90.5%, 90.4%, 84.6%, 82.0%, and 79.9%, respectively. The donor body mass index, ABO incompatibility, graft type, recipient age, center experience, and transplant era were found to be significant predictors of the overall graft survival. Adolescent age (12 to <18 years) was associated with a significantly worse long-term graft survival rate than younger or older ages. We conclude that LDLT for BA is a safe and effective treatment modality that does not compromise living donors. The optimum timing for LT is crucial for a successful outcome, and early referral to transplantation center can improve the short-term outcomes of LT for BA. Further investigation of the major cause of death in liver transplanted recipients with BA in the long-term is essential, especially among adolescents.","ja":"Biliary atresia (BA) is the most common indication for liver transplantation (LT) in pediatric population. This study analyzed the comprehensive factors that might influence the outcomes of patients with BA who undergo living donor LT by evaluating the largest cohort with the longest follow-up in the world. Between November 1989 and December 2015, 2,085 BA patients underwent LDLT in Japan. There were 763 male and 1,322 female recipients with a mean age of 5.9 years and body weight of 18.6 kg. The 1-, 5-, 10-, 15-, and 20-year graft survival rates for the BA patients undergoing LDLT were 90.5%, 90.4%, 84.6%, 82.0%, and 79.9%, respectively. The donor body mass index, ABO incompatibility, graft type, recipient age, center experience, and transplant era were found to be significant predictors of the overall graft survival. Adolescent age (12 to <18 years) was associated with a significantly worse long-term graft survival rate than younger or older ages. We conclude that LDLT for BA is a safe and effective treatment modality that does not compromise living donors. The optimum timing for LT is crucial for a successful outcome, and early referral to transplantation center can improve the short-term outcomes of LT for BA. Further investigation of the major cause of death in liver transplanted recipients with BA in the long-term is essential, especially among adolescents."},"publication_date":"2018-03","publication_name":{"en":"American Journal of Transplantation","ja":"American Journal of Transplantation"},"volume":"18","number":"3","starting_page":"659","ending_page":"668","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/ajt.14489"],"issn":["1600-6143"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28875240","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85028981662","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351457","label":"url"}],"paper_title":{"en":"Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria.","ja":"Potential predictive factors for microvascular invasion in hepatocellular carcinoma classified within the Milan criteria."},"authors":{"en":[{"name":"Imura Satoru"},{"name":"Teraoku Hiroki"},{"name":"Yoshikawa Masato"},{"name":"Ishikawa Daichi"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Iwahashi Shuichi"},{"name":"Ikemoto Tetsuya"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"居村 暁"},{"name":"寺奥 大貴"},{"name":"吉川 雅登"},{"name":"石川 大地"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"岩橋 衆一"},{"name":"池本 哲也"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"Microvascular invasion (mvi) is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. However, mvi is difficult to detect preoperatively. The aim of this study was to clarify the risk factors of postoperative recurrence and investigate predictive factors of mvi before hepatectomy for HCC classified within the Milan criteria. One hundred fifty-nine patients with hepatocellular carcinoma (HCC) classified within the Milan criteria, who underwent hepatectomy, were enrolled in this study. We investigated the risk factors of recurrence. In addition, we divided them into two groups: mvi-negative group and mvi-positive group, based on pathological findings after surgery. We compared the clinicopathological factors between the two groups and determined the risk factors for mvi. Overall survival rate at 1, 3, and 5 years were 91.6%, 80.5%, and 74.9%, and the recurrence-free survival rate at 1, 3, and 5-years were 72.3%, 51.6%, and 37.2%. Risk factor analysis for tumor recurrence revealed that total bilirubin, albumin, ICGR15, AFP-L3, tumor number, mvi, and tumor stage had a significant predictive value. Multivariate analysis revealed that tumor number and mvi were significant independent risk factors for tumor recurrence. Predictive analysis for risk factors of mvi revealed that multiple tumors and AFP-L3 > 10% were significant independent risk factors for mvi in HCC classified within the Milan criteria. The mvi was one of the independent risk factors for tumor recurrence in HCC classified within the Milan criteria. Multiple tumors and high AFP-L3 value were independent predictive factors for mvi.","ja":"Microvascular invasion (mvi) is an important risk factor for recurrent hepatocellular carcinoma (HCC), even after curative liver resection or orthotopic liver transplantation. However, mvi is difficult to detect preoperatively. The aim of this study was to clarify the risk factors of postoperative recurrence and investigate predictive factors of mvi before hepatectomy for HCC classified within the Milan criteria. One hundred fifty-nine patients with hepatocellular carcinoma (HCC) classified within the Milan criteria, who underwent hepatectomy, were enrolled in this study. We investigated the risk factors of recurrence. In addition, we divided them into two groups: mvi-negative group and mvi-positive group, based on pathological findings after surgery. We compared the clinicopathological factors between the two groups and determined the risk factors for mvi. Overall survival rate at 1, 3, and 5 years were 91.6%, 80.5%, and 74.9%, and the recurrence-free survival rate at 1, 3, and 5-years were 72.3%, 51.6%, and 37.2%. Risk factor analysis for tumor recurrence revealed that total bilirubin, albumin, ICGR15, AFP-L3, tumor number, mvi, and tumor stage had a significant predictive value. Multivariate analysis revealed that tumor number and mvi were significant independent risk factors for tumor recurrence. Predictive analysis for risk factors of mvi revealed that multiple tumors and AFP-L3 > 10% were significant independent risk factors for mvi in HCC classified within the Milan criteria. The mvi was one of the independent risk factors for tumor recurrence in HCC classified within the Milan criteria. Multiple tumors and high AFP-L3 value were independent predictive factors for mvi."},"publication_date":"2018-02","publication_name":{"en":"International Journal of Clinical Oncology","ja":"International Journal of Clinical Oncology"},"volume":"23","number":"1","starting_page":"98","ending_page":"103","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10147-017-1189-8"],"issn":["1437-7772"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29277815","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85039796842","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351462","label":"url"}],"paper_title":{"en":"The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.","ja":"The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy."},"authors":{"en":[{"name":"Yoshimoto Toshiaki"},{"name":"Imura Satoru"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Arakawa Yusuke"},{"name":"Iwahashi Shuichi"},{"name":"Saitou Yu"},{"name":"Takasu Chie"},{"name":"Ishikawa Daichi"},{"name":"Teraoku Hiroki"},{"name":"Bando Yoshimi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"良元 俊昭"},{"name":"居村 暁"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"荒川 悠佑"},{"name":"岩橋 衆一"},{"name":"齋藤 裕"},{"name":"髙須 千絵"},{"name":"石川 大地"},{"name":"寺奥 大貴"},{"name":"坂東 良美"},{"name":"島田 光生"}]},"description":{"en":"We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department. Thirty-eight patients with unresectable HCC who were administrated sorafenib from 2009 to 2015 were investigated retrospectively. The 1-year overall survival rate was 59.3%. The macroscopic vascular invasion and response rate were independent prognostic factors of survival. Surgical resection after sorafenib achieved long-term survival in two cases. Case 1: A patient with locally unresectable HCC showed significant response induced by sorafenib, which allowed complete surgical resection. This tumor tested positive for FGF4. Case 2: A patient with a history of hepatectomy for HCC had multiple distant metastases. Most lesions were reduced in size after sorafenib therapy and new lesions in the remnant liver and residual lung metastases were resected. The sorafenib-resistant lesions were negative for FGF4. Sorafenib combined with surgical resection is a feasible option in advanced HCC patients, if sorafenib has been effective.","ja":"We report the outcomes of sorafenib therapy for advanced hepatocellular carcinoma (HCC) in our Department. Thirty-eight patients with unresectable HCC who were administrated sorafenib from 2009 to 2015 were investigated retrospectively. The 1-year overall survival rate was 59.3%. The macroscopic vascular invasion and response rate were independent prognostic factors of survival. Surgical resection after sorafenib achieved long-term survival in two cases. Case 1: A patient with locally unresectable HCC showed significant response induced by sorafenib, which allowed complete surgical resection. This tumor tested positive for FGF4. Case 2: A patient with a history of hepatectomy for HCC had multiple distant metastases. Most lesions were reduced in size after sorafenib therapy and new lesions in the remnant liver and residual lung metastases were resected. The sorafenib-resistant lesions were negative for FGF4. Sorafenib combined with surgical resection is a feasible option in advanced HCC patients, if sorafenib has been effective."},"publication_date":"2018-01","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"38","number":"1","starting_page":"501","ending_page":"507","languages":["eng"],"referee":true,"identifiers":{"doi":["10.21873/anticanres.12250"],"issn":["1791-7530"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353858","label":"url"}],"paper_title":{"en":"【慢性炎症から肝胆膵癌にいたるランドスケープ】膵・胆管合流異常と胆道癌","ja":"【慢性炎症から肝胆膵癌にいたるランドスケープ】膵・胆管合流異常と胆道癌"},"authors":{"en":[{"name":"Ishibashi Hiroki"},{"name":"Shimada Mitsuo"},{"name":"Mori Hiroki"},{"name":"Morine Yuji"},{"name":"安藤 久實"}],"ja":[{"name":"石橋 広樹"},{"name":"島田 光生"},{"name":"森 大樹"},{"name":"森根 裕二"},{"name":"安藤 久實"}]},"publication_date":"2018","publication_name":{"en":"KAN TAN SUI","ja":"肝·胆·膵"},"volume":"77","number":"3","starting_page":"659","ending_page":"667","languages":["jpn"],"referee":true,"identifiers":{"issn":["0389-4991"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2004575","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29593191","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=353843","label":"url"}],"paper_title":{"en":"Treatment strategy for successful hepatic resection of icteric liver.","ja":"Treatment strategy for successful hepatic resection of icteric liver."},"authors":{"en":[{"name":"Yada Keigo"},{"name":"Morine Yuji"},{"name":"Ishibashi Hiroki"},{"name":"Mori Hiroki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"矢田 圭吾"},{"name":"森根 裕二"},{"name":"石橋 広樹"},{"name":"森 大樹"},{"name":"島田 光生"}]},"description":{"en":"The treatment strategy for jaundiced patients with hilar cholangiocarcinoma (HC) is not well established. In this study, we evaluate the feasibility of our perioperative protocol for jaundiced patients with HC. Twenty patients with HC who underwent hepatic resection at our institute were enrolled, and patients were divided into icteric(n=6) and normal(n=14) group. As a perioperative protocol, Oral administration of Inchinkoto(ICKT), steroid and nafamostat mesilate were introduced. The evaluation of functional future remnant liver(FRL) by asiaroscintigraphy, and postoperative outcomes were retrospectively compared. Indocyanine green dye retention rate at 15 minutes was higher, and LHL15 values was lower in icteric group. However, in the functional evaluation of FRL, which was the sum of GSA uptake of the future FRL, there was no significant difference of LHL15 values of the remnant liver functional reserve between the two groups. As results, according to the difference of liver function, serum AST level was not different between two groups. The number of patients with postoperative morbidity in the two groups was comparable. Even in HC patients with icteric liver, accurate assessment of liver functional reserve and effective perioperative treatment may attribute to successful hepatectomy and favorable post-operative outcomes. J. Med. Invest. 65:37-42, February, 2018.","ja":"The treatment strategy for jaundiced patients with hilar cholangiocarcinoma (HC) is not well established. In this study, we evaluate the feasibility of our perioperative protocol for jaundiced patients with HC. Twenty patients with HC who underwent hepatic resection at our institute were enrolled, and patients were divided into icteric(n=6) and normal(n=14) group. As a perioperative protocol, Oral administration of Inchinkoto(ICKT), steroid and nafamostat mesilate were introduced. The evaluation of functional future remnant liver(FRL) by asiaroscintigraphy, and postoperative outcomes were retrospectively compared. Indocyanine green dye retention rate at 15 minutes was higher, and LHL15 values was lower in icteric group. However, in the functional evaluation of FRL, which was the sum of GSA uptake of the future FRL, there was no significant difference of LHL15 values of the remnant liver functional reserve between the two groups. As results, according to the difference of liver function, serum AST level was not different between two groups. The number of patients with postoperative morbidity in the two groups was comparable. Even in HC patients with icteric liver, accurate assessment of liver functional reserve and effective perioperative treatment may attribute to successful hepatectomy and favorable post-operative outcomes. J. Med. Invest. 65:37-42, February, 2018."},"publication_date":"2018","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"65","number":"1.2","starting_page":"37","ending_page":"42","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.65.37"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2008008","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29460798","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85031825628","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=344990","label":"url"}],"paper_title":{"en":"Major liver resection reduces nonprotein respiratory quotient and increases nonesterified fatty acid at postoperative day 14 in patients with hepatocellular carcinoma.","ja":"Major liver resection reduces nonprotein respiratory quotient and increases nonesterified fatty acid at postoperative day 14 in patients with hepatocellular carcinoma."},"authors":{"en":[{"name":"Wada Shoko"},{"name":"Okumura Hisami"},{"name":"Katayama Takafumi"},{"name":"Morine Yuji"},{"name":"Imura Satoru"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"和田 宵湖"},{"name":"奥村 仙示"},{"name":"片山 貴文"},{"name":"森根 裕二"},{"name":"居村 暁"},{"name":"島田 光生"}]},"publication_date":"2017-10-20","publication_name":{"en":"Clinical Nutrition ESPEN","ja":"Clinical Nutrition ESPEN"},"volume":"23","starting_page":"194","ending_page":"199","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.clnesp.2017.10.001"],"issn":["2405-4577"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2005534","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28878284","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85029002400","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=333528","label":"url"}],"paper_title":{"en":"MicroRNA-449a deficiency promotes colon carcinogenesis.","ja":"MicroRNA-449a deficiency promotes colon carcinogenesis."},"authors":{"en":[{"name":"Niki Masanori"},{"name":"Nakajima Kohhei"},{"name":"Ishikawa Daichi"},{"name":"Nishida Jun"},{"name":"Ishifune Chieko"},{"name":"Tsukumo Shin-ichi"},{"name":"Shimada Mitsuo"},{"name":"Nagahiro Shinji"},{"name":"Mitamura Yoshinori"},{"name":"Yasutomo Koji"}],"ja":[{"name":"Niki Masanori"},{"name":"中島 公平"},{"name":"石川 大地"},{"name":"西田 純"},{"name":"石舟 智恵子"},{"name":"九十九 伸一"},{"name":"島田 光生"},{"name":"永廣 信治"},{"name":"三田村 佳典"},{"name":"安友 康二"}]},"description":{"en":"MicroRNAs have broad roles in tumorigenesis and cell differentiation through regulation of target genes. Notch signaling also controls cell differentiation and tumorigenesis. However, the mechanisms through which Notch mediates microRNA expression are still unclear. In this study, we aimed to identify microRNAs regulated by Notch signaling. Our analysis found that microRNA-449a (miR-449a) was indirectly regulated by Notch signaling. Although miR-449a-deficient mice did not show any Notch-dependent defects in immune cell development, treatment of miR-449a-deficient mice with azoxymethane (AOM) or dextran sodium sulfate (DSS) increased the numbers and sizes of colon tumors. These effects were associated with an increase in intestinal epithelial cell proliferation following AOM/DSS treatment. In patients with colon cancer, miR-449a expression was inversely correlated with disease-free survival and histological scores and was positively correlated with the expression of MLH1 for which loss-of function mutations have been shown to be involved in colon cancer. Colon tissues of miR-449a-deficient mice showed reduced Mlh1 expression compared with those of wild-type mice. Thus, these data suggested that miR-449a acted as a key regulator of colon tumorigenesis by controlling the proliferation of intestinal epithelial cells. Additionally, activation of miR-449a may represent an effective therapeutic strategy and prognostic marker in colon cancer.","ja":"MicroRNAs have broad roles in tumorigenesis and cell differentiation through regulation of target genes. Notch signaling also controls cell differentiation and tumorigenesis. However, the mechanisms through which Notch mediates microRNA expression are still unclear. In this study, we aimed to identify microRNAs regulated by Notch signaling. Our analysis found that microRNA-449a (miR-449a) was indirectly regulated by Notch signaling. Although miR-449a-deficient mice did not show any Notch-dependent defects in immune cell development, treatment of miR-449a-deficient mice with azoxymethane (AOM) or dextran sodium sulfate (DSS) increased the numbers and sizes of colon tumors. These effects were associated with an increase in intestinal epithelial cell proliferation following AOM/DSS treatment. In patients with colon cancer, miR-449a expression was inversely correlated with disease-free survival and histological scores and was positively correlated with the expression of MLH1 for which loss-of function mutations have been shown to be involved in colon cancer. Colon tissues of miR-449a-deficient mice showed reduced Mlh1 expression compared with those of wild-type mice. Thus, these data suggested that miR-449a acted as a key regulator of colon tumorigenesis by controlling the proliferation of intestinal epithelial cells. Additionally, activation of miR-449a may represent an effective therapeutic strategy and prognostic marker in colon cancer."},"publication_date":"2017-09-06","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"7","number":"1","starting_page":"10696","ending_page":"10696","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41598-017-10500-0"],"issn":["2045-2322"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2005524","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28747791","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=332060","label":"url"}],"paper_title":{"en":"Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1.","ja":"Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1."},"authors":{"en":[{"name":"Muguruma Naoki"},{"name":"Okamoto Koichi"},{"name":"Nakagawa Tadahiko"},{"name":"Sannomiya Katsutaka"},{"name":"Fujimoto Shota"},{"name":"Mitsui Yasuhiro"},{"name":"Kimura Tetsuo"},{"name":"Miyamoto Hiroshi"},{"name":"Higashijima Jun"},{"name":"Shimada Mitsuo"},{"name":"Horino Yoko"},{"name":"Matsumoto Shinya"},{"name":"Hanaoka Kenjiro"},{"name":"Nagano Tetsuo"},{"name":"Shibutani Makoto"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"六車 直樹"},{"name":"岡本 耕一"},{"name":"中川 忠彦"},{"name":"Sannomiya Katsutaka"},{"name":"藤本 将太"},{"name":"三井 康裕"},{"name":"木村 哲夫"},{"name":"宮本 弘志"},{"name":"東島 潤"},{"name":"島田 光生"},{"name":"Horino Yoko"},{"name":"Matsumoto Shinya"},{"name":"Hanaoka Kenjiro"},{"name":"Nagano Tetsuo"},{"name":"Shibutani Makoto"},{"name":"高山 哲治"}]},"description":{"en":"Aberrant crypt foci (ACF), the earliest precursor lesion of colorectal cancers (CRCs), are a good surrogate marker for CRC risk stratification and chemoprevention. However, the conventional ACF detection method with dye-spraying by magnifying colonoscopy is labor- and skill-intensive. We sought to identify rat and human ACF using a fluorescent imaging technique that targets a molecule specific for ACF. We found that glutathione S-transferase (GST) P1-1 was overexpressed in ACF tissues in a screening experiment. We then synthesized the fluorogenic probe, DNAT-Me, which is fluorescently quenched but is activated by GSTP1-1. A CRC cell line incubated with DNAT-Me showed strong fluorescence in the cytosol. Fluorescence intensities correlated significantly with GST activities in cancer cell lines. When we sprayed DNAT-Me onto colorectal mucosa excised from azoxymethane-treated rats and surgically resected from CRC patients, ACF with strong fluorescent signals were clearly observed. The ACF number determined by postoperative DNAT-Me imaging was almost identical to that determined by preoperative methylene blue staining. The signal-to-noise ratio for ACF in DNAT-Me images was significantly higher than that in methylene blue staining. Thus, we sensitively visualized ACF on rat and human colorectal mucosa by using a GST-activated fluorogenic probe without dye-spraying and magnifying colonoscopy.","ja":"Aberrant crypt foci (ACF), the earliest precursor lesion of colorectal cancers (CRCs), are a good surrogate marker for CRC risk stratification and chemoprevention. However, the conventional ACF detection method with dye-spraying by magnifying colonoscopy is labor- and skill-intensive. We sought to identify rat and human ACF using a fluorescent imaging technique that targets a molecule specific for ACF. We found that glutathione S-transferase (GST) P1-1 was overexpressed in ACF tissues in a screening experiment. We then synthesized the fluorogenic probe, DNAT-Me, which is fluorescently quenched but is activated by GSTP1-1. A CRC cell line incubated with DNAT-Me showed strong fluorescence in the cytosol. Fluorescence intensities correlated significantly with GST activities in cancer cell lines. When we sprayed DNAT-Me onto colorectal mucosa excised from azoxymethane-treated rats and surgically resected from CRC patients, ACF with strong fluorescent signals were clearly observed. The ACF number determined by postoperative DNAT-Me imaging was almost identical to that determined by preoperative methylene blue staining. The signal-to-noise ratio for ACF in DNAT-Me images was significantly higher than that in methylene blue staining. Thus, we sensitively visualized ACF on rat and human colorectal mucosa by using a GST-activated fluorogenic probe without dye-spraying and magnifying colonoscopy."},"publication_date":"2017-07-26","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"7","number":"1","starting_page":"6536","ending_page":"6536","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1038/s41598-017-06857-x"],"issn":["2045-2322"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27553665","label":"url"},{"@id":"https://www.scopus.com/pages/publications/84983383466","label":"url"},{"@id":"https://www.scopus.com/pages/publications/84987597528","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=320145","label":"url"}],"paper_title":{"en":"Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.","ja":"Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study."},"authors":{"en":[{"name":"Sato Yasushi"},{"name":"Ohnuma Hiroyuki"},{"name":"Nobuoka Takayuki"},{"name":"Hirakawa Masahiro"},{"name":"Sagawa Tamotsu"},{"name":"Fujikawa Koshi"},{"name":"Takahashi Yasuo"},{"name":"Minami Shinya"},{"name":"Katsuki Shinichi"},{"name":"Takahashi Minoru"},{"name":"Maeda Masahiro"},{"name":"Okagawa Yutaka"},{"name":"Uemura Naoki"},{"name":"Kikuch Syouhei"},{"name":"Okamoto Koichi"},{"name":"Miyamoto Hiroshi"},{"name":"Shimada Mitsuo"},{"name":"Takemasa Ichiro"},{"name":"Kato Junji"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"佐藤 康史"},{"name":"Ohnuma Hiroyuki"},{"name":"Nobuoka Takayuki"},{"name":"Hirakawa Masahiro"},{"name":"Sagawa Tamotsu"},{"name":"Fujikawa Koshi"},{"name":"Takahashi Yasuo"},{"name":"Minami Shinya"},{"name":"Katsuki Shinichi"},{"name":"Takahashi Minoru"},{"name":"Maeda Masahiro"},{"name":"Okagawa Yutaka"},{"name":"Uemura Naoki"},{"name":"Kikuch Syouhei"},{"name":"岡本 耕一"},{"name":"宮本 弘志"},{"name":"島田 光生"},{"name":"Takemasa Ichiro"},{"name":"Kato Junji"},{"name":"高山 哲治"}]},"description":{"en":"Conversion therapy is an option for unresectable metastatic gastric cancer when distant metastases are controlled by chemotherapy; however, the feasibility and efficacy remain unclear. This study aimed to assess the feasibility and efficacy of conversion therapy in patients with initially unresectable gastric cancer treated with docetaxel, cisplatin, and S-1 (DCS) chemotherapy by evaluating clinical outcomes. One hundred unresectable metastatic gastric cancer patients, enrolled in three DCS chemotherapy clinical trials, were retrospectively evaluated. The patients received oral S-1 (40 mg/m2 b.i.d.) on days 1-14 and intravenous cisplatin (60 mg/m2) and docetaxel (50-60 mg/m2) on day 8 every 3 weeks. Conversion therapy was defined when the patients could undergo R0 resection post-DCS chemotherapy and were able to tolerate curative surgery. Conversion therapy was achieved in 33/100 patients, with no perioperative mortality. Twenty-eight of the 33 patients (84.8 %) achieved R0 resection, and 78.8 % were defined as histological chemotherapeutic responders. The median overall survival (OS) of patients who underwent conversion therapy was 47.8 months (95 % CI 28.0-88.5 months). Patients who underwent R0 resection had significantly longer OS than those who underwent R1 and R2 resections (P = 0.0002). Of the patients with primarily unresectable metastases, 10 % lived >5 years. Among patients who underwent conversion therapy, multivariate analysis showed that the pathological response was a significant independent predictor for OS. DCS safely induced a high conversion rate, with very high R0 and pathological response rates, and was associated with a good prognosis; these findings warrant further prospective investigations.","ja":"Conversion therapy is an option for unresectable metastatic gastric cancer when distant metastases are controlled by chemotherapy; however, the feasibility and efficacy remain unclear. This study aimed to assess the feasibility and efficacy of conversion therapy in patients with initially unresectable gastric cancer treated with docetaxel, cisplatin, and S-1 (DCS) chemotherapy by evaluating clinical outcomes. One hundred unresectable metastatic gastric cancer patients, enrolled in three DCS chemotherapy clinical trials, were retrospectively evaluated. The patients received oral S-1 (40 mg/m2 b.i.d.) on days 1-14 and intravenous cisplatin (60 mg/m2) and docetaxel (50-60 mg/m2) on day 8 every 3 weeks. Conversion therapy was defined when the patients could undergo R0 resection post-DCS chemotherapy and were able to tolerate curative surgery. Conversion therapy was achieved in 33/100 patients, with no perioperative mortality. Twenty-eight of the 33 patients (84.8 %) achieved R0 resection, and 78.8 % were defined as histological chemotherapeutic responders. The median overall survival (OS) of patients who underwent conversion therapy was 47.8 months (95 % CI 28.0-88.5 months). Patients who underwent R0 resection had significantly longer OS than those who underwent R1 and R2 resections (P = 0.0002). Of the patients with primarily unresectable metastases, 10 % lived >5 years. Among patients who underwent conversion therapy, multivariate analysis showed that the pathological response was a significant independent predictor for OS. DCS safely induced a high conversion rate, with very high R0 and pathological response rates, and was associated with a good prognosis; these findings warrant further prospective investigations."},"publication_date":"2017-05","publication_name":{"en":"Gastric Cancer","ja":"Gastric Cancer"},"volume":"20","number":"3","starting_page":"517","ending_page":"526","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10120-016-0633-1"],"issn":["1436-3291"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28054178","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85008158342","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=322015","label":"url"}],"paper_title":{"en":"Hemosuccus pancreaticus caused by a mucinous cystic neoplasm of the pancreas.","ja":"Hemosuccus pancreaticus caused by a mucinous cystic neoplasm of the pancreas."},"authors":{"en":[{"name":"Matsumoto Yuri"},{"name":"Miyamoto Hiroshi"},{"name":"Fukuya Akira"},{"name":"Nakamura Fumika"},{"name":"Goji Takahiro"},{"name":"Kitamura Shinji"},{"name":"Kimura Tetsuo"},{"name":"Okamoto Koichi"},{"name":"Sogabe Masahiro"},{"name":"Muguruma Naoki"},{"name":"Shimada Mitsuo"},{"name":"Bando Yoshimi"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"Matsumoto Yuri"},{"name":"宮本 弘志"},{"name":"Fukuya Akira"},{"name":"中村 文香"},{"name":"郷司 敬洋"},{"name":"北村 晋志"},{"name":"木村 哲夫"},{"name":"岡本 耕一"},{"name":"曽我部 正弘"},{"name":"六車 直樹"},{"name":"島田 光生"},{"name":"坂東 良美"},{"name":"高山 哲治"}]},"description":{"en":"Hemosuccus pancreaticus is a gastrointestinal hemorrhage through the main pancreatic duct. Here, we report a rare case of hemosuccus pancreaticus due to a mucinous cystic neoplasm of the pancreas. A 62-year-old woman who had been followed for a branch duct intraductal papillary mucinous neoplasm visited our emergency room due to severe abdominal pain and bloody discharge. Computed tomography revealed that the pancreatic cyst increased the tension of the wall and a high-density area indicative of bleeding into the cyst was observed. Endoscopy showed opening of and hemorrhaging from the papilla of Vater. The patient was diagnosed with hemosuccus pancreaticus caused by hemorrhaging into the cyst from the branch duct intraductal papillary mucinous neoplasm. Based on this diagnosis, elective distal pancreatectomy was performed. The histopathological diagnosis was a mucinous cystic neoplasm with intermediate-grade dysplasia based upon the pathological findings that fibrous ovarian-type stroma existed abundantly and the stroma cells were positive for progesterone receptor and inhibin. Hemosuccus pancreaticus caused by a mucinous cystic neoplasm is extremely rare and there has been only one case reported to date. In conclusion, it should be recognized that pancreatic cystic neoplasms including mucinous cystic neoplasms may cause hemosuccus pancreaticus.","ja":"Hemosuccus pancreaticus is a gastrointestinal hemorrhage through the main pancreatic duct. Here, we report a rare case of hemosuccus pancreaticus due to a mucinous cystic neoplasm of the pancreas. A 62-year-old woman who had been followed for a branch duct intraductal papillary mucinous neoplasm visited our emergency room due to severe abdominal pain and bloody discharge. Computed tomography revealed that the pancreatic cyst increased the tension of the wall and a high-density area indicative of bleeding into the cyst was observed. Endoscopy showed opening of and hemorrhaging from the papilla of Vater. The patient was diagnosed with hemosuccus pancreaticus caused by hemorrhaging into the cyst from the branch duct intraductal papillary mucinous neoplasm. Based on this diagnosis, elective distal pancreatectomy was performed. The histopathological diagnosis was a mucinous cystic neoplasm with intermediate-grade dysplasia based upon the pathological findings that fibrous ovarian-type stroma existed abundantly and the stroma cells were positive for progesterone receptor and inhibin. Hemosuccus pancreaticus caused by a mucinous cystic neoplasm is extremely rare and there has been only one case reported to date. In conclusion, it should be recognized that pancreatic cystic neoplasms including mucinous cystic neoplasms may cause hemosuccus pancreaticus."},"publication_date":"2017-04-01","publication_name":{"en":"Clinical Journal of Gastroenterology","ja":"Clinical Journal of Gastroenterology"},"volume":"10","number":"2","starting_page":"185","ending_page":"190","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12328-016-0711-2"],"issn":["1865-7265"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2003322","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27557726","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=319206","label":"url"}],"paper_title":{"en":"Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative acute kidney injury","ja":"Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative acute kidney injury"},"authors":{"en":[{"name":"Mita Naoji"},{"name":"Kawahito Shinji"},{"name":"Soga Tomohiro"},{"name":"Takaishi Kazumi"},{"name":"Kitahata Hiroshi"},{"name":"Matsuhisa Munehide"},{"name":"Shimada Mitsuo"},{"name":"Hiroyuki Kinoshita"},{"name":"Tsutsumi Yasuo"},{"name":"Tanaka Katsuya"}],"ja":[{"name":"箕田 直治"},{"name":"川人 伸次"},{"name":"曽我 朋宏"},{"name":"高石 和美"},{"name":"北畑 洋"},{"name":"松久 宗英"},{"name":"島田 光生"},{"name":"Hiroyuki Kinoshita"},{"name":"堤 保夫"},{"name":"田中 克哉"}]},"description":{"en":"The aim of the present study was to evaluate the usefulness of a closed-loop system (STG-55; Nikkiso, Tokyo, Japan), a type of artificial endocrine pancreas for the continuous monitoring and control of intraoperative blood glucose, for preventing postoperative acute kidney injury (AKI) in patients undergoing hepatectomy. Thirty-eight patients were enrolled in this study. Glucose concentrations were controlled with either a manual injection of insulin based on a commonly used sliding scale (manual insulin group, n = 19) or the programmed infusion of insulin determined by the control algorithm of the artificial endocrine pancreas (programmed insulin group, n = 19). After the induction of anesthesia, a 20-G intravenous catheter was inserted into the peripheral forearm vein of patients in the programmed insulin group and connected to an artificial endocrine pancreas (STG-55). The target range for glucose concentrations was set to 100-150 mg/dL. The mean serum creatinine concentrations of preoperative, postoperative 24 and 48 h were 0.72, 0.78, and 0.79 mg/dL in the programmed insulin group, and 0.81, 0.95, and 1.03 mg/dL in the manual insulin group, respectively. Elevations in serum creatinine concentrations postoperative 48 h were significantly suppressed in the programmed insulin group. The STG-55 closed-loop system was effective for maintaining strict blood glucose control during hepatectomy with minimal variability in blood glucose concentrations and for suppressing elevations in serum creatinine concentrations. Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative AKI.","ja":"The aim of the present study was to evaluate the usefulness of a closed-loop system (STG-55; Nikkiso, Tokyo, Japan), a type of artificial endocrine pancreas for the continuous monitoring and control of intraoperative blood glucose, for preventing postoperative acute kidney injury (AKI) in patients undergoing hepatectomy. Thirty-eight patients were enrolled in this study. Glucose concentrations were controlled with either a manual injection of insulin based on a commonly used sliding scale (manual insulin group, n = 19) or the programmed infusion of insulin determined by the control algorithm of the artificial endocrine pancreas (programmed insulin group, n = 19). After the induction of anesthesia, a 20-G intravenous catheter was inserted into the peripheral forearm vein of patients in the programmed insulin group and connected to an artificial endocrine pancreas (STG-55). The target range for glucose concentrations was set to 100-150 mg/dL. The mean serum creatinine concentrations of preoperative, postoperative 24 and 48 h were 0.72, 0.78, and 0.79 mg/dL in the programmed insulin group, and 0.81, 0.95, and 1.03 mg/dL in the manual insulin group, respectively. Elevations in serum creatinine concentrations postoperative 48 h were significantly suppressed in the programmed insulin group. The STG-55 closed-loop system was effective for maintaining strict blood glucose control during hepatectomy with minimal variability in blood glucose concentrations and for suppressing elevations in serum creatinine concentrations. Strict blood glucose control by an artificial endocrine pancreas during hepatectomy may prevent postoperative AKI."},"publication_date":"2017-03","publication_name":{"en":"Journal of Artificial Organs","ja":"Journal of Artificial Organs"},"volume":"20","number":"1","starting_page":"76","ending_page":"83","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10047-016-0925-6"],"issn":["1619-0904"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28303455","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85015616972","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=323307","label":"url"}],"paper_title":{"en":"Duodenal cancer in a young patient with Peuts-Jeghers syndrome harboring an entire deletion of the STK11 gene.","ja":"Duodenal cancer in a young patient with Peuts-Jeghers syndrome harboring an entire deletion of the STK11 gene."},"authors":{"en":[{"name":"Teramae Satoshi"},{"name":"Okamoto Koichi"},{"name":"Tanaka Kumiko"},{"name":"Matsumoto Reika"},{"name":"Kitamura Shinji"},{"name":"Kimura Tetsuo"},{"name":"Sogabe Masahiro"},{"name":"Miyamoto Hiroshi"},{"name":"Muguruma Naoki"},{"name":"Bando Yoshimi"},{"name":"Shimada Mitsuo"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"Teramae Satoshi"},{"name":"岡本 耕一"},{"name":"田中 久美子"},{"name":"Matsumoto Reika"},{"name":"北村 晋志"},{"name":"木村 哲夫"},{"name":"曽我部 正弘"},{"name":"宮本 弘志"},{"name":"六車 直樹"},{"name":"坂東 良美"},{"name":"島田 光生"},{"name":"高山 哲治"}]},"publication_date":"2017-03","publication_name":{"en":"Clinical Journal of Gastroenterology","ja":"Clinical Journal of Gastroenterology"},"volume":"10","number":"3","starting_page":"232","ending_page":"239","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12328-017-0731-6"],"issn":["1865-7257"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2005526","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28032929","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=321989","label":"url"}],"paper_title":{"en":"Downregulation of miR-100/miR-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion.","ja":"Downregulation of miR-100/miR-125b is associated with lymph node metastasis in early colorectal cancer with submucosal invasion."},"authors":{"en":[{"name":"Fujino Yasuteru"},{"name":"Takeishi Shunsaku"},{"name":"Nishida Kensei"},{"name":"Okamoto Koichi"},{"name":"Muguruma Naoki"},{"name":"Kimura Tetsuo"},{"name":"Kitamura Shinji"},{"name":"Miyamoto Hiroshi"},{"name":"Fujimoto Akiko"},{"name":"Higashijima Jun"},{"name":"Shimada Mitsuo"},{"name":"Rokutan Kazuhito"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"藤野 泰輝"},{"name":"武石 俊作"},{"name":"西田 憲生"},{"name":"岡本 耕一"},{"name":"六車 直樹"},{"name":"木村 哲夫"},{"name":"北村 晋志"},{"name":"宮本 弘志"},{"name":"Fujimoto Akiko"},{"name":"東島 潤"},{"name":"島田 光生"},{"name":"六反 一仁"},{"name":"高山 哲治"}]},"description":{"en":"A majority of early colorectal cancers (CRCs) with submucosal invasion undergo surgical operation, despite a very low incidence of lymph node metastasis. Our study aimed to identify microRNAs (miRNAs) specifically responsible for lymph node metastasis in submucosal CRCs. MicroRNA microarray analysis revealed that miR-100 and miR-125b expression levels were significantly lower in CRC tissues with lymph node metastases than in those without metastases. These results were validated by quantitative real-time PCR in a larger set of clinical samples. The transfection of a miR-100 or miR-125b inhibitor into colon cancer HCT116 cells significantly increased cell invasion, migration, and MMP activity. Conversely, overexpression of miR-100 or miR-125b mimics significantly attenuated all these activities but did not affect cell growth. To identify target mRNAs, we undertook a gene expression array analysis of miR-100-silenced HCT116 cells as well as negative control cells. The Ingenuity Pathway Analysis, TargetScan software analyses, and subsequent verification of mRNA expression by real-time PCR identified mammalian target of rapamycin (mTOR) and insulin-like growth factor 1 receptor (IGF1R) as direct, and Fas and X-linked inhibitor-of-apoptosis protein (XIAP) as indirect candidate targets for miR-100 involved in lymph node metastasis. Knockdown of each gene by siRNA significantly reduced the invasiveness of HCT116 cells. These data clearly show that downregulation of miR-100 and miR-125b is closely associated with lymph node metastasis in submucosal CRC through enhancement of invasion, motility, and MMP activity. In particular, miR-100 may promote metastasis by upregulating mTOR, IGF1R, Fas, and XIAP as targets. Thus, miR-100 and miR-125b may be novel biomarkers for lymph node metastasis of early CRCs with submucosal invasion.","ja":"A majority of early colorectal cancers (CRCs) with submucosal invasion undergo surgical operation, despite a very low incidence of lymph node metastasis. Our study aimed to identify microRNAs (miRNAs) specifically responsible for lymph node metastasis in submucosal CRCs. MicroRNA microarray analysis revealed that miR-100 and miR-125b expression levels were significantly lower in CRC tissues with lymph node metastases than in those without metastases. These results were validated by quantitative real-time PCR in a larger set of clinical samples. The transfection of a miR-100 or miR-125b inhibitor into colon cancer HCT116 cells significantly increased cell invasion, migration, and MMP activity. Conversely, overexpression of miR-100 or miR-125b mimics significantly attenuated all these activities but did not affect cell growth. To identify target mRNAs, we undertook a gene expression array analysis of miR-100-silenced HCT116 cells as well as negative control cells. The Ingenuity Pathway Analysis, TargetScan software analyses, and subsequent verification of mRNA expression by real-time PCR identified mammalian target of rapamycin (mTOR) and insulin-like growth factor 1 receptor (IGF1R) as direct, and Fas and X-linked inhibitor-of-apoptosis protein (XIAP) as indirect candidate targets for miR-100 involved in lymph node metastasis. Knockdown of each gene by siRNA significantly reduced the invasiveness of HCT116 cells. These data clearly show that downregulation of miR-100 and miR-125b is closely associated with lymph node metastasis in submucosal CRC through enhancement of invasion, motility, and MMP activity. In particular, miR-100 may promote metastasis by upregulating mTOR, IGF1R, Fas, and XIAP as targets. Thus, miR-100 and miR-125b may be novel biomarkers for lymph node metastasis of early CRCs with submucosal invasion."},"publication_date":"2017-03","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"108","number":"3","starting_page":"390","ending_page":"397","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/cas.13152"],"issn":["1349-7006"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"26645019"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27262570","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=331242","label":"url"}],"paper_title":{"en":"Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma.","ja":"Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma."},"authors":{"en":[{"name":"Kimura Tetsuo"},{"name":"Miyamoto Hiroshi"},{"name":"Fukuya Akira"},{"name":"Kitamura Shinji"},{"name":"Okamoto Koichi"},{"name":"Kimura Masako"},{"name":"Muguruma Naoki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"},{"name":"Yoneda Akiko"},{"name":"Bando Yoshimi"},{"name":"Takishita Makoto"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"木村 哲夫"},{"name":"宮本 弘志"},{"name":"Fukuya Akira"},{"name":"北村 晋志"},{"name":"岡本 耕一"},{"name":"木村 雅子"},{"name":"六車 直樹"},{"name":"池本 哲也"},{"name":"島田 光生"},{"name":"米田 亜樹子"},{"name":"坂東 良美"},{"name":"Takishita Makoto"},{"name":"高山 哲治"}]},"description":{"en":"Neuroendocrine carcinoma (NEC) of the pancreas is very rare, and its origin is not fully elucidated. Here, we present a case of a small-size NEC of the pancreas that is genetically similar to invasive ductal adenocarcinoma (IDA). A 65-year-old man was referred to our hospital due to obstructive jaundice and found to have a 12-mm solid tumor in the pancreas head. The tumor exhibited low vascularity on enhanced computed tomography, and endoscopic retrograde pancreatographic imaging revealed an irregular obstruction in a branch duct of the pancreas. The patient was thereby diagnosed with a pancreatic ductal cancer, and stomach-preserving pancreaticoduodenectomy with regional lymph node resection was performed. Histochemical analysis of the resected tumor showed that the neoplastic cells with scanty cytoplasm and hyperchromatic nuclei strongly expressed chromogranin A and synaptophysin. The Ki-67 index was 40 % in the most proliferative tumor regions, and the tumor was diagnosed as a NEC of the pancreas. However, in the analysis of genetic alterations of the tumor tissue, the neoplastic cells showed altered KRAS, TP53, and SMAD4/DPC4, suggesting that the NEC in our case is genetically related to IDA. Our data suggest that poorly differentiated IDAs may transform into NECs.","ja":"Neuroendocrine carcinoma (NEC) of the pancreas is very rare, and its origin is not fully elucidated. Here, we present a case of a small-size NEC of the pancreas that is genetically similar to invasive ductal adenocarcinoma (IDA). A 65-year-old man was referred to our hospital due to obstructive jaundice and found to have a 12-mm solid tumor in the pancreas head. The tumor exhibited low vascularity on enhanced computed tomography, and endoscopic retrograde pancreatographic imaging revealed an irregular obstruction in a branch duct of the pancreas. The patient was thereby diagnosed with a pancreatic ductal cancer, and stomach-preserving pancreaticoduodenectomy with regional lymph node resection was performed. Histochemical analysis of the resected tumor showed that the neoplastic cells with scanty cytoplasm and hyperchromatic nuclei strongly expressed chromogranin A and synaptophysin. The Ki-67 index was 40 % in the most proliferative tumor regions, and the tumor was diagnosed as a NEC of the pancreas. However, in the analysis of genetic alterations of the tumor tissue, the neoplastic cells showed altered KRAS, TP53, and SMAD4/DPC4, suggesting that the NEC in our case is genetically related to IDA. Our data suggest that poorly differentiated IDAs may transform into NECs."},"publication_date":"2016-08","publication_name":{"en":"Clinical Journal of Gastroenterology","ja":"Clinical Journal of Gastroenterology"},"volume":"9","number":"4","starting_page":"261","ending_page":"265","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s12328-016-0655-6"],"issn":["1865-7265"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2004470","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26399352","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=306984","label":"url"}],"paper_title":{"en":"New ports placement in laparoscopic central lymph nodes dissection with left colic artery preservation for sigmoid colon and rectal cancer.","ja":"New ports placement in laparoscopic central lymph nodes dissection with left colic artery preservation for sigmoid colon and rectal cancer."},"authors":{"en":[{"name":"Higashijima Jun"},{"name":"Shimada Mitsuo"},{"name":"Iwata Takashi"},{"name":"Yoshikawa Kouzou"},{"name":"Nakao Toshihiro"},{"name":"Nishi Masaaki"},{"name":"Kashihara Hideya"},{"name":"Takasu Chie"}],"ja":[{"name":"東島 潤"},{"name":"島田 光生"},{"name":"岩田 貴"},{"name":"吉川 幸造"},{"name":"中尾 寿宏"},{"name":"西 正暁"},{"name":"柏原 秀也"},{"name":"髙須 千絵"}]},"description":{"en":"Lymph nodes (LNs) dissection around inferior mesenteric artery (IMA) with left colic artery (LCA) preservation is difficult due to the anatomical feature of IMA. The aim of this study is to evaluate the usefulness of new ports placement inserted from a suprapubic region in laparoscopic LNs dissection around IMA with LCA preservation for sigmoid colon and ractal cancer. Twenty-two patients who underwent laparoscopic colectomy for sigmoid colon and recal cancer were included. The new ports placement group (n=15, new group) was compared with the basic ports placement group (n=7, basic group). Average number of harvested LNs, total operation time, central LNs dissection time, intraoperative blood loss were compared. There was no significant difference in the average number of harvested LNs. The mean of intraoperative blood loss of new group was significantly lower than that of the basic group (40.0±39.8 ml vs 95.7±81.0 ml, p<0.05). In addition, the mean of operation time of the new group was significantly shorter than that of the basic group (250.0±55.7 min vs 353.4±80.2 min, p<0.05). The new ports placement is useful in laparoscopic LNs dissection around IMA with LCA preservation for sigmoid colon and rectal cancer.","ja":"Lymph nodes (LNs) dissection around inferior mesenteric artery (IMA) with left colic artery (LCA) preservation is difficult due to the anatomical feature of IMA. The aim of this study is to evaluate the usefulness of new ports placement inserted from a suprapubic region in laparoscopic LNs dissection around IMA with LCA preservation for sigmoid colon and ractal cancer. Twenty-two patients who underwent laparoscopic colectomy for sigmoid colon and recal cancer were included. The new ports placement group (n=15, new group) was compared with the basic ports placement group (n=7, basic group). Average number of harvested LNs, total operation time, central LNs dissection time, intraoperative blood loss were compared. There was no significant difference in the average number of harvested LNs. The mean of intraoperative blood loss of new group was significantly lower than that of the basic group (40.0±39.8 ml vs 95.7±81.0 ml, p<0.05). In addition, the mean of operation time of the new group was significantly shorter than that of the basic group (250.0±55.7 min vs 353.4±80.2 min, p<0.05). The new ports placement is useful in laparoscopic LNs dissection around IMA with LCA preservation for sigmoid colon and rectal cancer."},"publication_date":"2015","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"62","number":"3-4","starting_page":"223","ending_page":"227","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.62.223"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"26520097"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/22469734","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=252592","label":"url"}],"paper_title":{"en":"Treatment of rapid weight loss in a donor with hepatic steatosis in a living donor liver transplantation: a case report","ja":"Treatment of rapid weight loss in a donor with hepatic steatosis in a living donor liver transplantation: a case report"},"authors":{"en":[{"name":"Okumura Hisami"},{"name":"Kawaura Akihiko"},{"name":"Imura Satoru"},{"name":"Utsunomiya Toru"},{"name":"Shimada Mitsuo"},{"name":"Takeda Eiji"}],"ja":[{"name":"奥村 仙示"},{"name":"Kawaura Akihiko"},{"name":"居村 暁"},{"name":"宇都宮 徹"},{"name":"島田 光生"},{"name":"武田 英二"}]},"description":{"en":"The use of steatotic livers for transplantation is often associated with increased primary non-function. To reduce the risk of liver injury, steatosis of the donor liver in living donor liver transplantation (LDLT) was treated with restricted diet and exercise. A 21-year-old male donor, 167cm in height and 87kg in body weight, initially received a 1800kcal/day diet for 9 days which was then gradually reduced using a 1600kcal/day diet for 43 days, followed by a 1500kcal/day diet for one day and was finally maintained on a 1400kcal/day diet for 52 days. Daily exercise consumed 500kcal/day. The non-protein respiratory quotient (npRQ) gradually increased while the non-esterified fatty acids (NEFA) decreased during the course of the 105-day treatment. Consequently, the initial 80% steatosis was reduced to 10% and was accompanied by 13% weight loss for 81 days. The npRQ values and NEFA concentrations in the later period of dietary and exercise treatment were higher and lower, respectively, than in the early treatment period, indicating compensation through long-term treatment. Therefore, energy metabolism and NEFA levels represent important biomarkers for short-term intensive treatment by restricted diet and exercise in donors with hepatic steatosis.","ja":"The use of steatotic livers for transplantation is often associated with increased primary non-function. To reduce the risk of liver injury, steatosis of the donor liver in living donor liver transplantation (LDLT) was treated with restricted diet and exercise. A 21-year-old male donor, 167cm in height and 87kg in body weight, initially received a 1800kcal/day diet for 9 days which was then gradually reduced using a 1600kcal/day diet for 43 days, followed by a 1500kcal/day diet for one day and was finally maintained on a 1400kcal/day diet for 52 days. Daily exercise consumed 500kcal/day. The non-protein respiratory quotient (npRQ) gradually increased while the non-esterified fatty acids (NEFA) decreased during the course of the 105-day treatment. Consequently, the initial 80% steatosis was reduced to 10% and was accompanied by 13% weight loss for 81 days. The npRQ values and NEFA concentrations in the later period of dietary and exercise treatment were higher and lower, respectively, than in the early treatment period, indicating compensation through long-term treatment. Therefore, energy metabolism and NEFA levels represent important biomarkers for short-term intensive treatment by restricted diet and exercise in donors with hepatic steatosis."},"publication_date":"2012-05","publication_name":{"en":"Hepato-Gastroenterology","ja":"Hepato-Gastroenterology"},"volume":"59","number":"115","starting_page":"869","ending_page":"871","languages":["eng"],"referee":true,"identifiers":{"doi":["10.5754/hge10237"],"issn":["0172-6390"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=267365","label":"url"}],"paper_title":{"en":"II-4 抗癌剤 「肝胆膵」","ja":"II-4 抗癌剤 「肝胆膵」"},"authors":{"en":[{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"池本 哲也"},{"name":"島田 光生"}]},"publication_date":"2012-03","publication_name":{"en":"消化器外科レビュー","ja":"消化器外科レビュー"},"volume":"2012","starting_page":"216","ending_page":"221","languages":["jpn"],"referee":true,"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/19758670","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=233037","label":"url"}],"paper_title":{"en":"Dual hepatic artery reconstruction in living donor liver transplantation using a left hepatic graft with 2 hepatic arterial stumps.","ja":"Dual hepatic artery reconstruction in living donor liver transplantation using a left hepatic graft with 2 hepatic arterial stumps."},"authors":{"en":[{"name":"Uchiyama Hideaki"},{"name":"Harada Noboru"},{"name":"Sanefuji Kensaku"},{"name":"Kayashima Hiroto"},{"name":"Taketomi Akinobu"},{"name":"Soejima Yuji"},{"name":"Ikegami Toru"},{"name":"Shimada Mitsuo"},{"name":"Maehara Yoshihiko"}],"ja":[{"name":"内山 秀昭"},{"name":"Harada Noboru"},{"name":"Sanefuji Kensaku"},{"name":"Kayashima Hiroto"},{"name":"Taketomi Akinobu"},{"name":"副島 雄二"},{"name":"池上 徹"},{"name":"島田 光生"},{"name":"Maehara Yoshihiko"}]},"description":{"en":"A left hepatic graft in living donor liver transplantation (LDLT) often has 2 thin and short hepatic arterial stumps, which makes hepatic artery (HA) reconstructions much more difficult to perform. Consequently, some investigators regard using a left graft as a contraindication to LDLT, whereas others report that the reconstruction of only 1 HA is sufficient for most LDLTs. The aim of this retrospective study was to investigate whether 2 HAs on a left hepatic graft in an LDLT can be reconstructed safely and whether the outcomes of LDLTs are affected by reconstructing both HAs (dual reconstruction).","ja":"A left hepatic graft in living donor liver transplantation (LDLT) often has 2 thin and short hepatic arterial stumps, which makes hepatic artery (HA) reconstructions much more difficult to perform. Consequently, some investigators regard using a left graft as a contraindication to LDLT, whereas others report that the reconstruction of only 1 HA is sufficient for most LDLTs. The aim of this retrospective study was to investigate whether 2 HAs on a left hepatic graft in an LDLT can be reconstructed safely and whether the outcomes of LDLTs are affected by reconstructing both HAs (dual reconstruction)."},"publication_date":"2009-09-15","publication_name":{"en":"Surgery","ja":"Surgery"},"volume":"147","number":"6","starting_page":"878","ending_page":"886","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.surg.2009.06.028"],"issn":["1532-7361"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"29754483"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2003988","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/16537999","label":"url"},{"@id":"https://www.scopus.com/pages/publications/33645835974","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=161350","label":"url"}],"paper_title":{"en":"Prevention of lethal hepatic injury in Long-Evans Cinnamon(LEC) rats by D-galactosamine hydrochloride","ja":"Prevention of lethal hepatic injury in Long-Evans Cinnamon(LEC) rats by D-galactosamine hydrochloride"},"authors":{"en":[{"name":"Toshihiro Otsuka"},{"name":"Izumi Keisuke"},{"name":"Tokunaga Itsuo"},{"name":"Gotohda Takako"},{"name":"Kaneshige Ipposhi"},{"name":"Takiguchi Yoshiharu"},{"name":"Shinya Kaneda"},{"name":"Satake Nobuo"},{"name":"Ohnishi Takamasa"},{"name":"Tashiro Seiki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Toshihiro Otsuka"},{"name":"泉 啓介"},{"name":"徳永 逸夫"},{"name":"後藤田 貴子"},{"name":"Kaneshige Ipposhi"},{"name":"滝口 祥令"},{"name":"Shinya Kaneda"},{"name":"佐竹 宣法"},{"name":"大西 隆仁"},{"name":"田代 征記"},{"name":"島田 光生"}]},"description":{"en":"Repeated injections of D-galactosamine hydrochloride (GalN) increase the survival rate of Long-Evans Cinnamon (LEC) rats, an animal model of Wilson's disease. The aim of the present study was to investigate the mechanism of GalN for prevention of spontaneous lethal hepatic injury in LEC rats. Male LEC rats were given a single subcutaneous injection of 300 mg/kg of GalN or vehicle (0.9% NaCl) at 14 weeks, and killed at 28 weeks of age. Next, 6-week-old male LEC rats were given weekly subcutaneous injections of 300 mg/kg of GalN or vehicle for 3 or 12 weeks, and their hepatic 8-hydroxydeoxy-2'-guanosine (8-OHdG), glutathione peroxidase (GPX), and catalase activities were measured. None of GalN-treated rats died of hepatic injury (0/12), whereas the mortality rate of control rats given 0.9% NaCl was 17% (2/12). GalN administration for 12 weeks decreased the hepatic 8-OHdG, and GalN administration for either 3 or 12 weeks increased the glutathione peroxidase activity. GalN administration increased the serum level of alanine aminotransferase, and accelerated megalocytic degeneration of the hepatocytes. GalN treatment is effective in preventing lethal hepatitis in LEC rats and decrease of oxidative DNA damage by GalN plays an important role in increase of the survival rate.","ja":"Repeated injections of D-galactosamine hydrochloride (GalN) increase the survival rate of Long-Evans Cinnamon (LEC) rats, an animal model of Wilson's disease. The aim of the present study was to investigate the mechanism of GalN for prevention of spontaneous lethal hepatic injury in LEC rats. Male LEC rats were given a single subcutaneous injection of 300 mg/kg of GalN or vehicle (0.9% NaCl) at 14 weeks, and killed at 28 weeks of age. Next, 6-week-old male LEC rats were given weekly subcutaneous injections of 300 mg/kg of GalN or vehicle for 3 or 12 weeks, and their hepatic 8-hydroxydeoxy-2'-guanosine (8-OHdG), glutathione peroxidase (GPX), and catalase activities were measured. None of GalN-treated rats died of hepatic injury (0/12), whereas the mortality rate of control rats given 0.9% NaCl was 17% (2/12). GalN administration for 12 weeks decreased the hepatic 8-OHdG, and GalN administration for either 3 or 12 weeks increased the glutathione peroxidase activity. GalN administration increased the serum level of alanine aminotransferase, and accelerated megalocytic degeneration of the hepatocytes. GalN treatment is effective in preventing lethal hepatitis in LEC rats and decrease of oxidative DNA damage by GalN plays an important role in increase of the survival rate."},"publication_date":"2006-01-01","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"53","number":"1-2","starting_page":"81","ending_page":"86","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.53.81"],"issn":["1343-1420"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"29681069"},"force":{"see_also":[{"@id":"http://clincancerres.aacrjournals.org/cgi/content/abstract/9/7/2657","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/12855644","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=93000","label":"url"}],"paper_title":{"en":"Transcriptional repressor snail and progression of human hepatocellular carcinoma.","ja":"Transcriptional repressor snail and progression of human hepatocellular carcinoma."},"authors":{"en":[{"name":"Sugimachi Keishi"},{"name":"Tanaka Shinji"},{"name":"Kameyama Toshifumi"},{"name":"Taguchi Ken-ichi"},{"name":"Aishima Shin-ichi"},{"name":"Shimada Mitsuo"},{"name":"Sugimachi Keizo"},{"name":"Tsuneyoshi Masazumi"}],"ja":[{"name":"Sugimachi Keishi"},{"name":"Tanaka Shinji"},{"name":"Kameyama Toshifumi"},{"name":"Taguchi Ken-ichi"},{"name":"Aishima Shin-ichi"},{"name":"島田 光生"},{"name":"Sugimachi Keizo"},{"name":"Tsuneyoshi Masazumi"}]},"description":{"en":"Snail protein is a suppressive transcriptional factor of E-cadherin that mediates cell-to-cell adhesion, tumor progression, and metastases. We explored the expression and function of Snail and its family member Slug in human hepatocellular carcinoma (HCC) to identify its role in tumor progression. Transfection of Snail cDNA in Li-7, endogenous E-cadherin-positive human HCC cells, selectively induced the loss of E-cadherin protein expression. We then investigated the expression of Snail and Slug mRNA in 43 human tissue samples of HCC. Using in situ hybridization, Snail mRNA was determined to dominantly express in HCC cells, but not in bile duct cells, blood vessels or infiltrating leukocytes. The mRNA of Snail and Slug were quantified using real-time reverse transcriptase-PCR, and correlations with E-cadherin expression and clinicopathological factors were investigated. Snail mRNA was overexpressed in 7 cases (16%) of HCC compared with adjacent noncancerous liver tissue. E-Cadherin protein expression determined in the same 43 cases by immunohistochemistry was significantly down-regulated in those cases with Snail mRNA overexpression (P = 0.04). The tumor and nontumor ratio of Snail mRNA independently correlated with tumor invasiveness (P = 0.04). However, Slug mRNA correlated with neither E-cadherin expression nor tumor invasiveness. The data indicate that Snail both down-regulates E-cadherin expression and promotes the invasion in human HCC.","ja":"Snail protein is a suppressive transcriptional factor of E-cadherin that mediates cell-to-cell adhesion, tumor progression, and metastases. We explored the expression and function of Snail and its family member Slug in human hepatocellular carcinoma (HCC) to identify its role in tumor progression. Transfection of Snail cDNA in Li-7, endogenous E-cadherin-positive human HCC cells, selectively induced the loss of E-cadherin protein expression. We then investigated the expression of Snail and Slug mRNA in 43 human tissue samples of HCC. Using in situ hybridization, Snail mRNA was determined to dominantly express in HCC cells, but not in bile duct cells, blood vessels or infiltrating leukocytes. The mRNA of Snail and Slug were quantified using real-time reverse transcriptase-PCR, and correlations with E-cadherin expression and clinicopathological factors were investigated. Snail mRNA was overexpressed in 7 cases (16%) of HCC compared with adjacent noncancerous liver tissue. E-Cadherin protein expression determined in the same 43 cases by immunohistochemistry was significantly down-regulated in those cases with Snail mRNA overexpression (P = 0.04). The tumor and nontumor ratio of Snail mRNA independently correlated with tumor invasiveness (P = 0.04). However, Slug mRNA correlated with neither E-cadherin expression nor tumor invasiveness. The data indicate that Snail both down-regulates E-cadherin expression and promotes the invasion in human HCC."},"publication_date":"2003-06","publication_name":{"en":"Clinical Cancer Research","ja":"Clinical Cancer Research"},"volume":"9","number":"7","starting_page":"2657","ending_page":"2664","languages":["eng"],"referee":true,"identifiers":{"issn":["1078-0432"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381200"},"force":{"see_also":[{"@id":"http://www.transplantjournal.com/pt/re/transplantation/abstract.00007890-200302270-00025.htm;jsessionid=EYHAwiQ6XrKtNTTHu1DMmM03swS1AfasjO5byljCKtrF2E1Xd8gz!-1070481199!-949856145!9001!-1","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/12605127","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=93004","label":"url"}],"paper_title":{"en":"Feasibility of duct-to-duct biliary reconstruction in left-lobe adult-living-donor liver transplantation","ja":"Feasibility of duct-to-duct biliary reconstruction in left-lobe adult-living-donor liver transplantation"},"authors":{"en":[{"name":"Soejima Yuji"},{"name":"Shimada Mitsuo"},{"name":"Suehiro Taketoshi"},{"name":"Kishikawa Keiji"},{"name":"Minagawa Ryosuke"},{"name":"Hiroshige Shoji"},{"name":"Ninomiya Mizuki"},{"name":"Shiotani Satoko"},{"name":"Harada Noboru"},{"name":"Sugimachi Keizo"}],"ja":[{"name":"副島 雄二"},{"name":"島田 光生"},{"name":"Suehiro Taketoshi"},{"name":"Kishikawa Keiji"},{"name":"Minagawa Ryosuke"},{"name":"Hiroshige Shoji"},{"name":"Ninomiya Mizuki"},{"name":"Shiotani Satoko"},{"name":"Harada Noboru"},{"name":"Sugimachi Keizo"}]},"description":{"en":"A Roux-en-Y choledochojejunostomy (CDJ) has been the sole method of choice for the reconstruction of the bile duct in living-donor liver transplantation (LDLT) using left-lobe grafts. In this study, we evaluated the feasibility of duct-to-duct (DD) biliary reconstruction in adult-to-adult LDLT using left-lobe grafts. Between October 1996 and October 2001, 46 adult-to-adult LDLTs using the left lobe were performed at our institution. The DD biliary reconstruction (hepaticocholedochostomy) over a T-tube was performed for seven of the last nine recipients (DD group, n=7), whereas the conventional Roux-en-Y CDJ was used for the remaining cases (CDJ group, n=39). The technical problems and the incidence of biliary complications were compared between the groups. Bile leakage developed in only 1 of 7 (14%) in the DD group (leakage from a T-tube exit site), whereas it occurred in 8 of 39 (20%) in the CDJ group. Up to now, no patients from the DD group developed anastomotic stricture, whereas twelve (30.7%) patients from the CDJ group did. Other complications included bleeding from the Roux-en-Y jejunojejunostomy (n=1) and anastomotic occlusion caused by an internal stent (n=1), and both complications were associated with CDJ. In conclusion, DD anastomosis is a simple and viable option for biliary reconstruction in left-lobe LDLTs. A long-term follow-up, especially regarding the incidence of biliary stricture, is thus warranted in such patients.","ja":"A Roux-en-Y choledochojejunostomy (CDJ) has been the sole method of choice for the reconstruction of the bile duct in living-donor liver transplantation (LDLT) using left-lobe grafts. In this study, we evaluated the feasibility of duct-to-duct (DD) biliary reconstruction in adult-to-adult LDLT using left-lobe grafts. Between October 1996 and October 2001, 46 adult-to-adult LDLTs using the left lobe were performed at our institution. The DD biliary reconstruction (hepaticocholedochostomy) over a T-tube was performed for seven of the last nine recipients (DD group, n=7), whereas the conventional Roux-en-Y CDJ was used for the remaining cases (CDJ group, n=39). The technical problems and the incidence of biliary complications were compared between the groups. Bile leakage developed in only 1 of 7 (14%) in the DD group (leakage from a T-tube exit site), whereas it occurred in 8 of 39 (20%) in the CDJ group. Up to now, no patients from the DD group developed anastomotic stricture, whereas twelve (30.7%) patients from the CDJ group did. Other complications included bleeding from the Roux-en-Y jejunojejunostomy (n=1) and anastomotic occlusion caused by an internal stent (n=1), and both complications were associated with CDJ. In conclusion, DD anastomosis is a simple and viable option for biliary reconstruction in left-lobe LDLTs. A long-term follow-up, especially regarding the incidence of biliary stricture, is thus warranted in such patients."},"publication_date":"2003-02-27","publication_name":{"en":"Transplantation","ja":"Transplantation"},"volume":"75","number":"4","starting_page":"557","ending_page":"559","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1097/01.TP.0000048220.90971.5A"],"issn":["0041-1337"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://cat.inist.fr/?aModele=afficheN&cpsidt=1054176","label":"url"},{"@id":"https://www.scopus.com/pages/publications/0034990733","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=92327","label":"url"}],"paper_title":{"en":"Laparoscopic hepatectomy for hepatocellular carcinoma","ja":"Laparoscopic hepatectomy for hepatocellular carcinoma"},"authors":{"en":[{"name":"Shimada Mitsuo"},{"name":"Hashizume Makoto"},{"name":"Maehara Shin-ichiro"},{"name":"Tsujita Eiji"},{"name":"Rikimaru Tatsuya"},{"name":"Yamashita Yo-ichi"},{"name":"Tanaka Shinji"},{"name":"Adachi Eisuke"},{"name":"Sugimachi Keizo"}],"ja":[{"name":"島田 光生"},{"name":"Hashizume Makoto"},{"name":"Maehara Shin-ichiro"},{"name":"Tsujita Eiji"},{"name":"Rikimaru Tatsuya"},{"name":"Yamashita Yo-ichi"},{"name":"Tanaka Shinji"},{"name":"Adachi Eisuke"},{"name":"Sugimachi Keizo"}]},"publication_date":"2001-05","publication_name":{"en":"Surgical Endoscopy","ja":"Surgical Endoscopy"},"volume":"15","number":"6","starting_page":"541","ending_page":"544","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s004640080099"],"issn":["1432-2218"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/11221826","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=92309","label":"url"}],"paper_title":{"en":"Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model","ja":"Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model"},"authors":{"en":[{"name":"Yamashita Yo-ichi"},{"name":"Shimada Mitsuo"},{"name":"Hasegawa Hirofumi"},{"name":"Minagawa Ryosuke"},{"name":"Rikimaru Tatsuya"},{"name":"Hamatsu Takayuki"},{"name":"Tanaka Shinji"},{"name":"Shirabe Ken"},{"name":"Miyazaki Jun-ichi"},{"name":"Sugimachi Keizo"}],"ja":[{"name":"Yamashita Yo-ichi"},{"name":"島田 光生"},{"name":"Hasegawa Hirofumi"},{"name":"Minagawa Ryosuke"},{"name":"Rikimaru Tatsuya"},{"name":"Hamatsu Takayuki"},{"name":"Tanaka Shinji"},{"name":"Shirabe Ken"},{"name":"Miyazaki Jun-ichi"},{"name":"Sugimachi Keizo"}]},"description":{"en":"Applications of nonviral vectors for gene transfer into tumors in vivo have been limited by the relatively low expression levels of the transferred gene. The aim of this study is to evaluate the efficacy of electroporation-mediated interleukin-12 (IL-12) gene therapy for hepatocellular carcinoma (HCC). First, we investigated the optimal conditions of electric pulses (voltage, pulsing duration, numbers of shocks) of in vivo electroporation for gene transfer into HCC established by s.c. implantation of MH134 cells to C3H mice. This process made use of plasmid DNA that express the luciferase gene. We concluded that the optimal conditions for the electric pulses are as follows: voltage at 150 V; pulsing duration at 50 ms; nonpulsing duration at 950 ms; and the number of shocks at 10. Second, we tried to treat s.c. HCC by electroporation using plasmid DNA that expresses the murine interleukin-12 (mlL-12) gene. Intratumoral administration of the mIL-12 vector elevated serum IL-12 and IFN-gamma and significantly inhibited the growth not only of HCC into which the mIL-12 vector had been directly transferred, but also of the distant HCC. In addition, intratumoral administration of the mIL-12 vector inhibited spontaneous lung metastasis and delayed establishment of HCC injected 3 days after mIL-12 gene therapy. The IL-12 gene therapy induced more lymphocyte infiltration by NK cells, CD3+ cells, and Mac-1 positive cells into the tumor and reduced the number of microvessels. Therefore, more terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive tumor cells were found. These results demonstrate that gene therapy for HCC by electroporation in vivo using IL-12 is very efficient and is thus promising for further clinical trial.","ja":"Applications of nonviral vectors for gene transfer into tumors in vivo have been limited by the relatively low expression levels of the transferred gene. The aim of this study is to evaluate the efficacy of electroporation-mediated interleukin-12 (IL-12) gene therapy for hepatocellular carcinoma (HCC). First, we investigated the optimal conditions of electric pulses (voltage, pulsing duration, numbers of shocks) of in vivo electroporation for gene transfer into HCC established by s.c. implantation of MH134 cells to C3H mice. This process made use of plasmid DNA that express the luciferase gene. We concluded that the optimal conditions for the electric pulses are as follows: voltage at 150 V; pulsing duration at 50 ms; nonpulsing duration at 950 ms; and the number of shocks at 10. Second, we tried to treat s.c. HCC by electroporation using plasmid DNA that expresses the murine interleukin-12 (mlL-12) gene. Intratumoral administration of the mIL-12 vector elevated serum IL-12 and IFN-gamma and significantly inhibited the growth not only of HCC into which the mIL-12 vector had been directly transferred, but also of the distant HCC. In addition, intratumoral administration of the mIL-12 vector inhibited spontaneous lung metastasis and delayed establishment of HCC injected 3 days after mIL-12 gene therapy. The IL-12 gene therapy induced more lymphocyte infiltration by NK cells, CD3+ cells, and Mac-1 positive cells into the tumor and reduced the number of microvessels. Therefore, more terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive tumor cells were found. These results demonstrate that gene therapy for HCC by electroporation in vivo using IL-12 is very efficient and is thus promising for further clinical trial."},"publication_date":"2001-02-01","publication_name":{"en":"Cancer Research","ja":"Cancer Research"},"volume":"61","number":"3","starting_page":"1005","ending_page":"1012","languages":["eng"],"referee":true,"identifiers":{"issn":["0008-5472"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"29637301"},"force":{"see_also":[{"@id":"http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T91-3YMW3GG-9&_coverDate=03%2F31%2F2000&_alid=501684831&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5101&_sort=d&view=c&_acct=C000008258&_version=1&_urlVersion=0&_userid=106892&md5=6dc110e338a9b5dd5af3c1a6794f001f","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/10703859","label":"url"},{"@id":"https://www.scopus.com/pages/publications/0034000276","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=92102","label":"url"}],"paper_title":{"en":"Clinicopathologic features and postoperative prognosis of multicentric small hepatocellular carcinoma","ja":"Clinicopathologic features and postoperative prognosis of multicentric small hepatocellular carcinoma"},"authors":{"en":[{"name":"Utsunomiya Tohru"},{"name":"Shimada Mitsuo"},{"name":"Taguchi Ken-ichi"},{"name":"Hasegawa Hirofumi"},{"name":"Yamashita Yo-ichi"},{"name":"Hamatsu Takayuki"},{"name":"Aishima Shinichi"},{"name":"Sugimachi Keizo"}],"ja":[{"name":"Utsunomiya Tohru"},{"name":"島田 光生"},{"name":"Taguchi Ken-ichi"},{"name":"Hasegawa Hirofumi"},{"name":"Yamashita Yo-ichi"},{"name":"Hamatsu Takayuki"},{"name":"Aishima Shinichi"},{"name":"Sugimachi Keizo"}]},"description":{"en":"Assessment of clinicopathologic characteristics and postoperative prognoses for patients with multicentric hepatocellular carcinoma (HCC) is important to determine not only a need to operate, but also an appropriate treatment after hepatic resection. Between May 1990 and April 1998, among 116 patients with an initial hepatectomy for HCC measuring 3 cm or less in maximum diameter, 34 patients had multicentric HCC (MC group), and 82 patients had single nodular HCC (SN group). To clarify the clinicopathologic features of patients in the MC group versus the SN group, we compared both the clinicopathologic parameters and the postoperative prognosis after curative hepatectomy between the two groups. The percentages of patients positive for hepatitis B surface antigen and hepatitis C virus antibody were not significantly different between the two groups. No differences were noted in pathologic characteristics of the main tumor or tumor markers. On the other hand, in the MC group, the percentage of patients evaluated in a Child's classification as either B or C was significantly higher (p < 0.05) than that of patients in the SN group, indicating that patients with multicentric HCC have a poor hepatic functional reserve. Both survival and disease-free survival of patients in the MC group who underwent a curative hepatectomy did not differ statistically from those in the SN group. Our results indicate that hepatic resection is useful, even for patients with multicentric HCC, if a curative hepatectomy can be performed and liver function can be saved, despite their poor hepatic functional reserve.","ja":"Assessment of clinicopathologic characteristics and postoperative prognoses for patients with multicentric hepatocellular carcinoma (HCC) is important to determine not only a need to operate, but also an appropriate treatment after hepatic resection. Between May 1990 and April 1998, among 116 patients with an initial hepatectomy for HCC measuring 3 cm or less in maximum diameter, 34 patients had multicentric HCC (MC group), and 82 patients had single nodular HCC (SN group). To clarify the clinicopathologic features of patients in the MC group versus the SN group, we compared both the clinicopathologic parameters and the postoperative prognosis after curative hepatectomy between the two groups. The percentages of patients positive for hepatitis B surface antigen and hepatitis C virus antibody were not significantly different between the two groups. No differences were noted in pathologic characteristics of the main tumor or tumor markers. On the other hand, in the MC group, the percentage of patients evaluated in a Child's classification as either B or C was significantly higher (p < 0.05) than that of patients in the SN group, indicating that patients with multicentric HCC have a poor hepatic functional reserve. Both survival and disease-free survival of patients in the MC group who underwent a curative hepatectomy did not differ statistically from those in the SN group. Our results indicate that hepatic resection is useful, even for patients with multicentric HCC, if a curative hepatectomy can be performed and liver function can be saved, despite their poor hepatic functional reserve."},"publication_date":"2000-03","publication_name":{"en":"Journal of the American College of Surgeons","ja":"Journal of the American College of Surgeons"},"volume":"190","number":"3","starting_page":"331","ending_page":"335","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/S1072-7515(99)00268-9"],"issn":["1072-7515"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/10695993","label":"url"},{"@id":"https://www.scopus.com/pages/publications/0033979079","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=92066","label":"url"}],"paper_title":{"en":"The Significance of Thymidine Phosphorylase Activity in Hepatocellular Carsinoma and Chronic disease Livers: A Special Reference to Liver Fibrosis and Multicentric Tumor Occurrence","ja":"The Significance of Thymidine Phosphorylase Activity in Hepatocellular Carsinoma and Chronic disease Livers: A Special Reference to Liver Fibrosis and Multicentric Tumor Occurrence"},"authors":{"en":[{"name":"Shimada Mitsuo"},{"name":"Hasegawa Hirofumi"},{"name":"Rikimaru Katsuya"},{"name":"Gion Tomonobu"},{"name":"Hamatsu Takayuki"},{"name":"Yamashita Yo-ichi"},{"name":"Shirabe Ken"},{"name":"Sugimachi Ken"}],"ja":[{"name":"島田 光生"},{"name":"Hasegawa Hirofumi"},{"name":"Rikimaru Katsuya"},{"name":"Gion Tomonobu"},{"name":"Hamatsu Takayuki"},{"name":"Yamashita Yo-ichi"},{"name":"Shirabe Ken"},{"name":"Sugimachi Ken"}]},"description":{"en":"The role of thymidine phosphorylase (TP), an angiogenic factor, in hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to clarify the significance of TP in HCC. Thirty-seven patients with HCC, who underwent hepatectomy, were included. The TP activity in both cancerous and non-cancerous parts of livers were measured by an enzyme-linked immunosorbent assay. Another 11 patients without HCC were used to evaluate the TP activity in the non-cancerous parts of livers. Both the cancerous and non-cancerous TP activities were clinico-pathologically investigated with special reference to the multicentric occurrence of HCCs and the degree of liver fibrosis; consisting of normal, fibrosis and cirrhosis. The TP activity in the cancerous part was 94.6 +/- 70.2 U/mg protein, while that in non-cancerous parts of the liver was 80.9 +/- 48.8 U/mg protein. No significant difference was observed. The TP activity in the cancerous part did not correlate with any clinicopathological variables, such as tumor differentiation, portal vein invasion, intrahepatic metastases and prognosis. However, the TP activity in the non-cancerous parts of the liver correlated with the degree of fibrosis (normal/fibrosis/cirrhosis = 34:74:90 U/ mg protein, respectively). Furthermore, regarding the correlation between TP activity in the non-cancerous parts and the simultaneously multicentric occurrence of HCC, the TP activity in the multicentric group (n = 8; 121 U/mg protein) was significantly higher than that in the non-multicentric group (n = 29; 70 U/mg protein). The TP activity in the non-cancerous parts increased in proportion to the degree of liver fibrosis. Furthermore, it is suggested that the higher TP activity in the non-cancerous part is related to the multicentric occurrence of HCCs.","ja":"The role of thymidine phosphorylase (TP), an angiogenic factor, in hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to clarify the significance of TP in HCC. Thirty-seven patients with HCC, who underwent hepatectomy, were included. The TP activity in both cancerous and non-cancerous parts of livers were measured by an enzyme-linked immunosorbent assay. Another 11 patients without HCC were used to evaluate the TP activity in the non-cancerous parts of livers. Both the cancerous and non-cancerous TP activities were clinico-pathologically investigated with special reference to the multicentric occurrence of HCCs and the degree of liver fibrosis; consisting of normal, fibrosis and cirrhosis. The TP activity in the cancerous part was 94.6 +/- 70.2 U/mg protein, while that in non-cancerous parts of the liver was 80.9 +/- 48.8 U/mg protein. No significant difference was observed. The TP activity in the cancerous part did not correlate with any clinicopathological variables, such as tumor differentiation, portal vein invasion, intrahepatic metastases and prognosis. However, the TP activity in the non-cancerous parts of the liver correlated with the degree of fibrosis (normal/fibrosis/cirrhosis = 34:74:90 U/ mg protein, respectively). Furthermore, regarding the correlation between TP activity in the non-cancerous parts and the simultaneously multicentric occurrence of HCC, the TP activity in the multicentric group (n = 8; 121 U/mg protein) was significantly higher than that in the non-multicentric group (n = 29; 70 U/mg protein). The TP activity in the non-cancerous parts increased in proportion to the degree of liver fibrosis. Furthermore, it is suggested that the higher TP activity in the non-cancerous part is related to the multicentric occurrence of HCCs."},"publication_date":"2000-02-01","publication_name":{"en":"Cancer Letters","ja":"Cancer Letters"},"volume":"148","number":"2","starting_page":"165","ending_page":"172","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/S0304-3835(99)00331-6"],"issn":["0304-3835"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://www.annalsofsurgery.com/pt/re/annos/abstract.00000658-199801000-00012.htm;jsessionid=FCnGx3PSp4DT0TQJS1L3Tf71d3btwQsqT2YmDqWm3gD35nlM9GTY!1853810205!-949856144!8091!-1","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/9445114","label":"url"},{"@id":"https://www.scopus.com/pages/publications/0031893584","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=91548","label":"url"}],"paper_title":{"en":"Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma","ja":"Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma"},"authors":{"en":[{"name":"Shimada Mitsuo"},{"name":"Takenaka kenji"},{"name":"Taguchi Kenichi"},{"name":"Fujiwara Yuh"},{"name":"Gion Tomonobu"},{"name":"Kajiyama Kiyoshi"},{"name":"Maeda Takashi"},{"name":"Shirabe Ken"},{"name":"Yanaga Katsuhiko"},{"name":"Sugimachi Keizo"}],"ja":[{"name":"島田 光生"},{"name":"Takenaka kenji"},{"name":"Taguchi Kenichi"},{"name":"Fujiwara Yuh"},{"name":"Gion Tomonobu"},{"name":"Kajiyama Kiyoshi"},{"name":"Maeda Takashi"},{"name":"Shirabe Ken"},{"name":"Yanaga Katsuhiko"},{"name":"Sugimachi Keizo"}]},"description":{"en":"The aims of this study were to identify prognostic factors in patients who developed recurrent hepatocellular carcinoma (HCC) after repeat hepatectomy and to elucidate the role of multicentric occurrence in the second tumor after a first hepatectomy. A repeat hepatectomy for recurrent HCC has been established as the most effective treatment modality, whenever it is possible. However, the prognostic factors for recurrent HCC after repeat hepatectomy have yet to be clarified. Forty-one patients who underwent a curative repeat hepatectomy were retrospectively studied. Patient survival and disease-free survival after recurrence were univariately and multivariately analyzed using 38 clinicopathologic variables. The histologic grade of HCC at repeat hepatectomy was also compared with that at first hepatectomy. Patient survival after repeat hepatectomy did not differ substantially from that in 312 patients undergoing primary hepatectomy. However, the disease-free survival after repeat hepatectomy was significantly lower than that in patients with only a primary hepatectomy (p < 0.05). Multivariate analysis revealed only portal vein invasion in the first hepatectomy to be an independent and significantly poor prognostic factor. Regarding multicentric occurrence at repeat hepatectomy, only 6 of 40 patients (15%) whose specimens could be evaluated histologically were determined to be Edmondson and Steiner's Grade 1. The only prognostic factor identified in patients with recurrent HCC after repeat hepatectomy was portal vein invasion in the first hepatectomy. Most second tumors after the first hepatectomy are considered to be caused by metastatic recurrence, not by multicentric occurrence.","ja":"The aims of this study were to identify prognostic factors in patients who developed recurrent hepatocellular carcinoma (HCC) after repeat hepatectomy and to elucidate the role of multicentric occurrence in the second tumor after a first hepatectomy. A repeat hepatectomy for recurrent HCC has been established as the most effective treatment modality, whenever it is possible. However, the prognostic factors for recurrent HCC after repeat hepatectomy have yet to be clarified. Forty-one patients who underwent a curative repeat hepatectomy were retrospectively studied. Patient survival and disease-free survival after recurrence were univariately and multivariately analyzed using 38 clinicopathologic variables. The histologic grade of HCC at repeat hepatectomy was also compared with that at first hepatectomy. Patient survival after repeat hepatectomy did not differ substantially from that in 312 patients undergoing primary hepatectomy. However, the disease-free survival after repeat hepatectomy was significantly lower than that in patients with only a primary hepatectomy (p < 0.05). Multivariate analysis revealed only portal vein invasion in the first hepatectomy to be an independent and significantly poor prognostic factor. Regarding multicentric occurrence at repeat hepatectomy, only 6 of 40 patients (15%) whose specimens could be evaluated histologically were determined to be Edmondson and Steiner's Grade 1. The only prognostic factor identified in patients with recurrent HCC after repeat hepatectomy was portal vein invasion in the first hepatectomy. Most second tumors after the first hepatectomy are considered to be caused by metastatic recurrence, not by multicentric occurrence."},"publication_date":"1998-01","publication_name":{"en":"Annals of Surgery","ja":"Annals of Surgery"},"volume":"227","number":"1","starting_page":"80","ending_page":"85","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1097/00000658-199801000-00012"],"issn":["0003-4932"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9278644&dopt=Abstract","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/9278644","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=91502","label":"url"}],"paper_title":{"en":"Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin","ja":"Analysis of prognostic risk factors in hepatic resection for metastatic colorectal carcinoma with special reference to the surgical margin"},"authors":{"en":[{"name":"Shirabe Ken"},{"name":"Takenaka Kenji"},{"name":"Gion Tomonobu"},{"name":"Fujiwara Yuh"},{"name":"Shimada Mitsuo"},{"name":"Yanaga Katsuhiko"},{"name":"Maeda Takashi"},{"name":"Kajiyama Kiyoshi"},{"name":"Sugimachi Keizo"}],"ja":[{"name":"Shirabe Ken"},{"name":"Takenaka Kenji"},{"name":"Gion Tomonobu"},{"name":"Fujiwara Yuh"},{"name":"島田 光生"},{"name":"Yanaga Katsuhiko"},{"name":"Maeda Takashi"},{"name":"Kajiyama Kiyoshi"},{"name":"Sugimachi Keizo"}]},"description":{"en":"Liver resection for metastatic colorectal cancer has been established. Nevertheless, it is still controversial whether the surgical margin from the tumour edge to the cut surface of the liver is a significant prognostic factor in hepatic resection for colorectal metastatic liver cancer. To clarify the prognostic risk factors in hepatic resection for colorectal metastasis, univariate and multivariate analyses were performed. Between April 1985 and April 1995, 31 patients underwent curative hepatic resection for metastatic colorectal cancer. The clinical and pathological factors were examined retrospectively. Overall 1-, 3- and 5-year survival rates of the patients were 92, 42 and 39 per cent respectively. Pathological study of 16 resected specimens with a solitary liver tumour revealed hepatic vein invasion by cancer cells in two of 16 cases, portal vein invasion in three, microsatellite lesions in two and biliary tract invasion in six cases. In resected specimens with a solitary tumour measuring less than 4 cm in diameter, one of these factors was observed in only two of nine cases, whereas in specimens with a solitary tumour measuring more than 4 cm in diameter, these factors were observed in six of seven patients (P < 0.05). The distance from the tumour edge to the intrahepatic invasion was less than 10 mm. With univariate analysis, tumour size of 4 cm or more in diameter, an interval of 6 months or less between colorectal and hepatic resection, four or more gross tumours, bilobar involvement and a resection margin from the tumour of less than 10 mm were found to be significant factors indicating a poor prognosis. Cox's proportional hazards model identified a tumour of 4 cm or more in diameter and a resection margin from the tumour of less than 10 mm as poor prognostic factors (P < 0.05). In treating metastatic colorectal cancer to the liver, the surgical margin should be more than 10 mm because occult intrahepatic invasion was always found to be located within 10 mm from the edge of the tumour.","ja":"Liver resection for metastatic colorectal cancer has been established. Nevertheless, it is still controversial whether the surgical margin from the tumour edge to the cut surface of the liver is a significant prognostic factor in hepatic resection for colorectal metastatic liver cancer. To clarify the prognostic risk factors in hepatic resection for colorectal metastasis, univariate and multivariate analyses were performed. Between April 1985 and April 1995, 31 patients underwent curative hepatic resection for metastatic colorectal cancer. The clinical and pathological factors were examined retrospectively. Overall 1-, 3- and 5-year survival rates of the patients were 92, 42 and 39 per cent respectively. Pathological study of 16 resected specimens with a solitary liver tumour revealed hepatic vein invasion by cancer cells in two of 16 cases, portal vein invasion in three, microsatellite lesions in two and biliary tract invasion in six cases. In resected specimens with a solitary tumour measuring less than 4 cm in diameter, one of these factors was observed in only two of nine cases, whereas in specimens with a solitary tumour measuring more than 4 cm in diameter, these factors were observed in six of seven patients (P < 0.05). The distance from the tumour edge to the intrahepatic invasion was less than 10 mm. With univariate analysis, tumour size of 4 cm or more in diameter, an interval of 6 months or less between colorectal and hepatic resection, four or more gross tumours, bilobar involvement and a resection margin from the tumour of less than 10 mm were found to be significant factors indicating a poor prognosis. Cox's proportional hazards model identified a tumour of 4 cm or more in diameter and a resection margin from the tumour of less than 10 mm as poor prognostic factors (P < 0.05). In treating metastatic colorectal cancer to the liver, the surgical margin should be more than 10 mm because occult intrahepatic invasion was always found to be located within 10 mm from the edge of the tumour."},"publication_date":"1997-08","publication_name":{"en":"The British Journal of Surgery","ja":"The British Journal of Surgery"},"volume":"84","number":"8","starting_page":"1077","ending_page":"1080","languages":["eng"],"referee":true,"identifiers":{"issn":["0007-1323"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/8780578","label":"url"},{"@id":"https://www.scopus.com/pages/publications/0029810042","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=91381","label":"url"}],"paper_title":{"en":"Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan","ja":"Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan"},"authors":{"en":[{"name":"Shimada Mitsuo"},{"name":"Takenaka Kenji"},{"name":"Gion Tomonobu"},{"name":"Fujiwara Yuh"},{"name":"Kajiyama Kiyoshi"},{"name":"Maeda Takashi"},{"name":"Shirabe Ken"},{"name":"Nishizaki Takashi"},{"name":"Yanaga Katsuhiko"},{"name":"Sugimachi Keizo"}],"ja":[{"name":"島田 光生"},{"name":"Takenaka Kenji"},{"name":"Gion Tomonobu"},{"name":"Fujiwara Yuh"},{"name":"Kajiyama Kiyoshi"},{"name":"Maeda Takashi"},{"name":"Shirabe Ken"},{"name":"Nishizaki Takashi"},{"name":"Yanaga Katsuhiko"},{"name":"Sugimachi Keizo"}]},"description":{"en":"Little has been addressed on the characteristics and prognostic factors of recurrent hepatocellular carcinoma after undergoing a hepatic resection for primary hepatocellular carcinoma. The aim of this study was to clarify the aforementioned matters of recurrent hepatocellular carcinoma. One hundred fifty-nine patients with recurrent hepatocellular carcinoma were studied retrospectively. Twenty-four clinicopathologic variables, including the period until recurrence (less than or more than 1 year), types of recurrence (intrahepatic nodular type, intrahepatic multiple type, and extrahepatic type), and types of treatment after recurrence (no treatment, lipiodolization, ethanol injection, or hepatectomy) were univariately and multivariately analyzed. The following three variables were finally selected as independent and prognostic indicators after recurrence: (1) period until recurrence, (2) type of recurrence, and (3) types of treatment after recurrence. The prognostic factors in patients with recurrent hepatocellular carcinoma were as follows: (1) period until recurrence, (2) types of recurrence, and (3) types of treatments received after recurrence. The establishment of a follow-up system, including an examination for extrahepatic recurrence, and the development of an effective method of adjuvant chemotherapy are required to obtain better treatment results.","ja":"Little has been addressed on the characteristics and prognostic factors of recurrent hepatocellular carcinoma after undergoing a hepatic resection for primary hepatocellular carcinoma. The aim of this study was to clarify the aforementioned matters of recurrent hepatocellular carcinoma. One hundred fifty-nine patients with recurrent hepatocellular carcinoma were studied retrospectively. Twenty-four clinicopathologic variables, including the period until recurrence (less than or more than 1 year), types of recurrence (intrahepatic nodular type, intrahepatic multiple type, and extrahepatic type), and types of treatment after recurrence (no treatment, lipiodolization, ethanol injection, or hepatectomy) were univariately and multivariately analyzed. The following three variables were finally selected as independent and prognostic indicators after recurrence: (1) period until recurrence, (2) type of recurrence, and (3) types of treatment after recurrence. The prognostic factors in patients with recurrent hepatocellular carcinoma were as follows: (1) period until recurrence, (2) types of recurrence, and (3) types of treatments received after recurrence. The establishment of a follow-up system, including an examination for extrahepatic recurrence, and the development of an effective method of adjuvant chemotherapy are required to obtain better treatment results."},"publication_date":"1996-09","publication_name":{"en":"Gastroenterology","ja":"Gastroenterology"},"volume":"111","number":"9","starting_page":"720","ending_page":"726","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1053/gast.1996.v111.pm8780578"],"issn":["0016-5085"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8138265&dopt=Abstract","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/8138265","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=90399","label":"url"}],"paper_title":{"en":"Characteristics of hepatocellular carcinoma originating in the caudate lobe","ja":"Characteristics of hepatocellular carcinoma originating in the caudate lobe"},"authors":{"en":[{"name":"Shimada Mitsuo"},{"name":"Matsumata Takashi"},{"name":"Maeda Takashi"},{"name":"Yanaga Katsuhiko"},{"name":"Taketomi Akinobu"},{"name":"Sugimachi Keizo"}],"ja":[{"name":"島田 光生"},{"name":"Matsumata Takashi"},{"name":"Maeda Takashi"},{"name":"Yanaga Katsuhiko"},{"name":"Taketomi Akinobu"},{"name":"Sugimachi Keizo"}]},"description":{"en":"Nine patients with hepatocellular carcinoma originating in the caudate lobe who underwent hepatic resection were studied. The caudate lobe was divided into three parts, according to the criteria of Kumon, including the Spiegel lobe, the paracaval portion and the caudate process. The tumors were located in the Spiegel lobe in four, the paracaval portion in four and the caudate process in one. Surgical procedures consisted of right hepatic lobectomy in one, central bisegmentectomy in one and caudate lobectomy in seven. The mean surgical time was 379 +/- 129 min; the mean estimated blood loss was 2,994 +/- 2,303 ml. The above-mentioned surgical risks were more clearly recognized in the paracaval portion than in the Spiegel lobe. In addition, most patients experienced significant post-operative complications. Six of eight patients with 6 mo or longer follow-up had recurrences, and two of six patients died. The characteristics of hepatocellular carcinoma in the caudate lobe were as follows: (a) a higher surgical risk, and more definite risk in the paracaval portion; and (b) a higher rate of early recurrence. A left lobectomy for the Spiegel lobe, a right or left trisegmentectomy for the paracaval portion and a right lobectomy for the caudate process would be ideal from the point of view of the portal supply of the caudate lobe. However, in cirrhotic patients either a caudate lobectomy or partial resection might be preferable because longer survival can be expected.","ja":"Nine patients with hepatocellular carcinoma originating in the caudate lobe who underwent hepatic resection were studied. The caudate lobe was divided into three parts, according to the criteria of Kumon, including the Spiegel lobe, the paracaval portion and the caudate process. The tumors were located in the Spiegel lobe in four, the paracaval portion in four and the caudate process in one. Surgical procedures consisted of right hepatic lobectomy in one, central bisegmentectomy in one and caudate lobectomy in seven. The mean surgical time was 379 +/- 129 min; the mean estimated blood loss was 2,994 +/- 2,303 ml. The above-mentioned surgical risks were more clearly recognized in the paracaval portion than in the Spiegel lobe. In addition, most patients experienced significant post-operative complications. Six of eight patients with 6 mo or longer follow-up had recurrences, and two of six patients died. The characteristics of hepatocellular carcinoma in the caudate lobe were as follows: (a) a higher surgical risk, and more definite risk in the paracaval portion; and (b) a higher rate of early recurrence. A left lobectomy for the Spiegel lobe, a right or left trisegmentectomy for the paracaval portion and a right lobectomy for the caudate process would be ideal from the point of view of the portal supply of the caudate lobe. However, in cirrhotic patients either a caudate lobectomy or partial resection might be preferable because longer survival can be expected."},"publication_date":"1994-04","publication_name":{"en":"Hepatology","ja":"Hepatology"},"volume":"19","number":"4","starting_page":"911","ending_page":"915","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/hep.1840190417"],"issn":["0270-9139"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"http://www.ncbi.nlm.nih.gov/pubmed/2799912","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/2799912","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=90354","label":"url"}],"paper_title":{"en":"Significance of lecithin:cholesterol acyltransferase activity as a prognostic indicator of early allograft function in clinical liver transplantation","ja":"Significance of lecithin:cholesterol acyltransferase activity as a prognostic indicator of early allograft function in clinical liver transplantation"},"authors":{"en":[{"name":"Shimada Mitsuo"},{"name":"Yanaga Katsuhiko"},{"name":"Makowka Leonard"},{"name":"Kakizoe Saburo"},{"name":"Van Thiel DH"},{"name":"Starzl E Thomas"}],"ja":[{"name":"島田 光生"},{"name":"Yanaga Katsuhiko"},{"name":"Makowka Leonard"},{"name":"Kakizoe Saburo"},{"name":"Van Thiel DH"},{"name":"Starzl E Thomas"}]},"description":{"en":"Rapid and accurate assessment of allograft function in the early postoperative period is critical for successful liver transplantation. This study evaluated the efficacy of lecithin:cholesterol acyltransferase (LCAT) activity as an indicator of early allograft function in human orthotopic liver transplantation (OLTx). During a three-month period between September and November 1987, 9 of 11 adult OLTx recipients whose graft exhibited poor function were studied. Poor graft function was defined as primary nonfunction, need for retransplantation within a week after OLTx, or elevation of the prothrombin time over 20 sec early after OLTx. Plasma LCAT activities (measured pretransplant and at 0, 6, 12, 18, and 24 hr, as well as 3 days, after OLTx) and pretransplant clinical variables were compared with those of 15 control patients whose graft exhibited good function. A significant correlation was found between mean LCAT activities during the first 24-hr after OLTx and early allograft function (P less than 0.05, chi 2 = 5.23). When pretransplant histological findings of the 6 grafts with poor function and the 15 controls together were correlated with the mean LCAT activity within 24 hr following OLTx, a significant association was demonstrated (P less than 0.05). This study suggests that plasma LCAT activity is an effective and practical method for assessing early allograft function following OLTx.","ja":"Rapid and accurate assessment of allograft function in the early postoperative period is critical for successful liver transplantation. This study evaluated the efficacy of lecithin:cholesterol acyltransferase (LCAT) activity as an indicator of early allograft function in human orthotopic liver transplantation (OLTx). During a three-month period between September and November 1987, 9 of 11 adult OLTx recipients whose graft exhibited poor function were studied. Poor graft function was defined as primary nonfunction, need for retransplantation within a week after OLTx, or elevation of the prothrombin time over 20 sec early after OLTx. Plasma LCAT activities (measured pretransplant and at 0, 6, 12, 18, and 24 hr, as well as 3 days, after OLTx) and pretransplant clinical variables were compared with those of 15 control patients whose graft exhibited good function. A significant correlation was found between mean LCAT activities during the first 24-hr after OLTx and early allograft function (P less than 0.05, chi 2 = 5.23). When pretransplant histological findings of the 6 grafts with poor function and the 15 controls together were correlated with the mean LCAT activity within 24 hr following OLTx, a significant association was demonstrated (P less than 0.05). This study suggests that plasma LCAT activity is an effective and practical method for assessing early allograft function following OLTx."},"publication_date":"1989-10","publication_name":{"en":"Transplantation","ja":"Transplantation"},"volume":"48","number":"4","starting_page":"600","ending_page":"603","languages":["eng"],"referee":true,"identifiers":{"issn":["0041-1337"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197265"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/39696031","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416426","label":"url"}],"paper_title":{"en":"Impact of pure desmoplastic histological growth patterns in colorectal liver metastasis.","ja":"Impact of pure desmoplastic histological growth patterns in colorectal liver metastasis."},"authors":{"en":[{"name":"Takasu Chie"},{"name":"Morine Yuji"},{"name":"Yoshikawa Kozo"},{"name":"Tokunaga Takuya"},{"name":"Nishi Masaaki"},{"name":"Kashihara Hideya"},{"name":"Wada Yuma"},{"name":"Yoshimoto Toshiaki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"髙須 千絵"},{"name":"森根 裕二"},{"name":"Yoshikawa Kozo"},{"name":"徳永 卓哉"},{"name":"西 正暁"},{"name":"柏原 秀也"},{"name":"Wada Yuma"},{"name":"良元 俊昭"},{"name":"島田 光生"}]},"description":{"en":"Colorectal cancer (CRC) has increasingly come into worldwide cancer and almost half of patients have liver metastasis (CRLM) during the progression. Therefore, treatment of colorectal cancer liver metastasis (CRLM) is important to improve the prognosis of CRC patients. Histopathological growth patterns (HGPs) of CRLM have emerged as a reliable prognostic marker. In this study, we investigated the role of prognostic impact of pure desmoplastic HGPs (dHGPs), 100% desmoplastic, in CRLM. The present study evaluated the HGPs in 71 patients with CRLM who underwent surgery (R0) between 1995 and 2012. HGPs were classified by international consensus guidelines with H&E stained slides. The pure dHGPs was defined as a complete peripheral fibrotic rim around the tumor. The dHGP was present in 36.6% (n = 26) and the pure-dHGPs was present in 73% (n = 19) among dHGPs patients. Pure-dHGPs were significantly associated with sex (male), metachronous metastatic period, normal CEA level, shallow tumor invasion and less lymph node metastasis. Patients with dHGPs had longer overall survival (OS) compared to other HGPs (p < 0.05). Furthermore, pure dHGPs patients had longer OS than non-pure dHGPs (90.9% vs. 51.4%, p < 0.05). Multivariate analysis identified pure dHGPs (p = 0.04) and better primary tumor differentiation (p < 0.001) were identified as independent prognostic indicators for OS. Patients with pure dHGPs also had longer disease-free survival (DFS) compared to other HGPs (p < 0.05). Pure-dHGPs patients had longer DFS than non-pure dHGPs (63.4% vs. 28.8%, p < 0.05). Multivariate analysis identified pure dHGPs (p = 0.04) and better primary tumor differentiation (p = 0.03) as independent prognostic indicators. Pure desmoplastic HGP might be a good prognostic marker in CRLM.","ja":"Colorectal cancer (CRC) has increasingly come into worldwide cancer and almost half of patients have liver metastasis (CRLM) during the progression. Therefore, treatment of colorectal cancer liver metastasis (CRLM) is important to improve the prognosis of CRC patients. Histopathological growth patterns (HGPs) of CRLM have emerged as a reliable prognostic marker. In this study, we investigated the role of prognostic impact of pure desmoplastic HGPs (dHGPs), 100% desmoplastic, in CRLM. The present study evaluated the HGPs in 71 patients with CRLM who underwent surgery (R0) between 1995 and 2012. HGPs were classified by international consensus guidelines with H&E stained slides. The pure dHGPs was defined as a complete peripheral fibrotic rim around the tumor. The dHGP was present in 36.6% (n = 26) and the pure-dHGPs was present in 73% (n = 19) among dHGPs patients. Pure-dHGPs were significantly associated with sex (male), metachronous metastatic period, normal CEA level, shallow tumor invasion and less lymph node metastasis. Patients with dHGPs had longer overall survival (OS) compared to other HGPs (p < 0.05). Furthermore, pure dHGPs patients had longer OS than non-pure dHGPs (90.9% vs. 51.4%, p < 0.05). Multivariate analysis identified pure dHGPs (p = 0.04) and better primary tumor differentiation (p < 0.001) were identified as independent prognostic indicators for OS. Patients with pure dHGPs also had longer disease-free survival (DFS) compared to other HGPs (p < 0.05). Pure-dHGPs patients had longer DFS than non-pure dHGPs (63.4% vs. 28.8%, p < 0.05). Multivariate analysis identified pure dHGPs (p = 0.04) and better primary tumor differentiation (p = 0.03) as independent prognostic indicators. Pure desmoplastic HGP might be a good prognostic marker in CRLM."},"publication_date":"2024-12-18","publication_name":{"en":"BMC Cancer","ja":"BMC Cancer"},"volume":"24","number":"1","starting_page":"1528","ending_page":"1528","languages":["eng"],"identifiers":{"doi":["10.1186/s12885-024-13291-6"],"issn":["1471-2407"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197266"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2013070","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/39578830","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416423","label":"url"}],"paper_title":{"en":"Feasibility of robot-assisted surgery for defining circumferential resection margins for rectal cancer: a retrospective study.","ja":"Feasibility of robot-assisted surgery for defining circumferential resection margins for rectal cancer: a retrospective study."},"authors":{"en":[{"name":"Nakao Toshihiro"},{"name":"Shimada Mitsuo"},{"name":"Tokunaga Takuya"},{"name":"Nishi Masaaki"},{"name":"Kashihara Hideya"},{"name":"Takasu Chie"},{"name":"Wada Yuuma"},{"name":"Yoshimoto Toshiaki"}],"ja":[{"name":"中尾 寿宏"},{"name":"島田 光生"},{"name":"徳永 卓哉"},{"name":"西 正暁"},{"name":"柏原 秀也"},{"name":"髙須 千絵"},{"name":"和田 佑馬"},{"name":"良元 俊昭"}]},"description":{"en":"Local recurrence is a major problem after surgery for rectal cancer. Precision of the circumferential resection margin (CRM) has been shown to be an independent predictor of local recurrence. The purpose of this study is to evaluate the usefulness of robotic surgery for defining the CRM. A retrospective cohort study of patients with rectal cancer who underwent radical surgery at Tokushima University Hospital from January 2012 to April 2023 was included in this study to evaluate risk factors for CRM involvement. Short-term outcomes, including CRM rates, as well as long-term outcomes, were compared between patients who had undergone robot-assisted versus laparoscopic surgery following propensity score analysis. A total of 223 patients were analyzed in this study. Multivariate analysis demonstrated that lymph node metastasis was the most significant predictive factor for CRM involvement (p = 0.030), and that robot-assisted surgery tended to lead to less CRM involvement (p = 0.085). The CRM involvement rate for robotic and laparoscopic surgery before propensity score matching was 4.7% and 11.7%, respectively. Following propensity score matching, the CRM involvement rate for robotic surgery was 4.5% versus 11.4% for laparoscopic surgery. Disease-free survival (DFS) and overall survival (OS) rates for patients who had undergone robot-assisted and laparoscopic surgery were not significantly different before or after matching (DFS before matching: p = 0.876, DFS after matching: p = 0.805, OS before matching: p = 0.511, OS after matching: p = 0.458). Robot-assisted surgery may be useful in defining the CRM for rectal cancer.","ja":"Local recurrence is a major problem after surgery for rectal cancer. Precision of the circumferential resection margin (CRM) has been shown to be an independent predictor of local recurrence. The purpose of this study is to evaluate the usefulness of robotic surgery for defining the CRM. A retrospective cohort study of patients with rectal cancer who underwent radical surgery at Tokushima University Hospital from January 2012 to April 2023 was included in this study to evaluate risk factors for CRM involvement. Short-term outcomes, including CRM rates, as well as long-term outcomes, were compared between patients who had undergone robot-assisted versus laparoscopic surgery following propensity score analysis. A total of 223 patients were analyzed in this study. Multivariate analysis demonstrated that lymph node metastasis was the most significant predictive factor for CRM involvement (p = 0.030), and that robot-assisted surgery tended to lead to less CRM involvement (p = 0.085). The CRM involvement rate for robotic and laparoscopic surgery before propensity score matching was 4.7% and 11.7%, respectively. Following propensity score matching, the CRM involvement rate for robotic surgery was 4.5% versus 11.4% for laparoscopic surgery. Disease-free survival (DFS) and overall survival (OS) rates for patients who had undergone robot-assisted and laparoscopic surgery were not significantly different before or after matching (DFS before matching: p = 0.876, DFS after matching: p = 0.805, OS before matching: p = 0.511, OS after matching: p = 0.458). Robot-assisted surgery may be useful in defining the CRM for rectal cancer."},"publication_date":"2024-11-23","publication_name":{"en":"World Journal of Surgical Oncology","ja":"World Journal of Surgical Oncology"},"volume":"22","number":"1","starting_page":"310","ending_page":"310","languages":["eng"],"identifiers":{"doi":["10.1186/s12957-024-03591-3"],"issn":["1477-7819"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197267"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/39238172","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416422","label":"url"}],"paper_title":{"en":"Impact of robotic gastrectomy in patients with primary T3 or more advanced gastric cancer.","ja":"Impact of robotic gastrectomy in patients with primary T3 or more advanced gastric cancer."},"authors":{"en":[{"name":"Nishi Masaaki"},{"name":"Takasu Chie"},{"name":"Wada Yuuma"},{"name":"Yoshikawa Kozo"},{"name":"Tokunaga Takuya"},{"name":"Nakao Toshihiro"},{"name":"Kashihara Hideya"},{"name":"Yoshimoto Toshiaki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"西 正暁"},{"name":"髙須 千絵"},{"name":"和田 佑馬"},{"name":"Yoshikawa Kozo"},{"name":"徳永 卓哉"},{"name":"Nakao Toshihiro"},{"name":"柏原 秀也"},{"name":"良元 俊昭"},{"name":"島田 光生"}]},"description":{"en":"The use of robotic surgery (RS) for gastric cancer (GC) has been rapidly increasing. However, the utility of RS for advanced GC (AGC), especially T3 or more AGC, is unclear. Ninety patients who underwent curative upfront minimally invasive surgery (MIS) (D2 lymph node dissection) for fStage II or III GC were enrolled in this study. Among these patients, 68 underwent MIS for T3 or more AGC. Thirty-six patients underwent RS, and 32 patients underwent laparoscopic surgery (LS). The short-term and long-term surgical outcomes were compared between the two groups. In the T3 or more AGC cohort, there were no significant intergroup differences in the operative time or blood loss volume. The number of retrieved lymph nodes tended to be higher in the RS than LS group (38.5 vs. 33.0, p = .11). The drain amylase content on postoperative day 1 was significantly lower in the RS than LS group (243.5 vs. 521.0 IU/L, p < .01). The morbidity rate (Clavien-Dindo grade ≥2) was similar between the groups. There were no significant differences between the LS and RS groups in the 3-year overall survival rate (80.7% vs. 74.5%, respectively; p = .95) or 3-year disease-free survival rate (75.0% vs. 69.7%, respectively; p = .95). RS for primary T3 or more AGC was safe and contributed to similar short-term and long-term outcomes compared with LS.","ja":"The use of robotic surgery (RS) for gastric cancer (GC) has been rapidly increasing. However, the utility of RS for advanced GC (AGC), especially T3 or more AGC, is unclear. Ninety patients who underwent curative upfront minimally invasive surgery (MIS) (D2 lymph node dissection) for fStage II or III GC were enrolled in this study. Among these patients, 68 underwent MIS for T3 or more AGC. Thirty-six patients underwent RS, and 32 patients underwent laparoscopic surgery (LS). The short-term and long-term surgical outcomes were compared between the two groups. In the T3 or more AGC cohort, there were no significant intergroup differences in the operative time or blood loss volume. The number of retrieved lymph nodes tended to be higher in the RS than LS group (38.5 vs. 33.0, p = .11). The drain amylase content on postoperative day 1 was significantly lower in the RS than LS group (243.5 vs. 521.0 IU/L, p < .01). The morbidity rate (Clavien-Dindo grade ≥2) was similar between the groups. There were no significant differences between the LS and RS groups in the 3-year overall survival rate (80.7% vs. 74.5%, respectively; p = .95) or 3-year disease-free survival rate (75.0% vs. 69.7%, respectively; p = .95). RS for primary T3 or more AGC was safe and contributed to similar short-term and long-term outcomes compared with LS."},"publication_date":"2024-10","publication_name":{"en":"Asian Journal of Endoscopic Surgery","ja":"Asian Journal of Endoscopic Surgery"},"volume":"17","number":"4","starting_page":"e13383","ending_page":"e13383","languages":["eng"],"identifiers":{"doi":["10.1111/ases.13383"],"issn":["1758-5910"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197268"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/39290958","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416412","label":"url"}],"paper_title":{"en":"Evaluation of malignancy in gallbladder tumors using the apparent diffusion coefficient obtained by diffusion-weighted MRI.","ja":"Evaluation of malignancy in gallbladder tumors using the apparent diffusion coefficient obtained by diffusion-weighted MRI."},"authors":{"en":[{"name":"Yamada Shin-ichiro"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Teraoku Hiroki"},{"name":"Waki Yuhei"},{"name":"Nakasu Chiharu"},{"name":"Noma Takayuki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"山田 眞一郎"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"寺奥 大貴"},{"name":"脇 悠平"},{"name":"Nakasu Chiharu"},{"name":"野間 隆礼"},{"name":"島田 光生"}]},"description":{"en":"The utility of the apparent diffusion coefficient (ADC) of diffusion-weighted image (DWI) magnetic resonance imaging was examined for evaluating malignancy and prognosis in gallbladder tumors. A total of 63 patients (benign tumors, n=33; cancer, n=30) were included after surgical resection for gallbladder tumors, and their mean ADC values by DWI were obtained. Cases of advanced gallbladder cancer (n=25) were divided into ADC and ADC groups, and clinicopathological factors were compared. In 63 cases, ADC values in advanced gallbladder cancer were significantly lower compared with benign tumors and non-advanced gallbladder cancer (P<0.05), and ADC values in early gallbladder cancer were also significantly lower compared with benign tumors (P<0.05). In 25 advanced gallbladder cancer cases, the ADC group tended to have a higher rate of advanced stage disease (P=0.09). Disease-free survival and overall survival (OS) of the ADC group were worse compared with the ADC group (P<0.01). In the multivariate analysis of OS, poor differentiation and low ADC value were independent prognostic factors. ADC values may be useful for evaluating tumor malignancies in gallbladder tumors.","ja":"The utility of the apparent diffusion coefficient (ADC) of diffusion-weighted image (DWI) magnetic resonance imaging was examined for evaluating malignancy and prognosis in gallbladder tumors. A total of 63 patients (benign tumors, n=33; cancer, n=30) were included after surgical resection for gallbladder tumors, and their mean ADC values by DWI were obtained. Cases of advanced gallbladder cancer (n=25) were divided into ADC and ADC groups, and clinicopathological factors were compared. In 63 cases, ADC values in advanced gallbladder cancer were significantly lower compared with benign tumors and non-advanced gallbladder cancer (P<0.05), and ADC values in early gallbladder cancer were also significantly lower compared with benign tumors (P<0.05). In 25 advanced gallbladder cancer cases, the ADC group tended to have a higher rate of advanced stage disease (P=0.09). Disease-free survival and overall survival (OS) of the ADC group were worse compared with the ADC group (P<0.01). In the multivariate analysis of OS, poor differentiation and low ADC value were independent prognostic factors. ADC values may be useful for evaluating tumor malignancies in gallbladder tumors."},"publication_date":"2024-09-04","publication_name":{"en":"Oncology Letters","ja":"Oncology Letters"},"volume":"28","number":"5","starting_page":"533","ending_page":"533","languages":["eng"],"identifiers":{"doi":["10.3892/ol.2024.14666"],"issn":["1792-1082"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197269"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/Y920030020","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416427","label":"url"}],"paper_title":{"en":"【必携小児外科レジデントマニュアル2】倫理規定","ja":"【必携小児外科レジデントマニュアル2】倫理規定"},"authors":{"en":[{"name":"Ishibashi Hiroki"},{"name":"Mori Hiroki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"石橋 広樹"},{"name":"森 大樹"},{"name":"島田 光生"}]},"description":{"en":"<文献概要>はじめに 法は国家権力などによって強制される他律的な規範であり,守るべき最低限のルールである．一方,倫理は自主的な遵守が期待される自律的な規範である．これら2つは相反するものではなく互いに補完し合うべきもので,これまで「ヒポクラテスの誓い」に始まるさまざまな医の倫理が発展してきた．すなわち,医療を行うにあたり合理性をもって判断するために守るべき規範が医療倫理である．","ja":"<文献概要>はじめに 法は国家権力などによって強制される他律的な規範であり,守るべき最低限のルールである．一方,倫理は自主的な遵守が期待される自律的な規範である．これら2つは相反するものではなく互いに補完し合うべきもので,これまで「ヒポクラテスの誓い」に始まるさまざまな医の倫理が発展してきた．すなわち,医療を行うにあたり合理性をもって判断するために守るべき規範が医療倫理である．"},"publication_date":"2024-09","publication_name":{"en":"Japanese Journal of Pediatric Surgery","ja":"小児外科"},"volume":"56","number":"9","starting_page":"960","ending_page":"963","languages":["jpn"],"identifiers":{"doi":["10.24479/ps.0000000950"],"issn":["0385-6313"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197270"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/Y909260003","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416414","label":"url"}],"paper_title":{"en":"膵液瘻高リスク患者における膵頭十二指腸切除術後の早期経口摂取と膵液瘻発生との関連","ja":"膵液瘻高リスク患者における膵頭十二指腸切除術後の早期経口摂取と膵液瘻発生との関連"},"authors":{"en":[{"name":"七海 那須"},{"name":"Yasui-Yamada Sonoko"},{"name":"滝本 真望"},{"name":"関本 大介"},{"name":"Saitou Yu"},{"name":"Shimada Mitsuo"},{"name":"Hamada Yasuhiro"}],"ja":[{"name":"七海 那須"},{"name":"山田 苑子"},{"name":"滝本 真望"},{"name":"関本 大介"},{"name":"齋藤 裕"},{"name":"島田 光生"},{"name":"濵田 康弘"}]},"description":{"en":"【諸言】膵頭十二指腸切除術後の膵液瘻高リスク患者において，術後の経口摂取開始時期および経口摂取栄養量と膵液瘻発生等との関連について検討した．【方法】術後経口摂取開始時期がPOD5以降のNot early群，POD4以前のEarly群で主要アウトカム(膵液瘻発生)と副次アウトカム(術後在院日数，POD7までの蓄積経口摂取エネルギー量)を比較した．また，術後経口摂取エネルギー量・脂肪量で層別化し，膵液瘻オッズ比を算出した．【結果】BMI，膵液瘻リスク因子で調整した多変量解析の結果，Early群は膵液瘻発生のリスク因子ではなかった．Early群とNot Early群で術後在院日数に有意差はなく，蓄積経口摂取量はEarly群で有意に多かった．さらに，術後経口摂取エネルギー量・脂肪量の増加は膵液瘻発生と関連がなかった．【結論】膵頭十二指腸切除後の栄養管理として，膵液瘻高リスク患者においても，早期経口摂取および術後経口摂取エネルギー量・脂肪量の増加は膵液瘻発生と関連がなかった．(著者抄録)","ja":"【諸言】膵頭十二指腸切除術後の膵液瘻高リスク患者において，術後の経口摂取開始時期および経口摂取栄養量と膵液瘻発生等との関連について検討した．【方法】術後経口摂取開始時期がPOD5以降のNot early群，POD4以前のEarly群で主要アウトカム(膵液瘻発生)と副次アウトカム(術後在院日数，POD7までの蓄積経口摂取エネルギー量)を比較した．また，術後経口摂取エネルギー量・脂肪量で層別化し，膵液瘻オッズ比を算出した．【結果】BMI，膵液瘻リスク因子で調整した多変量解析の結果，Early群は膵液瘻発生のリスク因子ではなかった．Early群とNot Early群で術後在院日数に有意差はなく，蓄積経口摂取量はEarly群で有意に多かった．さらに，術後経口摂取エネルギー量・脂肪量の増加は膵液瘻発生と関連がなかった．【結論】膵頭十二指腸切除後の栄養管理として，膵液瘻高リスク患者においても，早期経口摂取および術後経口摂取エネルギー量・脂肪量の増加は膵液瘻発生と関連がなかった．(著者抄録)"},"publication_date":"2024-09","publication_name":{"en":"The Journal of Metabolism and Clinical Nutrition","ja":"日本病態栄養学会誌"},"volume":"27","number":"3","starting_page":"243","ending_page":"252","languages":["jpn"],"identifiers":{"issn":["1345-8167"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"50147246"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38951411","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416421","label":"url"}],"paper_title":{"en":"Circulating Exosomal MicroRNA Signature Predicts Peritoneal Metastasis in Patients with Advanced Gastric Cancer.","ja":"Circulating Exosomal MicroRNA Signature Predicts Peritoneal Metastasis in Patients with Advanced Gastric Cancer."},"authors":{"en":[{"name":"Wada Yuuma"},{"name":"Nishi Masaaki"},{"name":"Yoshikawa Kozo"},{"name":"Takasu Chie"},{"name":"Tokunaga Takuya"},{"name":"Nakao Toshihiro"},{"name":"Kashihara Hideya"},{"name":"Yoshimoto Toshiaki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"和田 佑馬"},{"name":"西 正暁"},{"name":"Yoshikawa Kozo"},{"name":"髙須 千絵"},{"name":"徳永 卓哉"},{"name":"Nakao Toshihiro"},{"name":"柏原 秀也"},{"name":"良元 俊昭"},{"name":"島田 光生"}]},"description":{"en":"Despite a radical operation, about half of gastric cancer (GC) patients with advanced GC experience peritoneal metastasis (PM), and the patients with PM have a poor prognosis. However, because staging laparoscopy was a highly invasive procedure for patients, identification of PM using a liquid biopsy can be useful for patients with GC. This study analyzed two genome-wide miRNA expression profiling datasets (GSE164174 and TCGA). The study prioritized biomarkers in pretreatment plasma specimens from clinical training and validation cohorts of patients with GC. The authors developed an integrated exosomal miRNA panel and established a risk-stratification model, which was combined with the miRNA panel and currently used tumor markers (CEA, CA19-9, CA125, and CA72-4 levels). The comprehensive discovery effort identified a four-miRNA panel that robustly predicted the metastasis with excellent accuracy in the TCGA dataset (area under the curve [AUC] 0.86). A circulating exosomal miRNA panel was established successfully with remarkable diagnostic accuracy in the clinical training (AUC 0.85) and validation (AUC 0.86) cohorts. Moreover, the predictive accuracy of the panel was significantly superior to that of conventional clinical factors (P < 0.01), and the risk-stratification model was dramatically superior to the panel and currently used clinical factors for predicting PM (AUC 0.94; univariate: odds ratio [OR] 77.00 [P < 0.01]; multivariate OR 57.71 [P = 0.01]). The novel risk-stratification model for predicting PM has potential for clinical translation as a liquid biopsy assay for patients with GC. The study findings highlight the potential clinical impact of the model for improved selection and management of patients with GC.","ja":"Despite a radical operation, about half of gastric cancer (GC) patients with advanced GC experience peritoneal metastasis (PM), and the patients with PM have a poor prognosis. However, because staging laparoscopy was a highly invasive procedure for patients, identification of PM using a liquid biopsy can be useful for patients with GC. This study analyzed two genome-wide miRNA expression profiling datasets (GSE164174 and TCGA). The study prioritized biomarkers in pretreatment plasma specimens from clinical training and validation cohorts of patients with GC. The authors developed an integrated exosomal miRNA panel and established a risk-stratification model, which was combined with the miRNA panel and currently used tumor markers (CEA, CA19-9, CA125, and CA72-4 levels). The comprehensive discovery effort identified a four-miRNA panel that robustly predicted the metastasis with excellent accuracy in the TCGA dataset (area under the curve [AUC] 0.86). A circulating exosomal miRNA panel was established successfully with remarkable diagnostic accuracy in the clinical training (AUC 0.85) and validation (AUC 0.86) cohorts. Moreover, the predictive accuracy of the panel was significantly superior to that of conventional clinical factors (P < 0.01), and the risk-stratification model was dramatically superior to the panel and currently used clinical factors for predicting PM (AUC 0.94; univariate: odds ratio [OR] 77.00 [P < 0.01]; multivariate OR 57.71 [P = 0.01]). The novel risk-stratification model for predicting PM has potential for clinical translation as a liquid biopsy assay for patients with GC. The study findings highlight the potential clinical impact of the model for improved selection and management of patients with GC."},"publication_date":"2024-06-29","publication_name":{"en":"Annals of Surgical Oncology","ja":"Annals of Surgical Oncology"},"volume":"31","number":"9","starting_page":"5997","ending_page":"6006","languages":["eng"],"identifiers":{"doi":["10.1245/s10434-024-15592-3"],"issn":["1534-4681"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197272"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38896182","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416420","label":"url"}],"paper_title":{"en":"Prognostic impact of the combination of p16, p21 and Immunoscore in rectal cancer.","ja":"Prognostic impact of the combination of p16, p21 and Immunoscore in rectal cancer."},"authors":{"en":[{"name":"Nakao Toshihiro"},{"name":"Shimada Mitsuo"},{"name":"Yoshikawa Kozo"},{"name":"Tokunaga Takuya"},{"name":"Nishi Masaaki"},{"name":"Kashihara Hideya"},{"name":"Takasu Chie"},{"name":"Wada Yuuma"},{"name":"Yoshimoto Toshiaki"}],"ja":[{"name":"Nakao Toshihiro"},{"name":"島田 光生"},{"name":"Yoshikawa Kozo"},{"name":"徳永 卓哉"},{"name":"西 正暁"},{"name":"柏原 秀也"},{"name":"髙須 千絵"},{"name":"和田 佑馬"},{"name":"良元 俊昭"}]},"description":{"en":"The association between p16 and p21, a marker of cellular senescence, and the Immunoscore, an immunological prognostic indicator, in rectal cancer patients undergoing curative surgery were investigated. A total of 82 patients who underwent curative surgery for rectal cancer were evaluated. The resected specimens were analyzed for p16, p21, CD3 and CD8 expression by immunohistochemistry. Immunoscore was calculated on the basis of CD3 and CD8 expressions. The clinicopathological characteristics and long-term outcomes were evaluated. Among the 82 patients, 24 (29.3%) were p16-positive and 11 (13.4%) were p21-positive. The patients were classified into the following five Immunoscore groups (IS0-5). IS0, IS1 and IS2 were classified as the low Immunoscore group (45 patients, 54.9%) and IS3 and IS4 as the high Immunoscore group (37 patients, 45.1%). There was no significant difference in age, sex, body mass index, American Society of Anesthesiologists physical status, depth of invasion of the tumor, lymph node metastasis and histological classification of the tumor with p16 or p21 expression or Immunoscore. p16-positive expression and low Immunoscore each showed a tendency to indicate poor prognosis of disease-free survival (DFS). Patients with the combination of p16 and p21 positivity and with p16 positivity and low Immunoscore showed significantly poor prognosis of DFS. Patients with p21 positive positivity and low Immunoscore tended to have worse DFS. p16, p21 and Immunoscore may be prognostic indicators of rectal cancer. The combination of them may provide more accurate prognostic prediction than either factor alone.","ja":"The association between p16 and p21, a marker of cellular senescence, and the Immunoscore, an immunological prognostic indicator, in rectal cancer patients undergoing curative surgery were investigated. A total of 82 patients who underwent curative surgery for rectal cancer were evaluated. The resected specimens were analyzed for p16, p21, CD3 and CD8 expression by immunohistochemistry. Immunoscore was calculated on the basis of CD3 and CD8 expressions. The clinicopathological characteristics and long-term outcomes were evaluated. Among the 82 patients, 24 (29.3%) were p16-positive and 11 (13.4%) were p21-positive. The patients were classified into the following five Immunoscore groups (IS0-5). IS0, IS1 and IS2 were classified as the low Immunoscore group (45 patients, 54.9%) and IS3 and IS4 as the high Immunoscore group (37 patients, 45.1%). There was no significant difference in age, sex, body mass index, American Society of Anesthesiologists physical status, depth of invasion of the tumor, lymph node metastasis and histological classification of the tumor with p16 or p21 expression or Immunoscore. p16-positive expression and low Immunoscore each showed a tendency to indicate poor prognosis of disease-free survival (DFS). Patients with the combination of p16 and p21 positivity and with p16 positivity and low Immunoscore showed significantly poor prognosis of DFS. Patients with p21 positive positivity and low Immunoscore tended to have worse DFS. p16, p21 and Immunoscore may be prognostic indicators of rectal cancer. The combination of them may provide more accurate prognostic prediction than either factor alone."},"publication_date":"2024-06-19","publication_name":{"en":"International Journal of Clinical Oncology","ja":"International Journal of Clinical Oncology"},"volume":"29","number":"8","starting_page":"1152","ending_page":"1160","languages":["eng"],"identifiers":{"doi":["10.1007/s10147-024-02519-x"],"issn":["1437-7772"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197273"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2024310352","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416428","label":"url"}],"paper_title":{"en":"【教科書にない小児外科疾患の最新情報-国内外の文献・ガイドラインから-】鼠径ヘルニア","ja":"【教科書にない小児外科疾患の最新情報-国内外の文献・ガイドラインから-】鼠径ヘルニア"},"authors":{"en":[{"name":"Ishibashi Hiroki"},{"name":"Mori Hiroki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"石橋 広樹"},{"name":"森 大樹"},{"name":"島田 光生"}]},"publication_date":"2024-06","publication_name":{"en":"Japanese Journal of Pediatric Surgery","ja":"小児外科"},"volume":"56","number":"6","starting_page":"619","ending_page":"622","languages":["jpn"],"identifiers":{"doi":["10.24479/ps.0000000853"],"issn":["0385-6313"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197274"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2012981","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38822331","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416419","label":"url"}],"paper_title":{"en":"Blue light irradiation inhibits the M2 polarization of the cancer-associated macrophages in colon cancer.","ja":"Blue light irradiation inhibits the M2 polarization of the cancer-associated macrophages in colon cancer."},"authors":{"en":[{"name":"Yoshimoto Toshiaki"},{"name":"Nishi Masaaki"},{"name":"Okikawa Shohei"},{"name":"Yoshikawa Kozo"},{"name":"Tokunaga Takuya"},{"name":"Nakao Toshihiro"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Wada Yuuma"},{"name":"Noma Takayuki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"良元 俊昭"},{"name":"西 正暁"},{"name":"Okikawa Shohei"},{"name":"Yoshikawa Kozo"},{"name":"徳永 卓哉"},{"name":"Nakao Toshihiro"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"和田 佑馬"},{"name":"野間 隆礼"},{"name":"島田 光生"}]},"description":{"en":"Recent studies have shown that blue light-emitting diode (LED) light has anti-tumor effects, suggesting the possibility of using visible light in cancer therapy. However, the effects of blue light irradiation on cells in the tumor microenvironment, including tumor-associated macrophages (TAMs), are unknown. Here, THP-1 cells were cultured in the conditioned medium (CM) of HCT-116 cells to prepare TAMs. TAMs were divided into LED-irradiated and control groups. Then, the effects of blue LED irradiation on TAM activation were examined. Expression levels of M2 macrophage markers CD163 and CD206 expression were significantly decreased in LED-irradiated TAMs compared with the control group. While control TAM-CM could induce HCT-116 cell migration, these effects were not observed in cells cultured in TAM-CM with LED irradiation. Vascular endothelial growth factor (VEGF) secretion was significantly suppressed in LED-exposed TAMs. PD-L1 expression was upregulated in HCT-116 cells cultured with TAM-CM but attenuated in cells cultured with LED-irradiated TAM-CM. In an in vivo model, protein expression levels of F4/80 and CD163, which are TAM markers, were reduced in the LED-exposed group. These results indicate that blue LED light may have an inhibitory effect on TAMs, as well as anti-tumor effects on colon cancer cells.","ja":"Recent studies have shown that blue light-emitting diode (LED) light has anti-tumor effects, suggesting the possibility of using visible light in cancer therapy. However, the effects of blue light irradiation on cells in the tumor microenvironment, including tumor-associated macrophages (TAMs), are unknown. Here, THP-1 cells were cultured in the conditioned medium (CM) of HCT-116 cells to prepare TAMs. TAMs were divided into LED-irradiated and control groups. Then, the effects of blue LED irradiation on TAM activation were examined. Expression levels of M2 macrophage markers CD163 and CD206 expression were significantly decreased in LED-irradiated TAMs compared with the control group. While control TAM-CM could induce HCT-116 cell migration, these effects were not observed in cells cultured in TAM-CM with LED irradiation. Vascular endothelial growth factor (VEGF) secretion was significantly suppressed in LED-exposed TAMs. PD-L1 expression was upregulated in HCT-116 cells cultured with TAM-CM but attenuated in cells cultured with LED-irradiated TAM-CM. In an in vivo model, protein expression levels of F4/80 and CD163, which are TAM markers, were reduced in the LED-exposed group. These results indicate that blue LED light may have an inhibitory effect on TAMs, as well as anti-tumor effects on colon cancer cells."},"publication_date":"2024-05","publication_name":{"en":"BMC Cancer","ja":"BMC Cancer"},"volume":"24","number":"1","starting_page":"664","ending_page":"664","languages":["eng"],"identifiers":{"doi":["10.1186/s12885-024-12440-1"],"issn":["1471-2407"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197275"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2012957","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/39502738","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416413","label":"url"}],"paper_title":{"en":"Lenvatinib-resistant hepatocellular carcinoma promotes malignant potential of tumor-associated macrophages via exosomal miR-301a-3p.","ja":"Lenvatinib-resistant hepatocellular carcinoma promotes malignant potential of tumor-associated macrophages via exosomal miR-301a-3p."},"authors":{"en":[{"name":"Waki Yuhei"},{"name":"Morine Yuji"},{"name":"Saitou Yu"},{"name":"Teraoku Hiroki"},{"name":"Yamada Shin-ichiro"},{"name":"Ikemoto Tetsuya"},{"name":"Tominaga Tatsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"脇 悠平"},{"name":"森根 裕二"},{"name":"齋藤 裕"},{"name":"寺奥 大貴"},{"name":"山田 眞一郎"},{"name":"池本 哲也"},{"name":"冨永 辰也"},{"name":"島田 光生"}]},"description":{"en":"The interactions between cancer cells and tumor-associated macrophages (TAMs) via microRNAs (miRNAs) play crucial roles in malignant potential and drug resistance. However, it remains unclear how lenvatinib-resistant hepatocellular carcinoma (LR HCC) promotes TAM tumor biology. Here we investigated the crosstalk between LR HCC cells and TAMs for cancer progression and lenvatinib resistance, focusing on an exosomal miRNA. We used two bioinformatics software programs to identify miRNAs that target PTEN in gastrointestinal cancers, then investigated exosomal miRNA expression in LR HCC conditioned medium (CM). After modifying TAMs with LR HCC CM (LR TAM), macrophage phenotype and PTEN-Nrf2 signaling pathway component expression were analyzed in LR TAMs. The malignant potential and drug resistance were investigated in naïve HCC cells cultured with LR TAM CM. LR HCC cells highly induced M2-like properties in macrophages compared with naïve HCC cells. Exosomal miR-301a-3p expression was increased in LR HCC CM, with higher activation of the PTEN/PI3K/GSK3β/Nrf2 signaling pathway in LR TAMs. Naïve HCC cells were educated with LR TAM CM to promote malignant potential and lenvatinib resistance. Inhibition of exosomal miR-301a-3p prevented the malignant potential of LR TAMs. Activation of Nrf2 signaling by LR HCC cell-derived exosomal miR-301a-3p skewed the transformation of macrophages to the M2 phenotype. Our study provides new findings on the role of miR-301a-3p, suggesting it is a promising therapeutic target to improve HCC lenvatinib resistance.","ja":"The interactions between cancer cells and tumor-associated macrophages (TAMs) via microRNAs (miRNAs) play crucial roles in malignant potential and drug resistance. However, it remains unclear how lenvatinib-resistant hepatocellular carcinoma (LR HCC) promotes TAM tumor biology. Here we investigated the crosstalk between LR HCC cells and TAMs for cancer progression and lenvatinib resistance, focusing on an exosomal miRNA. We used two bioinformatics software programs to identify miRNAs that target PTEN in gastrointestinal cancers, then investigated exosomal miRNA expression in LR HCC conditioned medium (CM). After modifying TAMs with LR HCC CM (LR TAM), macrophage phenotype and PTEN-Nrf2 signaling pathway component expression were analyzed in LR TAMs. The malignant potential and drug resistance were investigated in naïve HCC cells cultured with LR TAM CM. LR HCC cells highly induced M2-like properties in macrophages compared with naïve HCC cells. Exosomal miR-301a-3p expression was increased in LR HCC CM, with higher activation of the PTEN/PI3K/GSK3β/Nrf2 signaling pathway in LR TAMs. Naïve HCC cells were educated with LR TAM CM to promote malignant potential and lenvatinib resistance. Inhibition of exosomal miR-301a-3p prevented the malignant potential of LR TAMs. Activation of Nrf2 signaling by LR HCC cell-derived exosomal miR-301a-3p skewed the transformation of macrophages to the M2 phenotype. Our study provides new findings on the role of miR-301a-3p, suggesting it is a promising therapeutic target to improve HCC lenvatinib resistance."},"publication_date":"2024-05-13","publication_name":{"en":"Annals of Gastroenterological Surgery","ja":"Annals of Gastroenterological Surgery"},"volume":"8","number":"6","starting_page":"1084","ending_page":"1095","languages":["eng"],"identifiers":{"doi":["10.1002/ags3.12814"],"issn":["2475-0328"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197276"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38636083","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416418","label":"url"}],"paper_title":{"en":"Number of Healthy Teeth Can Predict the Response of Rectal Cancer to Chemoradiotherapy: A Retrospective Study.","ja":"Number of Healthy Teeth Can Predict the Response of Rectal Cancer to Chemoradiotherapy: A Retrospective Study."},"authors":{"en":[{"name":"Nakao Toshihiro"},{"name":"Shimada Mitsuo"},{"name":"Yoshikawa Kozo"},{"name":"Tokunaga Takuya"},{"name":"Nishi Masaaki"},{"name":"Kashihara Hideya"},{"name":"Takasu Chie"},{"name":"Wada Yuuma"},{"name":"Yoshimoto Toshiaki"}],"ja":[{"name":"Nakao Toshihiro"},{"name":"島田 光生"},{"name":"Yoshikawa Kozo"},{"name":"徳永 卓哉"},{"name":"西 正暁"},{"name":"柏原 秀也"},{"name":"髙須 千絵"},{"name":"和田 佑馬"},{"name":"良元 俊昭"}]},"description":{"en":"It has been reported that the oral and gut microbiomes are associated with the prognosis in patients who undergo surgery, chemotherapy, and radiation for colorectal cancer. This study is the first to identify a correlation between the number of healthy teeth, which is an oral health indicator, and the efficacy of preoperative chemotherapy for rectal cancer. This retrospective single-center study included 30 patients who underwent radical surgery after preoperative chemoradiotherapy (CRT) between December 2013 and June 2021. The relationship between number of teeth before CRT and the efficacy of CRT, CRT-related adverse events, postoperative complications, and long-term postoperative outcomes was examined. The number of healthy teeth was significantly greater in patients with downstaging of their disease than in those without downstaging ( = .027) and in patients with a complete response according to the Response Evaluation Criteria in Solid Tumors than in those who did not have a complete response ( = .014). Patients were divided into two groups according to whether they had ≥15 teeth or ≤14 teeth. There was no significant between-group difference in CRT-related adverse events. The incidence of all postoperative complications and grade II postoperative complications tended to be higher in patients with ≥15 teeth ( = .071 and = .092, respectively), as did the 5-year overall survival rate ( = .083) and the 5-year disease-free rate ( = .007). The number of healthy teeth predicted the response to preoperative CRT, postoperative complications, and the outcome of subsequent surgery in patients with rectal cancer.","ja":"It has been reported that the oral and gut microbiomes are associated with the prognosis in patients who undergo surgery, chemotherapy, and radiation for colorectal cancer. This study is the first to identify a correlation between the number of healthy teeth, which is an oral health indicator, and the efficacy of preoperative chemotherapy for rectal cancer. This retrospective single-center study included 30 patients who underwent radical surgery after preoperative chemoradiotherapy (CRT) between December 2013 and June 2021. The relationship between number of teeth before CRT and the efficacy of CRT, CRT-related adverse events, postoperative complications, and long-term postoperative outcomes was examined. The number of healthy teeth was significantly greater in patients with downstaging of their disease than in those without downstaging ( = .027) and in patients with a complete response according to the Response Evaluation Criteria in Solid Tumors than in those who did not have a complete response ( = .014). Patients were divided into two groups according to whether they had ≥15 teeth or ≤14 teeth. There was no significant between-group difference in CRT-related adverse events. The incidence of all postoperative complications and grade II postoperative complications tended to be higher in patients with ≥15 teeth ( = .071 and = .092, respectively), as did the 5-year overall survival rate ( = .083) and the 5-year disease-free rate ( = .007). The number of healthy teeth predicted the response to preoperative CRT, postoperative complications, and the outcome of subsequent surgery in patients with rectal cancer."},"publication_date":"2024-04-18","publication_name":{"en":"The American Surgeon","ja":"The American Surgeon"},"volume":"90","number":"11","starting_page":"2679","ending_page":"2686","languages":["eng"],"identifiers":{"doi":["10.1177/00031348241244628"],"issn":["1555-9823"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2000197","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38534391","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=406429","label":"url"}],"paper_title":{"en":"Generation of Highly Functional Hepatocyte-like Organoids from Human Adipose-Derived Mesenchymal Stem Cells Cultured with Endothelial Cells.","ja":"Generation of Highly Functional Hepatocyte-like Organoids from Human Adipose-Derived Mesenchymal Stem Cells Cultured with Endothelial Cells."},"authors":{"en":[{"name":"Chen Shuhai"},{"name":"Saitou Yu"},{"name":"Waki Yuhei"},{"name":"Ikemoto Tetsuya"},{"name":"Teraoku Hiroki"},{"name":"Yamada Shin-ichiro"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Chen Shuhai"},{"name":"齋藤 裕"},{"name":"Waki Yuhei"},{"name":"池本 哲也"},{"name":"寺奥 大貴"},{"name":"山田 眞一郎"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"Previously, we successfully established a highly functional, three-dimensional hepatocyte-like cell (3D-HLC) model from adipose-derived mesenchymal stem cells (ADSCs) via a three-step differentiation protocol. The aim of the present study was to investigate whether generating hepatocyte-like organoids (H-organoids) by adding endothelial cells further improved the liver-like functionality of 3D-HLCs and to assess H-organoids' immunogenicity properties. Genes representing liver maturation and function were detected by quantitative reverse transcription-PCR analysis. The expression of hepatic maturation proteins was measured using immunofluorescence staining. Cytochrome P (CYP)450 metabolism activity and ammonia metabolism tests were used to assess liver function. H-organoids were successfully established by adding human umbilical vein endothelial cells at the beginning of the definitive endoderm stage in our 3D differentiation protocol. The gene expression of alpha-1 antitrypsin, carbamoyl-phosphate synthase 1, and apolipoprotein E, which represent liver maturation state and function, was higher in H-organoids than non-organoid 3D-HLCs. H-organoids possessed higher CYP3A4 metabolism activity and comparable ammonia metabolism capacity than 3D-HLCs. Moreover, although H-organoids expressed human leukocyte antigen class I, they expressed little human leukocyte antigen class II, cluster of differentiation (CD)40, CD80, CD86, and programmed cell death ligand 1, suggesting their immunogenicity properties were not significantly upregulated during differentiation from ADSCs. In conclusion, we successfully established an H-organoid model with higher liver-like functionality than previously established 3D-HLCs and comparable immunogenicity to ADSCs.","ja":"Previously, we successfully established a highly functional, three-dimensional hepatocyte-like cell (3D-HLC) model from adipose-derived mesenchymal stem cells (ADSCs) via a three-step differentiation protocol. The aim of the present study was to investigate whether generating hepatocyte-like organoids (H-organoids) by adding endothelial cells further improved the liver-like functionality of 3D-HLCs and to assess H-organoids' immunogenicity properties. Genes representing liver maturation and function were detected by quantitative reverse transcription-PCR analysis. The expression of hepatic maturation proteins was measured using immunofluorescence staining. Cytochrome P (CYP)450 metabolism activity and ammonia metabolism tests were used to assess liver function. H-organoids were successfully established by adding human umbilical vein endothelial cells at the beginning of the definitive endoderm stage in our 3D differentiation protocol. The gene expression of alpha-1 antitrypsin, carbamoyl-phosphate synthase 1, and apolipoprotein E, which represent liver maturation state and function, was higher in H-organoids than non-organoid 3D-HLCs. H-organoids possessed higher CYP3A4 metabolism activity and comparable ammonia metabolism capacity than 3D-HLCs. Moreover, although H-organoids expressed human leukocyte antigen class I, they expressed little human leukocyte antigen class II, cluster of differentiation (CD)40, CD80, CD86, and programmed cell death ligand 1, suggesting their immunogenicity properties were not significantly upregulated during differentiation from ADSCs. In conclusion, we successfully established an H-organoid model with higher liver-like functionality than previously established 3D-HLCs and comparable immunogenicity to ADSCs."},"publication_date":"2024-03-20","publication_name":{"en":"Cells","ja":"Cells"},"volume":"13","number":"6","languages":["eng"],"identifiers":{"doi":["10.3390/cells13060547"],"issn":["2073-4409"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197277"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38438675","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416416","label":"url"}],"paper_title":{"en":"Comparison of the short-term surgical outcomes of lateral lymph node dissection for low rectal cancer using a robotic-assisted transabdominal approach alone or supported by a transanal approach.","ja":"Comparison of the short-term surgical outcomes of lateral lymph node dissection for low rectal cancer using a robotic-assisted transabdominal approach alone or supported by a transanal approach."},"authors":{"en":[{"name":"Tokunaga Takuya"},{"name":"Kashihara Hideya"},{"name":"Yoshikawa Kozo"},{"name":"Nakao Toshihiro"},{"name":"Nishi Masaaki"},{"name":"Takasu Chie"},{"name":"Wada Yuuma"},{"name":"Yoshimoto Toshiaki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"徳永 卓哉"},{"name":"柏原 秀也"},{"name":"Yoshikawa Kozo"},{"name":"中尾 寿宏"},{"name":"西 正暁"},{"name":"髙須 千絵"},{"name":"和田 佑馬"},{"name":"良元 俊昭"},{"name":"島田 光生"}]},"description":{"en":"Lateral lymph node metastases are a major cause of local recurrence after surgery for advanced low rectal cancer. Lateral lymph node dissection (LLND) may reduce the risk of local recurrence in patients with suspected lateral lymph node metastasis. Recent reports have shown that robotic-assisted LLND can help to reduce the postoperative complication rate, such as urinary disturbance. Furthermore, with the advent of transanal total mesorectal excision, a novel LLND procedure that combines a transabdominal approach with a transanal approach has been reported. This study aimed to clarify the safety and feasibility of robotic-assisted LLND supported by a transanal approach for advanced low rectal cancer. Thirty-nine patients diagnosed to have low rectal cancer between June 2019 and May 2023 were retrospectively enrolled and divided according to whether they underwent LLND via a robotic-assisted transabdominal approach alone (transabdominal group, n = 19) or in combination with a transanal approach (2team group, n = 20). The patient characteristics and short-term surgical outcomes were compared between the two groups. The total operation time was significantly shorter in the 2team group than in the transabdominal group (366 min vs. 513 min, P < 0.001), as was the time taken to perform unilateral LLND (64 min vs. 114 min, P < 0.001). Furthermore, there was significantly less intraoperative bleeding in the 2team group (30 mL vs. 80 mL, P = 0.004). There was no significant between-group difference in postoperative complications. The incidence of postoperative urinary disturbance was satisfactory at 5% in both groups. The operation time for LLND performed by a robotic-assisted transabdominal approach was shortened when supported by a transanal approach. The frequency of postoperative urinary disturbance was low in both groups. Therefore, robotic-assisted abdominal LLND supported by a transanal approach can be considered a promising treatment option for advanced low rectal cancer.","ja":"Lateral lymph node metastases are a major cause of local recurrence after surgery for advanced low rectal cancer. Lateral lymph node dissection (LLND) may reduce the risk of local recurrence in patients with suspected lateral lymph node metastasis. Recent reports have shown that robotic-assisted LLND can help to reduce the postoperative complication rate, such as urinary disturbance. Furthermore, with the advent of transanal total mesorectal excision, a novel LLND procedure that combines a transabdominal approach with a transanal approach has been reported. This study aimed to clarify the safety and feasibility of robotic-assisted LLND supported by a transanal approach for advanced low rectal cancer. Thirty-nine patients diagnosed to have low rectal cancer between June 2019 and May 2023 were retrospectively enrolled and divided according to whether they underwent LLND via a robotic-assisted transabdominal approach alone (transabdominal group, n = 19) or in combination with a transanal approach (2team group, n = 20). The patient characteristics and short-term surgical outcomes were compared between the two groups. The total operation time was significantly shorter in the 2team group than in the transabdominal group (366 min vs. 513 min, P < 0.001), as was the time taken to perform unilateral LLND (64 min vs. 114 min, P < 0.001). Furthermore, there was significantly less intraoperative bleeding in the 2team group (30 mL vs. 80 mL, P = 0.004). There was no significant between-group difference in postoperative complications. The incidence of postoperative urinary disturbance was satisfactory at 5% in both groups. The operation time for LLND performed by a robotic-assisted transabdominal approach was shortened when supported by a transanal approach. The frequency of postoperative urinary disturbance was low in both groups. Therefore, robotic-assisted abdominal LLND supported by a transanal approach can be considered a promising treatment option for advanced low rectal cancer."},"publication_date":"2024-03-04","publication_name":{"en":"Surgical Endoscopy","ja":"Surgical Endoscopy"},"volume":"38","number":"4","starting_page":"2070","ending_page":"2077","languages":["eng"],"identifiers":{"doi":["10.1007/s00464-024-10730-0"],"issn":["1432-2218"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197278"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2024289102","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416430","label":"url"}],"paper_title":{"en":"医療DXの可能性が広がる!XR(VR・AR・MR)とメタバースの最前線(第16回) XRを活用した骨盤手術 直腸がんに対する経肛門アプローチ","ja":"医療DXの可能性が広がる!XR(VR・AR・MR)とメタバースの最前線(第16回) XRを活用した骨盤手術 直腸がんに対する経肛門アプローチ"},"authors":{"en":[{"name":"Tokunaga Takuya"},{"name":"Kashihara Hideya"},{"name":"Shimada Mitsuo"},{"name":"杉本 真樹"}],"ja":[{"name":"徳永 卓哉"},{"name":"柏原 秀也"},{"name":"島田 光生"},{"name":"杉本 真樹"}]},"publication_date":"2024-03","publication_name":{"en":"INNERVISION","ja":"INNERVISION"},"volume":"39","number":"4","starting_page":"68","ending_page":"71","languages":["jpn"],"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197279"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2024154100","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416429","label":"url"}],"paper_title":{"en":"【腹腔鏡下噴門形成術-新技術認定制度に向けて】ラップ形成(Nissen-Rossetti法)","ja":"【腹腔鏡下噴門形成術-新技術認定制度に向けて】ラップ形成(Nissen-Rossetti法)"},"authors":{"en":[{"name":"Ishibashi Hiroki"},{"name":"Mori Hiroki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"石橋 広樹"},{"name":"森 大樹"},{"name":"島田 光生"}]},"publication_date":"2024-01","publication_name":{"en":"Japanese Journal of Pediatric Surgery","ja":"小児外科"},"volume":"56","number":"1","starting_page":"60","ending_page":"65","languages":["jpn"],"identifiers":{"doi":["10.24479/ps.0000000694"],"issn":["0385-6313"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197280"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/39462554","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416424","label":"url"}],"paper_title":{"en":"Impact of Daikenchuto (TU-100) on the early postoperative period in duodenal-jejunal bypass.","ja":"Impact of Daikenchuto (TU-100) on the early postoperative period in duodenal-jejunal bypass."},"authors":{"en":[{"name":"Kashihara Hideya"},{"name":"Okikawa Shohei"},{"name":"Morine Yuji"},{"name":"Yoshikawa Kozo"},{"name":"Tokunaga Takuya"},{"name":"Nishi Masaaki"},{"name":"Takasu Chie"},{"name":"Nishiyama Mitsue"},{"name":"Zushi Makoto"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"柏原 秀也"},{"name":"Okikawa Shohei"},{"name":"森根 裕二"},{"name":"Yoshikawa Kozo"},{"name":"徳永 卓哉"},{"name":"西 正暁"},{"name":"髙須 千絵"},{"name":"Nishiyama Mitsue"},{"name":"Zushi Makoto"},{"name":"島田 光生"}]},"description":{"en":"We investigated the effect of Daikenchuto (TU-100) on the early postoperative period in duodenal-jejunal bypass (DJB). Study 1:The effect of TU-100 on diabetic rats was investigated. Rats were sacrificed after receiving TU-100 for one week. Study 2:The effect of TU-100 on DJB was investigated. Rats in the DJB and TU-100 treated DJB groups were sacrificed 24 hours postoperation to evaluate blood glucose, cytokine expression, and gut microbiome. Study 1:TU-100 did not affect glucose or body weight. TU-100 suppressed intestinal inflammation and modified the gut microbiome. Specifically, Bifidobacterium and Blautia were increased, and Turicibacter were decreased in this group. Study 2:Both DJB and TU-100 treated DJB rats showed lower blood glucose at 24 hours postoperation than at preoperation. Cytokine expression in the liver and small intestine of the TU-100 treated DJB group was significantly lower than that of the DJB group. The gut microbiome composition in TU-100 treated DJB rats was altered. In particular, Bifidobacterium and Blautia were increased in this group. DJB suppressed blood glucose during the early postoperative period. TU-100 may enhance the anti-diabetic effect of metabolic surgery by changing the gut microbiome and suppressing inflammation in the early postoperative period. J. Med. Invest. 71 : 210-218, August, 2024.","ja":"We investigated the effect of Daikenchuto (TU-100) on the early postoperative period in duodenal-jejunal bypass (DJB). Study 1:The effect of TU-100 on diabetic rats was investigated. Rats were sacrificed after receiving TU-100 for one week. Study 2:The effect of TU-100 on DJB was investigated. Rats in the DJB and TU-100 treated DJB groups were sacrificed 24 hours postoperation to evaluate blood glucose, cytokine expression, and gut microbiome. Study 1:TU-100 did not affect glucose or body weight. TU-100 suppressed intestinal inflammation and modified the gut microbiome. Specifically, Bifidobacterium and Blautia were increased, and Turicibacter were decreased in this group. Study 2:Both DJB and TU-100 treated DJB rats showed lower blood glucose at 24 hours postoperation than at preoperation. Cytokine expression in the liver and small intestine of the TU-100 treated DJB group was significantly lower than that of the DJB group. The gut microbiome composition in TU-100 treated DJB rats was altered. In particular, Bifidobacterium and Blautia were increased in this group. DJB suppressed blood glucose during the early postoperative period. TU-100 may enhance the anti-diabetic effect of metabolic surgery by changing the gut microbiome and suppressing inflammation in the early postoperative period. J. Med. Invest. 71 : 210-218, August, 2024."},"publication_date":"2024","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"71","number":"3.4","starting_page":"210","ending_page":"218","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.71.210"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197281"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38735711","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416417","label":"url"}],"paper_title":{"en":"Feasibility of laparoscopic and endoscopic cooperative surgery for gastric gastrointestinal stromal tumor with tumor diameter of >5 cm.","ja":"Feasibility of laparoscopic and endoscopic cooperative surgery for gastric gastrointestinal stromal tumor with tumor diameter of >5 cm."},"authors":{"en":[{"name":"Iwakawa Yosuke"},{"name":"Nishi Masaaki"},{"name":"Wada Yuuma"},{"name":"Yoshikawa Kozo"},{"name":"Takasu Chie"},{"name":"Tokunaga Takuya"},{"name":"Nakao Toshihiro"},{"name":"Kashihara Hideya"},{"name":"Yoshimoto Toshiaki"},{"name":"Noma Takayuki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Iwakawa Yosuke"},{"name":"西 正暁"},{"name":"和田 佑馬"},{"name":"Yoshikawa Kozo"},{"name":"髙須 千絵"},{"name":"徳永 卓哉"},{"name":"Nakao Toshihiro"},{"name":"柏原 秀也"},{"name":"良元 俊昭"},{"name":"野間 隆礼"},{"name":"島田 光生"}]},"description":{"en":"Laparoscopic and endoscopic cooperative surgery (LECS) is an effective treatment for gastric gastrointestinal stromal tumors (GISTs). The utility of LECS for gastric GISTs of > 5 cm remains controversial. This study was performed to investigate the feasibility of LECS for gastric GISTs with a tumor diameter of >5 cm. We analyzed 43 patients with gastric GISTs who underwent LECS or laparoscopic partial gastrectomy (Lap-Partial Gx). We compared the surgical outcomes of LECS versus Lap-Partial Gx and of LECS for a tumor diameter of > 5 versus ≤ 5 cm. In the comparison of LECS versus Lap-Partial Gx, there were no significant intergroup differences in the operative time or blood loss volume. The morbidity rate was similar between the groups. No postoperative mortality occurred in either group. In the comparison of LECS for a tumor diameter of > 5 versus ≤ 5 cm, there were no significant intergroup differences in operative time, or blood loss volume. The morbidity rate was similar between the > 5-cm and ≤ 5-cm groups (0.0% vs. 4.5%, respectively ; p = 0.56). Additionally, no recurrence or death occurred during follow-up in either group. LECS is a feasible option for gastric GISTs with a tumor diameter of > 5 cm. J. Med. Invest. 71 : 148-153, February, 2024.","ja":"Laparoscopic and endoscopic cooperative surgery (LECS) is an effective treatment for gastric gastrointestinal stromal tumors (GISTs). The utility of LECS for gastric GISTs of > 5 cm remains controversial. This study was performed to investigate the feasibility of LECS for gastric GISTs with a tumor diameter of >5 cm. We analyzed 43 patients with gastric GISTs who underwent LECS or laparoscopic partial gastrectomy (Lap-Partial Gx). We compared the surgical outcomes of LECS versus Lap-Partial Gx and of LECS for a tumor diameter of > 5 versus ≤ 5 cm. In the comparison of LECS versus Lap-Partial Gx, there were no significant intergroup differences in the operative time or blood loss volume. The morbidity rate was similar between the groups. No postoperative mortality occurred in either group. In the comparison of LECS for a tumor diameter of > 5 versus ≤ 5 cm, there were no significant intergroup differences in operative time, or blood loss volume. The morbidity rate was similar between the > 5-cm and ≤ 5-cm groups (0.0% vs. 4.5%, respectively ; p = 0.56). Additionally, no recurrence or death occurred during follow-up in either group. LECS is a feasible option for gastric GISTs with a tumor diameter of > 5 cm. J. Med. Invest. 71 : 148-153, February, 2024."},"publication_date":"2024","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"71","number":"1.2","starting_page":"148","ending_page":"153","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.71.148"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"49197282"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38735728","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416411","label":"url"}],"paper_title":{"en":"Pancreatoduodenectomy combined with intestinal de-rotation as a complete artery-first approach for inexperienced surgeons.","ja":"Pancreatoduodenectomy combined with intestinal de-rotation as a complete artery-first approach for inexperienced surgeons."},"authors":{"en":[{"name":"Morine Yuji"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Teraoku Hiroki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"森根 裕二"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"寺奥 大貴"},{"name":"池本 哲也"},{"name":"島田 光生"}]},"description":{"en":"Recent technical advances have reduced the incidence of intraoperative complications associated with pancreatoduodenectomy (PD). We aimed to determine whether inexperienced surgeons (ISs) would be as successful as experienced surgeons (ESs) when performing the complete artery-first approach using the intestinal de-rotation method of PD. Seventy patients who underwent PD using the intestinal de-rotation method in Tokushima University Hospital were enrolled in the present study. Intra- and post-operative parameters were compared between patients operated on by ESs (n=20) or ISs (n=50). The surgical procedure lasted longer in the IS group (ES : 402 }68 min vs. IS : 483 }51 min, p<0.0001), but the volume of blood loss was similar (p=0.7304). There was no mortality in either group, and the incidences of postoperative complications with a Clavien-Dindo grade of>III did not differ between the groups. Grade B postoperative pancreatic fistulae developed in 20.0% of patients in the ES group and 22.0% in the IS group (p=0.9569). Finally, the postoperative hospital stay of the IS group (32 }33 days) was equivarent to that of the ES group (33 }16 days) (p=0.9256). ISs were able to perform similarly successful PDs using the intestinal de-rotation method to ESs. J. Med. Invest. 71 : 75-81, February, 2024.","ja":"Recent technical advances have reduced the incidence of intraoperative complications associated with pancreatoduodenectomy (PD). We aimed to determine whether inexperienced surgeons (ISs) would be as successful as experienced surgeons (ESs) when performing the complete artery-first approach using the intestinal de-rotation method of PD. Seventy patients who underwent PD using the intestinal de-rotation method in Tokushima University Hospital were enrolled in the present study. Intra- and post-operative parameters were compared between patients operated on by ESs (n=20) or ISs (n=50). The surgical procedure lasted longer in the IS group (ES : 402 }68 min vs. IS : 483 }51 min, p<0.0001), but the volume of blood loss was similar (p=0.7304). There was no mortality in either group, and the incidences of postoperative complications with a Clavien-Dindo grade of>III did not differ between the groups. Grade B postoperative pancreatic fistulae developed in 20.0% of patients in the ES group and 22.0% in the IS group (p=0.9569). Finally, the postoperative hospital stay of the IS group (32 }33 days) was equivarent to that of the ES group (33 }16 days) (p=0.9256). ISs were able to perform similarly successful PDs using the intestinal de-rotation method to ESs. J. Med. Invest. 71 : 75-81, February, 2024."},"publication_date":"2024","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"71","number":"1.2","starting_page":"75","ending_page":"81","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.71.75"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2011934","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38017374","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405971","label":"url"}],"paper_title":{"en":"Association between high expression of intratumoral fibroblast activation protein and survival in patients with intrahepatic cholangiocarcinoma.","ja":"Association between high expression of intratumoral fibroblast activation protein and survival in patients with intrahepatic cholangiocarcinoma."},"authors":{"en":[{"name":"Waki Yuhei"},{"name":"Morine Yuji"},{"name":"Noma Takayuki"},{"name":"Takasu Chie"},{"name":"Teraoku Hiroki"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"脇 悠平"},{"name":"森根 裕二"},{"name":"野間 隆礼"},{"name":"髙須 千絵"},{"name":"寺奥 大貴"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"池本 哲也"},{"name":"島田 光生"}]},"description":{"en":"Cancer-associated fibroblasts (CAFs) have been reported to exhibit protumorigenic effects. Among the well-known CAF markers such as smooth muscle actin (SMA) and fibroblast activation protein (FAP), high expression of SMA in the peritumoral stroma has been reported to be a prognostic factor in various cancers. However, the effect of high FAP expression in intrahepatic cholangiocarcinoma (IHCC) has not been fully clarified. We evaluated the expression of CAF markers, focusing on FAP expression in the peripheral and intratumoral regions, to clarify the association with survival in patients with IHCC. The study cohort comprised 37 patients who underwent curative resection for IHCC. The FAP expressions were evaluated in the peripheral and intratumoral regions of the resected tissues. Clinicopathological factors and survival outcomes were investigated between patients with high versus low FAP expression. Uni- and multivariate analyses were performed to identify the prognostic factors for overall survival and relapse-free survival. The median area percentages of FAP expression in the peripheral and intratumoral regions were 15.5% and 17.8%, respectively. High FAP expression in the intratumoral region was significantly associated with worse overall survival and disease-free survival than low FAP expression in the intratumoral region. Multivariate analysis identified high intratumoral FAP expression as a risk factor for worse overall survival (hazard ratio, 2.450; p = 0.049) and relapse-free survival (hazard ratio, 2.743; p = 0.034). High intratumoral FAP expression was associated with worse survival, suggesting that intratumoral FAP expression represents malignant progression in patients with IHCC.","ja":"Cancer-associated fibroblasts (CAFs) have been reported to exhibit protumorigenic effects. Among the well-known CAF markers such as smooth muscle actin (SMA) and fibroblast activation protein (FAP), high expression of SMA in the peritumoral stroma has been reported to be a prognostic factor in various cancers. However, the effect of high FAP expression in intrahepatic cholangiocarcinoma (IHCC) has not been fully clarified. We evaluated the expression of CAF markers, focusing on FAP expression in the peripheral and intratumoral regions, to clarify the association with survival in patients with IHCC. The study cohort comprised 37 patients who underwent curative resection for IHCC. The FAP expressions were evaluated in the peripheral and intratumoral regions of the resected tissues. Clinicopathological factors and survival outcomes were investigated between patients with high versus low FAP expression. Uni- and multivariate analyses were performed to identify the prognostic factors for overall survival and relapse-free survival. The median area percentages of FAP expression in the peripheral and intratumoral regions were 15.5% and 17.8%, respectively. High FAP expression in the intratumoral region was significantly associated with worse overall survival and disease-free survival than low FAP expression in the intratumoral region. Multivariate analysis identified high intratumoral FAP expression as a risk factor for worse overall survival (hazard ratio, 2.450; p = 0.049) and relapse-free survival (hazard ratio, 2.743; p = 0.034). High intratumoral FAP expression was associated with worse survival, suggesting that intratumoral FAP expression represents malignant progression in patients with IHCC."},"publication_date":"2023-11-28","publication_name":{"en":"BMC Gastroenterology","ja":"BMC Gastroenterology"},"volume":"23","number":"1","starting_page":"415","ending_page":"415","languages":["eng"],"identifiers":{"doi":["10.1186/s12876-023-03012-x"],"issn":["1471-230X"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2011947","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37968291","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405969","label":"url"}],"paper_title":{"en":"Effects of green light-emitting diode irradiation on hepatic differentiation of hepatocyte-like cells generated from human adipose-derived mesenchymal cells.","ja":"Effects of green light-emitting diode irradiation on hepatic differentiation of hepatocyte-like cells generated from human adipose-derived mesenchymal cells."},"authors":{"en":[{"name":"Waki Yuhei"},{"name":"Saitou Yu"},{"name":"Chen Shuhai"},{"name":"Ikemoto Tetsuya"},{"name":"Noma Takayuki"},{"name":"Teraoku Hiroki"},{"name":"Yamada Shin-ichiro"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"脇 悠平"},{"name":"齋藤 裕"},{"name":"Chen Shuhai"},{"name":"池本 哲也"},{"name":"野間 隆礼"},{"name":"寺奥 大貴"},{"name":"山田 眞一郎"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"Light-emitting diode (LED) irradiation has been used in the differentiation of mesenchymal stem cells into a variety of cell types. This study investigated the effect of green LED (GLED) irradiation on the differentiation of adipocyte-derived mesenchymal cells into hepatocyte-like cells (HLCs) and the mechanism of its action. HLCs in the hepatocyte maturation phase were irradiated with GLED (520 nm, 21 W/m, 5 min/day for 10 days). The cells were then assessed for expression of hepatocyte maturity genes and opsin 3 (OPN3), hepatocyte function, viability, apoptosis, and levels of reactive oxygen species (ROS), intracellular adenosine triphosphate (ATP) and calcium ions (Ca). GLED irradiation increased Alpha-1 antitrypsin and Ornithine transcarbamylase gene expression, promoted Cytochrome P450 3A4 activity and urea synthesis, and elevated intracellular ROS, ATP and Ca levels. OPN3 expression was significantly more upregulated in GLED-irradiated HLCs than in the non-irradiated HLCs. No significant difference in cell viability or apoptosis was observed between GLED-irradiated and non-irradiated HLCs. GLED irradiation can promote hepatocyte maturation and functions through OPN3. GLED irradiation also stimulated mitochondrial function via Ca/ATP/ROS activation. GLED irradiation has potential to support cell-based transplantation in patients.","ja":"Light-emitting diode (LED) irradiation has been used in the differentiation of mesenchymal stem cells into a variety of cell types. This study investigated the effect of green LED (GLED) irradiation on the differentiation of adipocyte-derived mesenchymal cells into hepatocyte-like cells (HLCs) and the mechanism of its action. HLCs in the hepatocyte maturation phase were irradiated with GLED (520 nm, 21 W/m, 5 min/day for 10 days). The cells were then assessed for expression of hepatocyte maturity genes and opsin 3 (OPN3), hepatocyte function, viability, apoptosis, and levels of reactive oxygen species (ROS), intracellular adenosine triphosphate (ATP) and calcium ions (Ca). GLED irradiation increased Alpha-1 antitrypsin and Ornithine transcarbamylase gene expression, promoted Cytochrome P450 3A4 activity and urea synthesis, and elevated intracellular ROS, ATP and Ca levels. OPN3 expression was significantly more upregulated in GLED-irradiated HLCs than in the non-irradiated HLCs. No significant difference in cell viability or apoptosis was observed between GLED-irradiated and non-irradiated HLCs. GLED irradiation can promote hepatocyte maturation and functions through OPN3. GLED irradiation also stimulated mitochondrial function via Ca/ATP/ROS activation. GLED irradiation has potential to support cell-based transplantation in patients."},"publication_date":"2023-11-15","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"13","number":"1","starting_page":"19954","ending_page":"19954","languages":["eng"],"identifiers":{"doi":["10.1038/s41598-023-45967-7"],"issn":["2045-2322"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2024041966","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=406431","label":"url"}],"paper_title":{"en":"原因が不明であった肝palisading granulomaの1例","ja":"原因が不明であった肝palisading granulomaの1例"},"authors":{"en":[{"name":"仲須 千春"},{"name":"Yamada Shin-ichiro"},{"name":"Teraoku Hiroki"},{"name":"Saitou Yu"},{"name":"Ikemoto Tetsuya"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"仲須 千春"},{"name":"山田 眞一郎"},{"name":"寺奥 大貴"},{"name":"齋藤 裕"},{"name":"池本 哲也"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"患者は50代女性.検診の腹部超音波検査で肝S3に16×14mm大の腫瘤を指摘され精査加療目的に当科紹介となった.既往歴・生肉食歴なし.術前の血液検査で異常なく,末梢好酸球も正常.造影CTの動脈・門脈相では辺縁に造影効果を認めるが,平衡相では造影されず,MRI T1強調像で低信号,T2強調像で低∼等信号,拡散強調像でやや高信号であった.PET-CTで肝臓への集積は認めなった.悪性腫瘍の可能性を完全に否定できず,腹腔鏡下肝部分切除を施行した.病理組織学的には腫瘤全体に凝固壊死像が見られ,辺縁に線維増生を伴い,組織球が柵状に配列したpalisading granulomaであった.原因特定のために複数の染色を行ったが,病原体は同定できなかった.palisading granulomaは術前診断が困難であり,診断的治療として腹腔鏡下肝切除術は有用であると考えられた.(著者抄録)","ja":"患者は50代女性.検診の腹部超音波検査で肝S3に16×14mm大の腫瘤を指摘され精査加療目的に当科紹介となった.既往歴・生肉食歴なし.術前の血液検査で異常なく,末梢好酸球も正常.造影CTの動脈・門脈相では辺縁に造影効果を認めるが,平衡相では造影されず,MRI T1強調像で低信号,T2強調像で低∼等信号,拡散強調像でやや高信号であった.PET-CTで肝臓への集積は認めなった.悪性腫瘍の可能性を完全に否定できず,腹腔鏡下肝部分切除を施行した.病理組織学的には腫瘤全体に凝固壊死像が見られ,辺縁に線維増生を伴い,組織球が柵状に配列したpalisading granulomaであった.原因特定のために複数の染色を行ったが,病原体は同定できなかった.palisading granulomaは術前診断が困難であり,診断的治療として腹腔鏡下肝切除術は有用であると考えられた.(著者抄録)"},"publication_date":"2023-10","publication_name":{"en":"Acta Hepatologica Japonica","ja":"肝臓"},"volume":"64","number":"10","starting_page":"504","ending_page":"509","languages":["jpn"],"identifiers":{"doi":["10.2957/kanzo.64.504"],"issn":["1881-3593"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2011935","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37715229","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405972","label":"url"}],"paper_title":{"en":"Clinical impact of myosteatosis measured by magnetic resonance imaging on long-term outcomes of hepatocellular carcinoma after radical hepatectomy.","ja":"Clinical impact of myosteatosis measured by magnetic resonance imaging on long-term outcomes of hepatocellular carcinoma after radical hepatectomy."},"authors":{"en":[{"name":"Yoshikawa Kouzou"},{"name":"Shimada Mitsuo"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Teraoku Hiroki"},{"name":"Takao Shoichiro"}],"ja":[{"name":"吉川 幸造"},{"name":"島田 光生"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"寺奥 大貴"},{"name":"髙尾 正一郎"}]},"description":{"en":"A variety of factors have been reported to affect long-term outcomes after radical resection of hepatocellular carcinoma (HCC). However, the indicators remain controversial. The purpose of this study was to evaluate the relationship between myosteatosis of the multifidus muscle and long-term outcomes after radical surgery for HCC. We retrospectively analyzed clinicopathological data for 187 patients with HCC who underwent radical surgery at Tokushima University between January 2009 and December 2020 and measured the density of fat in the multifidus muscle at L3 on their preoperative magnetic resonance images (MRI). Associations of myosteatosis and clinicopathological factors with long-term outcomes were evaluated. The patients were divided into a myosteatosis-negative group (n = 122) and a myosteatosis-positive group (n = 65). The cancer-specific survival rate after hepatectomy was significantly worse in the myosteatosis-positive group than in the myosteatosis-negative group (p = 0.03). Univariate analysis identified multiple tumors, stage III/IV disease, an alfa-fetoprotein level ≥ 10 ng/ml, PIVKA-II ≥ 400 AU/ml, vp(+) status, and myosteatosis to be prognostic factors for cancer-specific survival. Multivariate analysis revealed multiple tumors, an alfa-fetoprotein level ≥ 10 ng/ml, and myosteatosis to be independent prognostic factors. Myosteatosis measured by MRI is a simple and useful predictor of the long-term outcome after radical surgery for HCC.","ja":"A variety of factors have been reported to affect long-term outcomes after radical resection of hepatocellular carcinoma (HCC). However, the indicators remain controversial. The purpose of this study was to evaluate the relationship between myosteatosis of the multifidus muscle and long-term outcomes after radical surgery for HCC. We retrospectively analyzed clinicopathological data for 187 patients with HCC who underwent radical surgery at Tokushima University between January 2009 and December 2020 and measured the density of fat in the multifidus muscle at L3 on their preoperative magnetic resonance images (MRI). Associations of myosteatosis and clinicopathological factors with long-term outcomes were evaluated. The patients were divided into a myosteatosis-negative group (n = 122) and a myosteatosis-positive group (n = 65). The cancer-specific survival rate after hepatectomy was significantly worse in the myosteatosis-positive group than in the myosteatosis-negative group (p = 0.03). Univariate analysis identified multiple tumors, stage III/IV disease, an alfa-fetoprotein level ≥ 10 ng/ml, PIVKA-II ≥ 400 AU/ml, vp(+) status, and myosteatosis to be prognostic factors for cancer-specific survival. Multivariate analysis revealed multiple tumors, an alfa-fetoprotein level ≥ 10 ng/ml, and myosteatosis to be independent prognostic factors. Myosteatosis measured by MRI is a simple and useful predictor of the long-term outcome after radical surgery for HCC."},"publication_date":"2023-09-15","publication_name":{"en":"BMC Surgery","ja":"BMC Surgery"},"volume":"23","number":"1","starting_page":"281","ending_page":"281","languages":["eng"],"identifiers":{"doi":["10.1186/s12893-023-02188-z"],"issn":["1471-2482"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"46083777"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38187176","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=416415","label":"url"}],"paper_title":{"en":"Conversion surgery after successful response to chemotherapy (S-1 + oxaliplatin + nivolumab) in a patient with stage IV gastric cancer with peritoneal metastasis (P1, CY1): a case report.","ja":"Conversion surgery after successful response to chemotherapy (S-1 + oxaliplatin + nivolumab) in a patient with stage IV gastric cancer with peritoneal metastasis (P1, CY1): a case report."},"authors":{"en":[{"name":"Noma Takayuki"},{"name":"Nishi Masaaki"},{"name":"Takasu Chie"},{"name":"Wada Yuuma"},{"name":"Yoshikawa Kozo"},{"name":"Tokunaga Takuya"},{"name":"Nakao Toshihiro"},{"name":"Kashihara Hideya"},{"name":"Yoshimoto Toshiaki"},{"name":"Miyakami Yuko"},{"name":"Atsumi Kengo"},{"name":"Uehara Hisanori"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"野間 隆礼"},{"name":"西 正暁"},{"name":"髙須 千絵"},{"name":"和田 佑馬"},{"name":"Yoshikawa Kozo"},{"name":"徳永 卓哉"},{"name":"中尾 寿宏"},{"name":"柏原 秀也"},{"name":"良元 俊昭"},{"name":"宮上 侑子"},{"name":"Atsumi Kengo"},{"name":"上原 久典"},{"name":"島田 光生"}]},"description":{"en":"We here present a case report of a patient with Stage IV gastric cancer with peritoneal metastasis (P1, CY1) who underwent conversion surgery after a successful response to chemotherapy (S-1 + oxaliplatin + nivolumab). The patient was a woman in her 60 s. Her chief complaint was epigastric pain. Upper gastrointestinal endoscopy showed Type 4 advanced carcinoma on the lesser curvature of the gastric body. Biopsy showed Group 5 (poorly differentiated adenocarcinoma) and HER2 was negative. Staging laparoscopy revealed seeding in the round ligament of the liver (P1) and adenocarcinoma cells in ascites (CY1). Ten courses of chemotherapy (S-1 + oxaliplatin + nivolumab) were administered, after which contrast-enhanced computed tomography showed that the primary tumor had shrunk and seeding was no longer detectable. Upper gastrointestinal endoscopy revealed scar-like changes. A second staging laparoscopy revealed that ascites cytology was negative and a biopsy of the round ligament of the liver showed no malignant cells (P0, CY0). Conversion surgery comprising laparoscopic total gastrectomy with D2 lymph node dissection and resection of the round ligament of the liver was performed. The postoperative course was uneventful. Histopathological examination of the resected specimen revealed no tumor cells in the gastric mesentery or the round ligament of the liver. The pathological diagnosis was gastric cancer [M, U, L, Less, Ant, Post, type4, T3(SS), N0, M0 (H0, P0, CY0), ypStage IIA]. Adjuvant chemotherapy (S-1) was commenced. The patient is still alive 7 months later with no evidence of recurrence.","ja":"We here present a case report of a patient with Stage IV gastric cancer with peritoneal metastasis (P1, CY1) who underwent conversion surgery after a successful response to chemotherapy (S-1 + oxaliplatin + nivolumab). The patient was a woman in her 60 s. Her chief complaint was epigastric pain. Upper gastrointestinal endoscopy showed Type 4 advanced carcinoma on the lesser curvature of the gastric body. Biopsy showed Group 5 (poorly differentiated adenocarcinoma) and HER2 was negative. Staging laparoscopy revealed seeding in the round ligament of the liver (P1) and adenocarcinoma cells in ascites (CY1). Ten courses of chemotherapy (S-1 + oxaliplatin + nivolumab) were administered, after which contrast-enhanced computed tomography showed that the primary tumor had shrunk and seeding was no longer detectable. Upper gastrointestinal endoscopy revealed scar-like changes. A second staging laparoscopy revealed that ascites cytology was negative and a biopsy of the round ligament of the liver showed no malignant cells (P0, CY0). Conversion surgery comprising laparoscopic total gastrectomy with D2 lymph node dissection and resection of the round ligament of the liver was performed. The postoperative course was uneventful. Histopathological examination of the resected specimen revealed no tumor cells in the gastric mesentery or the round ligament of the liver. The pathological diagnosis was gastric cancer [M, U, L, Less, Ant, Post, type4, T3(SS), N0, M0 (H0, P0, CY0), ypStage IIA]. Adjuvant chemotherapy (S-1) was commenced. The patient is still alive 7 months later with no evidence of recurrence."},"publication_date":"2023-08-12","publication_name":{"en":"International Cancer Conference Journal","ja":"International Cancer Conference Journal"},"volume":"13","number":"1","starting_page":"11","ending_page":"16","languages":["eng"],"identifiers":{"doi":["10.1007/s13691-023-00628-4"],"issn":["2192-3183"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37097685","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405968","label":"url"}],"paper_title":{"en":"TU-100 Antagonizes the M2 Polarization Phenotype of Macrophages in the Tumor Microenvironment by Suppressing the TLR4/NF-B/STAT3 Axis.","ja":"TU-100 Antagonizes the M2 Polarization Phenotype of Macrophages in the Tumor Microenvironment by Suppressing the TLR4/NF-B/STAT3 Axis."},"authors":{"en":[{"name":"Chen Shuhai"},{"name":"Morine Yuji"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Teraoku Hiroki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Chen Shuhai"},{"name":"森根 裕二"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"寺奥 大貴"},{"name":"池本 哲也"},{"name":"島田 光生"}]},"description":{"en":"Macrophages are the most abundant immune cells in the tumor stroma, and their polarization states within the tumor microenvironment (TME) exert critical roles in tumorigenesis. TU-100 (Daikenchuto) is a commonly prescribed Japanese herbal medicine that has shown anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. However, its effects on tumor-associated macrophages (TAMs) remain unclear. TAMs were generated by macrophage exposure to tumor-conditioned medium (CM), and their polarization states were evaluated after TU-100 treatment. The underlying mechanism was further studied. TU-100 exhibited little cytotoxicity over a range of doses in M0 macrophages and TAMs. However, it could antagonize the M2-like polarization of macrophages evoked by tumor-CM exposure. These effects might be caused by the inhibition of TLR4/NF-B/STAT3 signaling in the M2-like phenotype of macrophages. Interestingly, TU-100 antagonized the malignancy promoting effects of M2 macrophages on hepatocellular carcinoma cell lines in vitro. Mechanistically, the administration of TU-100 restrained the high expression of MMP-2, COX-2, and VEGF in TAMs. TU-100 may alleviate the progression of cancer by regulating the M2 polarization of macrophages within the TME, suggesting a viable therapeutic approach.","ja":"Macrophages are the most abundant immune cells in the tumor stroma, and their polarization states within the tumor microenvironment (TME) exert critical roles in tumorigenesis. TU-100 (Daikenchuto) is a commonly prescribed Japanese herbal medicine that has shown anti-cancer effects by regulating cancer-associated fibroblasts (CAFs) in the TME. However, its effects on tumor-associated macrophages (TAMs) remain unclear. TAMs were generated by macrophage exposure to tumor-conditioned medium (CM), and their polarization states were evaluated after TU-100 treatment. The underlying mechanism was further studied. TU-100 exhibited little cytotoxicity over a range of doses in M0 macrophages and TAMs. However, it could antagonize the M2-like polarization of macrophages evoked by tumor-CM exposure. These effects might be caused by the inhibition of TLR4/NF-B/STAT3 signaling in the M2-like phenotype of macrophages. Interestingly, TU-100 antagonized the malignancy promoting effects of M2 macrophages on hepatocellular carcinoma cell lines in vitro. Mechanistically, the administration of TU-100 restrained the high expression of MMP-2, COX-2, and VEGF in TAMs. TU-100 may alleviate the progression of cancer by regulating the M2 polarization of macrophages within the TME, suggesting a viable therapeutic approach."},"publication_date":"2023-05","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"43","number":"5","starting_page":"1985","ending_page":"1992","languages":["eng"],"identifiers":{"doi":["10.21873/anticanres.16359"],"issn":["1791-7530"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2023202495","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=406434","label":"url"}],"paper_title":{"en":"術前に肝細胞癌との鑑別が困難であった筋腫型肝血管筋脂肪腫の1例","ja":"術前に肝細胞癌との鑑別が困難であった筋腫型肝血管筋脂肪腫の1例"},"authors":{"en":[{"name":"Noma Takayuki"},{"name":"Teraoku Hiroki"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Ikemoto Tetsuya"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"野間 隆礼"},{"name":"寺奥 大貴"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"池本 哲也"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"患者は40代女性.検診で肝から突出する15cmの巨大腫瘤を指摘され,精査加療目的に当科紹介となった.既往歴や背景肝に特記事項なく,腫瘍マーカーは正常であったが,造影CTの動脈・門脈相で肝右葉に15cm大の早期濃染と遅延相でwashoutを認めた.EOB-MRI肝細胞相ではdefectとして描出され肝細胞癌が疑われた.破裂の危険性を考慮し,まずTACEを行い,その後拡大肝右葉切除を施行した.病理組織学的には腫瘍の大半が平滑筋様細胞で構成されており,脂肪細胞は認めず,免疫組織化学染色にてVimentin,αSMA,HMB-45,melan Aが陽性であり,Perivascular epithelioid cell tumor(PEComa)として包括される腫瘍群の中の筋腫型の肝血管筋脂肪腫(Angiomyolipoma;AML)と診断した.今回我々は,術前に肝細胞癌との鑑別が困難であった,若年女性に発生した肝原発筋腫型AMLを経験したため報告する.(著者抄録)","ja":"患者は40代女性.検診で肝から突出する15cmの巨大腫瘤を指摘され,精査加療目的に当科紹介となった.既往歴や背景肝に特記事項なく,腫瘍マーカーは正常であったが,造影CTの動脈・門脈相で肝右葉に15cm大の早期濃染と遅延相でwashoutを認めた.EOB-MRI肝細胞相ではdefectとして描出され肝細胞癌が疑われた.破裂の危険性を考慮し,まずTACEを行い,その後拡大肝右葉切除を施行した.病理組織学的には腫瘍の大半が平滑筋様細胞で構成されており,脂肪細胞は認めず,免疫組織化学染色にてVimentin,αSMA,HMB-45,melan Aが陽性であり,Perivascular epithelioid cell tumor(PEComa)として包括される腫瘍群の中の筋腫型の肝血管筋脂肪腫(Angiomyolipoma;AML)と診断した.今回我々は,術前に肝細胞癌との鑑別が困難であった,若年女性に発生した肝原発筋腫型AMLを経験したため報告する.(著者抄録)"},"publication_date":"2023-04","publication_name":{"en":"Acta Hepatologica Japonica","ja":"肝臓"},"volume":"64","number":"4","starting_page":"201","ending_page":"208","languages":["jpn"],"identifiers":{"doi":["10.2957/kanzo.64.201"],"issn":["1881-3593"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2011942","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36826411","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405954","label":"url"}],"paper_title":{"en":"Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).","ja":"Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)."},"authors":{"en":[{"name":"Hasegawa Kiyoshi"},{"name":"Takemura Nobuyuki"},{"name":"Yamashita Tatsuya"},{"name":"Watadani Takeyuki"},{"name":"Kaibori Masaki"},{"name":"Kubo Shoji"},{"name":"Shimada Mitsuo"},{"name":"Nagano Hiroaki"},{"name":"Hatano Etsuro"},{"name":"Aikata Hiroshi"},{"name":"Iijima Hiroko"},{"name":"Ueshima Kazuomi"},{"name":"Ohkawa Kazuyoshi"},{"name":"Genda Takuya"},{"name":"Tsuchiya Kaoru"},{"name":"Torimura Takuji"},{"name":"Ikeda Masafumi"},{"name":"Furuse Junji"},{"name":"Akahane Masaaki"},{"name":"Kobayashi Satoshi"},{"name":"Sakurai Hideyuki"},{"name":"Takeda Atsuya"},{"name":"Murakami Takamichi"},{"name":"Motosugi Utaroh"},{"name":"Matsuyama Yutaka"},{"name":"Kudo Masatoshi"},{"name":"Tateishi Ryosuke"}],"ja":[{"name":"Hasegawa Kiyoshi"},{"name":"Takemura Nobuyuki"},{"name":"Yamashita Tatsuya"},{"name":"Watadani Takeyuki"},{"name":"Kaibori Masaki"},{"name":"Kubo Shoji"},{"name":"島田 光生"},{"name":"Nagano Hiroaki"},{"name":"Hatano Etsuro"},{"name":"Aikata Hiroshi"},{"name":"Iijima Hiroko"},{"name":"Ueshima Kazuomi"},{"name":"Ohkawa Kazuyoshi"},{"name":"Genda Takuya"},{"name":"Tsuchiya Kaoru"},{"name":"Torimura Takuji"},{"name":"Ikeda Masafumi"},{"name":"Furuse Junji"},{"name":"Akahane Masaaki"},{"name":"Kobayashi Satoshi"},{"name":"Sakurai Hideyuki"},{"name":"Takeda Atsuya"},{"name":"Murakami Takamichi"},{"name":"Motosugi Utaroh"},{"name":"Matsuyama Yutaka"},{"name":"Kudo Masatoshi"},{"name":"Tateishi Ryosuke"}]},"description":{"en":"The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance-diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described.","ja":"The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance-diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Here, new or revised algorithms and evidence on which the recommendations are based are described."},"publication_date":"2023-03-10","publication_name":{"en":"Hepatology Research","ja":"Hepatology Research"},"volume":"53","number":"5","starting_page":"383","ending_page":"390","languages":["eng"],"identifiers":{"doi":["10.1111/hepr.13892"],"issn":["1386-6346"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35947194","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405970","label":"url"}],"paper_title":{"en":"Impact of the hospital volume and setting on postoperative complications of surgery for gastroenterological cancers in a regional area of Western Japan.","ja":"Impact of the hospital volume and setting on postoperative complications of surgery for gastroenterological cancers in a regional area of Western Japan."},"authors":{"en":[{"name":"Kunisawa Susumu"},{"name":"Ishida Haku"},{"name":"Ikai Hiroshi"},{"name":"Nagano Hiroaki"},{"name":"Fujiwara Toshiyoshi"},{"name":"Ohdan Hideki"},{"name":"Fujiwara Yoshiyuki"},{"name":"Tajima Yoshitsugu"},{"name":"Ueno Tomio"},{"name":"Fujiwara Yoshinori"},{"name":"Shimada Mitsuo"},{"name":"Suzuki Yasuyuki"},{"name":"Watanabe Yuji"},{"name":"Hanazaki Kazuhiro"},{"name":"Kakeji Yoshihiro"},{"name":"Kumamaru Hiraku"},{"name":"Takahashi Arata"},{"name":"Miyata Hiroaki"},{"name":"Imanaka Yuichi"}],"ja":[{"name":"Kunisawa Susumu"},{"name":"Ishida Haku"},{"name":"Ikai Hiroshi"},{"name":"Nagano Hiroaki"},{"name":"Fujiwara Toshiyoshi"},{"name":"Ohdan Hideki"},{"name":"Fujiwara Yoshiyuki"},{"name":"Tajima Yoshitsugu"},{"name":"Ueno Tomio"},{"name":"Fujiwara Yoshinori"},{"name":"島田 光生"},{"name":"Suzuki Yasuyuki"},{"name":"Watanabe Yuji"},{"name":"Hanazaki Kazuhiro"},{"name":"Kakeji Yoshihiro"},{"name":"Kumamaru Hiraku"},{"name":"Takahashi Arata"},{"name":"Miyata Hiroaki"},{"name":"Imanaka Yuichi"}]},"description":{"en":"A research subgroup was established by the Japanese Society of Gastroenterological Surgery to improve the health care quality in the Chushikoku area of Western Japan. The records of four surgical procedures were extracted from the Japanese National Clinical Database and analyzed retrospectively to establish the association between hospital characteristics, defined using a combination of hospital case-volume and patients' hospital travel distance, and the incidences of perioperative complications of ≥ Grade 3 of the Clavien-Dindo classification after gastroenterological surgery. This study analyzed 11,515 cases of distal gastrectomy for gastric cancer, 4,705 cases of total gastrectomy for gastric cancer, 4,996 cases of right hemicolectomy for colon cancer, and 5,243 cases of lower anterior resection for rectal cancer, with composite outcome incidences of 5.6%, 10.2%, 5.5%, and 10.7%, respectively. After adjusting for patient characteristics and surgical procedures, no association was identified between the hospital category and surgical outcomes. The findings of our study of the Chushikoku region did not provide positive support for the consolidation and centralization of hospitals, based solely on hospital case volume. Our grouping was unique in that we included patient travel distance in the analysis, but further investigations from other perspectives are needed.","ja":"A research subgroup was established by the Japanese Society of Gastroenterological Surgery to improve the health care quality in the Chushikoku area of Western Japan. The records of four surgical procedures were extracted from the Japanese National Clinical Database and analyzed retrospectively to establish the association between hospital characteristics, defined using a combination of hospital case-volume and patients' hospital travel distance, and the incidences of perioperative complications of ≥ Grade 3 of the Clavien-Dindo classification after gastroenterological surgery. This study analyzed 11,515 cases of distal gastrectomy for gastric cancer, 4,705 cases of total gastrectomy for gastric cancer, 4,996 cases of right hemicolectomy for colon cancer, and 5,243 cases of lower anterior resection for rectal cancer, with composite outcome incidences of 5.6%, 10.2%, 5.5%, and 10.7%, respectively. After adjusting for patient characteristics and surgical procedures, no association was identified between the hospital category and surgical outcomes. The findings of our study of the Chushikoku region did not provide positive support for the consolidation and centralization of hospitals, based solely on hospital case volume. Our grouping was unique in that we included patient travel distance in the analysis, but further investigations from other perspectives are needed."},"publication_date":"2023-02","publication_name":{"en":"Surgery Today","ja":"Surgery Today"},"volume":"53","number":"2","starting_page":"214","ending_page":"222","languages":["eng"],"identifiers":{"doi":["10.1007/s00595-022-02569-6"],"issn":["1436-2813"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37164719","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405959","label":"url"}],"paper_title":{"en":"Impact of pancreatic resection in patients with liver cirrhosis.","ja":"Impact of pancreatic resection in patients with liver cirrhosis."},"authors":{"en":[{"name":"Teraoku Hiroki"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Waki Yuhei"},{"name":"Okikawa Shohei"},{"name":"Miyazaki Katsuki"},{"name":"Nakasu Chiharu"},{"name":"Noma Takayuki"},{"name":"Takahashi Akira"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"寺奥 大貴"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"脇 悠平"},{"name":"沖川 昌平"},{"name":"宮崎 克己"},{"name":"Nakasu Chiharu"},{"name":"野間 隆礼"},{"name":"Takahashi Akira"},{"name":"島田 光生"}]},"description":{"en":"Several reports have shown a high mortality rate in patients with liver cirrhosis (LC) who undergo pancreaticoduodenectomy, however, there are few reports on its long-term prognosis. Twelve patients with LC who had undergone pancreatic resection were enrolled. To compare clinicopathological variables, 159 non-LC patients who had undergone resection for pancreatic cancer were enrolled. Pancreaticoduodenectomy (PD) was performed in 5 LC patients and distal pancreatectomy (DP) was performed in 7 LC patients. Patients in the LC group had more co-morbidities, lower platelet counts and higher Fib4 index than the non-LC group. The postoperative complication rate was higher in the LC group (83.3% vs 47.8%). While the postoperative hospital stay and 30-day mortality rate were not different, the 90-day mortality rate was higher in the LC group (25.0% vs 2.5% ; p<0.01). Comparison by operative procedure showed no significant differences of postoperative outcomes in DP cases. However, in PD cases, postoperative complications were more frequent (100% vs 42.3%) and 90-day mortality was higher (40.0% vs 2.9% ; p<0.01) in the LC group. PD resulted in higher postoperative morbidity and mortality rates in patients with LC compared with non-LC patients. DP could be tolerated in the LC patients. J. Med. Invest. 70 : 189-194, February, 2023.","ja":"Several reports have shown a high mortality rate in patients with liver cirrhosis (LC) who undergo pancreaticoduodenectomy, however, there are few reports on its long-term prognosis. Twelve patients with LC who had undergone pancreatic resection were enrolled. To compare clinicopathological variables, 159 non-LC patients who had undergone resection for pancreatic cancer were enrolled. Pancreaticoduodenectomy (PD) was performed in 5 LC patients and distal pancreatectomy (DP) was performed in 7 LC patients. Patients in the LC group had more co-morbidities, lower platelet counts and higher Fib4 index than the non-LC group. The postoperative complication rate was higher in the LC group (83.3% vs 47.8%). While the postoperative hospital stay and 30-day mortality rate were not different, the 90-day mortality rate was higher in the LC group (25.0% vs 2.5% ; p<0.01). Comparison by operative procedure showed no significant differences of postoperative outcomes in DP cases. However, in PD cases, postoperative complications were more frequent (100% vs 42.3%) and 90-day mortality was higher (40.0% vs 2.9% ; p<0.01) in the LC group. PD resulted in higher postoperative morbidity and mortality rates in patients with LC compared with non-LC patients. DP could be tolerated in the LC patients. J. Med. Invest. 70 : 189-194, February, 2023."},"publication_date":"2023","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"70","number":"1.2","starting_page":"189","ending_page":"194","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.70.189"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37164714","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405958","label":"url"}],"paper_title":{"en":"Impact of L-type amino acid transporter 1 on intrahepatic cholangiocarcinoma.","ja":"Impact of L-type amino acid transporter 1 on intrahepatic cholangiocarcinoma."},"authors":{"en":[{"name":"Selenge Baasansuren"},{"name":"Yamada Shin-ichiro"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Takasu Chie"},{"name":"Teraoku Hiroki"},{"name":"Okikawa Shohei"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Selenge Baasansuren"},{"name":"山田 眞一郎"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"髙須 千絵"},{"name":"寺奥 大貴"},{"name":"沖川 昌平"},{"name":"島田 光生"}]},"description":{"en":"Amino acid transporters, such as L-type amino acid transporter 1 (LAT1), have an effect on tumor growth, metastasis, and survival of various solid tumors. However, the role of LAT1 in patients with intrahepatic cholangiocarcinoma (IHCC) remains unknown. Forty-six patients who had undergone initial hepatic resection for IHCC at Tokushima University Hospital were enrolled in this study. Immunohistochemical analysis of LAT1 and phosphorylated Akt (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were analyzed between LAT1-high and LAT1-low groups. The LAT1-high group showed a higher proportion of periductal infiltrating type and higher carcinoembryonic antigen/carbohydrate antigen 19-9 levels compared with the LAT1-low group. Multivariate analysis revealed that LAT1-high expression was an independent prognostic factor for disease-free survival. Furthermore, the proportion of p-AKT positivity was higher in the LAT1-high group than in the LAT1-low group. LAT1 expression was associated with poor prognosis of IHCC and higher p-Akt expression. J. Med. Invest. 70 : 160-165, February, 2023.","ja":"Amino acid transporters, such as L-type amino acid transporter 1 (LAT1), have an effect on tumor growth, metastasis, and survival of various solid tumors. However, the role of LAT1 in patients with intrahepatic cholangiocarcinoma (IHCC) remains unknown. Forty-six patients who had undergone initial hepatic resection for IHCC at Tokushima University Hospital were enrolled in this study. Immunohistochemical analysis of LAT1 and phosphorylated Akt (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were analyzed between LAT1-high and LAT1-low groups. The LAT1-high group showed a higher proportion of periductal infiltrating type and higher carcinoembryonic antigen/carbohydrate antigen 19-9 levels compared with the LAT1-low group. Multivariate analysis revealed that LAT1-high expression was an independent prognostic factor for disease-free survival. Furthermore, the proportion of p-AKT positivity was higher in the LAT1-high group than in the LAT1-low group. LAT1 expression was associated with poor prognosis of IHCC and higher p-Akt expression. J. Med. Invest. 70 : 160-165, February, 2023."},"publication_date":"2023","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"70","number":"1.2","starting_page":"160","ending_page":"165","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.70.160"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37164704","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405955","label":"url"}],"paper_title":{"en":"Short- and long-term outcomes of pancreatectomy in patients with hemodialysis.","ja":"Short- and long-term outcomes of pancreatectomy in patients with hemodialysis."},"authors":{"en":[{"name":"Teraoku Hiroki"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Okikawa Shohei"},{"name":"Miyazaki Katsuki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"寺奥 大貴"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"沖川 昌平"},{"name":"宮崎 克己"},{"name":"島田 光生"}]},"description":{"en":"Several reports have shown the high mortality rate of pancreatic resection in patients with hemodialysis (HD), however, its long-term outcome remains unclear. In this study, we examined cases of pancreatic resection in patients with HD and conducted a literature review. Four patients with HD who underwent pancreatic resection from 2004 to 2019 were enrolled. To compare the clinicopathological variables of HD and non-HD patients, 161 non-HD patients who had undergone surgical resection for pancreatic cancer were enrolled. Among four cases of pancreatic resection with HD, three cases were malignant diseases. All patients with HD had some co-morbidities (100% in HD group, 45.3% in the non-HD group) and postoperative complications (100% in the HD group, vs 46.6% in the non-HD group). Although one patient had severe postoperative complications and length of postoperative hospital stay was longer, the 30- and 90-day mortality rates were both 0% in patients with HD. However, three cases in the HD group (75%) died approximately 6 months after surgery, including one cancer-related death. Pancreatic surgery in patients with HD should be carefully indicated, especially pancreaticoduodenectomy or total pancreatectomy, because of the poor prognosis induced by non-cancer-related causes of death. J. Med. Invest. 70 : 105-109, February, 2023.","ja":"Several reports have shown the high mortality rate of pancreatic resection in patients with hemodialysis (HD), however, its long-term outcome remains unclear. In this study, we examined cases of pancreatic resection in patients with HD and conducted a literature review. Four patients with HD who underwent pancreatic resection from 2004 to 2019 were enrolled. To compare the clinicopathological variables of HD and non-HD patients, 161 non-HD patients who had undergone surgical resection for pancreatic cancer were enrolled. Among four cases of pancreatic resection with HD, three cases were malignant diseases. All patients with HD had some co-morbidities (100% in HD group, 45.3% in the non-HD group) and postoperative complications (100% in the HD group, vs 46.6% in the non-HD group). Although one patient had severe postoperative complications and length of postoperative hospital stay was longer, the 30- and 90-day mortality rates were both 0% in patients with HD. However, three cases in the HD group (75%) died approximately 6 months after surgery, including one cancer-related death. Pancreatic surgery in patients with HD should be carefully indicated, especially pancreaticoduodenectomy or total pancreatectomy, because of the poor prognosis induced by non-cancer-related causes of death. J. Med. Invest. 70 : 105-109, February, 2023."},"publication_date":"2023","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"70","number":"1.2","starting_page":"105","ending_page":"109","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.70.105"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36441784","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396263","label":"url"}],"paper_title":{"en":"Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis.","ja":"Essential amino acids as diagnostic biomarkers of hepatocellular carcinoma based on metabolic analysis."},"authors":{"en":[{"name":"Morine Yuji"},{"name":"Utsunomiya Tohru"},{"name":"Yamanaka-Okumura Hisami"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Kinoshita Shohei"},{"name":"Hirayama Akiyoshi"},{"name":"Tanaka Yasuhito"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"森根 裕二"},{"name":"Utsunomiya Tohru"},{"name":"Yamanaka-Okumura Hisami"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"池本 哲也"},{"name":"Imura Satoru"},{"name":"Kinoshita Shohei"},{"name":"Hirayama Akiyoshi"},{"name":"Tanaka Yasuhito"},{"name":"島田 光生"}]},"description":{"en":"Metabolomics, defined as the comprehensive identification of all small metabolites in a biological sample, has the power to shed light on phenotypic changes associated with various diseases, including cancer. To discover potential metabolomic biomarkers of hepatocellular carcinoma (HCC), we investigated the metabolomes of tumor and non-tumor tissue in 20 patients with primary HCC using capillary electrophoresis-time-of-flight mass spectrometry. We also analyzed blood samples taken immediately before and 14 days after hepatectomy to identify associated changes in the serum metabolome. Marked changes were detected in the different quantity of 61 metabolites that could discriminate between HCC tumor and paired non-tumor tissue and additionally between HCC primary tumors and colorectal liver metastases. Among the 30 metabolites significantly upregulated in HCC tumors compared with non-tumor tissues, 10 were amino acids, and 7 were essential amino acids (leucine, valine, tryptophan, isoleucine, methionine, lysine, and phenylalanine). Similarly, the serum metabolomes of HCC patients before hepatectomy revealed a significant increase in 16 metabolites, including leucine, valine, and tryptophan. Our results reveal striking differences in the metabolomes of HCC tumor tissue compared with non-tumor tissue, and identify the essential amino acids leucine, valine, and tryptophan as potential metabolic biomarkers for HCC.","ja":"Metabolomics, defined as the comprehensive identification of all small metabolites in a biological sample, has the power to shed light on phenotypic changes associated with various diseases, including cancer. To discover potential metabolomic biomarkers of hepatocellular carcinoma (HCC), we investigated the metabolomes of tumor and non-tumor tissue in 20 patients with primary HCC using capillary electrophoresis-time-of-flight mass spectrometry. We also analyzed blood samples taken immediately before and 14 days after hepatectomy to identify associated changes in the serum metabolome. Marked changes were detected in the different quantity of 61 metabolites that could discriminate between HCC tumor and paired non-tumor tissue and additionally between HCC primary tumors and colorectal liver metastases. Among the 30 metabolites significantly upregulated in HCC tumors compared with non-tumor tissues, 10 were amino acids, and 7 were essential amino acids (leucine, valine, tryptophan, isoleucine, methionine, lysine, and phenylalanine). Similarly, the serum metabolomes of HCC patients before hepatectomy revealed a significant increase in 16 metabolites, including leucine, valine, and tryptophan. Our results reveal striking differences in the metabolomes of HCC tumor tissue compared with non-tumor tissue, and identify the essential amino acids leucine, valine, and tryptophan as potential metabolic biomarkers for HCC."},"publication_date":"2022-11-22","publication_name":{"en":"Oncotarget","ja":"Oncotarget"},"volume":"13","starting_page":"1286","ending_page":"1298","languages":["eng"],"identifiers":{"doi":["10.18632/oncotarget.28306"],"issn":["1949-2553"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34557939","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386677","label":"url"}],"paper_title":{"en":"Intraoperative support with three-dimensional holographic cholangiography in hepatobiliary surgery.","ja":"Intraoperative support with three-dimensional holographic cholangiography in hepatobiliary surgery."},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Sugimoto Maki"},{"name":"Morine Yuji"},{"name":"Imura Satoru"},{"name":"Ikemoto Tetsuya"},{"name":"Yamada Shin-ichiro"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"Sugimoto Maki"},{"name":"森根 裕二"},{"name":"居村 暁"},{"name":"池本 哲也"},{"name":"山田 眞一郎"},{"name":"島田 光生"}]},"description":{"en":"This study was performed to investigate the potential of intraoperative three-dimensional (3D) holographic cholangiography, which provides a computer graphics model of the biliary tract, with mixed reality techniques. Two patients with intraductal papillary neoplasm of the bile duct were enrolled in the study. Intraoperative 3D cholangiography was performed in a hybrid operating room. Three-dimensional polygon data using the acquired cholangiography data were installed into a head mount display (HoloLens; Microsoft Corporation, Redmond, WA, USA). Upon completion of intraoperative 3D cholangiography, a hologram was immediately and successfully made in the operating room using the acquired cholangiography data, and several surgeons wearing the HoloLens succeeded in sharing the same hologram. Compared with usual two-dimensional cholangiography, this 3D holographic cholangiography technique contributed to more accurate reappearance of the bile ducts, especially the B1 origination site, and moving the hologram from the respective operators' angles by means of easy gesture-handling without any monitors. Intraoperative 3D holographic cholangiography might be a new next-generation operation-support tool in terms of immediacy, accurate anatomical reappearance, and ease of handling.","ja":"This study was performed to investigate the potential of intraoperative three-dimensional (3D) holographic cholangiography, which provides a computer graphics model of the biliary tract, with mixed reality techniques. Two patients with intraductal papillary neoplasm of the bile duct were enrolled in the study. Intraoperative 3D cholangiography was performed in a hybrid operating room. Three-dimensional polygon data using the acquired cholangiography data were installed into a head mount display (HoloLens; Microsoft Corporation, Redmond, WA, USA). Upon completion of intraoperative 3D cholangiography, a hologram was immediately and successfully made in the operating room using the acquired cholangiography data, and several surgeons wearing the HoloLens succeeded in sharing the same hologram. Compared with usual two-dimensional cholangiography, this 3D holographic cholangiography technique contributed to more accurate reappearance of the bile ducts, especially the B1 origination site, and moving the hologram from the respective operators' angles by means of easy gesture-handling without any monitors. Intraoperative 3D holographic cholangiography might be a new next-generation operation-support tool in terms of immediacy, accurate anatomical reappearance, and ease of handling."},"publication_date":"2022-05-23","publication_name":{"en":"Langenbeck's Archives of Surgery / Deutsche Gesellschaft für Chirurgie","ja":"Langenbeck's Archives of Surgery / Deutsche Gesellschaft für Chirurgie"},"volume":"407","number":"3","starting_page":"1285","ending_page":"1289","languages":["eng"],"identifiers":{"doi":["10.1007/s00423-021-02336-0"],"issn":["1435-2451"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2022156437","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396277","label":"url"}],"paper_title":{"en":"【1型糖尿病-診療と研究の最前線】治療研究 膵β細胞再生医療の可能性 脂肪由来幹細胞の有用性","ja":"【1型糖尿病-診療と研究の最前線】治療研究 膵β細胞再生医療の可能性 脂肪由来幹細胞の有用性"},"authors":{"en":[{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"池本 哲也"},{"name":"島田 光生"}]},"description":{"en":"1型糖尿病治療としての再生医療はいまだ研究段階の域をでていないが，本領域は急速に発展しており，さまざまなコンセプトのもとで臨床応用も目前に迫っている．本稿では，再生医療における幹細胞の役割，分類(分化能力，その起源)を明らかにし，現在，最も臨床応用が近いと考えられる体性幹細胞(なかでも脂肪由来幹細胞)における筆者らの研究成果と，医師主導治験確立に向けた取り組みを示すとともに，すでに行われている1型糖尿病に対する幹細胞を用いた臨床研究など(幹細胞を直接投与するもの，幹細胞からβ細胞様細胞へ分化誘導させるもの)をレビューし，将来，再生医療がどのように1型糖尿病治療にコミットメントしていくかの展望を示す．(著者抄録)","ja":"1型糖尿病治療としての再生医療はいまだ研究段階の域をでていないが，本領域は急速に発展しており，さまざまなコンセプトのもとで臨床応用も目前に迫っている．本稿では，再生医療における幹細胞の役割，分類(分化能力，その起源)を明らかにし，現在，最も臨床応用が近いと考えられる体性幹細胞(なかでも脂肪由来幹細胞)における筆者らの研究成果と，医師主導治験確立に向けた取り組みを示すとともに，すでに行われている1型糖尿病に対する幹細胞を用いた臨床研究など(幹細胞を直接投与するもの，幹細胞からβ細胞様細胞へ分化誘導させるもの)をレビューし，将来，再生医療がどのように1型糖尿病治療にコミットメントしていくかの展望を示す．(著者抄録)"},"publication_date":"2022-05","publication_name":{"en":"Journal of Clinical and Experimental Medicine","ja":"医学のあゆみ"},"volume":"281","number":"6","starting_page":"729","ending_page":"734","languages":["jpn"],"identifiers":{"issn":["0039-2359"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35393479","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396260","label":"url"}],"paper_title":{"en":"Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice.","ja":"Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice."},"authors":{"en":[{"name":"Tokuda Kazunori"},{"name":"Ikemoto Tetsuya"},{"name":"Yamashita Shoko"},{"name":"Miyazaki Katsuki"},{"name":"Okikawa Shohei"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Tokuda Kazunori"},{"name":"池本 哲也"},{"name":"Yamashita Shoko"},{"name":"Miyazaki Katsuki"},{"name":"Okikawa Shohei"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"Insulin-producing cells (IPCs) generated by our established protocol have reached the non-clinical 'proof of concept' stage. Our strategy for their clinical application is the autotransplantation of IPCs into patients with type 1 diabetes mellitus (T1DM). In this context, the autoimmunity that characterized T1DM is important, rather than allorejection. We aimed to determine how these IPCs respond to T1DM autoimmunity. IPCs were generated from the subcutaneous fat tissue of non-obese diabetic (NOD) mice using our protocol. IPCs derived from NOD mice were transplanted under the kidney capsules of NOD mice at the onset of diabetes and the subsequent changes in blood glucose concentration were characterized. Blood glucose decreased within 30 days of transplantation, but increased again after 40-60 days in three of four recipient NOD mice. In tissue samples, the numbers of CD4 and CD8 T cells were significantly higher 60 days after transplantation than 30 days after transplantation. In conclusion, IPCs significantly ameliorate the diabetes of mice in the short term, but are damaged by autoimmunity in the longer term, as evidenced by local T cells accumulation. This study provides new insights into potential stem cell therapies for T1DM.","ja":"Insulin-producing cells (IPCs) generated by our established protocol have reached the non-clinical 'proof of concept' stage. Our strategy for their clinical application is the autotransplantation of IPCs into patients with type 1 diabetes mellitus (T1DM). In this context, the autoimmunity that characterized T1DM is important, rather than allorejection. We aimed to determine how these IPCs respond to T1DM autoimmunity. IPCs were generated from the subcutaneous fat tissue of non-obese diabetic (NOD) mice using our protocol. IPCs derived from NOD mice were transplanted under the kidney capsules of NOD mice at the onset of diabetes and the subsequent changes in blood glucose concentration were characterized. Blood glucose decreased within 30 days of transplantation, but increased again after 40-60 days in three of four recipient NOD mice. In tissue samples, the numbers of CD4 and CD8 T cells were significantly higher 60 days after transplantation than 30 days after transplantation. In conclusion, IPCs significantly ameliorate the diabetes of mice in the short term, but are damaged by autoimmunity in the longer term, as evidenced by local T cells accumulation. This study provides new insights into potential stem cell therapies for T1DM."},"publication_date":"2022-04-07","publication_name":{"en":"Scientific Reports","ja":"Scientific Reports"},"volume":"12","number":"1","starting_page":"5852","ending_page":"5852","languages":["eng"],"identifiers":{"doi":["10.1038/s41598-022-09838-x"],"issn":["2045-2322"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2011693","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35169858","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396259","label":"url"}],"paper_title":{"en":"Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer.","ja":"Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer."},"authors":{"en":[{"name":"Okikawa Shohei"},{"name":"Morine Yuji"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Tokuda Kazunori"},{"name":"Teraoku Hiroki"},{"name":"Miyazaki Katsuki"},{"name":"Yamashita Shoko"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Okikawa Shohei"},{"name":"森根 裕二"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"Tokuda Kazunori"},{"name":"寺奥 大貴"},{"name":"Miyazaki Katsuki"},{"name":"Yamashita Shoko"},{"name":"池本 哲也"},{"name":"Imura Satoru"},{"name":"島田 光生"}]},"description":{"en":"Tumor-associated macrophage (TAMs) are paramount for tumor progression and immune tolerance in the tumor microenvironment of various types of cancer, including liver cancer. The aim of the present study was to investigate the effect of vascular endothelial growth factor (VEGF) inhibition on TAM polarization and function during their interactions with macrophages and liver cancer cells. TAMs were induced by culturing M0 macrophages with cancer cell-conditioned medium. TAMs cultured with cancer cell-conditioned medium and vascular endothelial growth factor (VEGF) inhibitor were defined as modified TAMs, and the expression levels of TAM-associated markers and VEGF receptor 2 were evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of TAMs and modified TAMs on cancer cell proliferation and migration were investigated using conditioned medium. Programmed death-ligand 1 (PD-L1) mRNA expression in modified TAMs and cancer cells cultured in modified TAM-conditioned medium (TAM-CM) for 48 h was examined using RT-qPCR. In order to investigate signaling pathways in macrophages, western blot analysis was performed. CD163 and CD206 and M2 macrophage marker expression was upregulated in TAMs and modified TAMs. Modified TAM-CM exhibited a decreased ability to promote cancer cell proliferation and migration in comparison with the use of TAM-CM. The VEGF concentration was significantly higher in the TAMs than in M0 macrophages; however, the modified TAMs displayed a significantly lower VEGF secretion than TAMs. PD-L1 expression was decreased in modified TAMs as compared with TAMs. Western blot analysis revealed that the Akt/mTOR signaling pathway was significantly suppressed in the modified TAMs compared with TAMs. It was observed that TAMs cultured in a VEGF-depleted environment displayed lower secretion levels of cytokines involved in tumor progression and a decreased immune tolerance-inducing ability. On the whole, the results of the present study suggested that VEGF inhibition in TAMs may be a potential therapeutic target for liver cancer.","ja":"Tumor-associated macrophage (TAMs) are paramount for tumor progression and immune tolerance in the tumor microenvironment of various types of cancer, including liver cancer. The aim of the present study was to investigate the effect of vascular endothelial growth factor (VEGF) inhibition on TAM polarization and function during their interactions with macrophages and liver cancer cells. TAMs were induced by culturing M0 macrophages with cancer cell-conditioned medium. TAMs cultured with cancer cell-conditioned medium and vascular endothelial growth factor (VEGF) inhibitor were defined as modified TAMs, and the expression levels of TAM-associated markers and VEGF receptor 2 were evaluated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of TAMs and modified TAMs on cancer cell proliferation and migration were investigated using conditioned medium. Programmed death-ligand 1 (PD-L1) mRNA expression in modified TAMs and cancer cells cultured in modified TAM-conditioned medium (TAM-CM) for 48 h was examined using RT-qPCR. In order to investigate signaling pathways in macrophages, western blot analysis was performed. CD163 and CD206 and M2 macrophage marker expression was upregulated in TAMs and modified TAMs. Modified TAM-CM exhibited a decreased ability to promote cancer cell proliferation and migration in comparison with the use of TAM-CM. The VEGF concentration was significantly higher in the TAMs than in M0 macrophages; however, the modified TAMs displayed a significantly lower VEGF secretion than TAMs. PD-L1 expression was decreased in modified TAMs as compared with TAMs. Western blot analysis revealed that the Akt/mTOR signaling pathway was significantly suppressed in the modified TAMs compared with TAMs. It was observed that TAMs cultured in a VEGF-depleted environment displayed lower secretion levels of cytokines involved in tumor progression and a decreased immune tolerance-inducing ability. On the whole, the results of the present study suggested that VEGF inhibition in TAMs may be a potential therapeutic target for liver cancer."},"publication_date":"2022-02-16","publication_name":{"en":"Oncology Reports","ja":"Oncology Reports"},"volume":"47","number":"4","languages":["eng"],"identifiers":{"doi":["10.3892/or.2022.8282"],"issn":["1791-2431"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35079106","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396256","label":"url"}],"paper_title":{"en":"A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma.","ja":"A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma."},"authors":{"en":[{"name":"Wada Yuuma"},{"name":"Shimada Mitsuo"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Baba Hideo"},{"name":"Mori Masaki"},{"name":"Goel Ajay"}],"ja":[{"name":"和田 佑馬"},{"name":"島田 光生"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"Baba Hideo"},{"name":"Mori Masaki"},{"name":"Goel Ajay"}]},"description":{"en":"The prognosis in patients with intrahepatic cholangiocarcinoma (ICC) is generally poor. To improve treatment selection, we sought to identify microRNA (miRNA) signature associated with survival outcomes in ICC. We first analysed the miRNA expression profiles of primary ICC from two public datasets to identify a miRNA panel to detect patients for short-term survival. We then analysed 309 specimens, including 241 FFPE samples from two clinical cohorts (training: n = 177; validation: n = 64) and matched plasma samples (n = 68), and developed a risk-stratification model incorporating the panel and CA 19-9 levels to predict survival outcomes in ICC. We identified a 7-miRNA panel that robustly classified patients with poor outcomes in the discovery cohorts (AUC = 0.80 and 0.88, respectively). We subsequently trained this miRNA panel in a clinical cohort (AUC = 0.83) and evaluated its performance in an independent validation cohort (AUC = 0.82) and plasma samples from the additional validation cohort (AUC = 0.78). Patients in both clinical cohorts who were classified as high-risk had significantly worse prognosis (p < 0.01). The risk-stratification model demonstrated superior performance compared to models (AUC = 0.85). We established a novel miRNA signature that could robustly predict survival outcomes in resected tissues and liquid biopsies to improve the clinical management of patients with ICC.","ja":"The prognosis in patients with intrahepatic cholangiocarcinoma (ICC) is generally poor. To improve treatment selection, we sought to identify microRNA (miRNA) signature associated with survival outcomes in ICC. We first analysed the miRNA expression profiles of primary ICC from two public datasets to identify a miRNA panel to detect patients for short-term survival. We then analysed 309 specimens, including 241 FFPE samples from two clinical cohorts (training: n = 177; validation: n = 64) and matched plasma samples (n = 68), and developed a risk-stratification model incorporating the panel and CA 19-9 levels to predict survival outcomes in ICC. We identified a 7-miRNA panel that robustly classified patients with poor outcomes in the discovery cohorts (AUC = 0.80 and 0.88, respectively). We subsequently trained this miRNA panel in a clinical cohort (AUC = 0.83) and evaluated its performance in an independent validation cohort (AUC = 0.82) and plasma samples from the additional validation cohort (AUC = 0.78). Patients in both clinical cohorts who were classified as high-risk had significantly worse prognosis (p < 0.01). The risk-stratification model demonstrated superior performance compared to models (AUC = 0.85). We established a novel miRNA signature that could robustly predict survival outcomes in resected tissues and liquid biopsies to improve the clinical management of patients with ICC."},"publication_date":"2022-01-25","publication_name":{"en":"British Journal of Cancer","ja":"British Journal of Cancer"},"volume":"126","number":"8","starting_page":"1196","ending_page":"1204","languages":["eng"],"identifiers":{"doi":["10.1038/s41416-022-01710-z"],"issn":["1532-1827"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35042069","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386687","label":"url"}],"paper_title":{"en":"A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.","ja":"A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases."},"authors":{"en":[{"name":"Wada Yuuma"},{"name":"Shimada Mitsuo"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Baba Hideo"},{"name":"Mori Masaki"},{"name":"Goel Ajay"}],"ja":[{"name":"和田 佑馬"},{"name":"島田 光生"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"Baba Hideo"},{"name":"Mori Masaki"},{"name":"Goel Ajay"}]},"description":{"en":"Cancer recurrence is an important predictor of survival outcomes in patients with colorectal cancer-associated liver metastasis (CRLM), who undergo radical hepatectomy. Therefore, identification of patients with the greatest risk of recurrence is critical for developing a precision oncology strategy that might include frequent surveillance (in low-risk patients) or a more aggressive treatment approach (in high-risk patients). We performed genome-wide expression profiling, to identify and develop a transcriptomic signature for predicting recurrence in patients with CRLM. We analysed a total of 383 patients with CRLM, including 63 patients from a publicly available data set (the NCBI's Gene Expression Omnibus with accession number GSE81423). and 320 patients from whom surgical specimens were collected for independent training (n = 169) and validation (n = 151) of identified biomarkers. Using Cox's proportional hazard regression analysis, we evaluated the clinical significance of the identified gene signature by comparing its performance with several key clinical factors. We identified a six-gene panel that robustly categorised patients with recurrence in the discovery (area under the curve (AUC) = 0.90). We showed that the panel was a significant predictor of recurrence in the clinical training (AUC = 0.83) and validation cohorts (AUC = 0.81). By combining our panel with key clinical factors, we established a risk-stratification model that emerged as an independent predictor of recurrence (AUC = 0.85; univariate: hazard ratio (HR) = 4.34, 95% confidence interval (CI) = 2.71-6.93, P < 0.001; multivariate: HR = 3.40, 95% CI = 1.76-6.56, P < 0.001). The stratification model revealed recurrence prediction in 89% of high-risk group and non-recurrence in 62% of low-risk group. We established a novel transcriptomic signature that robustly predicts recurrence, which has significant implications for the management of patients with CRLM.","ja":"Cancer recurrence is an important predictor of survival outcomes in patients with colorectal cancer-associated liver metastasis (CRLM), who undergo radical hepatectomy. Therefore, identification of patients with the greatest risk of recurrence is critical for developing a precision oncology strategy that might include frequent surveillance (in low-risk patients) or a more aggressive treatment approach (in high-risk patients). We performed genome-wide expression profiling, to identify and develop a transcriptomic signature for predicting recurrence in patients with CRLM. We analysed a total of 383 patients with CRLM, including 63 patients from a publicly available data set (the NCBI's Gene Expression Omnibus with accession number GSE81423). and 320 patients from whom surgical specimens were collected for independent training (n = 169) and validation (n = 151) of identified biomarkers. Using Cox's proportional hazard regression analysis, we evaluated the clinical significance of the identified gene signature by comparing its performance with several key clinical factors. We identified a six-gene panel that robustly categorised patients with recurrence in the discovery (area under the curve (AUC) = 0.90). We showed that the panel was a significant predictor of recurrence in the clinical training (AUC = 0.83) and validation cohorts (AUC = 0.81). By combining our panel with key clinical factors, we established a risk-stratification model that emerged as an independent predictor of recurrence (AUC = 0.85; univariate: hazard ratio (HR) = 4.34, 95% confidence interval (CI) = 2.71-6.93, P < 0.001; multivariate: HR = 3.40, 95% CI = 1.76-6.56, P < 0.001). The stratification model revealed recurrence prediction in 89% of high-risk group and non-recurrence in 62% of low-risk group. We established a novel transcriptomic signature that robustly predicts recurrence, which has significant implications for the management of patients with CRLM."},"publication_date":"2022-01-14","publication_name":{"en":"European Journal of Cancer","ja":"European Journal of Cancer"},"volume":"163","starting_page":"66","ending_page":"76","languages":["eng"],"identifiers":{"doi":["10.1016/j.ejca.2021.12.013"],"issn":["1879-0852"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34038612","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386683","label":"url"}],"paper_title":{"en":"Identification of microRNA-96-5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma.","ja":"Identification of microRNA-96-5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma."},"authors":{"en":[{"name":"Matsui Takeshi"},{"name":"Hamada-Tsutsumi Susumu"},{"name":"Naito Yutaka"},{"name":"Nojima Masanori"},{"name":"Iio Etsuko"},{"name":"Tamori Akihiro"},{"name":"Kubo Shoji"},{"name":"Ide Tatsuya"},{"name":"Kondo Yasuteru"},{"name":"Eguchi Yuichiro"},{"name":"Komori Atsumasa"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"},{"name":"Utsunomiya Tohru"},{"name":"Shirabe Ken"},{"name":"Kimura Koichi"},{"name":"Hiasa Yoichi"},{"name":"Chuaypen Natthaya"},{"name":"Tangkijvanich Pisit"},{"name":"Naiki-Ito Aya"},{"name":"Takahashi Satoru"},{"name":"Ochiya Takahiro"},{"name":"Tanaka Yasuhito"}],"ja":[{"name":"Matsui Takeshi"},{"name":"Hamada-Tsutsumi Susumu"},{"name":"Naito Yutaka"},{"name":"Nojima Masanori"},{"name":"Iio Etsuko"},{"name":"Tamori Akihiro"},{"name":"Kubo Shoji"},{"name":"Ide Tatsuya"},{"name":"Kondo Yasuteru"},{"name":"Eguchi Yuichiro"},{"name":"Komori Atsumasa"},{"name":"森根 裕二"},{"name":"島田 光生"},{"name":"Utsunomiya Tohru"},{"name":"Shirabe Ken"},{"name":"Kimura Koichi"},{"name":"Hiasa Yoichi"},{"name":"Chuaypen Natthaya"},{"name":"Tangkijvanich Pisit"},{"name":"Naiki-Ito Aya"},{"name":"Takahashi Satoru"},{"name":"Ochiya Takahiro"},{"name":"Tanaka Yasuhito"}]},"description":{"en":"The microRNA (miR) clusters miR-183/96/182 and miR-217/216a/216b are significantly upregulated in nonviral hepatocellular carcinoma (NBNC-HCC). Here, we investigate the impact of each member of these clusters on the clinical outcome of NBNC-HCC and analyze the antitumor effects of miR-96-5p. The association between recurrence-free survival of 111 NBNC-HCC patients and the levels of miR-183-5p, miR-96-5p, miR-182-5p, miR-217-5p, miR-216a-5p, and miR-216b-5p in tumor and adjacent tissues was investigated. The impact of miR-96-5p on apoptosis and invasion of a hepatoma cell line, HepG2, was investigated by cell counting, Transwell assay, and flow cytometry, respectively. MicroRNA-183-5p, miR-96-5p, miR-182-5p, miR-217-5p, and miR-216b-5p were significantly upregulated in tumor tissues compared to the adjacent tissues (p = 0.0005, p = 0.0030, p = 0.0002, p = 0.0011, and p = 0.0288, respectively). By multivariate Cox regression analysis, high tumor/adjacent ratios of miR-182-5p (p = 0.007) and miR-217-5p (p = 0.008) were associated with poor recurrence-free survival. In contrast, a low tumor/adjacent ratio of miR-96-5p (p < 0.001) was associated with poor recurrence-free survival. It suggested that further upregulation of miR-96-5p in tumors might have an inhibitory effect on recurrence. Transfection of miR-96-5p mimic significantly induced apoptosis of HepG2 cells, in association with downregulation of Nucleophosmin 1 (NPM1) and a decrease of phosphorylated AKT protein. Interestingly, simultaneous knockdown of the NPM1 and AKT genes induced apoptosis. MicroRNA-96-5p also suppressed proliferation and invasion, which inhibited epithelial-to-mesenchymal transition of HCC cells. MicroRNA-96-5p as a tumor suppressor would be valuable to stratify NBNC-HCC patients at high risk of recurrence.","ja":"The microRNA (miR) clusters miR-183/96/182 and miR-217/216a/216b are significantly upregulated in nonviral hepatocellular carcinoma (NBNC-HCC). Here, we investigate the impact of each member of these clusters on the clinical outcome of NBNC-HCC and analyze the antitumor effects of miR-96-5p. The association between recurrence-free survival of 111 NBNC-HCC patients and the levels of miR-183-5p, miR-96-5p, miR-182-5p, miR-217-5p, miR-216a-5p, and miR-216b-5p in tumor and adjacent tissues was investigated. The impact of miR-96-5p on apoptosis and invasion of a hepatoma cell line, HepG2, was investigated by cell counting, Transwell assay, and flow cytometry, respectively. MicroRNA-183-5p, miR-96-5p, miR-182-5p, miR-217-5p, and miR-216b-5p were significantly upregulated in tumor tissues compared to the adjacent tissues (p = 0.0005, p = 0.0030, p = 0.0002, p = 0.0011, and p = 0.0288, respectively). By multivariate Cox regression analysis, high tumor/adjacent ratios of miR-182-5p (p = 0.007) and miR-217-5p (p = 0.008) were associated with poor recurrence-free survival. In contrast, a low tumor/adjacent ratio of miR-96-5p (p < 0.001) was associated with poor recurrence-free survival. It suggested that further upregulation of miR-96-5p in tumors might have an inhibitory effect on recurrence. Transfection of miR-96-5p mimic significantly induced apoptosis of HepG2 cells, in association with downregulation of Nucleophosmin 1 (NPM1) and a decrease of phosphorylated AKT protein. Interestingly, simultaneous knockdown of the NPM1 and AKT genes induced apoptosis. MicroRNA-96-5p also suppressed proliferation and invasion, which inhibited epithelial-to-mesenchymal transition of HCC cells. MicroRNA-96-5p as a tumor suppressor would be valuable to stratify NBNC-HCC patients at high risk of recurrence."},"publication_date":"2022-01-14","publication_name":{"en":"Hepatology Research","ja":"Hepatology Research"},"volume":"52","number":"1","starting_page":"93","ending_page":"104","languages":["eng"],"identifiers":{"doi":["10.1111/hepr.13674"],"issn":["1386-6346"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35001195","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=396013","label":"url"}],"paper_title":{"en":"A \"diversity and inclusion\" lecture for promoting self-awareness among medical students.","ja":"A \"diversity and inclusion\" lecture for promoting self-awareness among medical students."},"authors":{"en":[{"name":"Takasu Chie"},{"name":"Kono Emiko"},{"name":"Morine Yuji"},{"name":"Yoshikawa Kouzou"},{"name":"Tokunaga Takuya"},{"name":"Nishi Masaaki"},{"name":"Kashihara Hideya"},{"name":"Yoshimoto Toshiaki"},{"name":"Yamashita Shoko"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"髙須 千絵"},{"name":"Kono Emiko"},{"name":"森根 裕二"},{"name":"吉川 幸造"},{"name":"徳永 卓哉"},{"name":"西 正暁"},{"name":"柏原 秀也"},{"name":"良元 俊昭"},{"name":"Yamashita Shoko"},{"name":"島田 光生"}]},"description":{"en":"The concept of 'diversity and inclusion' is being adopted worldwide, but it is not yet understood well in Japan. We conducted this study to evaluate the impact of a lecture aimed at increasing awareness of academic careers and the benefits of having diversity and inclusion. Two female surgeons delivered a 120-min lecture on \"diversity and inclusion\" to third-year medical students at Tokushima University. To assess the impact of the lecture, a questionnaire was distributed, for participants to complete anonymously before and after the lecture. Eighty-two students participated in the study (39 men, 38 women, and 5 unknown). Based on the questionnaire responses, 57.1% of the students had already perceived inequality in conduct because of gender. A comparison of pre- and post-lecture responses revealed a significant increase in confidence to succeed in their medical career (56.5% vs. 77.5%, p < 0.01). Learners were more likely to believe that gender would not become a barrier to career development (42.4% vs. 66.7%, p < 0.01). Moreover, 90.4% of the students felt positively about a career in surgery following the lecture. The lecture promoted awareness about diversity, self-awareness, and career development and motivated students to consider specializing in surgery later in their career.","ja":"The concept of 'diversity and inclusion' is being adopted worldwide, but it is not yet understood well in Japan. We conducted this study to evaluate the impact of a lecture aimed at increasing awareness of academic careers and the benefits of having diversity and inclusion. Two female surgeons delivered a 120-min lecture on \"diversity and inclusion\" to third-year medical students at Tokushima University. To assess the impact of the lecture, a questionnaire was distributed, for participants to complete anonymously before and after the lecture. Eighty-two students participated in the study (39 men, 38 women, and 5 unknown). Based on the questionnaire responses, 57.1% of the students had already perceived inequality in conduct because of gender. A comparison of pre- and post-lecture responses revealed a significant increase in confidence to succeed in their medical career (56.5% vs. 77.5%, p < 0.01). Learners were more likely to believe that gender would not become a barrier to career development (42.4% vs. 66.7%, p < 0.01). Moreover, 90.4% of the students felt positively about a career in surgery following the lecture. The lecture promoted awareness about diversity, self-awareness, and career development and motivated students to consider specializing in surgery later in their career."},"publication_date":"2022-01-10","publication_name":{"en":"Surgery Today","ja":"Surgery Today"},"volume":"52","number":"6","starting_page":"964","ending_page":"970","languages":["eng"],"identifiers":{"doi":["10.1007/s00595-021-02424-0"],"issn":["1436-2813"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34913022","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386682","label":"url"}],"paper_title":{"en":"Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer.","ja":"Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer."},"authors":{"en":[{"name":"Wada Yuuma"},{"name":"Shimada Mitsuo"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Zhu Zhongxu"},{"name":"Wang Xin"},{"name":"Etxart Ane"},{"name":"Park Yangsoon"},{"name":"Bujanda Luis"},{"name":"Park Ja In"},{"name":"Goel Ajay"}],"ja":[{"name":"和田 佑馬"},{"name":"島田 光生"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"Zhu Zhongxu"},{"name":"Wang Xin"},{"name":"Etxart Ane"},{"name":"Park Yangsoon"},{"name":"Bujanda Luis"},{"name":"Park Ja In"},{"name":"Goel Ajay"}]},"description":{"en":"Patients with locally advanced rectal cancer (LARC) are recommended to receive preoperative chemoradiotherapy (PCRT) followed by surgery. Response to PCRT varies widely: 60%-70% of patients with LARC do not derive therapeutic benefit from PCRT, whereas 15%-20% of patients achieve pathologic complete response (pCR). We sought to develop a liquid biopsy assay for identifying response to PCRT in patients with LARC. We analyzed two genome-wide microRNA (miRNA) expression profiling data sets from tumor tissue samples for discovery (GSE68204) and validation (GSE29298). We prioritized biomarkers in pretreatment plasma specimens from clinical training (n = 41; 15 responders and 26 nonresponders) and validation (n = 65; 29 responders and 36 nonresponders) cohorts of patients with LARC. We developed an integrated miRNA panel and established a risk assessment model, which was combined with the miRNA panel and carcinoembryonic antigen levels. Our comprehensive discovery effort identified an 8-miRNA panel that robustly predicted response to PCRT, with an excellent accuracy in the discovery (area under the curve [AUC] = 0.95) and validation (AUC = 0.92) cohorts. We successfully established a circulating miRNA panel with remarkable diagnostic accuracy in the clinical training (AUC = 0.82) and validation (AUC = 0.81) cohorts. Moreover, the predictive accuracy of the panel was significantly superior to conventional clinical factors in both cohorts ( < .01) and the risk assessment model was superior (AUC = 0.83). Finally, we applied our model to detect patients with pathologic complete response and showed that it was dramatically superior to currently used pathologic features (AUC = 0.92). Our novel risk assessment signature for predicting response to PCRT has a potential for clinical translation as a liquid biopsy assay in patients with LARC.","ja":"Patients with locally advanced rectal cancer (LARC) are recommended to receive preoperative chemoradiotherapy (PCRT) followed by surgery. Response to PCRT varies widely: 60%-70% of patients with LARC do not derive therapeutic benefit from PCRT, whereas 15%-20% of patients achieve pathologic complete response (pCR). We sought to develop a liquid biopsy assay for identifying response to PCRT in patients with LARC. We analyzed two genome-wide microRNA (miRNA) expression profiling data sets from tumor tissue samples for discovery (GSE68204) and validation (GSE29298). We prioritized biomarkers in pretreatment plasma specimens from clinical training (n = 41; 15 responders and 26 nonresponders) and validation (n = 65; 29 responders and 36 nonresponders) cohorts of patients with LARC. We developed an integrated miRNA panel and established a risk assessment model, which was combined with the miRNA panel and carcinoembryonic antigen levels. Our comprehensive discovery effort identified an 8-miRNA panel that robustly predicted response to PCRT, with an excellent accuracy in the discovery (area under the curve [AUC] = 0.95) and validation (AUC = 0.92) cohorts. We successfully established a circulating miRNA panel with remarkable diagnostic accuracy in the clinical training (AUC = 0.82) and validation (AUC = 0.81) cohorts. Moreover, the predictive accuracy of the panel was significantly superior to conventional clinical factors in both cohorts ( < .01) and the risk assessment model was superior (AUC = 0.83). Finally, we applied our model to detect patients with pathologic complete response and showed that it was dramatically superior to currently used pathologic features (AUC = 0.92). Our novel risk assessment signature for predicting response to PCRT has a potential for clinical translation as a liquid biopsy assay in patients with LARC."},"publication_date":"2021-12-02","publication_name":{"en":"JCO Precision Oncology","ja":"JCO Precision Oncology"},"volume":"5","languages":["eng"],"identifiers":{"doi":["10.1200/PO.21.00015"],"issn":["2473-4284"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2010199","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34473785","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386675","label":"url"}],"paper_title":{"en":"Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.","ja":"Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells."},"authors":{"en":[{"name":"Gao Luping"},{"name":"Morine Yuji"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Ikemoto Tetsuya"},{"name":"Tokuda Kazunori"},{"name":"Takasu Chie"},{"name":"Miyazaki Katsuki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"高 露萍"},{"name":"森根 裕二"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"池本 哲也"},{"name":"徳田 和憲"},{"name":"髙須 千絵"},{"name":"宮崎 克己"},{"name":"島田 光生"}]},"description":{"en":"As a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems. Because the mechanism controlling sorafenib-resistance is not well understood, this study focused on the connection between tumor characteristics and the Nrf2 signaling pathway in a sorafenib-resistant HCC cell line. A sorafenib-resistant HCC cell line (Huh7) was developed by increasing the dose of sorafenib in the culture medium until the target concentration was reached. Cell morphology, migration/invasion rates, and expression of stemness-related and ATP-binding cassette (ABC) transporter genes were compared between sorafenib-resistant Huh7 cells and parental Huh7 cells. Next, a small interfering RNA was used to knock down Nrf2 expression in sorafenib-resistant Huh7 cells, after which cell viability, stemness, migration, and ABC transporter gene expression were examined again. Proliferation, migration, and invasion rates of sorafenib-resistant Huh7 cells were significantly increased relative to the parental cells with or without sorafenib added to the medium. The expression levels of stemness markers and ABC transporter genes were up-regulated in sorafenib-resistant cells. After Nrf2 was knocked down in sorafenib-resistant cells, cell migration and invasion rates were reduced, and expression levels of stemness markers and ABC transporter genes were reduced. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant HCC cells.","ja":"As a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems. Because the mechanism controlling sorafenib-resistance is not well understood, this study focused on the connection between tumor characteristics and the Nrf2 signaling pathway in a sorafenib-resistant HCC cell line. A sorafenib-resistant HCC cell line (Huh7) was developed by increasing the dose of sorafenib in the culture medium until the target concentration was reached. Cell morphology, migration/invasion rates, and expression of stemness-related and ATP-binding cassette (ABC) transporter genes were compared between sorafenib-resistant Huh7 cells and parental Huh7 cells. Next, a small interfering RNA was used to knock down Nrf2 expression in sorafenib-resistant Huh7 cells, after which cell viability, stemness, migration, and ABC transporter gene expression were examined again. Proliferation, migration, and invasion rates of sorafenib-resistant Huh7 cells were significantly increased relative to the parental cells with or without sorafenib added to the medium. The expression levels of stemness markers and ABC transporter genes were up-regulated in sorafenib-resistant cells. After Nrf2 was knocked down in sorafenib-resistant cells, cell migration and invasion rates were reduced, and expression levels of stemness markers and ABC transporter genes were reduced. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant HCC cells."},"publication_date":"2021-09-02","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"16","number":"9","starting_page":"e0256755","ending_page":"e0256755","languages":["eng"],"identifiers":{"doi":["10.1371/journal.pone.0256755"],"issn":["1932-6203"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34475092","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386676","label":"url"}],"paper_title":{"en":"Frailty Can Predict Prognosis After Hepatectomy in Patients With Colorectal Liver Metastasis.","ja":"Frailty Can Predict Prognosis After Hepatectomy in Patients With Colorectal Liver Metastasis."},"authors":{"en":[{"name":"Tokuda Kazunori"},{"name":"Morine Yuji"},{"name":"Miyazaki Katsuki"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Nishi Masaaki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"徳田 和憲"},{"name":"森根 裕二"},{"name":"宮崎 克己"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"西 正暁"},{"name":"池本 哲也"},{"name":"島田 光生"}]},"description":{"en":"The aim of this study was to investigate frailty as a prognostic factor in patients with colorectal liver metastasis undergoing hepatectomy. Eighty-seven patients who underwent hepatectomy at our institution were enrolled. Frailty was defined as a score of ·4 on a clinical frailty scale. Patients were divided into frailty (n=29) and non-frailty (n=58) groups. Overall and cancer-specific survival rates were significantly worse in the frailty group compared with the non-frailty group, and multivariate analysis revealed frailty as an independent prognostic factor. Disease-free survival tended to be worse in the frailty group. Fifty-eight patients relapsed after the first hepatectomy. Twenty-one of 58 recurrent patients were allocated to the frailty group. After recurrence, chemotherapy was significantly more frequently performed in the non-frailty group compared with the frailty group. Frailty can predict the prognosis of patients with colorectal liver metastasis undergoing hepatectomy.","ja":"The aim of this study was to investigate frailty as a prognostic factor in patients with colorectal liver metastasis undergoing hepatectomy. Eighty-seven patients who underwent hepatectomy at our institution were enrolled. Frailty was defined as a score of ·4 on a clinical frailty scale. Patients were divided into frailty (n=29) and non-frailty (n=58) groups. Overall and cancer-specific survival rates were significantly worse in the frailty group compared with the non-frailty group, and multivariate analysis revealed frailty as an independent prognostic factor. Disease-free survival tended to be worse in the frailty group. Fifty-eight patients relapsed after the first hepatectomy. Twenty-one of 58 recurrent patients were allocated to the frailty group. After recurrence, chemotherapy was significantly more frequently performed in the non-frailty group compared with the frailty group. Frailty can predict the prognosis of patients with colorectal liver metastasis undergoing hepatectomy."},"publication_date":"2021-09","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"41","number":"9","starting_page":"4637","ending_page":"4644","languages":["eng"],"identifiers":{"doi":["10.21873/anticanres.15277"],"issn":["1791-7530"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2009303","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34159680","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386674","label":"url"}],"paper_title":{"en":"The BAFF/NF B axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts.","ja":"The BAFF/NF B axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts."},"authors":{"en":[{"name":"Gao Luping"},{"name":"Morine Yuji"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Ikemoto Tetsuya"},{"name":"Tokuda Kazunori"},{"name":"Miyazaki Katsuki"},{"name":"Okikawa Shouhei"},{"name":"Takasu Chie"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"高 露萍"},{"name":"森根 裕二"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"池本 哲也"},{"name":"徳田 和憲"},{"name":"宮崎 克己"},{"name":"Okikawa Shouhei"},{"name":"髙須 千絵"},{"name":"島田 光生"}]},"description":{"en":"The tumor microenvironment affects malignancy in hepatocellular carcinoma (HCC) cells, and cancer-associated fibroblasts (CAFs) play an important role in the microenvironment. As recent studies indicated a difference between CAFs isolated from chemoresistant and non-resistant cancer tissues, therefore we investigated the intracellular mechanism in resistant HCC co-cultured CAFs and interactions between these CAFs with cancer cells. We established a sorafenib-resistant (SR) Huh7 (human HCC) cell line, and characterized it with cytokine assays, then developed CAFs by co-culturing human hepatic stellate cells with resistant or parental Huh7 cells. The 2 types of CAFs were co-cultured with parental Huh7 cells, thereafter the cell viability of these Huh7 cells was checked under sorafenib treatment. The SR Huh7 (Huh7 ) cells expressed increased B-cell activating factor (BAFF), which promoted high expression of CAF-specific markers in Huh7 -co-cultured CAFs, showed activated BAFF, BAFF-R, and downstream of the NF B-Nrf2 pathway, and aggravated invasion, migration, and drug resistance in co-cultured Huh7 cells. When we knocked down BAFF expression in Huh7 cells, the previously increased malignancy and BAFF/NF B axis in Huh7 -co-cultured CAFs reversed, and enhanced chemoresistance in co-cultured Huh7 cells returned as well. In conclusion, the BAFF/NF B pathway was activated in CAFs co-cultured with cell-culture medium from resistant Huh7, which promoted chemoresistance, and increased the malignancy in co-cultured non-resistant Huh7 cells. This suggests that the BAFF/NF B axis in CAFs might be a potential therapeutic target in chemoresistance of HCC.","ja":"The tumor microenvironment affects malignancy in hepatocellular carcinoma (HCC) cells, and cancer-associated fibroblasts (CAFs) play an important role in the microenvironment. As recent studies indicated a difference between CAFs isolated from chemoresistant and non-resistant cancer tissues, therefore we investigated the intracellular mechanism in resistant HCC co-cultured CAFs and interactions between these CAFs with cancer cells. We established a sorafenib-resistant (SR) Huh7 (human HCC) cell line, and characterized it with cytokine assays, then developed CAFs by co-culturing human hepatic stellate cells with resistant or parental Huh7 cells. The 2 types of CAFs were co-cultured with parental Huh7 cells, thereafter the cell viability of these Huh7 cells was checked under sorafenib treatment. The SR Huh7 (Huh7 ) cells expressed increased B-cell activating factor (BAFF), which promoted high expression of CAF-specific markers in Huh7 -co-cultured CAFs, showed activated BAFF, BAFF-R, and downstream of the NF B-Nrf2 pathway, and aggravated invasion, migration, and drug resistance in co-cultured Huh7 cells. When we knocked down BAFF expression in Huh7 cells, the previously increased malignancy and BAFF/NF B axis in Huh7 -co-cultured CAFs reversed, and enhanced chemoresistance in co-cultured Huh7 cells returned as well. In conclusion, the BAFF/NF B pathway was activated in CAFs co-cultured with cell-culture medium from resistant Huh7, which promoted chemoresistance, and increased the malignancy in co-cultured non-resistant Huh7 cells. This suggests that the BAFF/NF B axis in CAFs might be a potential therapeutic target in chemoresistance of HCC."},"publication_date":"2021-07-16","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"112","number":"9","starting_page":"3545","ending_page":"3554","languages":["eng"],"identifiers":{"doi":["10.1111/cas.15041"],"issn":["1349-7006"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2010151","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34195849","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386672","label":"url"}],"paper_title":{"en":"Cancerssociated fibroblastnduced M2olarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor 1 pathway.","ja":"Cancerssociated fibroblastnduced M2olarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor 1 pathway."},"authors":{"en":[{"name":"Chen Shuhai"},{"name":"Morine Yuji"},{"name":"Tokuda Kazunori"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Nishi Masaaki"},{"name":"Ikemoto Tetsuya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"陳 述海"},{"name":"森根 裕二"},{"name":"徳田 和憲"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"西 正暁"},{"name":"池本 哲也"},{"name":"島田 光生"}]},"description":{"en":"Targeting the tumor stroma is an important strategy in cancer treatment. Cancerssociated fibroblasts (CAFs) and tumorssociated macrophages (TAMs) are two main components in the tumor microenvironment (TME) in hepatocellular carcinoma (HCC), which can promote tumor progression. Plasminogen activator inhibitor 1 (PAI 1) upregulation in HCC is predictive of unfavorable tumor behavior and prognosis. However, the crosstalk between cancer cells, TAMs and CAFs, and the functions of PAI 1 in HCC remain to be fully investigated. In the present study, macrophage polarization and key paracrine factors were assessed during their interactions with CAFs and cancer cells. Cell proliferation, wound healing and Transwell and Matrigel assays were used to investigate the malignant behavior of HCC cells . It was found that cancer cells and CAFs induced the M2 polarization of TAMs by upregulating the mRNA expression levels of CD163 and CD206, and downregulating IL 6 mRNA expression and secretion in the macrophages. Both TAMs derived from cancer cells and CAFs promoted HCC cell proliferation and invasion. Furthermore, PAI 1 expression was upregulated in TAMs after being stimulated with CAFonditioned medium and promoted the malignant behavior of the HCC cells by mediating epithelialesenchymal transition. CAFs were the main producer of C motif chemokine ligand 12 (CXCL12) in the TME and CXCL12 contributed to the induction of PAI 1 secretion in TAMs. In conclusion, the results of the present study suggested that CAFs promoted the M2 polarization of macrophages and induced PAI 1 secretion via CXCL12. Furthermore, it was found that PAI 1 produced by the TAMs enhanced the malignant behavior of the HCC cells. Therefore, these factors may be targets for inhibiting the crosstalk between tumor cells, CAFs and TAMs.","ja":"Targeting the tumor stroma is an important strategy in cancer treatment. Cancerssociated fibroblasts (CAFs) and tumorssociated macrophages (TAMs) are two main components in the tumor microenvironment (TME) in hepatocellular carcinoma (HCC), which can promote tumor progression. Plasminogen activator inhibitor 1 (PAI 1) upregulation in HCC is predictive of unfavorable tumor behavior and prognosis. However, the crosstalk between cancer cells, TAMs and CAFs, and the functions of PAI 1 in HCC remain to be fully investigated. In the present study, macrophage polarization and key paracrine factors were assessed during their interactions with CAFs and cancer cells. Cell proliferation, wound healing and Transwell and Matrigel assays were used to investigate the malignant behavior of HCC cells . It was found that cancer cells and CAFs induced the M2 polarization of TAMs by upregulating the mRNA expression levels of CD163 and CD206, and downregulating IL 6 mRNA expression and secretion in the macrophages. Both TAMs derived from cancer cells and CAFs promoted HCC cell proliferation and invasion. Furthermore, PAI 1 expression was upregulated in TAMs after being stimulated with CAFonditioned medium and promoted the malignant behavior of the HCC cells by mediating epithelialesenchymal transition. CAFs were the main producer of C motif chemokine ligand 12 (CXCL12) in the TME and CXCL12 contributed to the induction of PAI 1 secretion in TAMs. In conclusion, the results of the present study suggested that CAFs promoted the M2 polarization of macrophages and induced PAI 1 secretion via CXCL12. Furthermore, it was found that PAI 1 produced by the TAMs enhanced the malignant behavior of the HCC cells. Therefore, these factors may be targets for inhibiting the crosstalk between tumor cells, CAFs and TAMs."},"publication_date":"2021-07-01","publication_name":{"en":"International Journal of Oncology","ja":"International Journal of Oncology"},"volume":"59","number":"2","starting_page":"59","ending_page":"59","languages":["eng"],"identifiers":{"doi":["10.3892/ijo.2021.5239"],"issn":["1791-2423"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32988753","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386670","label":"url"}],"paper_title":{"en":"Utility of cone unit liver resection for small hepatocellular carcinoma: a propensity score matched analysis.","ja":"Utility of cone unit liver resection for small hepatocellular carcinoma: a propensity score matched analysis."},"authors":{"en":[{"name":"Imura Satoru"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Ikemoto Tetsuya"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"居村 暁"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"池本 哲也"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"Anatomical resection (AR) is performed widely for hepatocellular carcinoma (HCC). However, it is controversial whether typical AR, which removes the whole feeding territory of the tumor-bearing portal branch bordered by the landmark veins, is necessary. The aim of this study was to investigate the utility of small AR, so-called cone unit resection, for small HCC. Between 2007 and 2019, 372 hepatectomies were performed for HCC. Among them, 91 initial resections for small (<5 cm) solitary HCC were performed by typical AR (n = 44) or cone unit AR (n = 47). Propensity score matching was performed and clinicopathological features including prognosis were compared. At baseline, platelet count was higher, and liver function (serum albumin level) and indocyanine green retention at 15 min were better in the typical AR than cone unit AR group. There was no significant difference between the typical AR and cone unit AR group for tumor characteristics, short- and long-term outcomes. Even after propensity score matching (n = 29), the short- and long-term outcomes were also equivalent in between the two groups. There was no difference in prognosis of typical and cone unit AR. Therefore, cone unit AR is a feasible procedure for small HCC.","ja":"Anatomical resection (AR) is performed widely for hepatocellular carcinoma (HCC). However, it is controversial whether typical AR, which removes the whole feeding territory of the tumor-bearing portal branch bordered by the landmark veins, is necessary. The aim of this study was to investigate the utility of small AR, so-called cone unit resection, for small HCC. Between 2007 and 2019, 372 hepatectomies were performed for HCC. Among them, 91 initial resections for small (<5 cm) solitary HCC were performed by typical AR (n = 44) or cone unit AR (n = 47). Propensity score matching was performed and clinicopathological features including prognosis were compared. At baseline, platelet count was higher, and liver function (serum albumin level) and indocyanine green retention at 15 min were better in the typical AR than cone unit AR group. There was no significant difference between the typical AR and cone unit AR group for tumor characteristics, short- and long-term outcomes. Even after propensity score matching (n = 29), the short- and long-term outcomes were also equivalent in between the two groups. There was no difference in prognosis of typical and cone unit AR. Therefore, cone unit AR is a feasible procedure for small HCC."},"publication_date":"2021-05-26","publication_name":{"en":"HPB","ja":"HPB"},"volume":"23","number":"5","starting_page":"739","ending_page":"745","languages":["eng"],"identifiers":{"doi":["10.1016/j.hpb.2020.09.010"],"issn":["1477-2574"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2010113","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34136203","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386694","label":"url"}],"paper_title":{"en":"Intestinal hypoperfusion in patients with Crohn's disease revealed by intraoperative indocyanine green fluorescence imaging.","ja":"Intestinal hypoperfusion in patients with Crohn's disease revealed by intraoperative indocyanine green fluorescence imaging."},"authors":{"en":[{"name":"Higashijima Jun"},{"name":"Kono Toru"},{"name":"Shimada Mitsuo"},{"name":"Kashihara Hideya"},{"name":"Takasu Chie"},{"name":"Nishi Masaaki"},{"name":"Tokunaga Takuya"},{"name":"Sugitani Ayumu"},{"name":"Yoshikawa Kouzou"}],"ja":[{"name":"東島 潤"},{"name":"Kono Toru"},{"name":"島田 光生"},{"name":"柏原 秀也"},{"name":"髙須 千絵"},{"name":"西 正暁"},{"name":"徳永 卓哉"},{"name":"Sugitani Ayumu"},{"name":"吉川 幸造"}]},"description":{"en":"Anastomotic leakage has been reported as an independent risk factor for surgical recurrence at the anastomotic site in patients with Crohn's disease. An inadequate blood supply may contribute to this leakage. Real-time indocyanine green angiography has been useful for confirming vascular perfusion of the intestines. The aim of this study was to evaluate the use of intraoperative indocyanine green angiography to detect vascular perfusion of the intestines during ileocaecal resection in patients with Crohn's disease and colon cancer. We retrospectively evaluated the medical records of 26 consecutive patients with colon cancer arising in the caecum or ascending colon and 3 consecutive patients with Crohn's disease without a history of disease-related surgery. The patients in the 2 cohorts had undergone ileocaecal resection at Tokushima University Hospital between January 2018 and January 2021. After ileocaecal resection, blood flow was evaluated in ileal (oral) and colon (anal) stapled stumps by indocyanine green fluorescence angiography. The fluorescence time was defined as the time from indocyanine green injection and flush of the injection route to the point when the stump showed the strongest fluorescent signal in the monitor. The fluorescence time for the ileal and colon stumps in patients with Crohn's disease was 43.3 8.8 s each and was significantly longer than the fluorescence time in the patients with colon cancer (29.4 6.5 s and 29.6 6.8 s, respectively) (P < 0.05). Intraoperative indocyanine green fluorescence imaging is safe and reproducible for assessing intestinal perfusion prior to anastomosis in patients with colon cancer and Crohn's disease.","ja":"Anastomotic leakage has been reported as an independent risk factor for surgical recurrence at the anastomotic site in patients with Crohn's disease. An inadequate blood supply may contribute to this leakage. Real-time indocyanine green angiography has been useful for confirming vascular perfusion of the intestines. The aim of this study was to evaluate the use of intraoperative indocyanine green angiography to detect vascular perfusion of the intestines during ileocaecal resection in patients with Crohn's disease and colon cancer. We retrospectively evaluated the medical records of 26 consecutive patients with colon cancer arising in the caecum or ascending colon and 3 consecutive patients with Crohn's disease without a history of disease-related surgery. The patients in the 2 cohorts had undergone ileocaecal resection at Tokushima University Hospital between January 2018 and January 2021. After ileocaecal resection, blood flow was evaluated in ileal (oral) and colon (anal) stapled stumps by indocyanine green fluorescence angiography. The fluorescence time was defined as the time from indocyanine green injection and flush of the injection route to the point when the stump showed the strongest fluorescent signal in the monitor. The fluorescence time for the ileal and colon stumps in patients with Crohn's disease was 43.3 8.8 s each and was significantly longer than the fluorescence time in the patients with colon cancer (29.4 6.5 s and 29.6 6.8 s, respectively) (P < 0.05). Intraoperative indocyanine green fluorescence imaging is safe and reproducible for assessing intestinal perfusion prior to anastomosis in patients with colon cancer and Crohn's disease."},"publication_date":"2021-05-24","publication_name":{"en":"Annals of Medicine and Surgery","ja":"Annals of Medicine and Surgery"},"volume":"66","starting_page":"102402","ending_page":"102402","languages":["eng"],"identifiers":{"doi":["10.1016/j.amsu.2021.102402"],"issn":["2049-0801"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34009433","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386669","label":"url"}],"paper_title":{"en":"Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8 tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma.","ja":"Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8 tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma."},"authors":{"en":[{"name":"Miyazaki Katsuki"},{"name":"Morine Yuji"},{"name":"Imura Satoru"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Tokuda Kazunori"},{"name":"Okikawa Shohei"},{"name":"Yamashita Shoko"},{"name":"Oya Takeshi"},{"name":"Tsuneyama Koichi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"宮崎 克己"},{"name":"森根 裕二"},{"name":"居村 暁"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"徳田 和憲"},{"name":"沖川 昌平"},{"name":"山下 祥子"},{"name":"尾矢 剛志"},{"name":"常山 幸一"},{"name":"島田 光生"}]},"description":{"en":"To clarify whether the preoperative lymphocyte/C-reactive protein (CRP) ratio (LCR) is a prognostic factor for patients with intrahepatic cholangiocarcinoma (IHCC), and investigate its mechanism via tumor-infiltrating lymphocytes. The subjects of this retrospective study were 42 patients who had undergone hepatectomy for IHCC. We divided the patients into low LCR and high LCR groups (cutoff value: 8780) and analyzed their overall survival (OS) and disease-free survival (DFS) with respect to LCR and other clinicopathological factors. We also investigated the levels of stromal tumor-infiltrating lymphocytes (TILs) and CD8 TILs in surgical specimens, and the relationship between LCR and TILs. A low LCR was identified in 21 patients and was significantly correlated with older age, a high CRP-albumin ratio, and advanced disease stage, and was a prognostic factor for OS and DFS. Multivariate analysis revealed that a low LCR was an independent prognostic factor for worse OS (HR 10.40, P = 0.0077). Although the LCR and levels of stromal TILs were not significantly related, LCR and levels of CD8 TILs were significantly related (P = 0.0297). The preoperative LCR may predict the postsurgical prognosis of patients with IHCC and reflect the CD8 TILs.","ja":"To clarify whether the preoperative lymphocyte/C-reactive protein (CRP) ratio (LCR) is a prognostic factor for patients with intrahepatic cholangiocarcinoma (IHCC), and investigate its mechanism via tumor-infiltrating lymphocytes. The subjects of this retrospective study were 42 patients who had undergone hepatectomy for IHCC. We divided the patients into low LCR and high LCR groups (cutoff value: 8780) and analyzed their overall survival (OS) and disease-free survival (DFS) with respect to LCR and other clinicopathological factors. We also investigated the levels of stromal tumor-infiltrating lymphocytes (TILs) and CD8 TILs in surgical specimens, and the relationship between LCR and TILs. A low LCR was identified in 21 patients and was significantly correlated with older age, a high CRP-albumin ratio, and advanced disease stage, and was a prognostic factor for OS and DFS. Multivariate analysis revealed that a low LCR was an independent prognostic factor for worse OS (HR 10.40, P = 0.0077). Although the LCR and levels of stromal TILs were not significantly related, LCR and levels of CD8 TILs were significantly related (P = 0.0297). The preoperative LCR may predict the postsurgical prognosis of patients with IHCC and reflect the CD8 TILs."},"publication_date":"2021-05-19","publication_name":{"en":"Surgery Today","ja":"Surgery Today"},"volume":"51","number":"12","starting_page":"1985","ending_page":"1995","languages":["eng"],"identifiers":{"doi":["10.1007/s00595-021-02295-5"],"issn":["1436-2813"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33819484","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386673","label":"url"}],"paper_title":{"en":"A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer.","ja":"A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer."},"authors":{"en":[{"name":"Wada Yuuma"},{"name":"Shimada Mitsuo"},{"name":"Murano Tatsuro"},{"name":"Takamaru Hiroyuki"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Balaguer Francesc"},{"name":"Bujanda Luis"},{"name":"Pellise Maria"},{"name":"Kato Ken"},{"name":"Saito Yutaka"},{"name":"Ikematsu Hiroaki"},{"name":"Goel Ajay"}],"ja":[{"name":"和田 佑馬"},{"name":"島田 光生"},{"name":"Murano Tatsuro"},{"name":"Takamaru Hiroyuki"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"Balaguer Francesc"},{"name":"Bujanda Luis"},{"name":"Pellise Maria"},{"name":"Kato Ken"},{"name":"Saito Yutaka"},{"name":"Ikematsu Hiroaki"},{"name":"Goel Ajay"}]},"description":{"en":"We recently reported use of tissue-based transcriptomic biomarkers (microRNA [miRNA] or messenger RNA [mRNA]) for identification of lymph node metastasis (LNM) in patients with invasive submucosal colorectal cancers (T1 CRC). In this study, we translated our tissue-based biomarkers into a blood-based liquid biopsy assay for noninvasive detection of LNM in patients with high-risk T1 CRC. We analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from 2 clinical cohorts-a training cohort (N = 46) and a validation cohort (N = 142)-and matched formalin-fixed paraffin-embedded samples (N = 142). We performed quantitative reverse-transcription polymerase chain reaction, followed by logistic regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model combined with clinical risk factors. We used comprehensive expression profiling of a training cohort of LNM-positive and LMN-negative serum specimens to identify an optimized transcriptomic panel of 4 miRNAs (miR-181b, miR-193b, miR-195, and miR-411) and 5 mRNAs (AMT, forkhead box A1 [FOXA1], polymeric immunoglobulin receptor [PIGR], matrix metalloproteinase 1 [MMP1], and matrix metalloproteinase 9 [MMP9]), which robustly identified patients with LNM (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.72-0.94). We validated panel performance in an independent validation cohort (AUC, 0.82; 95% CI, 0.74-0.88). Our risk-stratification model was more accurate than the panel and an independent predictor for identification of LNM (AUC, 0.90; univariate: odds ratio [OR], 37.17; 95% CI, 4.48-308.35; P < .001; multivariate: OR, 17.28; 95% CI, 1.82-164.07; P = .013). The model limited potential overtreatment to only 18% of all patients, which is dramatically superior to pathologic features that are currently used (92%). A novel risk-stratification model for noninvasive identification of T1 CRC has the potential to avoid unnecessary operations for patients classified as high-risk by conventional risk-classification criteria.","ja":"We recently reported use of tissue-based transcriptomic biomarkers (microRNA [miRNA] or messenger RNA [mRNA]) for identification of lymph node metastasis (LNM) in patients with invasive submucosal colorectal cancers (T1 CRC). In this study, we translated our tissue-based biomarkers into a blood-based liquid biopsy assay for noninvasive detection of LNM in patients with high-risk T1 CRC. We analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from 2 clinical cohorts-a training cohort (N = 46) and a validation cohort (N = 142)-and matched formalin-fixed paraffin-embedded samples (N = 142). We performed quantitative reverse-transcription polymerase chain reaction, followed by logistic regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model combined with clinical risk factors. We used comprehensive expression profiling of a training cohort of LNM-positive and LMN-negative serum specimens to identify an optimized transcriptomic panel of 4 miRNAs (miR-181b, miR-193b, miR-195, and miR-411) and 5 mRNAs (AMT, forkhead box A1 [FOXA1], polymeric immunoglobulin receptor [PIGR], matrix metalloproteinase 1 [MMP1], and matrix metalloproteinase 9 [MMP9]), which robustly identified patients with LNM (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.72-0.94). We validated panel performance in an independent validation cohort (AUC, 0.82; 95% CI, 0.74-0.88). Our risk-stratification model was more accurate than the panel and an independent predictor for identification of LNM (AUC, 0.90; univariate: odds ratio [OR], 37.17; 95% CI, 4.48-308.35; P < .001; multivariate: OR, 17.28; 95% CI, 1.82-164.07; P = .013). The model limited potential overtreatment to only 18% of all patients, which is dramatically superior to pathologic features that are currently used (92%). A novel risk-stratification model for noninvasive identification of T1 CRC has the potential to avoid unnecessary operations for patients classified as high-risk by conventional risk-classification criteria."},"publication_date":"2021-04-02","publication_name":{"en":"Gastroenterology","ja":"Gastroenterology"},"volume":"161","number":"1","starting_page":"151","ending_page":"162.e1","languages":["eng"],"identifiers":{"doi":["10.1053/j.gastro.2021.03.062"],"issn":["1528-0012"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/33486623","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386692","label":"url"}],"paper_title":{"en":"A multicenter phase II trial of preoperative chemoradiotherapy with S-1 plus oxaliplatin and bevacizumab for locally advanced rectal cancer.","ja":"A multicenter phase II trial of preoperative chemoradiotherapy with S-1 plus oxaliplatin and bevacizumab for locally advanced rectal cancer."},"authors":{"en":[{"name":"Higashijima Jun"},{"name":"Tokunaga Takuya"},{"name":"Yoshimoto Toshiaki"},{"name":"Eto Shohei"},{"name":"Kashihara Hideya"},{"name":"Takasu Chie"},{"name":"Nishi Masaaki"},{"name":"Yoshikawa Kouzou"},{"name":"Okitsu Hiroshi"},{"name":"Ishikawa Masashi"},{"name":"Miyake Hidenori"},{"name":"Yagi Toshiyuki"},{"name":"Kono Toru"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"東島 潤"},{"name":"徳永 卓哉"},{"name":"良元 俊昭"},{"name":"江藤 祥平"},{"name":"柏原 秀也"},{"name":"髙須 千絵"},{"name":"西 正暁"},{"name":"吉川 幸造"},{"name":"沖津 宏"},{"name":"Ishikawa Masashi"},{"name":"三宅 秀則"},{"name":"Yagi Toshiyuki"},{"name":"Kono Toru"},{"name":"島田 光生"}]},"description":{"en":"We clarified the safety and efficacy of preoperative chemoradiotherapy for locally advanced rectal cancer using a multidrug regimen (S-1 +xaliplatin +evacizumab). This multicenter phase II trial involved 47 patients with locally advanced rectal cancer. All patients received S-1 orally (80 mg/m/day on days 1-5, 8-12, 15-19, and 22-26) and infusions of oxaliplatin (50 mg/m on days 1, 8, 15, and 22) and bevacizumab (5 mg/kg on days 1 and 15). The total radiation dose was 40 Gy delivered in daily fractions of 2 Gy via the four-field technique. The primary endpoint was the pathological complete response rate. The secondary endpoints were safety (incidence of adverse events) and clinical response, relapse-free survival, overall survival, local recurrence, R0 resection, downstaging, and treatment completion rates. All 47 patients received chemoradiotherapy, and 44 patients underwent curative resection. Two patients refused surgery and selected a watch-and-wait strategy. The pathological complete response rate was 18.2% in patients who underwent curative resection. The clinical response rate was 91.3% in 46 patients. Concerning hematotoxicity, there was one grade 4 adverse event (2.1%) and seven grade 3 events (14.9%). Diarrhea was the most frequent non-hematotoxic event, and the grade 3 event rate was 25.5%. Although preoperative chemoradiotherapy for patients with locally advanced rectal cancer using the S-1 +xaliplatin +evacizumab regimen did not achieve the expected pathological complete response rate, this regimen led to an improved clinical response rate.","ja":"We clarified the safety and efficacy of preoperative chemoradiotherapy for locally advanced rectal cancer using a multidrug regimen (S-1 +xaliplatin +evacizumab). This multicenter phase II trial involved 47 patients with locally advanced rectal cancer. All patients received S-1 orally (80 mg/m/day on days 1-5, 8-12, 15-19, and 22-26) and infusions of oxaliplatin (50 mg/m on days 1, 8, 15, and 22) and bevacizumab (5 mg/kg on days 1 and 15). The total radiation dose was 40 Gy delivered in daily fractions of 2 Gy via the four-field technique. The primary endpoint was the pathological complete response rate. The secondary endpoints were safety (incidence of adverse events) and clinical response, relapse-free survival, overall survival, local recurrence, R0 resection, downstaging, and treatment completion rates. All 47 patients received chemoradiotherapy, and 44 patients underwent curative resection. Two patients refused surgery and selected a watch-and-wait strategy. The pathological complete response rate was 18.2% in patients who underwent curative resection. The clinical response rate was 91.3% in 46 patients. Concerning hematotoxicity, there was one grade 4 adverse event (2.1%) and seven grade 3 events (14.9%). Diarrhea was the most frequent non-hematotoxic event, and the grade 3 event rate was 25.5%. Although preoperative chemoradiotherapy for patients with locally advanced rectal cancer using the S-1 +xaliplatin +evacizumab regimen did not achieve the expected pathological complete response rate, this regimen led to an improved clinical response rate."},"publication_date":"2021-01-23","publication_name":{"en":"International Journal of Clinical Oncology","ja":"International Journal of Clinical Oncology"},"volume":"26","number":"5","starting_page":"875","ending_page":"882","languages":["eng"],"identifiers":{"doi":["10.1007/s10147-021-01868-1"],"issn":["1437-7772"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2009435","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34759154","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386680","label":"url"}],"paper_title":{"en":"Regeneration of caudate lobe after living donor liver transplantation : Comparison with a surrogate model of left lobe graft.","ja":"Regeneration of caudate lobe after living donor liver transplantation : Comparison with a surrogate model of left lobe graft."},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Imura Satoru"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Yamada Shin-ichiro"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"居村 暁"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"山田 眞一郎"},{"name":"島田 光生"}]},"description":{"en":"Background : The aim of this study is to clarify the regeneration of the CL (caudate lobe) without any reconstructions of short hepatic veins (SHVr) after LDLT (living donor liver transplantation) and compare the regeneration of the CL after right hepatectomy (Rt. Hx), as the surrogate model of extended left lobe graft (Ex LLG) with complete SHVr. Methods : Eleven Ex LLGs with CL were included in this study. SHVr was not performed in all cases. The volumetry was performed before, one month and six months after LDLT. Seven patients who underwent Rt. Hx were also included in this study as the surrogate model. Results : In Ex LLGs with CL, the regeneration rate of the large CL (> 30 ml) was worse than that of small CL (< 30 ml). In the surrogate model, the regeneration rate of the CL was not worse than other segments. However, the regeneration rate of the large CL was also worse than that of small CL even in the presence of complete SHVr. Conclusions : The regeneration of the large CL was worse than that of the small CL regardless of the presence or absence of SHVr, indicating that SHVr in Ex LLG with CL might not be necessary. J. Med. Invest. 68 : 330-333, August, 2021.","ja":"Background : The aim of this study is to clarify the regeneration of the CL (caudate lobe) without any reconstructions of short hepatic veins (SHVr) after LDLT (living donor liver transplantation) and compare the regeneration of the CL after right hepatectomy (Rt. Hx), as the surrogate model of extended left lobe graft (Ex LLG) with complete SHVr. Methods : Eleven Ex LLGs with CL were included in this study. SHVr was not performed in all cases. The volumetry was performed before, one month and six months after LDLT. Seven patients who underwent Rt. Hx were also included in this study as the surrogate model. Results : In Ex LLGs with CL, the regeneration rate of the large CL (> 30 ml) was worse than that of small CL (< 30 ml). In the surrogate model, the regeneration rate of the CL was not worse than other segments. However, the regeneration rate of the large CL was also worse than that of small CL even in the presence of complete SHVr. Conclusions : The regeneration of the large CL was worse than that of the small CL regardless of the presence or absence of SHVr, indicating that SHVr in Ex LLG with CL might not be necessary. J. Med. Invest. 68 : 330-333, August, 2021."},"publication_date":"2021","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"68","number":"3.4","starting_page":"330","ending_page":"333","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.68.330"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2009391","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34759138","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386679","label":"url"}],"paper_title":{"en":"Value of the CRP-albumin ratio in patients with resectable pancreatic cancer.","ja":"Value of the CRP-albumin ratio in patients with resectable pancreatic cancer."},"authors":{"en":[{"name":"Arakawa Yusuke"},{"name":"Miyazaki Katsuki"},{"name":"Yoshikawa Masato"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"荒川 悠佑"},{"name":"宮崎 克己"},{"name":"吉川 雅登"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"池本 哲也"},{"name":"居村 暁"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"Background : The C-reactive protein (CRP)-albumin ratio (CAR) was reported as a prognostic factor of resectable hepatocellular carcinoma. The aim of this study was to analyse the significance of CAR in resectable pancreatic cancer. Patients and Methods : 163 patients with curative resection for pancreatic cancer were enrolled in this retrospective study. Cases of non-curative resection were excluded. The CAR was calculated with the preoperative plasma CRP and albumin values, with a cut-off value of 0.06, as calculated in a previous report. Results : Patients in the low CAR group had significantly better overall survival (OS) and disease-free survival (DFS) compared with the high CAR group (P < 0.05). On multivariate analysis, for high CAR, CA19-9 > 300 U /l and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. High CAR was significantly associated with advanced T stage. Conclusion : The CAR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 244-248, August, 2021.","ja":"Background : The C-reactive protein (CRP)-albumin ratio (CAR) was reported as a prognostic factor of resectable hepatocellular carcinoma. The aim of this study was to analyse the significance of CAR in resectable pancreatic cancer. Patients and Methods : 163 patients with curative resection for pancreatic cancer were enrolled in this retrospective study. Cases of non-curative resection were excluded. The CAR was calculated with the preoperative plasma CRP and albumin values, with a cut-off value of 0.06, as calculated in a previous report. Results : Patients in the low CAR group had significantly better overall survival (OS) and disease-free survival (DFS) compared with the high CAR group (P < 0.05). On multivariate analysis, for high CAR, CA19-9 > 300 U /l and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. High CAR was significantly associated with advanced T stage. Conclusion : The CAR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 244-248, August, 2021."},"publication_date":"2021","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"68","number":"3.4","starting_page":"244","ending_page":"255","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.68.244"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2009444","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/34759157","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=386671","label":"url"}],"paper_title":{"en":"Effective in vitro differentiation of adipose-derived stem cells into Schwann-like cells with folic acid supplementation.","ja":"Effective in vitro differentiation of adipose-derived stem cells into Schwann-like cells with folic acid supplementation."},"authors":{"en":[{"name":"Chen Shuhai"},{"name":"Ikemoto Tetsuya"},{"name":"Tokunaga Takuya"},{"name":"Okikawa Shohei"},{"name":"Miyazaki Katsuki"},{"name":"Tokuda Kazunori"},{"name":"Yamada Shin-ichiro"},{"name":"Saitou Yu"},{"name":"Imura Satoru"},{"name":"Morine Yuji"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"陳 述海"},{"name":"池本 哲也"},{"name":"徳永 卓哉"},{"name":"沖川 昌平"},{"name":"宮崎 克己"},{"name":"徳田 和憲"},{"name":"山田 眞一郎"},{"name":"齋藤 裕"},{"name":"居村 暁"},{"name":"森根 裕二"},{"name":"島田 光生"}]},"description":{"en":"Peripheral nerve injury (PNI) after pelvic surgery is a common issue with a significant impact on patients. Autologous nerve grafting is the gold standard treatment for PNI, but this technique cannot be applied to fine nerve fibers in the pelvis. Schwann-like cell (SLC) differentiation is a novel therapeutic strategy for this clinical condition. However, the efficiency of SLC differentiation remains unsatisfactory. We modified an SLC differentiation protocol using adipose-derived stem cells (ADSCs) and folic acid. Morphology, gene expression and secretion of neurotrophic factors were examined to assess the differentiation quality and phenotypic characteristics. Our new modified protocol effectively induced a Schwann cell (SC) phenotype in ADSCs as assessed by morphology and expression of SC markers [S100 calcium-binding protein B (S100B), P < 0.01 ; p75 neurotrophic receptor (p75NTR), P < 0.05]. SLCs produced by the new protocol displayed a repair phenotype with decreased expression of ERBB2 and early growth response protein 2 (EGR2) /ROX20 (P < 0.01). Furthermore, our new protocol enhanced both mRNA expression and secretion of nerve growth factors by SLCs (P < 0.01). This protocol enhanced the SC characteristics and functions of ADSC-derived SLCs. This promising protocol requires further research and may contribute to SC-based nerve regeneration. J. Med. Invest. 68 : 347-353, August, 2021.","ja":"Peripheral nerve injury (PNI) after pelvic surgery is a common issue with a significant impact on patients. Autologous nerve grafting is the gold standard treatment for PNI, but this technique cannot be applied to fine nerve fibers in the pelvis. Schwann-like cell (SLC) differentiation is a novel therapeutic strategy for this clinical condition. However, the efficiency of SLC differentiation remains unsatisfactory. We modified an SLC differentiation protocol using adipose-derived stem cells (ADSCs) and folic acid. Morphology, gene expression and secretion of neurotrophic factors were examined to assess the differentiation quality and phenotypic characteristics. Our new modified protocol effectively induced a Schwann cell (SC) phenotype in ADSCs as assessed by morphology and expression of SC markers [S100 calcium-binding protein B (S100B), P < 0.01 ; p75 neurotrophic receptor (p75NTR), P < 0.05]. SLCs produced by the new protocol displayed a repair phenotype with decreased expression of ERBB2 and early growth response protein 2 (EGR2) /ROX20 (P < 0.01). Furthermore, our new protocol enhanced both mRNA expression and secretion of nerve growth factors by SLCs (P < 0.01). This protocol enhanced the SC characteristics and functions of ADSC-derived SLCs. This promising protocol requires further research and may contribute to SC-based nerve regeneration. J. Med. Invest. 68 : 347-353, August, 2021."},"publication_date":"2021","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"68","number":"3.4","starting_page":"347","ending_page":"353","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.68.347"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2008733","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30805720","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=361184","label":"url"}],"paper_title":{"en":"Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials.","ja":"Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials."},"authors":{"en":[{"name":"Kouno Tooru"},{"name":"Shimada Mitsuo"},{"name":"Nishi Masaaki"},{"name":"Morine Yuji"},{"name":"Yoshikawa Kouzou"},{"name":"Katsuno Hidetoshi"},{"name":"Maeda Koutarou"},{"name":"Koeda Keisuke"},{"name":"Morita Satoshi"},{"name":"Watanabe Masahiko"},{"name":"Kusano Mitsuo"},{"name":"Sakamoto Junichi"},{"name":"Saji Shigetoyo"},{"name":"Sokuoka Hiroki"},{"name":"Sato Yasuto"},{"name":"Maehara Yoshihiko"},{"name":"Kanematsu Takashi"},{"name":"Kitajima Masaki"}],"ja":[{"name":"Kouno Tooru"},{"name":"島田 光生"},{"name":"西 正暁"},{"name":"森根 裕二"},{"name":"吉川 幸造"},{"name":"Katsuno Hidetoshi"},{"name":"Maeda Koutarou"},{"name":"Koeda Keisuke"},{"name":"Morita Satoshi"},{"name":"渡邊 正彦"},{"name":"Kusano Mitsuo"},{"name":"Sakamoto Junichi"},{"name":"Saji Shigetoyo"},{"name":"Sokuoka Hiroki"},{"name":"Sato Yasuto"},{"name":"Maehara Yoshihiko"},{"name":"Kanematsu Takashi"},{"name":"Kitajima Masaki"}]},"description":{"en":"Prolonged postoperative ileus (POI) is a common complication after open abdominal surgery (OAS). Daikenchuto (DKT), a traditional Japanese medicine that peripherally stimulates the neurogenic pathway, is used to treat prolonged POI in Japan. To analyze whether DKT accelerates the recovery from prolonged POI after OAS, we conducted a secondary analysis of three multicenter randomized controlled trials (RCTs). A secondary analysis of the three RCTs supported by the Japanese Foundation for Multidisciplinary Treatment of Cancer (project numbers 39-0902, 40-1001, 42-1002) assessing the effect of DKT on prolonged POI in patients who had undergone OAS for colon, liver, or gastric cancer was performed. The subgroup included 410 patients with no bowel movement (BM) before the first diet, a DKT group (n = 214), and a placebo group (n = 196). Patients received either 5 g DKT or a placebo orally, three times a day. The primary endpoint was defined as the time from the end of surgery to the first bowel movement (FBM). A sensitivity analysis was also performed on the age, body mass index and dosage as subgroup analyses. The primary endpoint was significantly accelerated in the DKT group compared with the placebo group (p = 0.004; hazard ratio 1.337). The median time to the FBM was 113.8 h in the placebo group and 99.1 h in the DKT treatment group. The subgroup analysis showed that DKT significantly accelerated the recovery from prolonged POI following OAS. UMIN000026292.","ja":"Prolonged postoperative ileus (POI) is a common complication after open abdominal surgery (OAS). Daikenchuto (DKT), a traditional Japanese medicine that peripherally stimulates the neurogenic pathway, is used to treat prolonged POI in Japan. To analyze whether DKT accelerates the recovery from prolonged POI after OAS, we conducted a secondary analysis of three multicenter randomized controlled trials (RCTs). A secondary analysis of the three RCTs supported by the Japanese Foundation for Multidisciplinary Treatment of Cancer (project numbers 39-0902, 40-1001, 42-1002) assessing the effect of DKT on prolonged POI in patients who had undergone OAS for colon, liver, or gastric cancer was performed. The subgroup included 410 patients with no bowel movement (BM) before the first diet, a DKT group (n = 214), and a placebo group (n = 196). Patients received either 5 g DKT or a placebo orally, three times a day. The primary endpoint was defined as the time from the end of surgery to the first bowel movement (FBM). A sensitivity analysis was also performed on the age, body mass index and dosage as subgroup analyses. The primary endpoint was significantly accelerated in the DKT group compared with the placebo group (p = 0.004; hazard ratio 1.337). The median time to the FBM was 113.8 h in the placebo group and 99.1 h in the DKT treatment group. The subgroup analysis showed that DKT significantly accelerated the recovery from prolonged POI following OAS. UMIN000026292."},"publication_date":"2019-02-25","publication_name":{"en":"Surgery Today","ja":"Surgery Today"},"volume":"49","number":"8","starting_page":"704","ending_page":"711","languages":["eng"],"identifiers":{"doi":["10.1007/s00595-019-01787-9"],"issn":["1436-2813"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2007125","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30730004","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=361191","label":"url"}],"paper_title":{"en":"The protective effect of epigallocatechin 3-gallate on mouse pancreatic islets via the Nrf2 pathway.","ja":"The protective effect of epigallocatechin 3-gallate on mouse pancreatic islets via the Nrf2 pathway."},"authors":{"en":[{"name":"Wada Yuuma"},{"name":"Takata Atsushi"},{"name":"Ikemoto Tetsuya"},{"name":"Morine Yuji"},{"name":"Imura Satoru"},{"name":"Iwahashi Shuichi"},{"name":"Saitou Yu"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"和田 佑馬"},{"name":"髙田 厚史"},{"name":"池本 哲也"},{"name":"森根 裕二"},{"name":"居村 暁"},{"name":"岩橋 衆一"},{"name":"齋藤 裕"},{"name":"島田 光生"}]},"description":{"en":"Epigallocatechin 3-gallate (EGCG), a green tea polyphenol, has been shown to have anti-oxidant and anti-inflammatory effects in vitro and in vivo. The aim of this study was to investigate the effects and mechanism of EGCG on isolated pancreatic islets as pre-conditioning for pancreatic islet transplantation. The pancreatic islets were divided into two groups: an islet culture medium group (control) and an islet culture medium with EGCG (100 M) group. We investigated the islet viability, Nrf2 expression, reactive oxygen species (ROS) production, and heme oxygenase-1 (HO-1) mRNA. Five hundred islet equivalents after 12 h of culture for the EGCG 100 M and control group were transplanted under the kidney capsule of streptozotocin-induced diabetic ICR mice. The cell viability and insulin secretion ability in the EGCG group were preserved, and the nuclear translocation of Nrf2 was increased in the EGCG group (p < 0.01). While the HO-1 mRNA levels were also higher in the EGCG group than in the control group (p < 0.05), the ROS production was lower (p < 0.01). An in vivo functional assessment showed that the blood glucose level had decreased in the EGCG group after transplantation (p < 0.01). EGCG protects the viability and function of islets by suppressing ROS production via the Nrf2 pathway.","ja":"Epigallocatechin 3-gallate (EGCG), a green tea polyphenol, has been shown to have anti-oxidant and anti-inflammatory effects in vitro and in vivo. The aim of this study was to investigate the effects and mechanism of EGCG on isolated pancreatic islets as pre-conditioning for pancreatic islet transplantation. The pancreatic islets were divided into two groups: an islet culture medium group (control) and an islet culture medium with EGCG (100 M) group. We investigated the islet viability, Nrf2 expression, reactive oxygen species (ROS) production, and heme oxygenase-1 (HO-1) mRNA. Five hundred islet equivalents after 12 h of culture for the EGCG 100 M and control group were transplanted under the kidney capsule of streptozotocin-induced diabetic ICR mice. The cell viability and insulin secretion ability in the EGCG group were preserved, and the nuclear translocation of Nrf2 was increased in the EGCG group (p < 0.01). While the HO-1 mRNA levels were also higher in the EGCG group than in the control group (p < 0.05), the ROS production was lower (p < 0.01). An in vivo functional assessment showed that the blood glucose level had decreased in the EGCG group after transplantation (p < 0.01). EGCG protects the viability and function of islets by suppressing ROS production via the Nrf2 pathway."},"publication_date":"2019-02-07","publication_name":{"en":"Surgery Today","ja":"Surgery Today"},"volume":"49","number":"6","starting_page":"536","ending_page":"545","languages":["eng"],"identifiers":{"doi":["10.1007/s00595-019-1761-0"],"issn":["1436-2813"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2006182","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30682046","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=354312","label":"url"}],"paper_title":{"en":"A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging.","ja":"A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging."},"authors":{"en":[{"name":"Yamada Shin-ichiro"},{"name":"Shimada Mitsuo"},{"name":"Morine Yuji"},{"name":"Imura Satoru"},{"name":"Ikemoto Tetsuya"},{"name":"Saitou Yu"},{"name":"Takasu Chie"},{"name":"Yoshikawa Masato"},{"name":"Teraoku Hiroki"},{"name":"Yoshimoto Toshiaki"}],"ja":[{"name":"山田 眞一郎"},{"name":"島田 光生"},{"name":"森根 裕二"},{"name":"居村 暁"},{"name":"池本 哲也"},{"name":"齋藤 裕"},{"name":"髙須 千絵"},{"name":"吉川 雅登"},{"name":"寺奥 大貴"},{"name":"良元 俊昭"}]},"description":{"en":"Dynamic magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-MRI) can be used not only to detect liver tumors but also to estimate liver function. The aim of this study was to establish a new EOB-MRI-based formula to determine the resection limit in patients undergoing hepatectomy. Twenty-eight patients with a normal liver (NL group) and five with an unresectable cirrhotic liver (UL group) who underwent EOB-MRI were included. Standardized liver function (SLF) was calculated based on the signal intensity (SI), the volume of each subsegment (S1-S8), and body surface area. A formula defining the resection limit was devised based on the difference in the SLF values of patients in the NL and UL groups. The formula was validated in 50 patients who underwent EOB-MRI and hepatectomy. The average SLF value in the NL and UL groups was 2038 and 962 FV/m2, respectively. The difference (1076 FV/m2) was consistent with a 70% in resection volume. Thus, the resection limit for hepatectomy was calculated as a proportion of 70%: 70 (SLF-962)/1076 (%). The one patient who underwent hepatectomy over the resection limit died due to liver failure. In other 49 patients, in whom the resection volume was less than the resection limit, procedures were safely performed. Our formula for resection limit based on EOB-MRI can improve the safety of hepatectomy.","ja":"Dynamic magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (EOB-MRI) can be used not only to detect liver tumors but also to estimate liver function. The aim of this study was to establish a new EOB-MRI-based formula to determine the resection limit in patients undergoing hepatectomy. Twenty-eight patients with a normal liver (NL group) and five with an unresectable cirrhotic liver (UL group) who underwent EOB-MRI were included. Standardized liver function (SLF) was calculated based on the signal intensity (SI), the volume of each subsegment (S1-S8), and body surface area. A formula defining the resection limit was devised based on the difference in the SLF values of patients in the NL and UL groups. The formula was validated in 50 patients who underwent EOB-MRI and hepatectomy. The average SLF value in the NL and UL groups was 2038 and 962 FV/m2, respectively. The difference (1076 FV/m2) was consistent with a 70% in resection volume. Thus, the resection limit for hepatectomy was calculated as a proportion of 70%: 70 (SLF-962)/1076 (%). The one patient who underwent hepatectomy over the resection limit died due to liver failure. In other 49 patients, in whom the resection volume was less than the resection limit, procedures were safely performed. Our formula for resection limit based on EOB-MRI can improve the safety of hepatectomy."},"publication_date":"2019-01-25","publication_name":{"en":"PLoS ONE","ja":"PLoS ONE"},"volume":"14","number":"1","starting_page":"e0210579","ending_page":"e0210579","languages":["eng"],"identifiers":{"doi":["10.1371/journal.pone.0210579"],"issn":["1932-6203"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2006419","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31064957","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=361183","label":"url"}],"paper_title":{"en":"Usefulness of blood flow evaluation by indocyanine green fluorescence system in laparoscopic anterior resection.","ja":"Usefulness of blood flow evaluation by indocyanine green fluorescence system in laparoscopic anterior resection."},"authors":{"en":[{"name":"Higashijima Jun"},{"name":"Shimada Mitsuo"},{"name":"Yoshikawa Kouzou"},{"name":"Miyatani Tomohiko"},{"name":"Tokunaga Takuya"},{"name":"Nishi Masaaki"},{"name":"Kashihara Hideya"},{"name":"Takasu Chie"}],"ja":[{"name":"東島 潤"},{"name":"島田 光生"},{"name":"吉川 幸造"},{"name":"宮谷 知彦"},{"name":"徳永 卓哉"},{"name":"西 正暁"},{"name":"柏原 秀也"},{"name":"髙須 千絵"}]},"description":{"en":"One of the major cause of anastomotic leakage (AL) in anterior resection of the rectum is insufficient blood flow of the remnant colon. The indocyanine green fluorescence system (ICG-FS) can visualize the blood flow of organs intra-operatively. The aim of this study is to investigate the usefulness of ICG-FS for evaluating the blood flow of the remnant colon in laparoscopic anterior resection. Rectal cancer patients (n=24) who underwent laparoscopic anterior resection were included in this study. After resection of the rectum, 7.5mg of ICG was administered intravenously, and the blood flow of the oral stump was evaluated by the ICG-FS. The relationship between the fluorescence time (FT) of the oral stump and AL was investigated retrospectively. Two of twenty-four patients (8.3%) suffered AL. The FT of these two cases were over 60 seconds. In the case with the FT was over 80 seconds, we performed additional resection of the late fluorescence portion of the remnant colon and could avoid AL. In patients whose FT was under 60 seconds, no patients suffered AL. ICG-FS may be useful for evaluating the blood flow of the remnant colon to avoid AL in laparoscopic anterior resection. J. Med. Invest. 66 : 65-69, February, 2019.","ja":"One of the major cause of anastomotic leakage (AL) in anterior resection of the rectum is insufficient blood flow of the remnant colon. The indocyanine green fluorescence system (ICG-FS) can visualize the blood flow of organs intra-operatively. The aim of this study is to investigate the usefulness of ICG-FS for evaluating the blood flow of the remnant colon in laparoscopic anterior resection. Rectal cancer patients (n=24) who underwent laparoscopic anterior resection were included in this study. After resection of the rectum, 7.5mg of ICG was administered intravenously, and the blood flow of the oral stump was evaluated by the ICG-FS. The relationship between the fluorescence time (FT) of the oral stump and AL was investigated retrospectively. Two of twenty-four patients (8.3%) suffered AL. The FT of these two cases were over 60 seconds. In the case with the FT was over 80 seconds, we performed additional resection of the late fluorescence portion of the remnant colon and could avoid AL. In patients whose FT was under 60 seconds, no patients suffered AL. ICG-FS may be useful for evaluating the blood flow of the remnant colon to avoid AL in laparoscopic anterior resection. J. Med. Invest. 66 : 65-69, February, 2019."},"publication_date":"2019","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"66","number":"1.2","starting_page":"65","ending_page":"69","languages":["eng"],"identifiers":{"doi":["10.2152/jmi.66.65"],"issn":["1349-6867"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29863192","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=341399","label":"url"}],"paper_title":{"en":"Changes of liver metabolites following hepatectomy with ischemia reperfusion towards liver regeneration.","ja":"Changes of liver metabolites following hepatectomy with ischemia reperfusion towards liver regeneration."},"authors":{"en":[{"name":"Saitou Yu"},{"name":"Morine Yuji"},{"name":"Iwahashi Shuichi"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Yamanaka-Okumura Hisami"},{"name":"Hirayama Akiyoshi"},{"name":"Soga Tomoyoshi"},{"name":"Tomita Masaru"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"齋藤 裕"},{"name":"森根 裕二"},{"name":"岩橋 衆一"},{"name":"池本 哲也"},{"name":"居村 暁"},{"name":"Yamanaka-Okumura Hisami"},{"name":"Hirayama Akiyoshi"},{"name":"Soga Tomoyoshi"},{"name":"Tomita Masaru"},{"name":"島田 光生"}]},"description":{"en":"Metabolome analysis is one of the omics which investigates the final product of a central dogma. Changes of liver metabolites during liver regeneration following hepatectomy (Hx) continue to remain unclear. The aim of the present study was to investigate the changes of liver metabolites following Hx with ischemia reperfusion (I/R) towards liver regeneration. Twenty-three patients who underwent Hx were enrolled in this study. Non-tumor tissues were sampled immediately before and after Hx and a comparison was made between the liver samples taken before and after Hx using capillary electrophoresis (CE)-time-of-flight mass spectrometry (TOFMS) as metabolome analysis. The metabolic pathway showed that there was a significant increase in \"lactate\" following Hx. There was a significant decrease in metabolites only in the first half of the tricarboxylic acid cycle (TCA) cycle, and adenosine triphosphate (ATP) by anaerobiotic glycolysis did not occur in time for energy consumption of the Hx. Principal component analysis revealed remarkably different component profiles between the samples taken before and after Hx. One hundred and three metabolites were selected as critical metabolites for separating components. Valine and tryptophan increased significantly after Hx and they were regulated by resected liver volume, ischemic time and liver function. The liver metabolites changed remarkably between before and after Hx. Especially, liver valine and tryptophan were increased.","ja":"Metabolome analysis is one of the omics which investigates the final product of a central dogma. Changes of liver metabolites during liver regeneration following hepatectomy (Hx) continue to remain unclear. The aim of the present study was to investigate the changes of liver metabolites following Hx with ischemia reperfusion (I/R) towards liver regeneration. Twenty-three patients who underwent Hx were enrolled in this study. Non-tumor tissues were sampled immediately before and after Hx and a comparison was made between the liver samples taken before and after Hx using capillary electrophoresis (CE)-time-of-flight mass spectrometry (TOFMS) as metabolome analysis. The metabolic pathway showed that there was a significant increase in \"lactate\" following Hx. There was a significant decrease in metabolites only in the first half of the tricarboxylic acid cycle (TCA) cycle, and adenosine triphosphate (ATP) by anaerobiotic glycolysis did not occur in time for energy consumption of the Hx. Principal component analysis revealed remarkably different component profiles between the samples taken before and after Hx. One hundred and three metabolites were selected as critical metabolites for separating components. Valine and tryptophan increased significantly after Hx and they were regulated by resected liver volume, ischemic time and liver function. The liver metabolites changed remarkably between before and after Hx. Especially, liver valine and tryptophan were increased."},"publication_date":"2018-01-30","publication_name":{"en":"Annals of Gastroenterological Surgery","ja":"Annals of Gastroenterological Surgery"},"volume":"2","number":"3","starting_page":"204","ending_page":"211","languages":["eng"],"identifiers":{"doi":["10.1002/ags3.12058"],"issn":["2475-0328"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2006710","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29863164","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=341473","label":"url"}],"paper_title":{"en":"Blue light-emitting diodes induce autophagy in colon cancer cells by Opsin 3.","ja":"Blue light-emitting diodes induce autophagy in colon cancer cells by Opsin 3."},"authors":{"en":[{"name":"Yoshimoto Toshiaki"},{"name":"Morine Yuji"},{"name":"Takasu Chie"},{"name":"Feng Rui"},{"name":"Ikemoto Tetsuya"},{"name":"Yoshikawa Kouzou"},{"name":"Iwahashi Shuichi"},{"name":"Saitou Yu"},{"name":"Kashihara Hideya"},{"name":"Akutagawa Masatake"},{"name":"Emoto Takahiro"},{"name":"Kinouchi Yosuke"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"良元 俊昭"},{"name":"森根 裕二"},{"name":"髙須 千絵"},{"name":"馮 睿"},{"name":"池本 哲也"},{"name":"吉川 幸造"},{"name":"岩橋 衆一"},{"name":"齋藤 裕"},{"name":"柏原 秀也"},{"name":"芥川 正武"},{"name":"榎本 崇宏"},{"name":"Kinouchi Yosuke"},{"name":"島田 光生"}]},"description":{"en":"Light emitting-diodes (LED) have various effects on living organisms and recent studies have shown the efficacy of visible light irradiation from LED for anticancer therapies. However, the mechanism of LED's effects on cancer cells remains unclear. The aim of the present study was to investigate the effects of LED on colon cancer cell lines and the role of photoreceptor Opsin 3 (Opn3) on LED irradiation in vitro. Human colon cancer cells (HT-29 or HCT-116) were seeded onto laboratory dishes and irradiated with 465-nm LED at 30 mW/cm for 30 minutes. Cell Counting Kit-8 was used to measure cell viability, and apoptosis and caspase 3/8 expression were evaluated by AnnexinV/PI and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Autophagy and expression of LC-3 and beclin-1 were also evaluated by autophagy assays, RT-PCR and Western blotting. We further tested Opn3 knockdown by Opn3 siRNA and the G G-protein inhibitor NF023 in these assays. Viability of HT-29 and HCT-116 cells was lower in 465-nm LED-irradiated cultures than in control cultures. LC-3 and beclin-1 expressions were significantly higher in LED-irradiated cultures, and autophagosomes were detected in irradiated cells. The reductive effect of cancer cell viability following blue LED irradiation was reversed by Opn3 knockdown or NF023 treatment. Furthermore, increased LC-3 and beclin-1 expression that resulted from blue LED irradiation was suppressed by Opn3 knockdown or NF023 treatment. Blue LED irradiation suppressed the growth of colon cancer cells and Opn3 may play an important role as a photoreceptor.","ja":"Light emitting-diodes (LED) have various effects on living organisms and recent studies have shown the efficacy of visible light irradiation from LED for anticancer therapies. However, the mechanism of LED's effects on cancer cells remains unclear. The aim of the present study was to investigate the effects of LED on colon cancer cell lines and the role of photoreceptor Opsin 3 (Opn3) on LED irradiation in vitro. Human colon cancer cells (HT-29 or HCT-116) were seeded onto laboratory dishes and irradiated with 465-nm LED at 30 mW/cm for 30 minutes. Cell Counting Kit-8 was used to measure cell viability, and apoptosis and caspase 3/8 expression were evaluated by AnnexinV/PI and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Autophagy and expression of LC-3 and beclin-1 were also evaluated by autophagy assays, RT-PCR and Western blotting. We further tested Opn3 knockdown by Opn3 siRNA and the G G-protein inhibitor NF023 in these assays. Viability of HT-29 and HCT-116 cells was lower in 465-nm LED-irradiated cultures than in control cultures. LC-3 and beclin-1 expressions were significantly higher in LED-irradiated cultures, and autophagosomes were detected in irradiated cells. The reductive effect of cancer cell viability following blue LED irradiation was reversed by Opn3 knockdown or NF023 treatment. Furthermore, increased LC-3 and beclin-1 expression that resulted from blue LED irradiation was suppressed by Opn3 knockdown or NF023 treatment. Blue LED irradiation suppressed the growth of colon cancer cells and Opn3 may play an important role as a photoreceptor."},"publication_date":"2018-01-11","publication_name":{"en":"Annals of Gastroenterological Surgery","ja":"Annals of Gastroenterological Surgery"},"volume":"2","number":"2","starting_page":"154","ending_page":"161","languages":["eng"],"identifiers":{"doi":["10.1002/ags3.12055"],"issn":["2475-0328"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29187449","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=341059","label":"url"}],"paper_title":{"en":"High STAT4 Expression Indicates Better Disease-free Survival in Patients with Gastric Cancer.","ja":"High STAT4 Expression Indicates Better Disease-free Survival in Patients with Gastric Cancer."},"authors":{"en":[{"name":"Nishi Masaaki"},{"name":"Batsaikhan Bat-Erdene"},{"name":"Yoshikawa Kozo"},{"name":"Higashijima Jun"},{"name":"Tokunaga Takuya"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Ishikawa Daichi"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"西 正暁"},{"name":"Batsaikhan Bat-Erdene"},{"name":"Yoshikawa Kozo"},{"name":"東島 潤"},{"name":"徳永 卓哉"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"石川 大地"},{"name":"島田 光生"}]},"description":{"en":"The aim of this study was to investigate the significance of signal transducer and activator of transcription 4 (STAT4) expression and the correlation between STAT4 and interferon gamma (IFN- ) in patients with gastric cancer. Sixty-two patients who underwent gastrectomy for gastric cancer were enrolled in the study. STAT4 and IFNG mRNA expression was evaluated by quantitative real-time polymerase chain reaction (PCR). Immunohistochemistry was performed to examine CD8 T-cells, and STAT4 and IFN- expression. STAT4 mRNA expression was significantly correlated with IFNG mRNA expression (p<0.05). Regarding disease-free survival, there was a significant difference between the groups with high and low STAT4 expression (5-year disease-free survival: 77.8% and 56.4%, p<0.05). Univariate analysis revealed that tumor differentiation and STAT4 expression were significant factors for tumor recurrence. High expression of STAT4 in gastric cancer predicted a better clinical outcome. STAT4 might be a useful biomarker to identify patients at high risk of recurrence after gastrectomy.","ja":"The aim of this study was to investigate the significance of signal transducer and activator of transcription 4 (STAT4) expression and the correlation between STAT4 and interferon gamma (IFN- ) in patients with gastric cancer. Sixty-two patients who underwent gastrectomy for gastric cancer were enrolled in the study. STAT4 and IFNG mRNA expression was evaluated by quantitative real-time polymerase chain reaction (PCR). Immunohistochemistry was performed to examine CD8 T-cells, and STAT4 and IFN- expression. STAT4 mRNA expression was significantly correlated with IFNG mRNA expression (p<0.05). Regarding disease-free survival, there was a significant difference between the groups with high and low STAT4 expression (5-year disease-free survival: 77.8% and 56.4%, p<0.05). Univariate analysis revealed that tumor differentiation and STAT4 expression were significant factors for tumor recurrence. High expression of STAT4 in gastric cancer predicted a better clinical outcome. STAT4 might be a useful biomarker to identify patients at high risk of recurrence after gastrectomy."},"publication_date":"2017-12","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"37","number":"12","starting_page":"6723","ending_page":"6729","languages":["eng"],"identifiers":{"doi":["10.21873/anticanres.12131"],"issn":["1791-7530"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28438872","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=341644","label":"url"}],"paper_title":{"en":"Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases.","ja":"Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver Metastases."},"authors":{"en":[{"name":"Yoshimoto Toshiaki"},{"name":"Morine Yuji"},{"name":"Imura Satoru"},{"name":"Ikemoto Tetsuya"},{"name":"Iwahashi Shuichi"},{"name":"Saitou Yu"},{"name":"Yamada Shin-ichiro"},{"name":"Ishikawa Daichi"},{"name":"Teraoku Hiroki"},{"name":"Yoshikawa Masato"},{"name":"Higashijima Jun"},{"name":"Takasu Chie"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"良元 俊昭"},{"name":"森根 裕二"},{"name":"居村 暁"},{"name":"池本 哲也"},{"name":"岩橋 衆一"},{"name":"齋藤 裕"},{"name":"山田 眞一郎"},{"name":"石川 大地"},{"name":"寺奥 大貴"},{"name":"吉川 雅登"},{"name":"東島 潤"},{"name":"髙須 千絵"},{"name":"島田 光生"}]},"description":{"en":"Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection. One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed. Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ·30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS). MDN ·30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM.","ja":"Surgical resection is currently considered the only potentially curative option as a treatment strategy of colorectal liver metastases (CRLM). However, the criteria for selection of resectable CRLM are not clear. The aim of this study was to confirm a new prognostic indicator of CRLM after hepatic resection. One hundred thirty nine patients who underwent initial surgical resection from 1994 to 2015 were investigated retrospectively. Prognostic factors of overall survival including the product of maximum diameter and number of metastases (MDN) were analyzed. Primary tumor differentiation, vessel invasion, lymph node (LN) metastasis, non-optimally resectable metastases, H score, grade of liver metastases, resection with non-curative intent and MDN were found to be prognostic factors of overall survival (OS). In multivariate analyses of clinicopathological features associated with OS, MDN and non-curative intent were independent prognostic factors. Patients with MDN ·30 had shown significantly poorer prognosis than patients with MDN <30 in OS and relapse-free survival (RFS). MDN ·30 is an independent prognostic factor of survival in patients with CRLM and optimal surgical criterion of hepatectomy for CRLM."},"publication_date":"2017-06","publication_name":{"en":"In Vivo","ja":"In Vivo"},"volume":"31","number":"3","starting_page":"419","ending_page":"423","languages":["eng"],"identifiers":{"doi":["10.21873/invivo.11076"],"issn":["1791-7549"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2005198","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28314278","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=330329","label":"url"}],"paper_title":{"en":"Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition.","ja":"Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition."},"authors":{"en":[{"name":"Yoshikawa Masato"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Imura Satoru"},{"name":"Higashijima Jun"},{"name":"Iwahashi Shuichi"},{"name":"Saitou Yu"},{"name":"Takasu Chie"},{"name":"Yamada Shin-ichiro"},{"name":"Ishikawa Daichi"},{"name":"Teraoku Hiroki"},{"name":"Takata Atsushi"},{"name":"Yoshimoto Toshiaki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"吉川 雅登"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"居村 暁"},{"name":"東島 潤"},{"name":"岩橋 衆一"},{"name":"齋藤 裕"},{"name":"髙須 千絵"},{"name":"山田 眞一郎"},{"name":"石川 大地"},{"name":"寺奥 大貴"},{"name":"髙田 厚史"},{"name":"良元 俊昭"},{"name":"島田 光生"}]},"description":{"en":"Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas. A subset of patients with hepatocellular carcinoma (HCC) exhibit increased serum CEA level, but the significance of this is unclear. In this study, we investigated the prognosis of patients with HCC with increased serum CEA, and explored the correlations with expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and epithelial-mesenchymal transition (EMT) and tumor angiogenesis. One hundred and twenty-three patients with HCC who underwent radical resection were divided into two groups according to a cut-off value of 5.0 ng/ml for serum CEA: high (n=24) and normal (n=99) groups. We compared the clinicopathological factors with serum CEA levels and its correlations with CEACAM1 expression, EMT-related factors and microvessel density (MVD) of tumor tissues by immunohistochemistry. In the high CEA group, the disease-free survival (DFS) rate was significantly worse than in the normal CEA group. Multivariate analysis revealed that a high CEA level was an independent factor predictive of recurrence. Furthermore, increased serum CEA levels were positively correlated with CEACAM1 expression. Moreover, CEACAM1 expression was positively correlated with expression of EMT-related factors and MVD of tumor tissues. Increased serum CEA level reflected CEACAM1 expression and was an independent factor predictive of recurrence in HCC through EMT and tumor angiogenesis.","ja":"Serum carcinoembryonic antigen (CEA) is used as an indicator of tumor progression in a variety of carcinomas. A subset of patients with hepatocellular carcinoma (HCC) exhibit increased serum CEA level, but the significance of this is unclear. In this study, we investigated the prognosis of patients with HCC with increased serum CEA, and explored the correlations with expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and epithelial-mesenchymal transition (EMT) and tumor angiogenesis. One hundred and twenty-three patients with HCC who underwent radical resection were divided into two groups according to a cut-off value of 5.0 ng/ml for serum CEA: high (n=24) and normal (n=99) groups. We compared the clinicopathological factors with serum CEA levels and its correlations with CEACAM1 expression, EMT-related factors and microvessel density (MVD) of tumor tissues by immunohistochemistry. In the high CEA group, the disease-free survival (DFS) rate was significantly worse than in the normal CEA group. Multivariate analysis revealed that a high CEA level was an independent factor predictive of recurrence. Furthermore, increased serum CEA levels were positively correlated with CEACAM1 expression. Moreover, CEACAM1 expression was positively correlated with expression of EMT-related factors and MVD of tumor tissues. Increased serum CEA level reflected CEACAM1 expression and was an independent factor predictive of recurrence in HCC through EMT and tumor angiogenesis."},"publication_date":"2017-03","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"37","number":"3","starting_page":"1169","ending_page":"1175","languages":["eng"],"identifiers":{"doi":["10.21873/anticanres.11430"],"issn":["1791-7530"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28233105","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=330331","label":"url"}],"paper_title":{"en":"Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial.","ja":"Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial."},"authors":{"en":[{"name":"Maehara Yoshihiko"},{"name":"Shirabe Ken"},{"name":"Kohnoe Shunji"},{"name":"Emi Yasunori"},{"name":"Oki Eiji"},{"name":"Kakeji Yoshihiro"},{"name":"Baba Hideo"},{"name":"Ikeda Masataka"},{"name":"Kobayashi Michiya"},{"name":"Takayama Tadatoshi"},{"name":"Natsugoe Shoji"},{"name":"Haraguchi Masashi"},{"name":"Yoshida Kazuhiro"},{"name":"Terashima Masanori"},{"name":"Sasako Mitsuru"},{"name":"Yamaue Hiroki"},{"name":"Kokudo Norihiro"},{"name":"Uesaka Katsuhiko"},{"name":"Uemoto Shinji"},{"name":"Kosuge Tomoo"},{"name":"Sawa Yoshiki"},{"name":"Shimada Mitsuo"},{"name":"Doki Yuichiro"},{"name":"Yamamoto Masakazu"},{"name":"Taketomi Akinobu"},{"name":"Takeuchi Masahiro"},{"name":"Akazawa Kouhei"},{"name":"Yamanaka Takeharu"},{"name":"Shimokawa Mototsugu"}],"ja":[{"name":"Maehara Yoshihiko"},{"name":"Shirabe Ken"},{"name":"Kohnoe Shunji"},{"name":"Emi Yasunori"},{"name":"Oki Eiji"},{"name":"Kakeji Yoshihiro"},{"name":"Baba Hideo"},{"name":"Ikeda Masataka"},{"name":"Kobayashi Michiya"},{"name":"Takayama Tadatoshi"},{"name":"Natsugoe Shoji"},{"name":"Haraguchi Masashi"},{"name":"Yoshida Kazuhiro"},{"name":"Terashima Masanori"},{"name":"Sasako Mitsuru"},{"name":"Yamaue Hiroki"},{"name":"Kokudo Norihiro"},{"name":"Uesaka Katsuhiko"},{"name":"Uemoto Shinji"},{"name":"Kosuge Tomoo"},{"name":"Sawa Yoshiki"},{"name":"島田 光生"},{"name":"Doki Yuichiro"},{"name":"Yamamoto Masakazu"},{"name":"Taketomi Akinobu"},{"name":"Takeuchi Masahiro"},{"name":"Akazawa Kouhei"},{"name":"Yamanaka Takeharu"},{"name":"Shimokawa Mototsugu"}]},"description":{"en":"The use of absorbable sutures in wound closure has been shown to reduce the incidence of surgical site infection (SSI); however, there is no evidence that the intra-abdominal use of absorbable rather than silk sutures reduces the incidence of SSI after gastrointestinal surgery. We report the findings of a phase II trial, designed to evaluate the impact of the intra-abdominal use of absorbable sutures on the incidence of SSI. At 19 Japanese hospitals, 1147 patients undergoing elective gastrectomy, colorectal surgery, hepatectomy, or pancreaticoduodenectomy (PD) were randomly assigned to absorbable or silk intra-abdominal suture groups. The primary efficacy endpoint was the incidence of SSI. The secondary efficacy endpoints were the locations of SSI, time to resolution of SSI, length of hospital stay, and the incidence of bile leakage in hepatectomy and pancreatic fistula. The incidence of SSI was 11.3%, 15.5%, 11.3%, and 36.9% after gastrectomy, colorectal surgery, hepatectomy, and PD, respectively. The incidence of SSI was higher in the absorbable suture group than in the silk suture group for all the surgical procedures, but the difference was not significant. The intra-abdominal use of absorbable sutures did not have enough of an effect on the reduction of SSI in this phase II trial to justify the planning of a large-scale phase III trial.","ja":"The use of absorbable sutures in wound closure has been shown to reduce the incidence of surgical site infection (SSI); however, there is no evidence that the intra-abdominal use of absorbable rather than silk sutures reduces the incidence of SSI after gastrointestinal surgery. We report the findings of a phase II trial, designed to evaluate the impact of the intra-abdominal use of absorbable sutures on the incidence of SSI. At 19 Japanese hospitals, 1147 patients undergoing elective gastrectomy, colorectal surgery, hepatectomy, or pancreaticoduodenectomy (PD) were randomly assigned to absorbable or silk intra-abdominal suture groups. The primary efficacy endpoint was the incidence of SSI. The secondary efficacy endpoints were the locations of SSI, time to resolution of SSI, length of hospital stay, and the incidence of bile leakage in hepatectomy and pancreatic fistula. The incidence of SSI was 11.3%, 15.5%, 11.3%, and 36.9% after gastrectomy, colorectal surgery, hepatectomy, and PD, respectively. The incidence of SSI was higher in the absorbable suture group than in the silk suture group for all the surgical procedures, but the difference was not significant. The intra-abdominal use of absorbable sutures did not have enough of an effect on the reduction of SSI in this phase II trial to justify the planning of a large-scale phase III trial."},"publication_date":"2017-02-23","publication_name":{"en":"Surgery Today","ja":"Surgery Today"},"volume":"47","number":"9","starting_page":"1060","ending_page":"1071","languages":["eng"],"identifiers":{"doi":["10.1007/s00595-017-1480-3"],"issn":["1436-2813"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381234"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2002629","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25368233","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297570","label":"url"}],"paper_title":{"en":"Cyclopamine decreased the expression of Sonic Hedgehog and its downstream genes in colon cancer stem cells.","ja":"Cyclopamine decreased the expression of Sonic Hedgehog and its downstream genes in colon cancer stem cells."},"authors":{"en":[{"name":"Batsaikhan Bat-Erdene"},{"name":"Yoshikawa Kozo"},{"name":"Kurita Nobuhiro"},{"name":"Iwata Takashi"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Batsaikhan Bat-Erdene"},{"name":"Yoshikawa Kozo"},{"name":"栗田 信浩"},{"name":"岩田 貴"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"島田 光生"}]},"description":{"en":"Backround: Most solid cancers including colon cancer are believed to be initiated from and maintained by cancer stem cells (CSCs), that are responsible for treatment resistance, resulting in tumor relapse. The aim of this study was to clarify the possible role of the Sonic Hedgehog (Shh) signaling pathway in the regulation of cancer stem cells. The HCT-116 cell line was cultured with fetal bovine serum in RPMI-1640 medium and its sphere was grown in serum-free non-adherent culture. Gene expressions were analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) from cells treated with and without cyclopamine. HCT-116 sphere-derived cells grown in serum-free, non-adherent culture, showed significantly increased expression of stem cell markers, Shh downstream genes and epithelial-mesenchymal transition (EMT) markers compared to parental cells grown in conventional culture. The expression of stemness markers, Shh downstream genes and EMT markers were higher in cancer spheres than the parental cell line and down-regulated by cyclopamine treatment in a dose-dependent manner. Overall, these findings show that cyclopamine treatment could down-regulate the expression of stemness markers, shh downstream genes and EMT markers on HCT-116 spheres.","ja":"Backround: Most solid cancers including colon cancer are believed to be initiated from and maintained by cancer stem cells (CSCs), that are responsible for treatment resistance, resulting in tumor relapse. The aim of this study was to clarify the possible role of the Sonic Hedgehog (Shh) signaling pathway in the regulation of cancer stem cells. The HCT-116 cell line was cultured with fetal bovine serum in RPMI-1640 medium and its sphere was grown in serum-free non-adherent culture. Gene expressions were analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) from cells treated with and without cyclopamine. HCT-116 sphere-derived cells grown in serum-free, non-adherent culture, showed significantly increased expression of stem cell markers, Shh downstream genes and epithelial-mesenchymal transition (EMT) markers compared to parental cells grown in conventional culture. The expression of stemness markers, Shh downstream genes and EMT markers were higher in cancer spheres than the parental cell line and down-regulated by cyclopamine treatment in a dose-dependent manner. Overall, these findings show that cyclopamine treatment could down-regulate the expression of stemness markers, shh downstream genes and EMT markers on HCT-116 spheres."},"publication_date":"2014-11","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"34","number":"11","starting_page":"6339","ending_page":"6344","languages":["eng"],"identifiers":{"issn":["1791-7530"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"28036499"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25436343","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297565","label":"url"}],"paper_title":{"en":"CD133 expression is correlated with poor prognosis in colorectal cancer.","ja":"CD133 expression is correlated with poor prognosis in colorectal cancer."},"authors":{"en":[{"name":"Kashihara Hideya"},{"name":"Shimada Mitsuo"},{"name":"Kurita Nobuhiro"},{"name":"Iwata Takashi"},{"name":"Sato Hirohiko"},{"name":"Kozo Yoshikawa"},{"name":"Higashijima Jun"},{"name":"Chikakiyo Motoya"},{"name":"Nishi Masaaki"},{"name":"Matsumoto Noriko"}],"ja":[{"name":"柏原 秀也"},{"name":"島田 光生"},{"name":"栗田 信浩"},{"name":"岩田 貴"},{"name":"Sato Hirohiko"},{"name":"Kozo Yoshikawa"},{"name":"東島 潤"},{"name":"近清 素也"},{"name":"西 正暁"},{"name":"Matsumoto Noriko"}]},"description":{"en":"Cancer stem cells (CSC) was reported to play an important role in various kinds of cancer. CD133 is one of the cancer stem cell markers in solid cancers. However, the correlation between CD133 expression and the clinicopathological factors in colorectal cancer (CRC) remains unclear. Forty patients with CRC who underwent operations were enrolled. Expression of CD133 was investigated by immunohistochemistry (IHC). The staining was observed in the cytoplasm of cancer cells and the patients who have the staining were defined as CD133-positive cases. The patients were divided into two groups: the CD133-positive group (n = 22) and negative group (n = 18). Clinicopathological factors were compared between the two groups. The prognostic factors were investigated by multivariate analysis. In the CD133-positive group, the incidence of lymph node and liver metastasis, lymphatic and venous invasion, as well as the progression of stage of cancer were higher than that in the CD133-negative group. The 5-year survival rate and the disease-free survival rate in the CD133-positive group were lower than that in the CD133-negative group. The multivariate analysis revealed that CD133 expression tended to be an independent prognostic factor. CD133 expression is correlated with poor prognosis in CRC.","ja":"Cancer stem cells (CSC) was reported to play an important role in various kinds of cancer. CD133 is one of the cancer stem cell markers in solid cancers. However, the correlation between CD133 expression and the clinicopathological factors in colorectal cancer (CRC) remains unclear. Forty patients with CRC who underwent operations were enrolled. Expression of CD133 was investigated by immunohistochemistry (IHC). The staining was observed in the cytoplasm of cancer cells and the patients who have the staining were defined as CD133-positive cases. The patients were divided into two groups: the CD133-positive group (n = 22) and negative group (n = 18). Clinicopathological factors were compared between the two groups. The prognostic factors were investigated by multivariate analysis. In the CD133-positive group, the incidence of lymph node and liver metastasis, lymphatic and venous invasion, as well as the progression of stage of cancer were higher than that in the CD133-negative group. The 5-year survival rate and the disease-free survival rate in the CD133-positive group were lower than that in the CD133-negative group. The multivariate analysis revealed that CD133 expression tended to be an independent prognostic factor. CD133 expression is correlated with poor prognosis in CRC."},"publication_date":"2014-09","publication_name":{"en":"Hepato-Gastroenterology","ja":"Hepato-Gastroenterology"},"volume":"61","number":"134","starting_page":"1563","ending_page":"1567","languages":["eng"],"identifiers":{"doi":["10.5754/hge13657"],"issn":["0172-6390"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381235"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2002607","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25202048","label":"url"},{"@id":"https://www.scopus.com/pages/publications/84908691381","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297554","label":"url"}],"paper_title":{"en":"Effect of light irradiation by light emitting diode on colon cancer cells.","ja":"Effect of light irradiation by light emitting diode on colon cancer cells."},"authors":{"en":[{"name":"Matsumoto Noriko"},{"name":"Yoshikawa Kouzou"},{"name":"Shimada Mitsuo"},{"name":"Kurita Nobuhiro"},{"name":"Sato Horohiko"},{"name":"Iwata Takashi"},{"name":"Higashijima Jun"},{"name":"Chikakiyo Motoya"},{"name":"Nishi Masaaki"},{"name":"Kashihara Hideya"},{"name":"Takasu Chie"},{"name":"Eto Shohei"},{"name":"Takahashi Akira"},{"name":"Akutagawa Masatake"},{"name":"Emoto Takahiro"}],"ja":[{"name":"Matsumoto Noriko"},{"name":"吉川 幸造"},{"name":"島田 光生"},{"name":"栗田 信浩"},{"name":"佐藤 宏彦"},{"name":"岩田 貴"},{"name":"東島 潤"},{"name":"近清 素也"},{"name":"西 正暁"},{"name":"柏原 秀也"},{"name":"髙須 千絵"},{"name":"Eto Shohei"},{"name":"髙橋 章"},{"name":"芥川 正武"},{"name":"榎本 崇宏"}]},"description":{"en":"Recent studies have demonstrated the efficacy of irradiation from light emitting diodes (LED) for wound healing, anti-inflammation and anticancer therapies. However, little is known about the effects of visible light in colon cancer cells. The purpose of this study was to evaluate the biological response (including gene expression changes) of human colon cancer cells to different wavelengths of LED irradiation. Human colon cancer cells (HT29 or HCT116) were seeded onto laboratory dishes that were then put on LED irradiation equipment with a 465 nm-, 525 nm-, or 635 nm-LED. Irradiation at 15 or 30 mW was performed 10 min/day, each day for 5 days. The cell counting kit8 was then used to measure cell viability. Apoptosis and expression of several mRNAs (caspase, MAPK and autophagy pathway) in HT29 cultures irradiated with 465 nm LED were evaluated via AnnexinV/PI and RT-PCR, respectively. Viability of HT29 and HCT116 cells was lower in 465 nm-LED irradiated cultures than in control cultures, but viability of HT29 cells did not differ between control cultures and 525 nm-LED or 635 nm-LED irradiated cultures. Moreover, the expression of FAS, caspase-3, capase-8, and JUK were significantly higher in 465 nm-LED irradiated cultures than in control cultures, and expression of ERK1/2 and LC3 was lower in blue-irradiated cells. LED irradiation at 465 nm inhibited the proliferation of HT29 cells and of HCT116 cells. Notably, LED irradiation at 465 nm promoted apoptosis inHT29 cultures via the extrinsic apoptosis pathway and the MAPK pathway.","ja":"Recent studies have demonstrated the efficacy of irradiation from light emitting diodes (LED) for wound healing, anti-inflammation and anticancer therapies. However, little is known about the effects of visible light in colon cancer cells. The purpose of this study was to evaluate the biological response (including gene expression changes) of human colon cancer cells to different wavelengths of LED irradiation. Human colon cancer cells (HT29 or HCT116) were seeded onto laboratory dishes that were then put on LED irradiation equipment with a 465 nm-, 525 nm-, or 635 nm-LED. Irradiation at 15 or 30 mW was performed 10 min/day, each day for 5 days. The cell counting kit8 was then used to measure cell viability. Apoptosis and expression of several mRNAs (caspase, MAPK and autophagy pathway) in HT29 cultures irradiated with 465 nm LED were evaluated via AnnexinV/PI and RT-PCR, respectively. Viability of HT29 and HCT116 cells was lower in 465 nm-LED irradiated cultures than in control cultures, but viability of HT29 cells did not differ between control cultures and 525 nm-LED or 635 nm-LED irradiated cultures. Moreover, the expression of FAS, caspase-3, capase-8, and JUK were significantly higher in 465 nm-LED irradiated cultures than in control cultures, and expression of ERK1/2 and LC3 was lower in blue-irradiated cells. LED irradiation at 465 nm inhibited the proliferation of HT29 cells and of HCT116 cells. Notably, LED irradiation at 465 nm promoted apoptosis inHT29 cultures via the extrinsic apoptosis pathway and the MAPK pathway."},"publication_date":"2014-09","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"34","number":"9","starting_page":"4709","ending_page":"4716","languages":["eng"],"identifiers":{"issn":["1791-7530"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"28283903"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25108825","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297566","label":"url"}],"paper_title":{"en":"Protein kinase Cι is a new prognostic factor in gastric cancer.","ja":"Protein kinase Cι is a new prognostic factor in gastric cancer."},"authors":{"en":[{"name":"Kashihara Hideya"},{"name":"Shimada Mitsuo"},{"name":"Kurita Nobuhiro"},{"name":"Iwata Takashi"},{"name":"Sato Hirohiko"},{"name":"Yoshikawa Kozo"},{"name":"Miyatani Tomohiko"},{"name":"Takasu Chie"},{"name":"Matsumoto Noriko"}],"ja":[{"name":"柏原 秀也"},{"name":"島田 光生"},{"name":"栗田 信浩"},{"name":"岩田 貴"},{"name":"Sato Hirohiko"},{"name":"Yoshikawa Kozo"},{"name":"宮谷 知彦"},{"name":"髙須 千絵"},{"name":"Matsumoto Noriko"}]},"description":{"en":"Protein kinase Cι (PKCι) is an important oncogenic K-ras effector, and its expression is correlated with tumor angiogenesis. The role of PKCι in gastric cancer remains unclear. The aim of this study was to clarify the role of PKCι in gastric cancer. Twenty-eight patients with gastric cancer who underwent gastrectomy were enrolled in this study. The expression of PKCι mRNA was determined, as were the clinicopathological factors. The patients were divided into PKCι high and low expression groups. The 5-year survival rate, ERK mRNA level and VEGF mRNA level were compared between the two groups. The prognostic factors were investigated by a multivariate analysis. High expression of PKCι was observed to be associated with a lack of differentiation, tumor invasion ≥muscularis propria≤, stage III and IV disease and peritoneal dissemination. The 5-year survival rate in the PKCι high group was lower than that in the PKCι low group. The multivariate analysis revealed that a high expression level of PKCι was an independent prognostic factor. The expression levels of ERK and VEGF in the PKCι high group were higher than those in the PKCι low group. Our results indicate that PKCι is correlated with tumor progression and angiogenesis. PKCι may be a new prognostic factor for gastric cancer.","ja":"Protein kinase Cι (PKCι) is an important oncogenic K-ras effector, and its expression is correlated with tumor angiogenesis. The role of PKCι in gastric cancer remains unclear. The aim of this study was to clarify the role of PKCι in gastric cancer. Twenty-eight patients with gastric cancer who underwent gastrectomy were enrolled in this study. The expression of PKCι mRNA was determined, as were the clinicopathological factors. The patients were divided into PKCι high and low expression groups. The 5-year survival rate, ERK mRNA level and VEGF mRNA level were compared between the two groups. The prognostic factors were investigated by a multivariate analysis. High expression of PKCι was observed to be associated with a lack of differentiation, tumor invasion ≥muscularis propria≤, stage III and IV disease and peritoneal dissemination. The 5-year survival rate in the PKCι high group was lower than that in the PKCι low group. The multivariate analysis revealed that a high expression level of PKCι was an independent prognostic factor. The expression levels of ERK and VEGF in the PKCι high group were higher than those in the PKCι low group. Our results indicate that PKCι is correlated with tumor progression and angiogenesis. PKCι may be a new prognostic factor for gastric cancer."},"publication_date":"2014-08-10","publication_name":{"en":"Surgery Today","ja":"Surgery Today"},"volume":"45","number":"6","starting_page":"759","ending_page":"764","languages":["eng"],"identifiers":{"doi":["10.1007/s00595-014-1010-5"],"issn":["1436-2813"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381238"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/25075050","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297569","label":"url"}],"paper_title":{"en":"Expression of Stathmin1 in gastric adenocarcinoma.","ja":"Expression of Stathmin1 in gastric adenocarcinoma."},"authors":{"en":[{"name":"Batsaikhan Bat-Erdene"},{"name":"Yoshikawa Kozo"},{"name":"Kurita Nobuhiro"},{"name":"Iwata Takashi"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Batsaikhan Bat-Erdene"},{"name":"Yoshikawa Kozo"},{"name":"栗田 信浩"},{"name":"岩田 貴"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"島田 光生"}]},"description":{"en":"Over expression of Stathmin1 (STMN1), activation-induced cytidine deaminase (AID) and protein kinase C iota (PKCi) proteins participate in the regulation of carcinogenesis. In the present study, we investigated the expression of STMN1 in patients with gastric adenocarcinoma and also determined the correlation of STMN1 with AID and PKCi proteins. This study was conducted in the Tokushima University Hospital between September 2009 and September 2010 on a total of 59 patients with gastric adenocarcinoma. Stathmin1, AID and PKCi protein expressions were evaluated by immuno-histochemistry in gastric adenocarcinoma. A strong expression of STMN1 was significantly associated with gender- and poorly differentiated gastric adenocarcinoma (p<0.05). A high mRNA level of STMN1 was found in the tumor tissue of gastric adenocarcinoma compared to non-tumor tissue (p<0.05). In addition, STMN1 expression was significantly correlated with AID and PKCi protein expressions in gastric adenocarcinoma (p<0.05). High mRNA level of the Stathmin1 gene was significantly expressed in gastric tumor tissue than non-tumor and strong expression of STMN1 protein is correlated with poorly-differentiated gastric adenocarcinoma.","ja":"Over expression of Stathmin1 (STMN1), activation-induced cytidine deaminase (AID) and protein kinase C iota (PKCi) proteins participate in the regulation of carcinogenesis. In the present study, we investigated the expression of STMN1 in patients with gastric adenocarcinoma and also determined the correlation of STMN1 with AID and PKCi proteins. This study was conducted in the Tokushima University Hospital between September 2009 and September 2010 on a total of 59 patients with gastric adenocarcinoma. Stathmin1, AID and PKCi protein expressions were evaluated by immuno-histochemistry in gastric adenocarcinoma. A strong expression of STMN1 was significantly associated with gender- and poorly differentiated gastric adenocarcinoma (p<0.05). A high mRNA level of STMN1 was found in the tumor tissue of gastric adenocarcinoma compared to non-tumor tissue (p<0.05). In addition, STMN1 expression was significantly correlated with AID and PKCi protein expressions in gastric adenocarcinoma (p<0.05). High mRNA level of the Stathmin1 gene was significantly expressed in gastric tumor tissue than non-tumor and strong expression of STMN1 protein is correlated with poorly-differentiated gastric adenocarcinoma."},"publication_date":"2014-08","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"34","number":"8","starting_page":"4217","ending_page":"4221","languages":["eng"],"identifiers":{"issn":["1791-7530"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24890568","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297555","label":"url"}],"paper_title":{"en":"Role of CD151 expression in gallbladder carcinoma.","ja":"Role of CD151 expression in gallbladder carcinoma."},"authors":{"en":[{"name":"Matsumoto Noriko"},{"name":"Morine Yuji"},{"name":"Utsunomiya Tohru"},{"name":"Imura Satoru"},{"name":"Ikemoto Tetsuya"},{"name":"Arakawa Yusuke"},{"name":"Iwahashi Shuichi"},{"name":"Saitou Yu"},{"name":"Yamada Shiniciro"},{"name":"Ishikawa Daichi"},{"name":"Takasu Chie"},{"name":"Miyake Hidenori"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Matsumoto Noriko"},{"name":"森根 裕二"},{"name":"Utsunomiya Tohru"},{"name":"居村 暁"},{"name":"池本 哲也"},{"name":"荒川 悠佑"},{"name":"岩橋 衆一"},{"name":"齋藤 裕"},{"name":"Yamada Shiniciro"},{"name":"Ishikawa Daichi"},{"name":"髙須 千絵"},{"name":"三宅 秀則"},{"name":"島田 光生"}]},"description":{"en":"CD151 is a member of the tetraspanin family, which interacts with laminin-binding integrins and other tetraspanins. CD151 is involved in several pathologic activities associated with tumor progression, including metastasis and angiogenesis. The aim of this study was to clarify the clinical use of CD151 expression in gallbladder cancer (GBC). Forty-five patients with GBC who had undergone operative treatment were enrolled in this study. Expressions of CD151 in the resected GBC specimens were evaluated with anti-CD151 antibody. The patients were divided into positive and negative groups according to CD151 expression: CD151-positive group (n = 26) and CD151-negative group (n = 19). Clinicopathologic factors, including Ki-67 and matrix metallopeptidase 9, also were compared between the two groups. CD151-positive expression was 58% and correlated with poorer prognosis; 5-year survival of CD151-positive and CD151-negative groups was 29% and 78%, respectively (P = .006). CD151 expression also correlated with lymphatic invasion and curability. Multivariate analysis revealed that CD151-positive expression was an independent prognostic factor (hazard ratio 2.97, P = .02). In addition, CD151 expression correlated with matrix metallopeptidase 9 expression (P < .05) but not with Ki67 expression. Those findings suggested that CD151-positive expression might be a potential prognostic indicator and one of the target molecules for the regulation of tumor metastasis for patients with GBC.","ja":"CD151 is a member of the tetraspanin family, which interacts with laminin-binding integrins and other tetraspanins. CD151 is involved in several pathologic activities associated with tumor progression, including metastasis and angiogenesis. The aim of this study was to clarify the clinical use of CD151 expression in gallbladder cancer (GBC). Forty-five patients with GBC who had undergone operative treatment were enrolled in this study. Expressions of CD151 in the resected GBC specimens were evaluated with anti-CD151 antibody. The patients were divided into positive and negative groups according to CD151 expression: CD151-positive group (n = 26) and CD151-negative group (n = 19). Clinicopathologic factors, including Ki-67 and matrix metallopeptidase 9, also were compared between the two groups. CD151-positive expression was 58% and correlated with poorer prognosis; 5-year survival of CD151-positive and CD151-negative groups was 29% and 78%, respectively (P = .006). CD151 expression also correlated with lymphatic invasion and curability. Multivariate analysis revealed that CD151-positive expression was an independent prognostic factor (hazard ratio 2.97, P = .02). In addition, CD151 expression correlated with matrix metallopeptidase 9 expression (P < .05) but not with Ki67 expression. Those findings suggested that CD151-positive expression might be a potential prognostic indicator and one of the target molecules for the regulation of tumor metastasis for patients with GBC."},"publication_date":"2014-06-02","publication_name":{"en":"Surgery","ja":"Surgery"},"volume":"156","number":"5","starting_page":"1212","ending_page":"1217","languages":["eng"],"identifiers":{"doi":["10.1016/j.surg.2014.04.053"],"issn":["1532-7361"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"28081400"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26158164","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297556","label":"url"}],"paper_title":{"en":"Duodenal-Jejunal Bypass Improves Insulin Resistance by Enhanced Glucagon-Like Peptide-1 Secretion Through Increase of Bile Acids.","ja":"Duodenal-Jejunal Bypass Improves Insulin Resistance by Enhanced Glucagon-Like Peptide-1 Secretion Through Increase of Bile Acids."},"authors":{"en":[{"name":"Kashihara Hideya"},{"name":"Shimada Mitsuo"},{"name":"Kurita Nobuhiro"},{"name":"Iwata Takashi"},{"name":"Sato Hirohiko"},{"name":"Yoshikawa Kozo"},{"name":"Miyatani Tomohiko"},{"name":"Takasu Chie"},{"name":"Matsumoto Noriko"},{"name":"Ishibashi Hiroki"}],"ja":[{"name":"柏原 秀也"},{"name":"島田 光生"},{"name":"栗田 信浩"},{"name":"岩田 貴"},{"name":"Sato Hirohiko"},{"name":"Yoshikawa Kozo"},{"name":"宮谷 知彦"},{"name":"髙須 千絵"},{"name":"Matsumoto Noriko"},{"name":"石橋 広樹"}]},"description":{"en":"The aim of this study is to investigate the mechanisms of improvement in insulin resistance after duodenal-jejunal bypass (DIB), especially regarding the correlation between bile acids and glucagon-like peptide-1 (GLP-1). SD rats were divided into two groups: DIB or Sham group. Blood glucose, insulin, GLP-1, bile acids, and the number of L cells in the small intestine were investigated three weeks after the operations. Next, to assess the effect of the bile acids on GLP-1 secretion in ileum, bile diversion model (=inhibition of rapid bile exposure to the ileum; BD group) were performed and postoperative glycemic parameters were measured. DJB improved insulin resistance and increased GLP-1 compared with sham. Higher bile acids in DJB were found than that in sham. The number of L cells in the common limb of DJB was increased compared with that in the distal segment of sham. In BD group, insulin resistance had not improved. GLP-1, bile acids, and the number of L cells revealed no significant changes compared with sham. DJB has a potential to improve insulin resistance, which may be related to enhanced GLP-1 secretion through the increase of bile acids in the common limb of the small intestine.","ja":"The aim of this study is to investigate the mechanisms of improvement in insulin resistance after duodenal-jejunal bypass (DIB), especially regarding the correlation between bile acids and glucagon-like peptide-1 (GLP-1). SD rats were divided into two groups: DIB or Sham group. Blood glucose, insulin, GLP-1, bile acids, and the number of L cells in the small intestine were investigated three weeks after the operations. Next, to assess the effect of the bile acids on GLP-1 secretion in ileum, bile diversion model (=inhibition of rapid bile exposure to the ileum; BD group) were performed and postoperative glycemic parameters were measured. DJB improved insulin resistance and increased GLP-1 compared with sham. Higher bile acids in DJB were found than that in sham. The number of L cells in the common limb of DJB was increased compared with that in the distal segment of sham. In BD group, insulin resistance had not improved. GLP-1, bile acids, and the number of L cells revealed no significant changes compared with sham. DJB has a potential to improve insulin resistance, which may be related to enhanced GLP-1 secretion through the increase of bile acids in the common limb of the small intestine."},"publication_date":"2014-06","publication_name":{"en":"Hepato-Gastroenterology","ja":"Hepato-Gastroenterology"},"volume":"61","number":"132","starting_page":"1049","ending_page":"1054","languages":["eng"],"identifiers":{"doi":["10.5754/hge13029"],"issn":["0172-6390"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381241"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297580","label":"url"}],"paper_title":{"en":"P1胃癌に対しS-1+PTXi.p.を行い5年生存が得られた1例","ja":"P1胃癌に対しS-1+PTXi.p.を行い5年生存が得られた1例"},"authors":{"en":[{"name":"松本 規子"},{"name":"Shimada Mitsuo"},{"name":"Kurita Nobuhiro"},{"name":"Sato Horohiko"},{"name":"Iwata Takashi"},{"name":"Yoshikawa Kouzou"},{"name":"Higashijima Jun"},{"name":"Chikakiyo Motoya"},{"name":"Nishi Masaaki"},{"name":"Kashihara Hideya"}],"ja":[{"name":"松本 規子"},{"name":"島田 光生"},{"name":"栗田 信浩"},{"name":"佐藤 宏彦"},{"name":"岩田 貴"},{"name":"吉川 幸造"},{"name":"東島 潤"},{"name":"近清 素也"},{"name":"西 正暁"},{"name":"柏原 秀也"}]},"publication_date":"2014-04","publication_name":{"en":"Journal of Japanese College of Surgeons","ja":"日本外科系連合学会誌"},"volume":"39","number":"2","starting_page":"199-203","ending_page":"199-203","languages":["jpn"],"identifiers":{"issn":["0385-7883"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381242"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297577","label":"url"}],"paper_title":{"en":"腹腔鏡下切除を施行した骨形成性直腸癌同時肝転移の1例","ja":"腹腔鏡下切除を施行した骨形成性直腸癌同時肝転移の1例"},"authors":{"en":[{"name":"Kashihara Hideya"},{"name":"Shimada Mitsuo"},{"name":"Kurita Nobuhiro"},{"name":"Sato Horohiko"},{"name":"Yoshikawa Kouzou"},{"name":"Higashijima Jun"}],"ja":[{"name":"柏原 秀也"},{"name":"島田 光生"},{"name":"栗田 信浩"},{"name":"佐藤 宏彦"},{"name":"吉川 幸造"},{"name":"東島 潤"}]},"publication_date":"2014-04","publication_name":{"en":"Journal of Japan Surgical Association","ja":"日本臨床外科学会雑誌"},"volume":"75","number":"7","starting_page":"185","ending_page":"190","languages":["jpn"],"identifiers":{"doi":["10.3919/jjsa.75.1949"],"issn":["1882-5133"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381243"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297572","label":"url"}],"paper_title":{"en":"肝切除後のVTE予防策は?","ja":"肝切除後のVTE予防策は?"},"authors":{"en":[{"name":"Kurita Nobuhiro"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"栗田 信浩"},{"name":"島田 光生"}]},"publication_date":"2014-03","publication_name":{"en":"エキスパートによる消化器外科静脈血栓塞栓症診療指針","ja":"エキスパートによる消化器外科静脈血栓塞栓症診療指針"},"starting_page":"103-105","ending_page":"103-105","languages":["jpn"],"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381244"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24511045","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297567","label":"url"}],"paper_title":{"en":"The role of activation-induced cytidine deaminase expression in gastric adenocarcinoma.","ja":"The role of activation-induced cytidine deaminase expression in gastric adenocarcinoma."},"authors":{"en":[{"name":"Batsaikhan Bat-Erdene"},{"name":"Kurita Nobuhiro"},{"name":"Iwata Takashi"},{"name":"Sato Hirohiko"},{"name":"Yoshikawa Kozo"},{"name":"Takasu Chie"},{"name":"Kashihara Hideya"},{"name":"Matsumoto Noriko"},{"name":"Ishibashi Hiroki"},{"name":"Shimada Mitsuo"}],"ja":[{"name":"Batsaikhan Bat-Erdene"},{"name":"栗田 信浩"},{"name":"岩田 貴"},{"name":"Sato Hirohiko"},{"name":"Yoshikawa Kozo"},{"name":"髙須 千絵"},{"name":"柏原 秀也"},{"name":"Matsumoto Noriko"},{"name":"石橋 広樹"},{"name":"島田 光生"}]},"description":{"en":"Gastric adenocarcinoma is one of the most common malignant tumors and the leading cause of malignancy-related death worldwide. Studies have reported overexpression of activation-induced cytidine deaminase (AID) and protein kinase c iota (PKCi) proteins showing involvement in the regulation of carcinogenesis. In the present study, we investigated the expression of AID and PKCi in patients with gastric adenocarcinoma and determined the correlation between these proteins. This study was conducted between September 2009 and September 2010 on a total of 59 patients with gastric adenocarcinoma at the Tokushima University Hospital. AID, PKCi and mutated p53 protein expressions were evaluated by immunohistochemistry in gastric adenocarcinoma. High AID and PKCi expression was significantly (p<0.05) associated with poorly-differentiated gastric adenocarcinoma. In addition, PKCi expression was significantly correlated with clinicopathological findings such as a lymph node metastasis, and venous and lymphatic invasion (p<0.05). Furthermore, AID expression was significantly correlated with PKCi and mutated p53 protein expression in gastric adenocarcinoma (p<0.05). High AID and PKCi expressions were significantly correlated with poorly-differentiated gastric adenocarcinoma.","ja":"Gastric adenocarcinoma is one of the most common malignant tumors and the leading cause of malignancy-related death worldwide. Studies have reported overexpression of activation-induced cytidine deaminase (AID) and protein kinase c iota (PKCi) proteins showing involvement in the regulation of carcinogenesis. In the present study, we investigated the expression of AID and PKCi in patients with gastric adenocarcinoma and determined the correlation between these proteins. This study was conducted between September 2009 and September 2010 on a total of 59 patients with gastric adenocarcinoma at the Tokushima University Hospital. AID, PKCi and mutated p53 protein expressions were evaluated by immunohistochemistry in gastric adenocarcinoma. High AID and PKCi expression was significantly (p<0.05) associated with poorly-differentiated gastric adenocarcinoma. In addition, PKCi expression was significantly correlated with clinicopathological findings such as a lymph node metastasis, and venous and lymphatic invasion (p<0.05). Furthermore, AID expression was significantly correlated with PKCi and mutated p53 protein expression in gastric adenocarcinoma (p<0.05). High AID and PKCi expressions were significantly correlated with poorly-differentiated gastric adenocarcinoma."},"publication_date":"2014-02","publication_name":{"en":"Anticancer Research","ja":"Anticancer Research"},"volume":"34","number":"2","starting_page":"995","ending_page":"1000","languages":["eng"],"identifiers":{"issn":["1791-7530"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381247"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/24127772","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=297552","label":"url"}],"paper_title":{"en":"Benefits of simultaneous laparoscopic resection of primary colorectal cancer and liver metastases.","ja":"Benefits of simultaneous laparoscopic resection of primary colorectal cancer and liver metastases."},"authors":{"en":[{"name":"Takasu Chie"},{"name":"Shimada Mitsuo"},{"name":"Sato Hirohiko"},{"name":"Miyatani Tomohiko"},{"name":"Imura Satoru"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Kanamoto Mami"},{"name":"Kurita Nobuhiro"},{"name":"Eto Shohei"},{"name":"Utsunomiya Tohru"}],"ja":[{"name":"髙須 千絵"},{"name":"島田 光生"},{"name":"Sato Hirohiko"},{"name":"宮谷 知彦"},{"name":"居村 暁"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"金本 真美"},{"name":"栗田 信浩"},{"name":"Eto Shohei"},{"name":"Utsunomiya Tohru"}]},"description":{"en":"Recently, consensus on the optimal strategy for resectable synchronous colorectal liver metastases (LM) seems to have shifted toward simultaneous resection. However, there are still relatively few reports about simultaneous laparoscopic resection. The aim of this study is to evaluate the outcomes of patients who underwent simultaneous laparoscopic resection. We evaluated 14 patients who underwent simultaneous resection of primary colorectal cancer and LM in our hospital from 2004 to 2012. Patients were selected by matched pair analysis based on the number of LM (≤4) and tumor size (≤5 cm). We divided them into two groups: the simultaneous laparoscopic resection of primary colorectal cancer and LM (Lap-S) group (n = 7) and the simultaneous open resection of primary colorectal cancer and LM (Open-S) group (n = 7). Clinical and oncologic outcomes were compared between the groups. The Lap-S patients were significantly older than the Open-S patients. The mean operative times of Lap-S and Open-S were 472 min and 466 min, respectively. The mean blood loss was significantly smaller in the Lap-S group (153 mL) than in the Open-S group (496 mL). There was no surgical mortality in either group. The incidence of postoperative complications in the Lap-S and Open-S groups was 12.3% and 33.0%, respectively. The mean postoperative hospital stay was significantly shorter in the Lap-S group (16 days) than in the Open-S group (36 days). There was no significant difference in long-term survival between the two groups. Lap-S patients had equivalent long-term outcomes to Open-S patients. Therefore, given its technical feasibility and safety, Lap-S may be one of the most promising options in selected patients.","ja":"Recently, consensus on the optimal strategy for resectable synchronous colorectal liver metastases (LM) seems to have shifted toward simultaneous resection. However, there are still relatively few reports about simultaneous laparoscopic resection. The aim of this study is to evaluate the outcomes of patients who underwent simultaneous laparoscopic resection. We evaluated 14 patients who underwent simultaneous resection of primary colorectal cancer and LM in our hospital from 2004 to 2012. Patients were selected by matched pair analysis based on the number of LM (≤4) and tumor size (≤5 cm). We divided them into two groups: the simultaneous laparoscopic resection of primary colorectal cancer and LM (Lap-S) group (n = 7) and the simultaneous open resection of primary colorectal cancer and LM (Open-S) group (n = 7). Clinical and oncologic outcomes were compared between the groups. The Lap-S patients were significantly older than the Open-S patients. The mean operative times of Lap-S and Open-S were 472 min and 466 min, respectively. The mean blood loss was significantly smaller in the Lap-S group (153 mL) than in the Open-S group (496 mL). There was no surgical mortality in either group. The incidence of postoperative complications in the Lap-S and Open-S groups was 12.3% and 33.0%, respectively. The mean postoperative hospital stay was significantly shorter in the Lap-S group (16 days) than in the Open-S group (36 days). There was no significant difference in long-term survival between the two groups. Lap-S patients had equivalent long-term outcomes to Open-S patients. Therefore, given its technical feasibility and safety, Lap-S may be one of the most promising options in selected patients."},"publication_date":"2013-10-15","publication_name":{"en":"Asian Journal of Endoscopic Surgery","ja":"Asian Journal of Endoscopic Surgery"},"volume":"7","number":"1","starting_page":"31","ending_page":"37","languages":["eng"],"identifiers":{"doi":["10.1111/ases.12066"],"issn":["1758-5910"]},"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"32381248"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=236902","label":"url"}],"paper_title":{"en":"肝硬変患者に対するテーラーメイド栄養管理の血液生化学指標についての検討","ja":"肝硬変患者に対するテーラーメイド栄養管理の血液生化学指標についての検討"},"authors":{"en":[{"name":"Okumura Hisami"},{"name":"山内 利香"},{"name":"浦野 恵理"},{"name":"寺本 有沙"},{"name":"Imura Satoru"},{"name":"Utsunomiya Toru"},{"name":"Shimada Mitsuo"},{"name":"Takeda Eiji"}],"ja":[{"name":"奥村 仙示"},{"name":"山内 利香"},{"name":"浦野 恵理"},{"name":"寺本 有沙"},{"name":"居村 暁"},{"name":"宇都宮 徹"},{"name":"島田 光生"},{"name":"武田 英二"}]},"publication_date":"2011","publication_name":{"en":"栄養アセスメント","ja":"栄養アセスメント"},"volume":"28","number":"1","starting_page":"18","ending_page":"20","languages":["jpn"],"published_paper_type":"research_institution"},"priority":"input_data"}
{"insert":{"user_id":"1000314537","type":"published_papers","id":"26744031"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26940140","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=315087","label":"url"}],"paper_title":{"en":"Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation.","ja":"Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation."},"authors":{"en":[{"name":"Iwahashi Shuichi"},{"name":"Shimada Mitsuo"},{"name":"Utsunomiya Tohru"},{"name":"Imura Satoru"},{"name":"Morine Yuji"},{"name":"Ikemoto Tetsuya"},{"name":"Takasu Chie"},{"name":"Saitou Yu"},{"name":"Yamada Shinichiro"}],"ja":[{"name":"岩橋 衆一"},{"name":"島田 光生"},{"name":"Utsunomiya Tohru"},{"name":"居村 暁"},{"name":"森根 裕二"},{"name":"池本 哲也"},{"name":"髙須 千絵"},{"name":"齋藤 裕"},{"name":"Yamada Shinichiro"}]},"description":{"en":"We reported that poor prognoses of hepatocellular carcinoma (HCC) patients after radiofrequency ablation (RFA) are owing to up-regulation of expression of hypoxia-inducible factor-1 and epithelial cell adhesion molecule. We investigated aggressive progression in residual liver tumors (RLTs) after RFA to focus on expression of epithelial-mesenchymal transition (EMT)-related genes and miRNAs. Ten patients with recurrent HCC post-RFA who underwent hepatectomy (RFA group) and 78 patients with HCC without prior RFA (non-RFA group) were enrolled. We examined expression of transforming growth factor (TGF)-β, Twist, vimentin, and Snail-1 mRNAs in tumor tissues, and expression of miR-34a and miR-200c. Expression of TGF-β, Twist and Snail-1 in the RFA group was significantly higher than that in the non-RFA group (P < 0.05); vimentin expression in the RFA group was higher than that in the non-RFA group (P = 0.07). Expression of miR-200c and miR-34a in the RFA group was significantly lower than that in the non-RFA group (miR-200c: P = 0.04; miR-34a: P < 0.01). Increased expression of EMT markers through down-regulation of miRNA expression in RLTs after RFA may be related to poor prognoses of HCC patients with aggressive local recurrence after RFA.","ja":"We reported that poor prognoses of hepatocellular carcinoma (HCC) patients after radiofrequency ablation (RFA) are owing to up-regulation of expression of hypoxia-inducible factor-1 and epithelial cell adhesion molecule. We investigated aggressive progression in residual liver tumors (RLTs) after RFA to focus on expression of epithelial-mesenchymal transition (EMT)-related genes and miRNAs. Ten patients with recurrent HCC post-RFA who underwent hepatectomy (RFA group) and 78 patients with HCC without prior RFA (non-RFA group) were enrolled. We examined expression of transforming growth factor (TGF)-β, Twist, vimentin, and Snail-1 mRNAs in tumor tissues, and expression of miR-34a and miR-200c. Expression of TGF-β, Twist and Snail-1 in the RFA group was significantly higher than that in the non-RFA group (P < 0.05); vimentin expression in the RFA group was higher than that in the non-RFA group (P = 0.07). Expression of miR-200c and miR-34a in the RFA group was significantly lower than that in the non-RFA group (miR-200c: P = 0.04; miR-34a: P < 0.01). Increased expression of EMT markers through down-regulation of miRNA expression in RLTs after RFA may be related to poor prognoses of HCC patients with aggressive local recurrence after RFA."},"publication_date":"2016-03-03","publication_name":{"en":"Cancer Letters","ja":"Cancer Letters"},"volume":"375","number":"1","starting_page":"47","ending_page":"50","languages":["eng"],"identifiers":{"doi":["10.1016/j.canlet.2016.02.041"],"issn":["1872-7980"]}},"priority":"input_data"}